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Abstract 
The work presented in this thesis aimed to study the application of fluorescence lifetime 
spectroscopy (FLS) and fluorescence lifetime imaging microscopy (FLIM) to investigate their 
potential for diagnostic contrast of diseased tissue with a particular emphasis on 
autofluorescence (AF) measurements of gastrointestinal (GI) disease. 
Initially, an ex vivo study utilising confocal FLIM was undertaken with 420-nm-excitation to 
characterise the  fluorescence lifetime (FL) images obtained from 71 GI samples from 35 
patients. A significant decrease in FL was observed between normal colon and polyps (p = 
0.024), and normal colon and inflammatory bowel disease (IBD) (p = 0.015). Confocal FLIM was 
also performed on 23 bladder samples. A longer, although not significant, FL for cancer was 
observed, in paired specimens (n = 5) instilled with a photosensitizer. 
The first in vivo study was a clinical investigation of skin cancer using a fibre-optic FL 
spectrofluorometer and involved the interrogation of 27 lesions from 25 patients. A significant 
decrease in the FL of basal cell carcinomas compared to healthy tissue was observed (p = 0.002) 
with 445-nm-excitation. 
A novel clinically viable FLS fibre-optic probe was then applied ex vivo to measure 60 samples 
collected from 23 patients. In a paired analysis of neoplastic polyps and normal colon obtained 
from the same region of the colon in the same patient (n = 12), a significant decrease in FL was 
observed (p = 0.021) with 435-nm-excitation. In contrast, with 375-nm-excitation, the mean FL 
of IBD specimens (n = 4) was found to be longer than that of normal tissue, although not 
statistically significant. Finally, the FLS system was applied in vivo in 17 patients, with initial 
data indicating that 435-nm-excitation results in AF lifetimes that are broadly consistent with ex 
vivo studies, although no diagnostically significant differences were observed in the signals 
obtained in vivo. 
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Chapter 1: Thesis outline 
Worldwide, gastrointestinal (GI) disease is a common cause of care-seeking and hospital 
admission, the  a common cause of death, and the leading cause of cancer death [1]. It affects 
people of all ages, gender and ethnic backgrounds and the healthcare burden of GI and liver 
disease is enormous, with a progressive increase in the incidence and prevalence of most 
diseases such as colorectal and oesophageal cancers, Barrett's oesophagus, and inflammatory 
bowel disease. In the United Kingdom, the annual cost to the NHS of GI disease is at least £18.7 
billion [2]. This burden will inevitably increase as the population ages and obesity becomes 
endemic. GI tract diseases comprise a wide spectrum of disorders including inflammation, 
ulcerations and pre-neoplastic and neoplastic lesions of the oesophagus, stomach, duodenum 
and colon. Possible causes include: damage due to either acute-life-threatening conditions or 
recurring injuries that are not immediately life threatening but severely impairing the quality of 
life; active or chronic immune response and accumulation of genetic mutations and interplay 
with environmental factors. 
GI diseases are usually investigated by close inspection by means of standard white light 
endoscopy (WLE). However, it is possible that a diagnosis can be missed or delayed because a 
number of disorders, including early GI cancers, are frequently invisible or difficult to visualise 
under inspection with WLE. In addition, it is often difficult to distinguish between benign and 
early or pre-malignant lesions. There is therefore increasing interest in developing techniques 
to enhance the contrast of diseased tissue regions beyond what is possible with current state-of-
the-art endoscopy equipment. This PhD primarily aimed to address this challenge by applying 
fluorescence lifetime imaging (FLIM) and spectroscopy (FLS) technologies to study diseased 
tissue with a view to developing new fluorescence lifetime-based tools for clinical endoscopy. 
Initially, single point FLS instruments could be used to guide biopsies or to undertake “optical 
biopsy” in situ and there is the future prospect of wide-field FLIM endoscopes that could enable 
rapid imaging of tissue with fields of view of several centimetres with the potential to be used as 
a label-free red-flag screening technique, alerting clinicians to regions requiring more detailed 
investigation, i.e. by conventional biopsy or resection. 
This thesis begins with a discussion of the pathology of GI disease and describes the current 
status of GI endoscopy, reviewing recent technological advances in the field including 
autofluorescence imaging and spectroscopy, confocal laser endomicroscopy and other emerging 
approaches to minimally-invasive endoscopic detection of disease. It outlines the basic 
principles of fluorescence measurement and imaging, including of fluorescence lifetime and 
surveys the experimental work to date applying fluorescence lifetime spectroscopy and imaging 
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of some of the most common GI diseases. The description of the research undertaken for this 
thesis then begins with an experimental study of the fluorescence lifetime signatures of ex vivo 
human GI and bladder tissue using confocal FLIM microscopy. This is followed by a discussion 
of the development of three novel clinically-deployable multispectral fluorescence lifetime 
endoscopic instruments and their application to ex vivo and in vivo studies of GI disease. 
Chapter 2 provides some background on the anatomy and histopathology of the GI tract for this 
interdisciplinary PhD thesis. The pathologies of inflammation, dysplasia and cancers of the GI 
tract are described with the causes of diseases and their effects.  Early GI cancers are discussed 
in more detail, including a summary of the most controversial and divisive issues in endoscopic 
diagnosis and pathology. An overview of the current state-of-the-art of general endoscopy is 
then given, along with an introduction to the most recent advances in the field and a review of 
the pre-clinical and clinical experience with currently available “optical biopsy techniques” such 
as confocal endomicroscopy. The clinical utility and relevance to clinicians of these emerging 
techniques and a summary of the current unmet clinical needs in endoscopy are also discussed. 
In chapter 3, the basic science underlying fluorescence, fluorescence lifetime and 
autofluorescence of biological tissue are introduced. Then, the optical instrumentation used for 
the experiments described in this thesis is introduced with a discussion of the challenges faced 
during this project.  A FLIM confocal endoscope with subcellular resolution and a wide-field 
FLIM endoscopy system recently developed in the Photonics Group for clinical application are 
described with a discussion of initial results from proof of principle studies and the current 
limitations of these instruments. A review of published clinical and preclinical experience with 
autofluorescence spectroscopy and imaging is presented. 
Chapter 4 presents the initial results from the first (to the best of the author's knowledge) ex 
vivo study of human GI tissue using confocal FLIM microscopy. This includes a survey of the 
typical morphological and lifetime characteristics in FL images of different GI tissue sites and 
states (normal, diseased), for which an ex vivo imaging protocol was designed to resect, 
transport and investigate the various tissue types. It was seen that the fluorescence lifetime of 
dysplastic or neoplastic samples could be either shorter or longer than that of normal tissue and 
that, within the same sample, epithelia and connective tissue presented different fluorescence 
lifetime distributions according to their structural composition. These fluorescence lifetime 
image data were compared to images from immunohistochemistry assays and selective stains 
on blocks of selected cases that enhanced the structural contrast of epithelia and connective 
tissue.  Autofluorescence emission spectra were also measured and compared to spectra 
obtained from pure solutions of analytes using a spectrofluorometer to help determine the most 
prevalent fluorophores involved in the fluorescence decay signatures. 
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The confocal FLIM microscope was also applied to image “cold-cut” bladder tissue biopsy 
samples and these results are presented in chapter 5. For this study, imaging following 
treatment with a photosensitising agent (Hexvix®) instilled into the bladder prior to cystoscopy 
was undertaken. Fluorescence emission spectra from tissue samples were also compared with 
pure solutions of protoporphyrin IX. Based on this limited data set, it appears that the mean 
fluorescence lifetimes of suspected bladder cancer biopsies are consistently longer than those of 
the healthy biopsies for intra patient comparisons. 
Chapter 6 describes the design, construction and clinical application of a compact, clinically 
deployable single point multispectral FLS fibre-probe system that was implemented for the 
autofluorescence lifetime measurements undertaken for this thesis. Using a first prototype of 
this system, a clinical investigation of skin cancer, with an emphasis on basal cell carcinoma 
(BCC), was conducted in vivo before surgical excision of the irradiated region, at Lund University 
Hospital in Sweden. A statistically significant decrease in the fluorescence lifetime of BCCs 
compared to neighbouring healthy tissue was observed that was in broad agreement with 
previous ex vivo studies. 
In chapter 7, the application of a more compact, endoscopically deployable version of the fibre-
optic FLS probe system to an ex vivo clinical investigation of GI diseases is presented with an 
emphasis on colonic polyps and inflammatory bowel disease. These measurements were 
undertaken in the Endoscopy Unit at Charing Cross Hospital where a total of 64 samples were 
collected from 24 patients undergoing endoscopy.  FL measurements were initially performed 
ex vivo immediately following endoscopic biopsy or resection of the investigated lesion.  
Fluorescence lifetime was seen to provide contrast between normal and diseased tissue in both 
colonic polyps and inflammatory bowel disease. Furthermore, in the case of neoplastic polyps 
excited at 435 nm, this contrast was statistically significant. These results suggested that it may 
be possible to discriminate polyps from normal tissue and IBD using 435 nm excited 
fluorescence lifetime measurements and IBD from normal tissue and polyps using the 
fluorescence lifetime measured with 375 nm excitation but more extensive work is required to 
confirm their clinical utility. 
Finally, chapter 8 presents the application of this newly developed fibre-optic FLS instrument 
to an in vivo clinical trial undertaken in 17 patients undergoing GI endoscopy as part of their 
clinical investigations at Charing Cross hospital. Initial results found the fluorescence lifetimes 
of GI tissue measured in vivo to be in relatively good agreement with those measured ex vivo. 
Statistically significant differences were found for 375 nm excitation in the spectrally averaged 
mean fluorescence lifetimes from the three regions of normal colon investigated, with the 
greatest difference observed between right and left colon. The mean fluorescence lifetimes for 
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polyps were found to be shorter than those observed in normal tissue for 435 nm excitation - in 
agreement with the ex vivo results – but the lifetime differences between polyps and normal 
tissue were not significant for either excitation wavelength for this number of samples.   
Chapter 9 summarises the key results and experiments from this thesis and presents an 
overview of the various themes addressed during this PhD. A discussion of the future potential 
clinical impact of this work is presented together with the plan to extend the in vivo 
measurements using the existing FLS fibre-optic point-probe system to validate the lifetime 
contrast observed and with a discussion of the prospects to develop a “red flag” FLIM 
endoscopic imaging modality. 
The appendix includes a list of the journal publications, book chapters and conference 
presentations related to the work in the thesis.  
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Chapter 2: Introduction to the gastrointestinal tract, 
conventional endoscopy and advanced endoscopic 
techniques 
New developments in endoscopic techniques may soon challenge histology as the diagnostic 
gold standard. The conceptual paradigm of a “red flag” technique, capable of examining tissue 
function and morphology in real time to replace conventional biopsies, is taking shape and 
starting to become a reality. These techniques offer the potential of increased detection rates of 
high-risk lesions, the ability to target biopsies and resections, reducing need for biopsy, and 
reducing costs and uncertainty for patients. However, whether they could be useful in clinical 
practice remains to be seen, and is still under investigation. 
The first section of this chapter will introduce some background of essential anatomy and 
histopathology of the gastrointestinal tract to set the stage for the research conducted in this 
thesis. Indications for endoscopy and commonly encountered pathology are then briefly 
presented in the second section. The third section gives a brief general introduction to the 
standard technique of gastrointestinal endoscopy with a description of the equipment 
commonly used in the endoscopy suite. The fourth section of the chapter will introduce relevant 
clinical problems and the most recent advances in the field of endoscopy along with their 
fundamental principles, as well as their potential roles as tools for the endoscopist. The clinical 
and preclinical experience for each of these techniques is also briefly reviewed. Finally, a 
summary of the unmet clinical needs in endoscopy is discussed. 
2.1 Anatomy of the gastrointestinal tract 
The gastrointestinal tract (figure 2-1) extends from the mouth to the anal canal and most of its 
elements are housed in the abdomen (the lower third of the oesophagus, stomach, small and 
large bowel) and suspended by thin folds of elastic tissue (mesenteries) from the dorsal 
(posterior) abdominal wall and partly from the ventral (anterior) abdominal wall. 
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Figure 2-1: The gastrointestinal tract. Source: © 1998-2013 Mayo Foundation for Medical Education 
and Research [3]. 
The abdomen is separated from the thorax by the diaphragm, whose ligaments create openings 
(e.g. hiatus) for a number of structures, including the oesophagus, allowing them to pass 
through these two regions or posteriorly to them. 
The whole GI tract is supplied by three major arteries: the coeliac trunk supplying the foregut, 
the superior mesenteric artery supplying the midgut, and the inferior mesenteric artery for the 
hindgut.  The inferior vena cava is the major systemic vein draining all the abdominal viscera 
through the liver (sinusoids and hepatic veins), and returning all deoxygenated blood into the 
right atrium of the heart.  Innervation of the GI tract is provided from the prevertebral plexus 
containing sympathetic, parasympathetic and visceral sensory fibres. 
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For more comprehensive and detailed information, the reader is referred to references [4] and 
[5,6]. 
Oesophagus 
The oesophagus is a 40-cm-long tube (on average), extending from the pharynx to the abdomen, 
descending through the thorax mainly to the left of the midline and posteriorly to the trachea, 
and piercing the diaphragmatic hiatus at the level of the 10th thoracic vertebra, anteriorly to the 
vertebral column.  Its upper and middle thirds are located in the mediastinum (thorax), whereas 
its lower third (about 3 cm) is normally housed in the abdomen. The abdominal oesophagus 
then becomes continuous with the stomach in a region referred to as the cardia. 
Internally, the gastro-oesophageal junction (GOJ) is demarcated by a net transition from 
squamous oesophageal epithelium to gastric epithelium, called squamocolumnar junction (SCJ), 
but in some cases this transition may not exactly correspond to the same level of the anatomical 
junction, but can be found in the lower third of the oesophagus at a variable height above it. 
Stomach 
The stomach is a J-shaped saccular dilatation of the GI tract between the oesophagus and the 
duodenum. It is usually located in the left hypochondrium and epigastrium, but it may be 
variable in size and shape. 
The stomach is divided into three regions: fundus, body and antrum. It has an anterior and 
posterior wall, and a lesser (right) and a greater (left) curvature. 
The fundus is the most proximal region, typically located above the level of oesophageal orifice.  
The body is the widest region, extending from the fundus to the incisura angularis (angular 
notch) along the lesser curvature. The antrum is the distal end of the stomach, extending from 
the incisura to the pylorus (pyloric sphincter), which separates the stomach from the duodenum 
(small intestine). 
The pyloric sphincter is a thickening of the gastric circular muscle layer and regulates the flow 
of chyme between the stomach and the duodenum. 
Small intestine 
The small intestine is the longest part of the GI tract (6-7 m) and extends from the pylorus to the 
ileocaecal valve.  It consists of the duodenum, the jejunum, and the ileum. 
Duodenum 
It is the first part of the small intestine with a C-shaped structure open to the left, sheltering the 
head of the pancreas on its concave side. The duodenum is about 25 cm long and can be divided 
in four parts.  The superior part, clinically referred as to bulb, is 5 cm long and extends from the 
36 
 
pyloric ring to the neck of the gallbladder. The second part is about 8 cm long and contains both 
the major duodenal papilla, which is the common outlet for bile and pancreatic juice, and the 
minor duodenal papilla, which is the orifice for the accessory pancreatic duct. The third part is 
the longest section (10 cm) and crosses anteriorly the posterior abdominal wall together with 
the inferior vena cava and the aorta, and posteriorly the superior mesenteric artery and vein. 
The fourth part (3 cm) turns upwards and ascends the up to the duodenojejunal flexure, where 
it terminates. 
Only the pylorus and the duodenojejunal flexure are surrounded by a fold of peritoneum, the 
remainder of the duodenum is retroperitoneal and almost immobile. The peritoneal fold 
suspending the duodenojejunal flexure is often referred to as ligament of Treitz. 
Jejunum 
The jejunum represents the proximal 2-sixths of the small intestine, and is mostly located in the 
left quadrants of the abdomen, but parts may extend into the pelvis. Its inner mucosa is 
peculiarly lined by prominent circular folds (plicae circulares), which confer to this section a 
unique endoscopic appearance. 
Ileum 
The ileum comprises the distal three-sixths of the small intestine, and is mostly positioned in 
the right lower quadrant. Compared with the ileum, it has a thinner wall, and no or significantly 
less plicae circulares. The distal ileum (terminal ileum) opens to the large bowel through two 
lips protruding into the lumen of the caecum, and this flap constitutes what is commonly 
referred to as ileocaecal valve. The ileocaecal valve regulates the flux of contents from the small 
intestine to the colon and prevents reflux of colonic material to the ileum. 
Colon 
The large intestine is about 1-1.5 m long and extends from the ileocaecal valve to the anus.  In a 
proximal to distal direction, it consists of the caecum (about 8 cm wide and 8 cm long) and 
appendix (about 8 cm long), ascending colon (15 cm long), transverse colon (about 50 cm long), 
descending colon (about 30 cm long), sigmoid colon (usually 40 cm long but its length and 
position are rather variable), rectum (about 18-20 cm long and inferiorly it widens to form the 
rectal ampulla) and anal canal (about 4 cm long). 
The caecum and the appendix are located in the right iliac fossa, from where the large intestine 
continues upward as ascending colon up to the right flank and the right hypochondrium under 
the liver. Just below the liver, it bends to the left forming the hepatic flexure and crosses nearly 
horizontally the abdomen as the transverse colon to the left hypocondrium under the spleen.  
Just below the spleen, it bends sharply downward forming the splenic flexure, and continues 
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toward the left flank as the descending colon. Into the left groin, the descending colon enters the 
pelvic inlet as the sigmoid colon and continues medially on the posterior wall of the pelvis as the 
rectum. The anal canal is the most terminal part of the large intestine, and lies in the perineum 
between the anal verge and the rectum above. It turns posteriorly through the pelvic floor and 
opens at the anal orifice. 
Compared to the small intestine, the colon has a large internal diameter. The main 
characteristics of the large bowel are: the taeniae coli, which is a longitudinal muscle organised 
into three narrow bands, though these are primarily present in the caecum and colon, and less 
in the rectum; and the haustra coli, which are responsible for its sacculated appearance. 
The main function of the large bowel is the absorption of fluids and salts from the intestinal 
contents in order to form solid faeces. 
From the caecum to the rectum there is a gradual significant decrease in the inner intestinal 
circumference. The sigmoid colon has the smallest diameter (2.5 cm when contracted) and 
therefore the highest intraluminal pressure of any other region of the large bowel.  There is also 
an increase in thickness of the mucosa from the caecum (500 µm) to the rectum (1000 µm). 
Further on, we will investigate whether regional variations in thickness, diameter and perhaps 
changes in epithelial and connective tissue composition may have a role in the marked intra- 
and interpatient variability in autofluorescence and spectral properties of normal colonic tissue. 
2.1.1 Histology of the gastrointestinal tract 
The wall of the GI tract is composed of three layers: an interior mucous membrane, a muscular 
layer and an exterior serous layer (figure 2-2). 
 
Figure 2-2: Schematic cross-section of the gut. The lumen is the inside space of the gut. The abdominal 
wall is external to the gut. The peritoneal cavity is a virtual space between the parietal and the visceral 
peritoneum. 
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The mucous membrane comprises the mucosa (inner) and the submucosa (outer), divided by 
the muscularis mucosae, a layer of smooth muscle. The mucosa is lined with columnar 
epithelium including goblet cells. The invagination of the mucosa creates glandular structures 
(cryptae) and, in the small intestine, finger-like projections (villi). The cells of the mucosa 
primarily produce mucus, digestive enzymes, and hormones. 
The mucosa is therefore a mucous tissue lining various tubular structures consisting of 
epithelium, lamina propria, and a layer of smooth muscle (muscularis mucosae). 
The basement membrane is a thin membrane upon which is posed a single layer of cells. The 
basement membrane is made up of proteins held together by type IV collagen. 
The lamina propria is a thin highly vascular layer of connective tissue under the basement 
membrane lining a layer of epithelium. 
A schematic illustration of the mucosal structure, for example in normal colon, in sagittal and 
transverse section, is shown in figure 2-3. 
 
Figure 2-3: Schematic illustration of colonic mucosal structure in sagittal (a) and transverse (b) 
section, showing the crypts, the basement membrane, and the lamina propria. The crypts consist mainly of 
columnar epithelial cells and goblet cells. Adapted and reproduced with permission from [7]. 
The submucosa is a layer of loose connective tissue beneath the mucous membrane. The 
submucosa consists of loose tissue containing blood vessels and the submucosal nerve plexus.  
The muscular layer consists of an inner circular and an outer longitudinal muscle sub-layers. It 
also contains the myenteric nerve plexus. 
The serous coat (serosa) is composed of loose connective tissue lined by a simple flattened 
squamous epithelium (mesothelium), derived from mesoderm, the middle of the three primary 
germ layers of the embryo, lying between the ectoderm and endoderm. 
(a) (b)
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Regional variations 
The duodenum has large circular folds (valves of Kerckring) projecting into the lumen (figure 
2-4). 
 
Figure 2-4: Endoscopic image of the second portion of the duodenum, showing the typical valves of 
Kerckring. Source of acquisition: Drs Coda & Thillainayagam, Endoscopy Unit, Charing Cross Hospital, 
Imperial College Healthcare NHS Trust. 
Unlike the folds in the stomach, they are permanent, and they do not disappear when the lumen 
is distended. 
In contrast with the haustral folds (haustra coli) of the large bowel, they are smaller and 
interspersed more seamlessly between each other, and involve the whole circumference of the 
bowel. 
Also, the duodenum has the mucus Brunner’s glands, which peculiarly extend up into the 
submucosa. Similar submucosal mucous glands are seen in the oesophagus, although in this 
organ, the ducts draining the mucus to the surface are frequently squamous-lined. Such glands 
and ducts are not present in any other region of the bowel. 
The jejunum and ileum have villi, though those of the jejunum appear generally longer and more 
numerous than those of the ileum. Particularly, in the terminal ileum nodules of aggregated 
lymphatic tissue (Peyer’s patches), can be recognized. Similarly, the mucosa and the submucosa 
of the appendix contain lymphoid follicles. 
Unlike the small intestine, villi are not present in the large intestine. In general, intestinal glands 
extend from the muscularis mucosae and open to the luminal surface and contain numerous 
goblet cells.  Goblet cells are columnar epithelial cells producing and secreting mucin. 
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2.1.2 Pathology of the gastrointestinal tract 
Depending on the nature and characteristic of the injury, a wide variety of disorders can affect 
the GI tract. Herein, only some pathologies of relevance to the endoscopist, and more specifically 
those conditions that have been investigated in this study, are described. Extensive information 
on this subject can be found in references [8] and [9]. 
Early GI cancers 
Early GI cancers are defined as being limited to the mucosa or submucosa but not invading the 
muscularis propria, regardless of the presence of lymph node metastases (except oesophagus). 
The overall incidence of lymph node metastasis in early cancers of the GI tract is extremely low 
(0-5%)[10,11]. This allows for less invasive endoscopic treatments, thereby improving the 
quality of life when compared to surgery [12]. 
Early detection of these cancers is the critical goal for diagnostic endoscopy since it allows 
endoscopic intervention with disease localised without lymph node involvement and greatly 
improves patient survival, particularly as new local endoscopic treatment options are available 
[13,14]. 
The endoscopic classification of these lesions was first established by the Japanese Gastric 
Cancer Association (JCGA) [15]. It was then ratified in 2002 at an international consensus 
meeting in Paris [16] and has now been accepted worldwide (see table 2-1) [17]. The lesions 
are divided into three main groups: protruding, flat (non-protruding and non-excavated), and 
excavated. 
The lesion height is measured in comparison with the height of the closed jaws of the biopsy 
forceps (2.5 mm) above the surrounding mucosa. Lesions protruding > 2.5 mm above the level 
of the closed jaws of the biopsy forceps (i.e. 3 mm) are classified as protruding, whereas those 
protruding below this level (i.e. 2 mm or lower) are classified as flat. Lesion morphology assists 
with evaluating the risk of invasive disease and guides the approach to the type of resection 
required (e.g. endoscopic or surgical) [18].  
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Classification Grade 
Protruding   
 Pedunculated 0-Ip 
 Sessile 0-Is 
Non-protruding and non-excavated   
 Slightly elevated 0-IIa 
 Completely flat 0-IIb 
 Slightly depressed 0-IIc 
 Elevated and depressed types 0-IIc + IIa 
Excavated   
 Ulcer 0-III 
 Excavated and depressed types 0-IIc + III or 0-III + IIc 
Table 2-1: The Paris endoscopic classification of superficial neoplastic lesions in the GI tract. 
In figure 2-5, the diverse endoscopic appearance of early gastric cancer is classified according to 
the Paris endoscopic classification. 
 
Figure 2-5: Endoscopic appearance of early gastric cancer: (a) 0-I, Protruded type; (b) 0-IIa, superficial 
elevated type; (c) 0-IIb, flat type; (d), 0-IIc, superficial depressed type; (e) 0-IIa+IIc, combined type 
(superficial elevation with depression); (f) 0-IIc+III, combined type (superficial depression with ulceration). 
Images provided courtesy of Dr Takuji Gotoda, Endoscopy Unit, National Cancer Center Hospital, Tokyo, 
Japan. 
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Usually, early cancers are detected as 0-I and 0-III types in most of the world, but widespread 
use of newer imaging methods have enabled identification of superficial lesions such as faint 
mucosal irregularity or discoloration, which had been previously overlooked. Over 50% of 
cancers diagnosed in Japan are early cancers while its frequency is only 10% in the West [19]. 
Apart from the diagnostic difficulty of biopsy as a reason for the low incidence of early GI cancer 
in the West, different histological criteria between the West and Japan would be another reason.  
For example, in the context of early gastric cancer, most mucosal cancer of intestinal type in 
Japan is not diagnosed as cancer in the West, but classified as dysplasia (figure 2-6) [13]. 
 
Figure 2-6: Controversies in diagnosing early gastric cancer: (a) a small depressed lesion is noticed on 
the posterior wall of the upper gastric body after contrast chromoscopy with indigo carmine dye solution; (b) 
lesion without invasive finding is noticed on the biopsy, which is classified as dysplasia (Vienna classification 
category 4.1.) by Western pathologists. In contrast, this lesion is classified as well differentiated 
adenocarcinoma (Vienna classification 4.2.) in Japan. (c) After the resection, submucosal invasive 
adenocarcinoma with lymphatic involvement (Vienna classification 5.2.) is found. Reproduced with 
permission from [13]. 
There are large discrepancies in the diagnostic criterion between the Western and Japanese 
pathologist. These differences have caused considerable problems in the interpretation of 
Japanese cancer research by Western clinicians and researchers. 
Carcinoma is defined as invasion into the submucosal layer, muscularis mucosa, or at least 
lamina propria in the West. However, in Japan, cellular atypia and structural atypia is also 
considered as GI neoplasia regardless of invasive findings.  
The Vienna classification (table 2-2) has been introduced in 1998 to develop common 
worldwide terminology for GI epithelial neoplasia and resolve these discrepancies [20,21]. 
The lesions are divided into five categories. Non-invasive neoplasia includes low and high-grade 
dysplasia (LGD and HGD) in which the basement membrane is not infiltrated. Invasive lesions 
include intramucosal neoplasia infiltrating the submucosa.  
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Category Treatment 
1. Negative for neoplasia/dysplasia No treatment 
2. Indefinite for neoplasia/dysplasia Follow-up 
3. Non-invasive low grade neoplasia (low grade adenoma/dysplasia) Follow-up 
4. Non-invasive high grade neoplasia Endoscopic resection, surgery 
4.1 High grade adenoma  
4.2 Non-invasive carcinoma (carcinoma in situ)  
4.3 Suspicion of invasive carcinoma  
5. Invasive neoplasia Surgery (recently ESD) 
5.1 Intramucosal carcinoma  
5.2 Submucosal carcinoma or beyond  
Table 2-2: The Vienna Classification of GI epithelial neoplasia. ESD = endoscopic submucosal 
dissection. 
However, the practical application of this classification has been problematic because the 
judgment of invasion beyond the basement membrane is often difficult to define. Modified 
criteria based on objective molecular analysis, such as DNA aneuploidy, have been proposed 
[22]. 
To quantify the risk of lymph node metastases, mucosal (m) and submucosal (sm) layers have 
each been divided into three sections: m1 (epithelium), m2 (lamina propria), and m3 
(muscularis mucosae) and sm1, sm2, and sm3. In addition, sm1 is subclassified into a, b, and c 
according to the degree of horizontal extension (figure 2-7). 
 
Figure 2-7: Pathological classification of early GI cancers according to depth of invasion: m1, confined 
to the epithelium; m2, invasion to the lamina propria; m3, infiltration of the muscularis mucosa; sm1, up to 
the upper third of the submucosa; sm2, to the mid third; and sm3, to the lower third of the submucosa. 
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It is the depth that mainly determines the necessity of intervention. The depth of invasion is 
measured microscopically from histology sections and the risk of lymph node metastasis is 
known to be related with a defined micrometric cut-off. 
In squamous cell carcinoma (SCC) of the oesophagus, when infiltration is less than 200 μm, the 
risk of nodal metastases is low [23]. For early oesophageal adenocarcinoma and early gastric 
cancer (EGC), a submucosal infiltration micrometric cut-off of 500 μm has been proposed [24]. 
In the colon, the risk of lymph node metastasis is negligible when the tumour invasion is less 
than 1000 μm [25]. 
Endoscopic mucosal resection is now accepted worldwide as a first line treatment modality for 
early cancers of the GI tract [13]. Endoscopic Submucosal Dissection (ESD) is a new and more 
radical treatment for EGICs providing high rates of en bloc resection and low rate of recurrence 
compared with conventional endoscopic mucosal resection (EMR) [26]. This method facilitates 
one piece resection even in patients with large or ulcerative lesions. 
The key steps of the ESD procedure for stomach and colon are shown in figure 2-8, figure 2-9, 
and [27]. 
 
Figure 2-8: (a) early gastric cancer (0-IIa+IIc type, 15 mm) of the fundus, along the lesser curvature just 
below the cardia, after staining with indigo-carmine.  (b) Residual ulcer after ESD.  (c) En bloc excised lesion 
fixed orientated on a board for histopathological assessment.  (d) Well differentiated (G1) intramucosal ADC 
of intestinal type, vertical margins free of tumour (H&E, 20x original magnification). Reproduced with 
permission from [26]. 
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Figure 2-9: (a) laterally spreading tumour (non-granular type, 40 mm) of the sigmoid colon. (b) ESD of 
the submucosal layer by It-knife. (c) Residual mucosal defect immediately after ESD. (d) Well differentiated 
(G1) ADC. The lesion is largely intramucosal, with focal infiltration of the muscularis mucosae (H&E, 10x 
original magnification). Reproduced with permission from [26]. 
Reflux oesophagitis 
The oesophagus is lined by a stratified squamous epithelium, whose function is essentially to 
make it resistant to a variety of irritants, including acids and alkalis. Secretion of mucin and 
bicarbonate by submucosal glands also concurs to protect its mucosal lining.  A high pressure 
area at the distal end, referred to as lower oesophageal sphincter, prevents reflux of gastric 
content into the oesophageal lumen. Conditions that alter these defence mechanisms, can 
predispose to and cause gastro-oesophageal reflux disease (GORD) and reflux oesophagitis. 
Endoscopic features of GORD are erythema, friability, longitudinal erosions and ulceration, 
usually located on the top of the oesophageal folds. 
The Los Angeles classification, the most commonly used endoscopic classification of the reflux 
oesophagitis is illustrated in figure 2-10 [28,29]. 
The term mucosal break is introduced to encompass the old terms erosion and ulceration. 
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Figure 2-10: The Los Angeles classification for reflux oesophagitis. The diagram shows a sagittal section 
through the gastro-oesophageal region (oesophageal mucosa in pink, gastric mucosa in red). The mucosal 
breaks are shown in yellow. SCJ = squamocolumnar junction. Adapted and reproduced with permission from 
[29,30]. 
Hyperaemia, intraepithelial infiltrates of eosinophils and neutrophils, and basal layer 
hyperplasia, are common findings. Complications of reflux oesophagitis include ulceration, 
strictures and Barrett oesophagus. 
Barrett’s oesophagus 
Barrett’s oesophagus (BO) is a condition in which squamous mucosa is replaced by columnar 
epithelium as a result of chronic gastric (and probably duodenal) content reflux. This 
replacement is referred to as intestinal metaplasia, histologically defined as the presence of 
“goblet cells”. 
The conventional endoscopic view, before and after the spray of an absorptive dye (methylene 
blue), followed by optical magnification with a zoom endoscope (110 to 150x, Olympus 
GIFQ160Z), and the histological characteristics of BO are shown in figure 2-11. 
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Figure 2-11: (a) Conventional endoscopic view of BO with concomitant esophagitis. (b) Positive staining 
of Barrett’s epithelium after absorption chromoscopy with methylene blue dye solution. (c) Villous cerebroid 
pits with finger-like projections seen with magnification endoscopy. (d) Histological section of (c) showing 
intestinal metaplasia with adjacent round and elongated glands, and numerous goblet cells. Adapted from 
[31]. 
Barrett’s oesophagus is associated with an increased risk of oesophageal adenocarcinoma, 
particularly when dysplasia arises within its epithelium. To date, dysplasia can be detected only 
histologically. Therefore, when BO is identified, a protocol consisting of 4 quadrant biopsies 
every 1 to 2 cm (figure 2-12) with biopsies of mucosal abnormalities are taken above the level 
of the lower oesophageal sphincter. Although it has never been validated, this protocol is 
currently the standard method for detecting dysplasia in patients with BO. 
 
(a)
(d)
(b)
(c)
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Figure 2-12: The Seattle biopsy protocol for detection of dysplasia in Barrett’s oesophagus. Adapted and 
reproduced with permission from [32]. 
However, since each 2 cm segment has an average mucosal area of 14 cm2, and the total mucosal 
surface obtained by 4 biopsies is no more than 0.5 cm2, it is clear that only a small fraction of the 
Barrett's segment (less than 3.5% of the total surface of a 2-cm-long segment) is sampled, 
therefore dysplasia can easily go undetected [32]. A fortiori, many patients with BO without 
dysplasia (low risk of progression to ADC) clearly undergo unnecessary biopsies. 
Standard videoendoscopy identifies BO and visible mucosal abnormalities (e.g. nodules, 
depressed areas) but cannot distinguish intestinal metaplasia from dysplasia. This underscores 
the need for novel imaging techniques that may help target areas of dysplasia, thus assisting in 
the early diagnosis of dysplasia and cancer and allow for their timely treatment. 
BO can be circumferential or appear in the form of one or multiple tongues or patches or isles of 
red velvet coloured mucosa extending from the gastro-oesophageal junction. Depending on the 
length of the columnar segment involved (< or >3 cm) it is subdivided into short or long BO. 
The endoscopic classification of Barrett’s oesophagus is illustrated in figure 2-13. This 
classification was named the “Prague C & M classification” because it was first presented at an 
open meeting at the Prague September 2004 United European Gastroenterology Week. 
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Figure 2-13: Diagrammatic representation of endoscopic Barrett’s oesophagus showing an area 
classified as C6M14. C = extension of circumferential metaplasia; M = maximal extent of the metaplasia; GOJ = 
gastro-oesophageal junction. Adapted from and reproduced with permission from [33]. 
Goblet cells are essential for the diagnosis of BO. Their distinct mucus vacuoles confer to these 
cells the characteristic appearance of wine goblets. Foveolar mucus cells are insufficient for the 
diagnosis. 
Increased epithelial proliferation, atypical mitoses, and hyperchromatic nuclei, irregular 
distribution of chromatin, high nucleus-cytoplasm ratio can be observed in both low (LGD) and 
high grade dysplasia (HGD). Gland architecture is subverted, showing irregular gland shapes, 
abnormal cellular and nuclear orientation and crowed clusters of cells (e.g. gland-within-gland). 
In HGD, both cytological and morphological changes appear more severe. Intramucosal 
carcinoma is defined by the invasion of neoplastic cells into the lamina propria but still within 
the muscularis mucosae. 
Oesophageal cancers 
Cancers of the oesophagus, despite the recent advances in diagnosis and treatment, remain a 
highly lethal malignancy that increased dramatically in incidence during the last 3 decades, and 
this is particularly true for the adenocarcinoma [34]. 
Two main types of oesophageal cancer exist: adenocarcinoma and squamous cell carcinoma.  
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Adenocarcinoma of the oesophagus 
Adenocarcinoma typically originates within a segment of Barrett’s oesophagus, through 
progression to dysplasia, and is often associated with long-standing GORD. It usually involves 
the lower third of the oesophagus and may extend to the gastric cardia and fundus. 
Initially, it may appear as a small nodule or a flat or raised or depressed dyschromic area in the 
context of intact columnar epithelium. Exophytic masses up to 5 cm can then develop over the 
years, or alternatively infiltrate diffusely the oesophageal wall or assume the appearance of a 
large ulceration. BO is frequently present in and around the tumour. 
Intestinal type morphology is commonly seen, with crowded back-to-back glands producing 
abundant mucin. 
Squamous cell carcinoma of the oesophagus 
Squamous cell carcinomas (SCC) usually affect the middle third of the oesophagus, and originate 
from small areas of squamous dysplasia. Early lesions appear as grey-whitish plaques or 
thickenings. Advanced forms of SCC may appear as polypoid or either infiltrative or ulcerated 
lesions, often causing strictures of the lumen and invading external surrounding organs (e.g. 
trachea, mediastinum, etc.). 
Histologically, nests of malignant cells reproduce the architecture of a squamous epithelium. 
Adenocarcinoma of the stomach 
Gastric adenocarcinoma can be classified in two variants, intestinal and diffuse. Cancers of 
intestinal type tend to present as bulky exophytic masses composed of irregular glands (figure 
2-14), while the diffuse type usually shows an infiltrative tendency, with typical signet-ring cells 
and scant glandular structure. 
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Figure 2-14: Retrograde endoscopic view of a gastric cancer involving the cardia and the gastric fundus. 
In retroflexion, the image is inverted and the endoscope appears at the top of the figures (white arrow in (a)). 
The luminal extension of the neoplastic infiltration is indicated by the green arrows in (a, b) and (c). Long, 
deep ulcerations in the context of the cancer are visible (purple arrows). Source of acquisition: Drs Coda & 
Thillainayagam, Endoscopy Unit, Charing Cross Hospital, Imperial College Healthcare NHS Trust. 
Most gastric cancers arise from the gastric antrum, along the lesser curvature. Neoplastic cells 
in the intestinal type have mucin filled vacuoles, and abundant mucin is present in gland lumina. 
On contrary, diffuse type neoplastic cells tend to infiltrate the mucosa either individually or in 
scattered clusters, do not form glands and have large mucin vacuoles pushing the nuclei to the 
base, giving the appearance of signet ring cells. 
Diffuse type gastric cancer may elicit a strong desmoplastic reaction that thickens and stiffens 
the wall creating leather bottle morphology, referred to as linitis plastica (figure 2-15). 
 
Figure 2-15: Anterograde endoscopic view of a diffuse type gastric cancer infiltrating circumferentially 
the gastric body. The green arrows indicate the motionless thickening and stiffening of the gastric wall 
creating the so called leather bottle appearance, linitis plastica. Source of acquisition: Drs Coda & 
Thillainayagam, Endoscopy Unit, Charing Cross Hospital, Imperial College Healthcare NHS Trust. 
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Inflammatory bowel disease 
Inflammatory bowel disease (IBD) is an idiopathic condition characterised by chronic or 
recurring immune response and inflammation of the GI tract. IBD comprises Crohn’s disease 
(CD) and ulcerative colitis (UC), which can be distinguished on the basis of disease morphology 
and distribution of the regions usually involved. CD can affect any part of the GI tract from the 
mouth to the anal canal, whereas UC usually affects only the colon, and in most cases only the 
rectum is involved, extending up to the splenic flexure at the most. In addition, the inflammation 
in CD may extend into the full thickness of the wall of the segment affected, while in UC it only 
involves the mucosa and the submucosa. 
Dysplasia and malignant transformation represent the most important complication of these 
diseases and the risk begins to rise at 8-10 years after onset. The risk of cancer is influenced by 
the duration and extent of disease and is also linked to the endoscopic appearance at 
colonoscopy [35-37]. At present, annual endoscopic surveillance is recommended after 8-10 
years of disease. 
In patients with UC, if no lesions are observed, four biopsy specimens are taken randomly at 
every 10 cm between the rectum and the caecum for a total of 40-50 biopsies per colonoscopy 
[38]. 
However, even this massive sampling examines less than 1% of the total colonic mucosa 
surface. Thus, there is a strong interest in developing novel techniques that may be able to guide 
targeted biopsies and assist in discriminating between normal and dysplastic areas. 
Collagenous colitis and lymphocytic colitis are two other types of bowel inflammation that affect 
the colon. Collagenous colitis and lymphocytic colitis are also collectively called microscopic 
colitis and are not related to CD or UC. In microscopic colitis there is no sign of inflammation on 
the surface of the colon visible during the endoscopic examination, therefore a biopsy is 
necessary to make a diagnosis. Microscopic colitis does not increase the risk of colon cancer. 
Crohn’s disease 
The most common regions of the GI tract affected by Crohn’s disease are the terminal ileum 
(40% of cases), the ileocaecal valve and the caecum. The presence of aphthous ulcers, which 
may progress and become serpiginous, and skip lesions (clear-cut delineated areas of disease) is 
characteristic of CD. Strictures can occur as a result of transmural inflammation. Linear ulcers 
may develop and extend deeply to become fistulae. 
Crypts are damaged by intense infiltration of neutrophils (crypt abscesses). Crypt architecture 
appears distorted as a consequence of relapsing destruction and regeneration attempts to 
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restore the damaged glands. Changes such as pseudo-pyloric metaplasia, Paneth cell metaplasia, 
and non-caseating granulomas are frequently observed in CD. 
Ulcerative colitis 
Ulcerative colitis almost always begins in the rectum and extends proximally into the colon in a 
contiguous manner (figure 2-16). Based on the amount of colorectal involved, three types of 
disease distribution are recognized; (1) ulcerative proctitis; (2) left-sided colitis; (3) pancolitis. 
 
Figure 2-16: Endoscopic image of ulcerative colitis. Source of acquisition: Drs Coda & Thillainayagam, 
Endoscopy Unit, Charing Cross Hospital, Imperial College Healthcare NHS Trust. 
The affected mucosa appears erythematous, friable, and granular, with broad-based superficial 
ulcers that can merge into larger ulcerations. Regenerating mucosa can protrude into the lumen 
forming mucosal elevations such as pseudopolyps or mucosal bridges. 
As with CD, neutrophil infiltration, crypt abscesses, architectural distortion, and epithelial 
metaplasia are frequently observed in UC, though the inflammation generally tends to be more 
uniform, diffuse and limited to the mucosa. 
Polyps 
The entire GI tract can be affected by polyps but they are most common in the colon. Polyps are 
overgrown areas of mucosal epithelium that carry a risk of becoming malignant. 
Polyps may take various sizes and shapes (sessile, pedunculated, and flat) and are normally 
classified into 2 groups: neoplastic (consisting of adenomas with low grade or high grade 
dysplasia, and carcinomas) and non-neoplastic (hyperplastic, inflammatory pseudopolyps, 
hamartomas). Neoplastic polyps are of greatest clinical significance because of their established 
role in the stepwise process that results in colorectal cancer (adenoma-carcinoma sequence) 
[39]. However, macroscopic discrimination between neoplastic and non-neoplastic polyps 
during endoscopy is extremely difficult; thus, they are all removed when detected. 
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It is ascertained that the majority of colorectal carcinomas pass through a premalignant 
adenoma phase, termed adenoma-carcinoma sequence (figure 2-17(a)) [39,40]. 
 
Figure 2-17: (a) the adenoma-carcinoma sequence in colorectal cancer. (b) The de novo colorectal cancer 
pathway. Adapted and reproduced with permission from [41,42]. 
Adenomas originate as diminutive polyps; as they grow and increase in size they can then 
assume either the form of a sessile or pedunculated polyp and a tubular or villous microscopic 
architecture. Adenomatous change is referred to as LGD. Low-grade dysplastic adenomas that 
progress toward cancer develop high-grade dysplasia. 
However, only two thirds of colorectal cancer seems to develop through the stage of adenoma, 
the other third may develop de novo from normal epithelium (figure 2-17(b))[43,44]. The 
different clinico-pathological features of flat polyps, compared to sessile and pedunculated 
polyps, may explain the proportion of de novo carcinomas. 
Flat polyps are prevalently located in the right colon and their prevalence increases with age.  
Early recognition of these polyps is important due to the greater incidence of high grade 
dysplasia and carcinoma compared to sessile and pedunculated polyps (8-61% in Japan, 12-4% 
in Western Countries) [45]. 
Flat and depressed lesions larger than 10 mm in diameter, are almost twice as likely as 
protruded lesions, of similar size, to contains areas of severe dysplasia or foci of invasive 
carcinoma [46]. Similarly, the incidence of flat type early cancer increases with age, has a higher 
frequency in right colon, has smaller size than polypoid type early cancer and has lower 
frequency of adenomatous component [45]. 
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Inflammatory polyps 
Inflammatory polyps may form as a result of recurrent abrasion and ulceration followed by 
intervening healing periods. 
Hyperplasia of the epithelium and of the lamina propria, mixed inflammatory infiltrates, and 
erosion are the most distinctive histological features. 
Hamartomatous polyps 
Hamartomatous polyps usually occur in the context of the following diseases: Juvenile 
polyposis; Peutz-Jeghers syndrome; Cowden and Ruvalcaba-Ryley syndromes; and Cronkhite-
Canada syndrome. 
Juvenile polyps are typically red and pedunculated, with cystic dilatation of glands. 
The hamartomatous polyps of Peutz-Jeghers syndrome are large and pedunculated with a 
lobulated structure. Arborizing network of connective tissue is a histological hallmark of these 
polyps. 
Hyperplastic polyps 
Hyperplastic polyps are common epithelial protrusions found most frequently in the rectum 
and left colon, and are typically small in diameter (about 5 mm). 
They are essentially made of piled up goblet cells creating a serrated surface architecture- when 
seen in cross-section- that is characteristic of these polyps. 
It is appreciated that these lesions have no malignant potential, but it is important to distinguish 
them from sessile serrated adenomas, which conversely can carry a risk of becoming malignant. 
Adenomatous polyps 
Colonic adenomas are characterised by the presence of epithelial dysplasia. These polyps are 
precursors to colorectal cancer. They range from about 3 mm to 15 cm and can be sessile, 
pedunculated, and flat (figure 2-18).  
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Figure 2-18: Endoscopic images of a sessile (a), pedunculated (b) and a flat (c) polyp. The true extension 
of the flat polyp (c) is revealed by chromoscopy with indigo carmine dye solution. Source of acquisition: Drs 
Coda & Thillainayagam, Endoscopy Unit, Charing Cross Hospital, Imperial College Healthcare NHS Trust. 
The histological hallmark of dysplasia is the presence of hyperchromatic, elongated and 
stratified nuclei. These changes can be best seen at the head of the polyps (intraluminal 
protruded portion). Notably, a reduction of the number of goblet cells is observed.  
Pedunculated polyps have a fibromuscular stalk, which contain blood vessels originating from 
the submucosal layer, and are usually free from dysplastic epithelium. 
Based on their architecture, adenomatous polyps can be classified as tubular, tubulovillous, or 
villous. In general, small, rounded or tubular glands are seen in tubular adenomas, while villous 
adenomas are covered by soft villi. Tubulovillous adenomas combine both tubular and villous 
features. 
Sessile serrated adenomas do not display the typical cytological features of dysplasia that are 
commonly seen in other adenomas. Serrated architecture often overlaps histologically with that 
seen in hyperplastic polyps. Therefore, diagnosis of these polyps can be challenging. Differential 
diagnosis is often based on clinicopathological correlation, as these polyps are most commonly 
found in the right colon, and the presence of serrated architecture seen throughout the full 
length of the glands, including the crypt base. In contrast, hyperplastic polyps are more common 
in the rectum, left colon, and their serrated appearance is typically confined to the surface of the 
glands. 
Intramucosal carcinoma is defined by the breach of the basement membrane (towards the 
lamina propria and the muscularis mucosae) by dysplastic cells. Invasion beyond the muscularis 
mucosa, and into the submucosa, including the submucosal stalk of a pedunculated polyp, 
constitutes invasive carcinoma. 
Adenocarcinoma of the colon 
Colorectal cancer develops within pre-existing foci of adenomatous tissue. This occurs usually, 
but not always, in a polypoid lesion. 
(a) (b) (c)
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At least two genetic pathways have been identified involving both a stepwise accumulation of 
multiple mutations (genetic abnormalities) and epigenetic events, such as gene silencing, which 
enhance progression once mutations have occurred. These are: 1) the classic adenoma-
carcinoma sequence (figure 2-17a), whose pathognomonic molecular defects involve the 
adenomatous polyposis coli gene (APC); 2) the microsatellite instability, which is associated 
with defects in DNA mismatch repair systems. 
Right-sided colon cancers often present as polypoid, exophytic masses and rarely cause 
obstruction due to the large diameter of these regions of colon. In contrast, left-sided colon 
cancers grow circumferentially as annular lesions causing narrowing of the lumen and 
obstruction. 
Histologically, colorectal carcinoma is composed of irregularly infiltrating malignant glands.  
The cells are columnar and have elongated (“cigar-shaped”), tall nuclei. Cells have irregular size 
and shape, increased nuclear-to-cytoplasmic ratio, and high mitotic index, indicating rapid 
growth of the cancer. 
The invasive tumour is usually surrounded by a desmoplastic response and focal necrosis is 
common. 
Based on the degree of differentiation (from well to poorly differentiated), gland formation can 
be jeopardised. Missing crypts, total loss of goblet cells, and indistinguishable intercellular space 
are common findings. 
The endoscopic views of advanced colon carcinomas are shown in figure 2-19.  
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Figure 2-19: Endoscopic views of a cancer of the transverse colon (a, b), and the sigmoid colon (c, d). In 
(a) and (b), the tumour involves almost ¾ of the luminal circumference from the distal margin, whereas in 
(c) and (d), the tumour involves approximately the entire circumference of the bowel. In (d), the transition 
zone between normal and neoplastic epithelium is clearly shown by inspection with Narrow Band Imaging 
(NBI). Source of acquisition: Drs Coda & Thillainayagam, Endoscopy Unit, Charing Cross Hospital, Imperial 
College Healthcare NHS Trust.  
(a) (b)
(c) (d)
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2.2 General indications for endoscopy 
Depending on the patient’s symptoms, objective signs and clinical history, the indications for 
endoscopy can be classified as indications for upper and lower GI endoscopy, and each group is 
further divided in diagnostic and therapeutic according to the aim of the procedure [38,47]. 
2.2.1 Upper GI endoscopy 
Table 2-3 shows the most widely accepted indications worldwide for upper GI endoscopy. 
Diagnostic Therapeutic 
Dyspepsia Bleeding 
Dysphagia Feeding tube placement 
Weight loss & Malabsorption Dilatation of strictures 
Diarrhoea Stenting of strictures 
Anaemia Tumour debulking 
Nausea & vomiting  
Screening  
Table 2-3: General indications for upper GI endoscopy. 
Patient preparation & sedation 
Preparation consists in giving nil by mouth for 6 hours before the procedure. Following consent, 
the patients are accompanied to the endoscopy room and positioned on a bed, on their left 
lateral position. 
Prior to gastroscopy, a local anaesthetic spray (xylocaine) is usually administered with or 
without a light sedative - typically 2-2.5 mg midazolam IV. Patients are then asked to insert a 
mouth guard when they feel ready for the procedure to commence. 
Common pathology 
Pathologies frequently encountered during upper GI endoscopy are: 
 Hiatus hernia 
 Oesophagitis 
 Vascular lesion 
 Ulcer 
 Cancer 
All of them have been described in more detail in section 2.1.2.  
60 
 
2.2.2 Lower GI endoscopy 
Specific indications for colonoscopy are summarised in table 2-4. Indications for lower GI 
endoscopy can be further classified according to the risk that the procedure may carry 
(bleeding, perforation), and the potential diagnostic yield provided. For example, bleeding 
consistently has the highest yield for cancer and large polyps, while surveillance for ulcerative 
colitis and after polypectomy typically provides the lowest cancer yields [48]. 
High-risk indications include: 
 Polypectomy of large polyps 
 Stricture dilation 
 Stent placement 
 Acute colonic pseudo-obstruction 
Pre-existing conditions associated with high-risk colonoscopy are: 
 Sigmoid volvulus 
 Caecal volvulus 
 Prior radiation therapy 
 Chronic steroid use 
 Colonic strictures 
 Severe diverticular disease 
 Severe colitis 
 Pelvic adhesions 
 Severe collagenous colitis  
61 
 
Diagnostic Therapeutic 
Bleeding Bleeding 
FOBT-positive stools Polypectomy 
Anaemia (malabsorption syndrome excluded) Dilatation of strictures 
Change in bowel habit Stenting of strictures 
Abdominal pain and constipation Tumour debulking 
Chronic diarrhoea  
Abnormal imaging (x-ray, US, CT)  
Surveillance (polyps, IBD, cancer resection)  
IBD assessment  
Screening  
Table 2-4: General indications for lower GI endoscopy. FOBT = Faecal occult blood test; 
US = ultrasound; CT = computed tomography; IBD = inflammatory bowel disease. 
Patient preparation & sedation 
Preparation consists in a low residue diet 3-5 days before the procedure and the administration 
of stimulants and bowel cleansers typically 12-24 hours before the procedure. Following 
consent, the patients are accompanied to the endoscopy room and positioned on a bed, on their 
left lateral position. A combination of pain killers and sedatives is generally given intravenously, 
along with antispasmodics if required. 
Common Pathology 
Common pathologies detected at colonoscopy include: 
 Haemorrhoids 
 Polyps 
 Colitis 
 Cancer 
 Diverticula 
 Ulcer 
 Vascular lesions 
Most of the above listed diseases have been described in more detail in section 2.1.2.  
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2.3 Introduction to endoscopy 
Diagnosis of GI illnesses is usually made on the basis of the patient’s clinical history and 
objective physical examination. In addition, visual inspection and assessment of the inner 
surfaces of the organ of concern is often necessary, and this procedure, commonly referred to as 
endoscopy, is typically performed by inserting a flexible plastic tube (endoscope) through which 
light can be delivered at distance (figure 2-20). 
 
Figure 2-20: Image of a conventional video-endoscope (Olympus GIF Q160) with biopsy forceps inserted 
though the endoscope working channel. Adapted from [49]. 
For the assessment of the upper GI tract (i.e. oesophagus, stomach, duodenum), the endoscope 
is swallowed by the patient typically after topical anaesthesia of the pharynx with or without 
light sedation. Assessment of the lower GI tract (colon and terminal ileum) is performed 
through the anus. In essence, there are three main components of the GI tract that can be 
assessed through an endoscopic investigation: the lumen; the wall and lesions intrinsic to the 
bowel; and masses external to the bowel, which may compress ab extrinseco and erode into the 
lumen. In many cases, a biopsy, followed by histopathological assessment of the tissue removed, 
is often required for confirmation. To this end, various devices can be inserted through the 
endoscope to take biopsy samples (figure 2-20) or perform minimally invasive endoluminal 
surgery (e.g. polypectomy, endoscopic mucosal resection, etc.). 
This section briefly describes some basic concepts and terminology in GI endoscopy, along with 
an introduction to both flexible fibre-optic endoscopes and modern video-endoscopy systems 
employed for diagnosis and therapy. More comprehensive information can be found in 
references [50-52].  
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2.3.1 Technical aspects 
A number of considerations are necessary to give a full panorama of what is endoscopy and how 
it is performed safely and effectively. 
Appropriately trained endoscopists and assistants, a purpose-built endoscopy suite (figure 
2-21), state of art equipment and facilities, including a dedicated area for endoscope 
disinfection, and recovery bays, are clearly indispensable. It is essential to have mobile 
equipment on trolleys that can be transferred to the bedside at all times. Adequate resources 
and storage for the multiple endoscopic procedures are also essential. It is critical that all 
electric devices such as electrocautery units are checked periodically. This also includes devices 
employed for research only. 
 
Figure 2-21: The endoscopy room 1 at Charing Cross Hospital, Imperial College Healthcare NHS Trust. 
Fibre-optic endoscopes 
The main part of a flexible fibre-optic endoscope (figure 2-22) is the fibre-bundle, which 
transmits the image through thousands of ultrathin (6-12 µm) glass fibres. 
64 
 
 
Figure 2-22: Image of a fibre-optic endoscope (Olympus) with biopsy forceps inserted though the 
endoscope working channel. The inset shows the dead space between the fibres seen through the eyepiece. 
Adapted from [53]. 
Each fibre has an inner core of glass surrounded by an outer layer typically made of a lower 
refractive index glass. Light enters and propagates along each individual fibre undergoing total 
internal reflection. 
The fibres are arranged coherently into a bundle, allowing an image to be transmitted with the 
number of image pixels being defined by the number of fibres within the bundle. The dead space 
between the fibres is responsible for the fine mesh visible through the eyepiece (inset in figure 
2-22). 
Excessive bending or torqueing may break the individual fibres, and a broken fibre usually 
appears as a black spot in the visualised image. An eye-piece typically magnifies the image at the 
endoscopist’s end of the bundle by a factor of 15 to 30x. 
Other components include the objective lens system, which focuses objects at the distal tip onto 
the bundle; the light source; a nozzle for air insufflation; a nozzle for water flushing to clean the 
objective lens; and a suction channel, which removes gas and fluids and allows passage of a 
variety of accessories through the endoscope into the intestinal lumen (figure 2-23). 
End connected to a light source
End inserted through the GI tract
Biopsy forceps inserted through
the working channel
Handle
Eyepiece
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Figure 2-23: Cross section of a typical fibre-optic gastrointestinal endoscope. Reproduced with 
permission from [54]. 
The handle has valves for suction, air insufflation and suction, and control knobs (up-down and 
right-left) to orientate the tip of the endoscope in the four cardinal directions. A small mark at 
12 o’clock in the field of view facilitates orientation for photography and indicates the “up” 
deflection of the tip. 
Conventional fibre-optic endoscopes have a field of view of 110-120 degrees and a depth of 
focus of 3 to 100 mm away from the tip. 
Video-endoscopes 
Electronic video-endoscopes are now used worldwide. The image is generated by a charge-
couple device (CCD) located at the distal end of the endoscope. A CCD is essentially an array of 
hundred thousand individual photo cells (pixels) receiving photons reflected from the 
illuminated tissue, and producing electrons in response according to the amount of light 
collected. Modern high resolution endoscopes are able to discriminate mucosal details up to 10 
µm in diameter, which is over 10 times higher than the resolution capability of the average 
naked human eye. 
Figure 2-24 illustrates a schematic diagram of the distal end of a typical video-endoscope. 
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Figure 2-24: Schematic diagram of the distal end of a typical video-endoscope. In the top diagram, the 
illumination light guides, the air/water nozzle for lens cleaning, the objective lens, and the suction/working 
channels are visible.  In the bottom diagram, a cross-section of the tip of the endoscope is given to indicate 
the location of the CCD. 
As with fibre-optic endoscopes, video-endoscopes are equipped with controls for air, water, 
suction to remove air or liquids and to feed down the endoscope a variety of accessories, and 
wheels for up-down and right-left bending of the distal tip (figure 2-25). 
 
Figure 2-25: Cross-sectional view of a conventional video-endoscope (Olympus LUCERA 260 Series GI 
endoscope) showing the internal channels for suction/operation (red), air insufflation (green), and lens 
cleaning/irrigation (blue). Adapted from [55]. 
Light guideAir/water nozzle
Objective lens Suction/working channel outlet
Light guide
Light guide
Objective lensCCD
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The accessory channel of a standard video-endoscope has a diameter of 2.8 mm. Therapeutic 
endoscopes have a larger channel (6 mm) for removal of blood clots and debris. On the handle 
control, buttons have been designed to switch between white light imaging and other auxiliary 
imaging functions (e.g. NBI, AFI, i-Scan, etc.), activate video-recording, freezing the image and 
taking pictures. 
Inherent advantages of video-endoscopes are the distance of the control unit from the 
endoscopist’s face, and the possibility for everyone in the endoscopy suite to watch the monitor 
and take an active part in the procedure, therefore allowing more accurate assistance. 
Image documentation and storage for subsequent analysis and interpretation, follow-up, 
teaching and research, are also of great value. 
Video-endoscopes are also typically more robust and less sensitive to bending and torqueing 
than fibre-optic bundles. 
Accessories 
The endoscopic examination is performed under direct vision, and a variety of accessories can 
be fed through the working channel of the endoscope to increase the information and accuracy 
of the procedures beyond the visual appearance and the subjective interpretation of the 
operator. These includes biopsy forceps, cytology brushes, needles for injection, snares and 
knifes for cold or diathermic therapy, ultrasound probes, and pH and impedance probes. 
Biopsy forceps are the most commonly used accessory in endoscopy. They vary in diameter (2.3 
to 7 mm) and are for single use only. After obtaining the specimen, the tissue is removed from 
the cup and put in a pre-filled formalin pot for histological assessment.  
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2.4 Advanced imaging and measurement of the gastrointestinal tract: 
novel techniques and future developments 
Traditionally, endoscopy has depended upon using white light to evaluate the mucosal surface 
of the GI tract. It is only recently that this frontier was breached with the advent of novel 
imaging technologies. One such example is autofluorescence imaging, which is based on the 
principle that excitation of tissue with specific wavelengths (e.g. in the blue) can lead to 
emission at longer wavelengths. The emitted light can report on subtle changes in the 
concentration of specific chemicals in tissue that have the ability to fluoresce when excited.  
In recent years, a range of innovative techniques have been developed and adapted for clinical 
endoscopy with the aim of providing a “red flag” technique, and perhaps ultimately revealing 
lesions that are still invisible under conventional white light endoscopy.  Some of these methods 
enhance and optimize the inherent contrast available in fresh tissue, and offer the possibility of 
assessing both tissue structure and function in real-time. 
Optical biopsy techniques, which interrogate the mucosal surface of the GI tract with light 
without the need to physically remove the tissue, are highly desirable as they could facilitate 
clinical decision making in ambiguous situations. This would bring more accurate and reliable 
information directly at the point of service, circumventing the cost and time required for 
histology, and improving the overall quality of care for patients. In theory, these novel 
techniques offer the yearned possibility of increased detection rates of high-risk lesions, the 
ability to target biopsies and resections, reducing need for biopsy, and reducing costs and 
uncertainty for both patients and clinicians. 
Whether these techniques could be useful in clinical practice is still under investigation.  Further 
validation studies are urgently awaited, and several groups worldwide are currently working 
toward this milestone. 
Commercially available techniques include high-definition endoscopy (HDE) [56-58], narrow 
band imaging (NBI) [59], magnifying chromoendoscopy (MCE) [60], autofluorescence imaging 
(AFI) [61] and confocal laser endomicroscopy (CLE), whether by integrated technology or 
through-the-scope probe-based confocal endomicroscopy (pCLE) [62,63]. Amongst these 
techniques, endoscopic confocal microscopy has gained prominence since 2004, when the first 
in vivo study appeared on the clinical scene [62].  Probe-based confocal laser endomicroscopy 
(pCLE), an evolution and miniaturization of confocal laser endomicroscopy (CLE), was 
subsequently launched in 2007 [63,64] for clinical applications in gastroenterology, and highly 
promising results have been recently reported since then.  Many other potential applications 
are yet to be validated and research to make CLE label-free is currently in progress. 
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However, to-date, none of these techniques have become widespread in clinical practice or been 
able to demonstrate sufficiently specific contrast for easy and rapid detection of dysplasia.  As 
such, there is still a need to develop diagnostic endoscopic imaging technologies to interrogate 
tissue and identify lesions that cannot be detected using existing techniques. 
The advent of biophotonics in endoscopy has opened new horizons and created important new 
opportunities for enhanced disease identification and histochemical characterisation.  One such 
example is fluorescence lifetime imaging microscopy, often referred to as FLIM of 
autofluorescence, which offers the potential to improve the overall diagnostic accuracy by 
proving label-free quantitative contrast [65-68]. 
A number of other translational label-free optical techniques are currently being investigated 
owing to their potential to acquire non-invasive biochemical information and to image with 
subcellular resolution beyond what is possible with currently available techniques but the 
published experience is limited. 
Optical coherence tomography (OCT) allows imaging at greater depths within tissue compared 
to CLE but does not normally supply functional information.  Raman spectroscopy and coherent 
anti-Stokes Raman scattering (CARS) microscopy can be used to obtain highly detailed 
spectroscopic information but usually require long data acquisition times and could not be used 
for wide-field imaging [69]. 
Point spectroscopy using probes inserted through the working channel of conventional 
endoscopes has been able to differentiate non-neoplastic from neoplastic tissues and to probe 
the biochemical environment of diseased tissue [70]. The altered autofluorescence spectra 
reflect changes in the molecular composition and biochemical environment of diseased tissue. 
Some examples of studies in GI disease using diffuse reflectance spectroscopy (DRS), which 
detects changes in the physical properties of cells, include in vivo detection of dysplasia in colon 
polyps [71] and Barrett’s oesophagus [70,72], and, recently, near-infrared diffuse reflectance 
imaging has also been applied to ex vivo surgical specimens of colon cancer [73]. 
An alternative to intrinsic optical signals is the use of exogenous labels such as labelled 
monoclonal antibodies against the carcinoembryonic antigen (CEA), or the epidermal growth 
factor receptor (EGFR), or photosensitizers administered topically. These markers can then be 
imaged using a range of instruments such as confocal endomicroscopy or prototype 
fluorescence endoscopes [74-76]. These techniques are generally referred as to molecular 
imaging. However, most of these diagnostic applications are still in early stage development. 
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The following sections review the fundamental principles of the most recent advanced 
techniques in endoscopy, with a particular emphasis on autofluorescence imaging and 
spectroscopy, and confocal laser endomicroscopy. 
2.4.1 Magnification and high definition endoscopy 
As in modern television technology, high definition videoendoscopes utilize CCDs with over a 
million pixels compared to older CCDs with an average of 300,000. 
Magnifying endoscopes (zoom endoscopes) have a lens system built into the distal tip of the 
instrument. This zoom can be used to magnify areas of GI mucosa from x6 to x150. The main 
difficulty when using this endoscope is to keep the instrument still, and maintain the interface 
between tissue and tip of the instrument constant for accurate focusing. Particularly in upper GI 
endoscopy, breathing and peristalsis require continuous adjustments. 
Magnification is often combined with the use of vital dyes (chromoscopy) to enhance the 
contrast in the surface (figure 2-26). 
 
Figure 2-26: (a) Conventional endoscopic view of Barrett’s oesophagus with concomitant oesophagitis.  
(b) Positive staining of Barrett’s epithelium after absorption chromoscopy with methylene blue dye solution 
(1%, 10 ml). (c) Villous cerebroid pits with finger-like projections seen with magnification endoscopy 
(pattern 5 according to Endo’s classification [77]). (d) Histological section of (c) showing intestinal 
metaplasia with glands of different size and shape, and numerous goblet cells. Adapted from [31]. 
(a)
(d)
(b)
(c)
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Clinical experience 
Upper GI tract 
Lugol’s vital staining is the most commonly used method to enhance the detection of 
oesophageal squamous dysplasia and early squamous cell carcinoma in high risk populations, 
and variable sensitivity (91%-100%) and specificity (40% to 95%) have been reported [78-80]. 
In Barrett’s oesophagus, methylene blue is undoubtedly the preferred dye to enhance the 
detection of dysplasia and early cancer, although its value is still controversial due to the 
reported wide range of sensitivities (32%-98%) and specificities (23%-100%)[81], high level of 
interobserver variability [82], and inconsistent rates of increased detection [83-87]. 
Using magnifying endoscopy and methylene blue, Endo et al. proposed a classification of five 
oesophageal pit patterns to distinguish metaplastic epithelium from gastric phenotypes. Based 
on correlation with histology and mucin phenotypes, types 4 and 5 were found to be highly 
related to the presence of intestinal metaplasia [77]. 
The clinical experience with other staining methods in Barrett’s oesophagus remains limited 
and their role has not yet been established. Among others, use of indigo carmine in combination 
with enhanced magnification endoscopy has been found useful in distinguishing non-dysplastic 
from dysplastic pit patterns [88]. 
Four different mucosal pit patterns were identified using magnifying endoscopy with acetic acid 
in patients with short-segment Barrett's oesophagus without dysplasia. In this study, types 3 
and 4 were shown to contain intestinal metaplasia in respectively 87% and 100% of biopsy 
specimens [89]. 
In my personal experience in the upper GI tract, magnification with both methylene blue or 
acetic acid coloration of the mucosal surface in Barrett’s oesophagus showed a very high 
correlation with histology in detecting specialized intestinal metaplasia [31]. 
Methylene blue staining with magnifying endoscopy has also been applied to detect gastric 
intestinal metaplasia and dysplasia with 84% and 83% accuracy, respectively. In this study, 
specific mucosal patterns were identified and classified in three groups: non-metaplastic, 
non-dysplastic mucosa; metaplastic mucosa; and dysplastic mucosa [90]. However, in some 
cases it is practically difficult to achieve reliable and clear pattern identification (and inter-
observer agreement) due to uneven spreading of the dye and heterogeneous staining of the 
gastric mucosa.  
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Lower GI tract 
By using magnifying endoscopes and indigo-carmine dye spraying, Kudo et al. [60] have 
proposed a classification of five different polyp pit patterns associated with a percentage of 
correlation with the histology. This classification was meant to predict an increasing risk of 
neoplastic changes and assist clinicians in their therapeutic strategy planning. Kato et al. [91], in 
one of the largest studies comparing these pit patterns with histology (3438 lesions) found an 
accuracy of 75% for non-neoplastic lesions, 94% for adenomas and 85% for carcinomas. 
Magnifying endoscopy is gaining more importance as some of the colon cancers may not 
develop via the classical sequence adenoma-cancer but have only the transient phase of a small 
flat adenoma (de novo sequence)[44]. 
In a multicentre trial with 1000 colonoscopies, the number of adenomas detected was almost 
40% higher with the combination of magnification and chromoendoscopy compared with 
standard colonoscopy [92]. 
In contrast, in another large study including 203 patients, high resolution endoscopy yielded a 
higher adenoma detection rate, and a higher number of flat adenomas <5 mm, than pan-colonic 
chromoendoscopy with indigo carmine [93]. 
High definition endoscopy combined with dye staining is expected to become the standard of 
care for selected patients who need surveillance (e.g. colorectal cancer, ulcerative colitis, 
Barrett’s oesophagus). However, many aspects of this technique still need to be standardized 
e.g. the amount of dye to spray, the use of a spraying catheter, the power to be applied when 
spraying which in turn determines the more or less homogeneous coloration of the target area.  
Nonetheless, although the effectiveness of chromoendoscopy has been shown [94,95], staining 
of the entire colon remains a time-consuming procedure. 
2.4.2 Virtual chromoendoscopy 
Narrow Band Imaging (NBI) 
NBI (Olympus Corporation, Japan) is a digital filter technique that improves the visibility of 
capillaries, veins and other subtle tissue structures, by optimising the absorbance and scattering 
of light without the use of contrast or absorptive dyes. Example images of NBI in comparison 
with conventional white light endoscopy (WLE) are shown in figure 2-27. 
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Figure 2-27: Example images of areas of suspected early cancers of the gastric antrum (a, b) and cardia 
(c, d) imaged using standard WLE (a, c) and NBI (b, d) to demonstrate the contrast enhancement provided by 
NBI. Images provided courtesy of Professor Paolo Trentino (University of Rome “La Sapienza”, Italy). 
This system adapts the conventional additive RGB (red, green and blue) colour model of a 
conventional electronic endoscope with an ordinary light source and through the application of 
narrow band filters to enhance the tissue microvascular architecture (figure 2-28). 
 
(a)
(d)
(b)
(c)
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Figure 2-28: Schematic diagram showing the difference between a standard RGB filter (a) and the NBI 
filter (b). Compared to the full range of white light illumination, the filtered light penetrates the tissue less, 
highlighting the superficial details of the mucosa. Additionally, the filtered centered wavelengths fall within 
haemoglobin absorption bands (inset on right of (b)[71]), and this leads to a higher contrast for vascular 
structures. 
NBI uses two bands of light, at 415 nm (blue) and at 540 nm (green). Narrow band blue light 
preferably displays superficial capillary networks, while green light selectively displays deeper 
subepithelial vessels, and when combined, they offer an extremely high contrast image of the 
tissue surface. Commercial NBI systems apply image processing so as to display capillaries on 
the surface in brown and veins in the subsurface in cyan. 
NBI is based upon the phenomenon that incident light with longer wavelength undergoes less 
scattering and thus penetrates further into the tissue. Blue light penetrates only superficially, 
whereas red light penetrates into deeper layers. The choice of the two bands of light at 415 nm 
and 540 nm is determined by the peaks of absorption of haemoglobin (maxima at 415, 542 and 
577 nm for oxyhaemoglobin, and at 430 nm and 555 nm for deoxyhaemoglobin [71] (see inset 
on right of figure 2-28(b)), thus the centered wavelengths resulting from the narrowband 
filtering lead to a higher contrast for vascular structures. 
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The first prototype of NBI-system was developed by Gono et al. in Japan [59,96]. White light 
from a Xenon lamp is conveyed through a rotary RGB filter that separates the white light into 
the colours red, green, and blue, which are used to sequentially illuminate the mucosa via the 
illumination channel of the endoscope (figure 2-28). The red, green, and blue reflected light is 
detected sequentially by a monochromatic charged coupled device (CCD) placed at the tip of the 
endoscope, and the three images are integrated into a single colour image by the video 
processor. In addition to the conventional RGB filters for white light endoscopy, the narrow 
band imaging system has filters of which the band-pass ranges have been narrowed and the 
relative contribution of blue light has been increased. 
Compared with chromoendoscopy, NBI offers the advantage of providing contrast without the 
use of dyes but the general endoscopists’ confidence with this system is still under debate. One 
aspect of NBI is that images are less bright than those of WLE; therefore it is often difficult to 
observe large areas from a distant view as the image quality significantly degrades with 
distance. This makes it more suited to detailed mucosal inspection rather than screening. 
Clinical experience 
Various studies have reported on the usefulness of NBI for enhanced detection of dysplasia and 
neoplasia both in the upper and in the lower GI tract. The results are inconsistent and suggest 
that the clinical utility of NBI in day-to-day practice is limited.  
NBI as an adjunct technique to high-resolution endoscopy, showed a comparable performance 
to chromoendoscopy when applied in a randomised cross-over study of 28 patients with BO, 
and did not improve the overall sensitivity for identifying patients with high grade dysplasia or 
early cancer [97]. In a study with 56 patients with BO undergoing endoscopic surveillance for 
previously detected dysplasia, NBI detected significantly more dysplasia, and with recourse to 
fewer targeted biopsies, compared to WLE alone [98]. 
In a recent study by Sharma et al. [99] in 123 patients with BO with mean circumferential and 
maximal extents of 1.8 and 3.6 cm, respectively, NBI revealed more areas of dysplasia in 
patients with fewer biopsies when compared to high definition WLE plus four quadrant biopsies 
(Seattle protocol, see section 2.1.2). 
The vascular pattern intensity (VPI), a measure of microvascular density, was proposed by East 
et al. [100,101] as a new classification parameter to discriminate neoplastic from non-neoplastic 
polyps with NBI. 
In a study of 62 patients with hereditary non-polyposis colorectal cancer, the adenoma 
detection rate was almost doubled when a second inspection with NBI was performed 
compared to standard colonoscopy alone [102]. 
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Using microvascular networks as a marker of neoplasia in a variety of organs including colon, 
oesophagus, and lungs, a meta-analysis of 11 studies comparing NBI-based diagnoses of 
neoplasia with histopathology revealed a high diagnostic precision for detection of neoplasia, 
with an overall sensitivity and specificity of 94% and 83% respectively [103]. In contrast, other 
studies have failed to demonstrate an improved detection of neoplastic polyps [56,104,105] and 
dysplasia in patients with longstanding ulcerative colitis [106]. 
FICE and i-Scan 
Along with NBI, the most recent development in virtual chromoendoscopy is the computed 
post-processing spectral estimation technology invented by Professor Miyake [107,108] and 
introduced by Fujinon with the Fuji intelligent chromoendoscopy (FICE) system (Fujinon 
Corporation, Japan). A similar system has been released in April 2007 by the Pentax 
Corporation, the so called i-Scan technology (Pentax, Japan). 
In contrast to NBI, where the illumination light is filtered to achieve contrast, in FICE and i-Scan 
the contrast is obtained after the illumination has reached the tissue by processing the spectral 
reflectance captured by the CCD. 
The FICE system is based on computed spectral estimation of photons reflected from an 
ordinary white light image. In this way, white light images are sent to a Spectral Estimation 
Matrix processing circuit and reconstructed in three distinct virtual single-wavelength images: 
red; green; and blue. By combining these three single wavelength images, a resultant FICE 
enhanced colour image is then obtained as shown in figure 2-29. 
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Figure 2-29: The principle and flow chart of FICE imaging [109]. 
i-Scan technology is based on digital filter enhancement and software manipulation of colour 
tone, sharpness and contrast of high-definition images (1.25 million pixels). i-Scan can be used 
in three modes depending on the level of enhancement desired: (1) Surface Enhancement (SE), 
for easier demarcation of edges and flat lesions by enhancing light-to-dark contrast; (2) 
Contrast Enhancement (CE) for better identification of depressed lesions by enhancing areas of 
low intensity; and (3) Tone Enhancement (TE) for improved mucosal structure assessment by 
increasing the illumination and emphasis on vascular features. 
Example images of i-Scan in comparison with conventional WLE are shown in figure 2-30. 
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Figure 2-30: Example images of a small hyperplastic polyp in WLE (a) and i-Scan (b) to demonstrate the 
contrast enhancement provided by i-Scan. Reproduced with permission from [110]. 
Clinical experience 
In patients with BO complicated by suspected HGD or early cancer, FICE showed similar 
sensitivity to acetic acid chromoendoscopy (87% for both techniques on a “per lesion” basis, 
and 92% vs. 83% on a “per patient” analysis for FICE and chromoendoscopy respectively) [111]. 
An increase in sensitivity was observed by combining targeted biopsies plus standard 4 
quadrant random biopsies (88% and 96% in the “per patient” analysis for FICE and 
chromoendoscopy respectively). 
When compared to WLE, transnasal FICE provided clearer delineation of the oesophagogastric 
junction by identifying the palisade vessels, a reliable, but often invisible to WLE, anatomical 
marker of oesophageal origin for measuring the extension of Barrett mucosa with 
accuracy [112]. However, detection of dysplasia was not attempted due to the limited FOV of the 
endoscopes used. 
In a study by Neumann et al. [113], double-balloon enteroscopy-assisted FICE failed to improve 
the detection or delineation of ulcers and erosions in 3 patients with Crohn’s disease but was 
found to be useful for the characterization of adenomatous polyps and angiodysplasias of the 
small bowel. 
Hoffman et al. [110] reported a significantly increased detection rate of small (≤5 mm) 
adenomas for i-Scan when compared to WLE alone (11 vs. 5 respectively). The inspection was 
conducted in the last 30 cm of colon during the withdrawal phase of colonoscopy. Interestingly, 
(a) (b)
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the same detection rate was found for both conventional chromoendoscopy with methylene 
blue and i-Scan, although chromoendoscopy was considerably more time consuming than i-Scan 
(13 vs. 5 minutes). They also showed that i-Scan is a useful adjunct technique to vital staining 
with Lugol’s solution for identifying mucosal breaks in patients with non-erosive reflux disease 
(NERD) [114]. 
2.4.3 Fluorescence endoscopy 
Fluorescence provides a powerful means of achieving optical contrast in microscopy and 
endoscopy based on specific molecular characteristics of the tissue. It will be introduced in 
more detail in chapter 3. 
Fluorescence endoscopy can use endogenous (autofluorescence imaging) or exogenous 
fluorophores (i.e. fluorescein) to achieve contrast and distinguish between normal and diseased 
tissue. 
Particularly, autofluorescence is generated by intra- and extracellular endogenous fluorophores 
such as collagen, elastin and pyridine nucleotides, and the distribution of these fluorophores can 
be different in normal and diseased tissue. 
However, intensity-based autofluorescence contrast is often not sufficiently specific because it 
is difficult to make quantitative intensity measurements. 
Photodynamic Diagnosis (PDD) 
One of the major issues in measuring tissue autofluorescence is that the fluorescent signal is 
often weak. Exogenous sensitizers aim to provide highly specific contrast, but must be certified 
for human use, which of course requires assessments for safety and pharmacokinetics, etc. 
PDD uses photo-sensitising chemicals to enable abnormal tissues to be more easily identified 
compared to conventional diagnostic techniques. While PDD is a widely used technique in 
urology and dermatology employing 5-aminolaevulinic acid sensitisation, its development and 
use in gastroenterology has not been so rapid, despite initial promising results [115-117]. 
Disadvantages of this technique include the high concentrations of 5-ALA often required, the 
inherent risk of photosensitivity and the long procedural time. 
A number of different aromatic compounds have been used in PDD, most of which were 
previously employed in photodynamic therapy. These include various derivatives of 
haematoporphyrin, chlorins, and phtalocyanines. However, 5-aminolevulinic acid (5-ALA) 
emerged quite early among all other compounds due to its lower potential phototoxicity [118] 
and high tumour selectivity [119]. 5-ALA is a precursor in the biosynthesis of haem, whose 
exogenous administration can interfere with the synthesis of ALA feedback mechanism and 
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induce accumulation of the fluorescent precursor protoporphyrin IX (PpIX). PpIX is 
preferentially up taken by malignant tissues, and its tumour selectivity has been demonstrated 
for a variety of neoplasms, including cancers of the GI tract [120-123]. 
The recent introduction of a more selective and less phototoxic esterified derivative of 5-ALA, 
hexaminolevulinate (Hexvix, PhotoCure ASA, Norway), coupled to the development of a 
prototype fluorescence videoendoscope (13902 PIKS, Karl Storz, Germany) adjusted to the 
optimal emission wavelength of this sensitizer (375–400 nm), has prompted new enthusiasm in 
exogenous induced fluorescence. 
The PDD videoendoscope prototype is equipped with a 300 W xenon lamp (D-light C, Karl Storz, 
Germany) and a 380-430 nm band pass filter that can be operated by pressing a switch on the 
handle. A 450 nm long pass filter is integrated in the CCD at the distal end of the endoscope. 
Clinical experience 
PDD with photosensitizers administered either intravenously or topically has also been applied 
to detection of dysplasia and early cancer in Barrett’s oesophagus [117,124-126], ulcerative 
colitis [127,128], adenomatous and hyperplastic polyps [129,130], and in the biliary tree [131]. 
The recent introduction of a more selective and less phototoxic esterified derivative of 5-ALA, 
hexaminolevulinate (Hexvix, PhotoCure ASA, Norway), coupled to the development of a 
prototype fluorescence videoendoscope (13902 PIKS, Karl Storz, Germany) adjusted to the 
optimal emission wavelength of this sensitizer (375–400 nm), has prompted new enthusiasm in 
exogenous fluorescence contrast agents. 
The PDD videoendoscope prototype is equipped with a 300 W xenon lamp (D-light C, Karl Storz, 
Germany) and a 380-430 nm band pass filter that can be operated by pressing a switch on the 
handle. A 450 nm long pass filter is integrated in the CCD at the distal end of the endoscope. 
Enlicher et al. [132] observed selective Hexvix fluorescence of neoplastic polyps (with 
intraepithelial dysplasia) in contrast with invasive cancers, which only showed a weak 
fluorescence, and hyperplastic polyps, which did not fluoresce at all. It was suggested that 
hexaminolevulinate-based fluorescence endoscopy may be thereby useful for enhanced 
detection of premalignant lesions. 
Mayinger et al. [75] reported a higher adenoma detection rate (38% more polyps) and overall 
accuracy superior to white light-endoscopy (81% vs. 69% respectively) using Hexvix 
administered topically as an enema. PDD was shown to be particularly sensitive to detection of 
flat polyps, which were almost completely missed by standard white-light inspection (13/16 vs. 
3/16). 
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In a study by Ortner et al. [133] conducted in 53 patients with BO, delayed observation of 5-ALA 
fluorescence induced spectra helped discriminate LGD from non from non-dysplastic Barrett 
epithelium with a sensitivity of 76% and a specificity of 63%. An aqueous solution of 5-ALA was 
sprayed on the oesophageal mucosa during follow up gastroscopy, 8 weeks after initial 
screening endoscopy using the Seattle protocol. A second gastroscopy was performed after 1-2 
hours, using an optical fibre inserted through the working channel of a therapeutic gastroscope. 
Fluorescence measurements were made in a circumferential pattern on the Barrett’s segments 
and biopsies were taken from areas exhibiting high fluorescence intensity of PpIX in delayed 
fluorescence spectra to correlate spectra results with histology. The optical fibre used allowed 
fluorescence to be collected from an area of 1 mm2. Immediate and delayed fluorescence spectra 
were then recorded from all biopsies ex vivo and as a 27% sampling error was found, they 
compared only the ex vivo spectra with histology. All samples included in the analysis were 
examined by three pathologists. Protein expression immunohistochemistry of p53 was also 
performed in all the samples examined by the third pathologist. Importantly, despite taking 
fewer specimens (median 7 vs. 28 with fluorescence spectroscopy and standard screening 
endoscopy, respectively), dysplasia was detected in 14 of 53 patients (four of which with HGD, 
six with short segments) compared to only five patients (all with long segments) previously 
diagnosed by standard screening endoscopy. In addition, three early cancers were detected for 
the first time. In a similar crossover study by the same group [134] conducted on 42 patients 
with longstanding ulcerative colitis, dysplastic mucosa was discriminated from non-dysplastic 
mucosa with a sensitivity and specificity of 73% and 81%, respectively. Interestingly, flat 
dysplasia was detected by fluorescence guided spectroscopy in 10 patients, only three of which 
were previously diagnosed by standard colonoscopy with four quadrant biopsies.  
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Autofluorescence Imaging (AFI) 
AFI is a technique based on the principle that excitation of tissue with specific wavelength (e.g. 
in the blue) leads to emission of a longer wavelength of light. In the GI tract, AFI detects subtle 
changes in the concentration of specific chemicals in tissue that have the ability to fluoresce 
when excited (endogenous fluorophores). Malignant transformation is associated with emission 
of relatively longer wavelength of light (shift from green toward the red end of the spectrum).  
Currently, the only commercially available AFI devices are RGB–based videoendoscopes with 
trimodal (WLE + NBI + AFI) capability (EVIS LUCERA SPECTRUM, Olympus Medical Systems Co, 
Japan). Two separate monochromatic CCDs are located at the tip of these endoscopes. One CCD 
is for high definition WLE and NBI, and the other CCD is specific for AFI. 
In AFI mode, blue light (390-470 nm) and green light (540-560 nm) is sequentially generated by 
a xenon lamp and conveyed through a rotating colour filter wheel. An interference filter situated 
proximally to the AFI CCD blocks the blue light excitation but allows tissue autofluorescence 
(500-630 nm) and reflected green light to filter through [135]. 
The autofluorescence and green reflectance images are captured and integrated by the video 
processor into a single pseudocolour image where normal mucosa typically appears green, and 
dysplastic or neoplastic tissue purple (figure 2-31).  
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Figure 2-31: Example images of a suspected early cancer of the gastric antrum imaged using standard 
WLE (a) and AFI (b), to demonstrate the contrast enhancement provided by AFI (Olympus, Japan). Images 
provided courtesy of Dr Chizu Yokoi (National Center for Global Health and Medicine, Tokyo, Japan). 
However, the reason for the difference in fluorescence between normal and diseased tissue 
observed in current commercial AFI systems is still unclear and intensity-based contrast is often 
not sufficiently specific [135-137]. 
The clinical experience with AFI will be discussed in chapter 3 together with research and 
preclinical studies of autofluorescence imaging and spectroscopy. 
2.4.4 Confocal microscopy 
Confocal microscopy was invented by Minsky in the 1950s [138,139]. Since its conception and 
development, confocal microscopy has been extensively used in biology and medicine for 
imaging living intact tissues without having to physically cut up and prepare thin sections as in 
histology. 
In confocal microscopy, the light source, the sample plane, and the detector are all confocal, i.e. 
in conjugate image planes (figure 2-32). The illumination light is focused to a point in the 
sample and all the fluorescence collected by the objective lens from that point is forced to pass 
through a pinhole to reach the detector. Although other parts of the sample are also illuminated, 
light from out of focus planes in the sample is blocked by the pinhole and does not reach the 
detector. 
(a) (b)
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Figure 2-32: Schematic diagram of confocal microscopy principles. The blue rays (pre- and post-
objective and excitation filter) indicate the laser illumination delivered to the tissue sample. Only the 
fluorescence emitted from a tissue layer in focus (orange rays) will pass through the pinhole and will be 
detected. The light emitted from tissue layers out of focus (red and green rays) will be rejected. Illumination 
and collection therefore occur in the same focal plane (i.e. confocal). Adapted from [140] 
Thus, the main advantage of a confocal microscope is its optical sectioning ability, giving insight 
into the three-dimensional tissue structure and providing a virtual real-time histological 
diagnosis. 
2.4.5 Confocal laser endomicroscopy 
Confocal laser endomicroscopy (CLE) is one of the newest advancements in diagnostic 
endoscopy and is a highly promising technique for investigating the mucosal surface together 
with its immediate sub-surface areas. Cell structures and tissue morphological characteristics 
can be visualized to a maximum depth of 250 μm. 
Two types of confocal endomicroscope have been developed: a confocal laser endomicroscope 
(CLE, Pentax, Japan), in which a miniaturized confocal scanner has been integrated into the 
distal tip of a conventional endoscope, and a probe based system (pCLE, Cellvizio, Mauna Kea 
Technology, France), which can be passed through the working channel of standard endoscopes 
and has an external laser scanning unit. 
Endoscope based Confocal Laser Endomicroscopy (eCLE) 
The confocal laser endomicroscope is based on micro-electro-mechanical system (MEMS) 
scanning mirror technology. The MEMS scanning mirror oscillates to provide a scan pattern to 
the beam of light. 
A single mode (Gaussian beam profile) fibre, acting as both the illumination point source and 
the detection pinhole, and a miniature objective lens at the distal end of a conventional video 
Dichroic beamsplitter
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endoscope (EG3870K, EC-3870CILK, Pentax, Japan) enable confocal microscopy in addition to 
standard videoendoscopy. 
A blue laser integrated into the endoscope light source is coupled into a single mode fibre that 
delivers an excitation wavelength of 488 nm to the sample, and fluorescence emitted by the 
sample is detected at wavelengths above 505 nm. Viewing of a specific tissue depth is enabled 
by scanning successive points within the tissue in a grid of pixels along the x and y axes (parallel 
to the tissue surface) to produce sections of 475 x 475 µm (FOV) at variable imaging depth 
(range 0-250 μm). The lateral resolution is 0.7 μm and the axial resolution is 7 μm. eCLE can 
produce conventional white light endoscopic images and confocal images at the same time with 
a pixel density of 1024 x 512 pixels at an acquisition rate of 1.6 frames per second or 
1024 x 1024 pixels at 0.8 frames/second [141,142]. 
The distal tip of the endoscope contains an air and water jet nozzle, 2 light guides, an auxiliary 
water jet channel (used for topical application of the contrast agent, and a 2.8-mm working 
channel. Actuation of imaging plane depth is controlled using two remote control buttons on the 
handle [62]. 
Probe based Confocal Laser Endomicroscopy (pCLE) 
pCLE consists of a coherent single mode fibre bundle, a miniature microscope objective and two 
scanning mirrors at the proximal end of the bundle. The bundle has an outer diameter of 2 mm 
and can be introduced through the working channel of most endoscopes. In pCLE, a laser is 
sequentially focused onto single fibres at the proximal end of the bundle. The light exiting the 
fibre at the distal end is focused to a point in the sample using a miniature objective. Confocal 
fluorescence is focused by the objective onto the same fibre in the bundle. The light is detected 
on a detector, and the beam is eventually scanned over all fibres in the fibre bundle to build up 
an image. The lateral and axial resolution range from 2.5 to 5 and 15 to 20 μm respectively 
[143]. pCLE has a fixed image plane depth varying between 55 µm and 130 µm depending on 
the probe used [142]. 
Comparison of eCLE and pCLE 
The main advantage of eCLE over pCLE is that the imaging plane depth is user tunable because 
the laser scanner is integrated into the endoscope (figure 2-33(b)) and allows optical sectioning 
of the tissue at higher axial resolution (lateral resolution 0.7 μm, axial resolution 7 μm vs. 
2.5 μm and 15 μm respectively), whereas in pCLE the imaging plane depth is fixed and cannot be 
adjusted (figure 2-33(a)) [141,143,144]. 
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Figure 2-33: Confocal endomicroscopy systems clinically approved and currently available on the 
market. (a) The probe based system (Mauna Kea Technology, France). (b) In the confocal laser 
endomicroscope (Pentax, Japan). Adapted and reproduced with permission from [144]. 
In pCLE, the resolution is limited by the number of fibres (30,000) but the image acquisition is 
faster than that of eCLE (12 vs. 0.8-1.6 frames per second). One disadvantage of eCLE is the 
insertion tube diameter of the distal tip (12.8 mm) compared to the standard outer diameters of 
conventional endoscopes (9-11.1 mm). In contrast, pCLE, due to the small diameter of the 
bundle, permits the imaging of narrowed lumina such as the biliary and pancreatic ducts, 
ureters and neoplastic or inflammatory strictures. Disadvantages of pCLE include limited 
lifespan (20 procedures), higher maintenance cost [141], and occupation of the endoscope 
working channel. 
Problems with current CLE systems 
A general drawback of this technique is that intravenous, e.g. fluorescein sodium, and topical 
fluorescence agents, e.g. acriflavine, are used to achieve contrast. The avoidance of contrast 
agents would reduce both procedural time and any potential for associated adverse effects. 
Fluorescein diffuses through the extracellular matrix of the epithelium and the lamina propria 
but does not stain cell nuclei [145]. Acriflavine is a carcinogenic dye [146], and this clearly limits 
its clinical utility [141]. 
Another drawback is the duration of the procedure, which can be almost twice as long as 
conventional endoscopy. In a study of contrast dynamics in porcine models, it has been reported 
that the best contrast and image quality can be achieved within the first 8 min after intravenous 
injection of 1% fluorescein with highest signal-to-noise ratio (SNR) after 5 min. The SNR 
decreased significantly after 8 minutes [147]. Furthermore, confocal endomicroscopy does not 
yet provide functional information about the tissue, and is an examiner-dependent technique. 
Interobserver and intraobserver variability has not been adequately studied [148], and the 
interpretation of the intensity images is often somewhat challenging among users, who may 
(a)
(b)
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require substantial supplementary training in histology or the presence of the pathologist in the 
endoscopy room to achieve acceptable diagnostic accuracy [149,150]. 
2.5 Endoscope based Confocal Laser Endomicroscopy (eCLE) 
In 2004, Kiesslich et al. [62] showed that colonic dysplasia was detected using eCLE with a 
sensitivity of 97.4% and a specificity of 99.4%. Other potential applications are detection of 
dysplasia in Barrett’s oesophagus and differentiation of benign and malignant biliary strictures.  
Kiesslich et al. proved that the overall accuracy for eCLE in predicting Barrett's oesophagus and 
associated neoplasia is 96.8% and 97.4% respectively [151]. Detection by eCLE of dysplasia in 
Peutz–Jeghers syndrome, and in vivo diagnosis and characterization of Helicobacter pylori 
gastritis and Whipple's disease has also been reported [152-154]. 
The potential of eCLE to differentiate colorectal lesions was recently demonstrated by 
Sanduleanu et al. [155]. In this study, low grade dysplasia was distinguished from high-grade 
dysplasia with high accuracy (96.7%), and eCLE predicted the final histology for all cases with 
95.7% accuracy (figure 2-34). 
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Figure 2-34: (a) eCLE and (b) corresponding histological images (30x original magnification) of normal 
colonic mucosa. (c) eCLE and (d) corresponding histological images (15x original magnification) of an 
adenomatous polyp. (e) eCLE and corresponding (f) histological images (20x original magnification) of a 
poorly differentiated adenocarcinoma; the red arrow and the red arrowhead indicate an area of 
neoangiogenesis and islands of malignant cells (dark cells) respectively. Adapted and reproduced with 
permission from [155]. 
(e)
(b)
(d)(c)
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Spectrally encoded confocal microscopy (SECM), a variant of CLE that facilitates the 
incorporation of confocal microscopy into small, portable catheters or endoscopes, was applied 
on 50 gastro-oesophageal biopsy samples from 36 patients and revealed subcellular details of 
various mucosal types and associated clinical conditions, including fundic gland polyps, 
eosinophilic oesophagitis and dysplasia in BO, all of which were confirmed and correlated with 
histopathology [156]. However, in SECM, contrast is due to reflected or simply back scattered 
light and not fluorescence. 
In a pilot study conducted on 43 ex vivo endoscopic biopsy specimens using SECM, Yoo et al. 
[157] were able to identify and count individual eosinophils with 100% sensitivity and 
specificity for diagnosing eosinophilic oesophagitis when a cut-off threshold of 15 eosinophils 
per field was used. A high degree of correlation with histology and intra- and interobserver 
agreement was also observed. Other key histopathological features of this disease, including 
basal cells hyperplasia and eosinophil abscess and degranulation, were also accurately 
identified. 
2.6 Probe based Confocal Laser Endomicroscopy (pCLE) 
Oesophagus 
Barrett’s oesophagus 
In a prospective, double blind review of 20 pCLE images of 40 sites of BO tissue by using 
matching biopsies as the reference standard, the preliminary evaluation accuracy and inter-
observer agreement of pCLE was assessed among eleven experts in BO imaging from 4 different 
endoscopy centres from the United States and Europe [158]. Although the study was limited by 
the small sample size, high preliminary accuracy in diagnosis of BO dysplasia and neoplasia was 
achieved with both inexperienced (90%) and experienced observers (95%). The main strength 
of the present study relative to other published data is the inclusion of a large group of 
endoscopists, only four of whom had previous experience with pCLE. Their high performance 
demonstrated that rapid training in image interpretation is feasible. 
The first international multicentre, randomized, controlled trial using pCLE in 101 patients with 
Barrett’s oesophagus (BO) was published in September 2011. The sensitivity and specificity of 
pCLE in addition to high definition white light endoscopy (HD-WLE) was compared with HD-
WLE alone for the detection of high grade dysplasia and adenocarcinoma [159]. Use of pCLE 
with HD-WLE showed increased “per-location” sensitivity for the detection of HGD and AC 
compared to HD-WLE alone (68.3% vs. 34.2%). Instead, “per-location” specificity was slightly 
reduced (87.8% vs. 92.7%). Nevertheless, no statistically significant differences in “per-patient” 
sensitivity were observed between HD-WLE, NBI or pCLE. However, a high negative predictive 
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value was collectively observed, and authors speculated that pCLE might facilitate early rule-out 
of dysplasia with high degree of confidence, allowing better informed decisions to be made for 
the management and subsequent treatment of patients with BO (figure 2-35). 
 
Figure 2-35: pCLE example images showing non-dysplastic BO (a) and BO with early oesophageal 
adenocarcinoma (b). Adapted and reproduced with permission from [159]. 
In a study by Bajbouj et al. [160], optical biopsy with pCLE was compared to standard 
endoscopic biopsy in the endoscopic evaluation of 68 patients (670 pairs of biopsies) with 
Barrett’s oesophagus. Confocal images were interpreted live during examination as well as in a 
blinded controlled manner 3 months post endoscopy, and findings compared with histology. 
pCLE was found to be comparable to endoscopic biopsy in excluding neoplasia, but due to low 
its low PPV and sensitivity, authors concluded that pCLE may currently not replace the standard 
practice for the diagnosis of BO associated neoplasia. 
Eosinophilic oesophagitis 
A description of EO using pCLE, which was confirmed by corresponding histopathological 
analysis, was recently reported by Neumann et al. [161]. pCLE revealed small cells such as 
eosinophils within dilated intercellular spaces, capillary ectasia and mild mucosal oedema. 
Biliary and pancreatic ducts 
Current techniques to detect malignant biliary and pancreatic strictures are of low sensitivity.   
The delay in tissue confirmation of malignancy can place a patient at risk for progression of 
disease precluding surgical resection. On the other hand, the inability to confirm whether a 
stricture is benign or malignant could lead to unnecessary surgery. 
(a) (b)
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The first international multicentre experience with pCLE to diagnose indeterminate 
pancreatobiliary strictures has been published in November 2011 [162]. A total of 102 patients 
undergoing endoscopic retrograde cholangiopancreatography (ERCP) for diagnosis of their 
clinical conditions were recruited in five academic centres. pCLE outperformed tissue sampling 
in sensitivity (98% vs. 45%), negative predictive value (97% vs. 69%), and overall accuracy 
(81% vs. 75%). However, pathology was unbeatable in specificity and positive predictive value. 
Delivery of the confocal miniprobe through a cholangioscope or via a catheter did not lead to 
significant differences in sensitivity and specificity. The authors suggested that pCLE may 
potentially increase diagnostic accuracy of ERCP in discerning benign from malignant strictures. 
Loeser et al. [163] used pCLE in 14 patients with indeterminate biliary strictures together with 
standard biopsies and brushings. In parallel, they also examined rat bile ducts ex vivo using 
multiphoton microscopy to better understand the nature of the human bile duct structures 
visualized during confocal endomicroscopy. Of the 14 patients, 6 patients had a diagnosis of 
cancer. None of the criteria used to evaluate possible malignancy in the confocal images was 
found to be sufficiently specific for malignancy. An abnormal reticular network, which may 
reflect changes in lymphatic vessels, was never seen in benign strictures and the authors 
proposed that in the absence of markers of potential malignancy, if a normal reticular pattern is 
visible then the diagnosis of malignancy is unlikely. The reticular pattern seen in normal tissue 
was believed to be a network of lymphatic vessels as shown in multiphoton reconstructions of 
intact rat bile ducts and confirmed by special stains. 
In 2008, Meining et al. [164] used pCLE to examine the biliary tract of 14 patients with biliary 
strictures at the liver hilus or the common bile duct. Patterns indicative of neoplasia were 
identified and pCLE predicted neoplasia with an overall accuracy of 86%, surprisingly 
outperforming preoperative tissue sampling (79%). After surgery, histopathology revealed 
invasive adenocarcinoma in 2 patients in which preoperative biopsy specimens were negative 
for neoplasia, whereas pCLE indicated the presence of malignancy. Also the median signal-to-
noise ratio derived from a region of interest in both normal and neoplastic epithelium was 
significantly different (lower in neoplasia) accounting for less broad intrinsic fluorescence 
intensity distribution in neoplastic tissue, which reflects different concentration of fluorophores 
following structural neoplastic rearrangement. A dark grey background with poor mucosal 
structure and large white streaks (vessels) was mainly seen in neoplastic strictures. On the 
contrary, a reticular pattern of different grey scales and villous structure without white streaks 
was seen in patients without neoplasia. 
Peroral pancreaticoscopy and pCLE has also been reported by the same group in a case of 
intraductal papillary mucinous neoplasm (IPMN) [165]. IPMN often goes unrecognized in 
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patients with chronic pancreatitis and its diagnosis is rather challenging. Based on the findings 
obtained with these two imaging methods, the diagnosis of IPMN was formed and was then 
confirmed by histology. 
Colon 
Inflammatory Bowel Disease 
Normal-appearing mucosa in the terminal ileum (TI) of 27 patients with IBD and normal 
mucosa from 30 controls were imaged using Cellvizio Ultra-High Definition coloflex miniprobes 
(Mauna Kea Technologies, France) and then sampled for histologic confirmation [166]. By 
manual segmentation they were able to quantify epithelial cells and gaps introducing a novel 
endomicroscopic parameter called “gap density”, defined as the number of gaps per 1000 
epithelial cells. They found that the epithelial gap density of the TI in patients with IBD is 3 
times higher than that of normal patients. The hypothesis is that higher gap density reflects 
increased cytokine-induced epithelial cell shedding and this parameter could be used to predict 
better response to conventional IBD therapy. There was no positive correlation of gap density 
with disease activity. On the contrary, severe clinical activity was associated with lower gap 
densities, suggesting that this parameter may play a role more as an indicator of the underlying 
disease mechanism rather than of the degree of disease activity.  Though patients with Crohn’s 
disease displayed different distributions from those with ulcerative colitis, gap density could 
not differentiate between the 2 disease populations due to the limited sample size. 
In another study from the same group [167], pCLE of the TI was performed in 8 patients with 
Crohn’s disease and 6 controls. In parallel, optical sections were obtained from the small 
intestines of IL-10-deficient knockout and normal mice using a rigid FIVE 1 confocal probe 
(Optiscan Pty. Ltd., Australia). In patients with Crohn’s disease, the mean gap density, identified 
by the absence of acriflavine-stained nuclei, was found to be 6 times higher than that of control 
patients (117 vs. 17.7 gaps per 1000 cells).  Consistently, the mean gap density in IBD induced 
mice was 1.7 times higher than that of normal mice. 
Confocal imaging of dysplasia-associated lesional mass (DALM) in a patient with chronic 
ulcerative colitis, was also reported [168]. Morphological characterization with pCLE was 
performed both over the lesion and adjacent inflamed mucosa, showing features suggestive of 
dysplasia and inflammation respectively. The main aspect of inflamed mucosa consisted of 
dilation of crypt openings, irregular arrangement of crypts, crypt destruction and fusion, and 
crypt abscess. Dark mucin-depleted goblet cells and villiform epithelial digitations were 
recognized as dysplastic features in agreement with the Mainz classification for prediction of 
intraepithelial neoplasia [62]. 
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A prospective pilot study on 22 patients under surveillance for ulcerative colitis was conducted 
by van den Broek et al. [169] using NBI plus HDE followed by pCLE before taking targeted and 
random biopsies. Reasonable diagnostic accuracy was achieved though movement artefacts 
significantly impaired significantly the video quality. 
Colorectal neoplasia and dysplasia 
Considering histology as gold standard, Buchner et al. demonstrated that pCLE can accurately 
discriminate between hyperplastic and adenomatous polyps, and detect residual adenomatous 
tissue after endoscopic mucosal resection (EMR) [170]. They then compared pCLE to NBI and 
FICE, collectively named as virtual chromoendoscopy, in 119 polyps (81 neoplastic, 38 
hyperplastic) from 75 patients [171]. The pCLE had higher sensitivity compared to virtual 
chromoendoscopy (91% vs. 77%) for classification of colorectal polyps using histopathology as 
gold standard. In this study, high-definition WLE was used as the primary inspective technique. 
Prior to pCLE imaging, either FICE or NBI, depending on availability, were used after detection 
of a suspicious lesion. 
They have also examined the learning curve faced by clinicians in correctly identifying benign 
and neoplastic colorectal lesions by using pCLE [172]. Accuracy of image interpretation and 
acquisition increased with the number of images observed (up to 86% beyond 60 lesions). 
Considering histology as a gold standard, Buchner et al. demonstrated that pCLE can accurately 
discriminate between hyperplastic and adenomatous polyps, and has higher sensitivity than 
virtual chromoendoscopy (99% vs. 77%) [171]. 
In a recent prospective multicentre study, 92 patients who had their lesion removed by EMR in 
a previous colonoscopy were referred for follow-up colonoscopy within one year and inspection 
of EMR scars (n = 129) with NBI or FICE and pCLE to detect residual neoplasia. Accuracy of 
pCLE alone and in combination with NBI or FICE against histopathology as the gold standard, 
was of 81% and 90% respectively, whereas the cumulative accuracy of virtual 
chromoendoscopy (NBI + FICE) alone was 77% [173]. 
In vivo characterization of 32 superficial colorectal neoplastic lesions with pCLE was performed 
by De Palma et al. in 20 consecutive patients [174]. Probe-based CLE presumptive diagnoses 
were compared with histopathology of resected lesions or targeted biopsies. The sensitivity and 
specificity of p-CLE to differentiate neoplastic from hyperplastic lesions were 100% and 84.6% 
respectively. 
The use of molecular biomarkers in combination with confocal endomicroscopy was first 
investigated by Hsiung et al. [175] to develop a fluorescent probe for detecting colon cancer.  
They identified a specific heptapeptide sequence, VRPMPLQ, which was conjugated with 
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fluorescein and tested in patients undergoing colonoscopy. The fluorescein-conjugated peptide 
was administered topically and was found to bind more strongly to dysplastic cells than to 
adjacent normal cells with 81% sensitivity and 82% specificity. 
Wang et al. [63] conducted a pioneering observational study using pCLE in 54 patients 
undergoing bowel cancer screening colonoscopy with the aim to track the uptake and 
distribution of fluorescein from the crypts to the lamina propria after topical administration.  
This contributed to further understanding of the functional anatomy of the colonic glands in 
normal, hyperplastic and adenomatous tissue in vivo. As with histology, the typical shape and 
size of glands for each tissue type were clearly discriminated and there was correlation between 
tissue morphology and time of transit, with significantly longer time of passage through 
adenomatous mucosa (> 5 s) compared to hyperplastic or normal tissue. High diagnostic 
accuracy was achieved using the speed of absorption of fluorescein (contrast ratio) as a 
discriminant function to distinguish normal from diseased mucosa (89%), hyperplasia from 
adenoma (96%), and even tubular from villous adenoma (93%). 
Focal high-grade dysplasia was identified using pCLE in a patient with longstanding ulcerative 
colitis presenting with colorectal squamous metaplasia, which had been incidentally found with 
random rectal biopsies (10 cm from the anal verge) at surveillance colonoscopy.  Histology of 
pCLE targeted biopsies confirmed the presence of squamous dysplasia. pCLE showed 
disorganized vascularity with abnormal capillary loops as well as crowded and intensely dense 
nuclei in the squamous tissue. 
Moderate to good interobserver agreement among three international experts and 76% 
accuracy in diagnosis of neoplasia was achieved using pCLE in a study on 53 patients with 75 
colorectal lesions, 50 of which were neoplastic [176]. The authors concluded that current 
accuracy and interobserver agreement do not yet support routine clinical use in screening or 
surveillance colonoscopy. 
2.6.1 Endocytoscopy (EC) 
Endocytoscopy (EC, Olympus Corporation, Japan) is a novel imaging technique, enabling 
microscopic imaging of the GI mucosal surface with a magnification up to 1400x. 
EC is based on a contact light microscope which enables real-time visualization of cellular 
structures of the superficial epithelial layer in a plane parallel to the mucosal surface.  
Cytological and architectural features, such as the size and shape of cells, nuclei and the 
nucleus:cytoplasm ratio, can be assessed. 
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This technique uses a fixed focus, high power objective lens that projects highly magnified 
images onto a CCD at a rate of 30 frames per second [177]. 
As for CLE, two types of endocytoscopy systems are currently available on the market. A probe 
based handheld miniprobe (pEC), providing magnification up to 570x and 1400x, which can be 
passed through the working channel of a conventional endoscope, and a system integrated into 
the distal tip of an endoscope (iEC) providing magnification up to 580x. 
FOVs are 300 x 300 µm, 120 x 120 µm, and 400 x 400 µm for 570x pEC, 1400x pEC, and 580x 
iEC respectively. The axial resolution varies from 0 to 50 µm and the lateral resolution from 1.7 
to 4 µm. 
Using both systems, contact with the tissue surface is necessary for imaging. Endocytoscopy 
requires preparation of the mucosal layer with absorptive contrast agents like methylene blue 
or toluidine blue [178]. Prior to imaging and tissue staining the mucosal surface must be treated 
with a mucolytic to remove excess mucous. Repeat staining is often needed after ~ 5 minutes of 
imaging. 
Clinical experience 
Promising initial results, primarily in identifying and discriminating neoplastic from 
non-neoplastic tissue, have been shown in a few prospective studies [177,179-181]. Notably, EC 
was able to detect dysplasia in aberrant crypt foci of normal colon mucosa surrounding cancer 
[180], and discriminate invasive colon cancers from adenomatous polyps [179]. In contrast, 
only a limited role was found in detecting and predicting early oesophageal squamous cell 
carcinoma [182]. The potential of EC for the in vivo characterization of duodenal mucosa in 
celiac disease has also been reported [183]. 
Nevertheless, there is currently a paucity of interest and research on EC, possibly due to the 
requirement of topical staining, the relative lack of axial discrimination and the low resolution 
images compared to other microscopy techniques such as CLE. 
2.6.2 Two-photon and multi-photon microscopy 
Biological tissues are of course inherently three dimensional (3D) and typically have a high 
degree of scattering due to discontinuities in refractive index and the heterogeneity of their 
constituents, which makes high resolution 3D imaging challenging. 
Optically sectioned fluorescence imaging can be realized with single-photon confocal (visible 
light) or multiphoton excitation. In multiphoton microscopy (MPM), the excitation occurs 
through the absorption of multiple photons of lower energy (typically halved in two photon 
microscopy). No pinhole is required to prevent out-of-focus fluorescence from reaching the 
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detector as excitation only occurs at the excitation spot. However, high incident power is 
required for multiphoton absorption to take place. 
A major advantage of MPM is the longer wavelength light necessary to induce fluorescence 
(generally near-infrared, 700-1000 nm). Tissue absorption and scattering are limited in near 
infrared (NIR) allowing for deep-penetration imaging. 
A number of groups have developed miniaturized MPM endoscopes [184-187]. However, there 
is no commercially available multiphoton endoscope system to date. 
Recently, Rivera et al. [188] demonstrated a compact flexible raster scanning microendoscope 
capable of MPM and SHG by imaging ex vivo mouse tissue at 800 nm excitation. Images were 
acquired at 4.1 frames/s with a FOV of 110 μm × 110 μm using a double clad fibre and a mode-
locked Ti:Sapphire as the excitation source. The distal end of the fibre was mounted onto a 
resonant/non-resonant scanner, which moved the fibre tip in a raster pattern across the back 
aperture of a miniaturized gradient-index lens assembly, enabling 2D lateral scanning. 
2.6.3 Second (SHG) and Third (THG) Harmonic Generation Imaging 
Similarly to MPM, SHG and THG also depend on respectively two or three photons interacting 
simultaneously with the tissue under investigation. A long excitation wavelength, typically in 
the 700-1000 nm range, is required for these phenomena to take place [189]. However, unlike 
MPM, in which two photons are absorbed to produce a single fluorescent photon, with SHG and 
THG photons are scattered and not absorbed by the tissue, to produce a new photon with twice 
(SHG) or thrice (THG) the energy of the incident photons. With these techniques, due to the 
absence of absorption, heating and damage of the sample are less likely to occur. Another 
advantage is their capability for three-dimensional imaging. 
SHG techniques allow the imaging of “non-centrosymmetric” structures such as collagen, with 
reported tissue penetration depths between 100–300 μm with laser excitation in the NIR range. 
Therefore, they have been increasingly applied to characterize the structural changes occurring 
in the extracellular matrix during disease. One such example is the desmoplastic reaction that 
typically accompanies the progression of many cancers. 
An important potential application of SHG microscopy in gastroenterology is imaging fibrosis in 
chronic liver disease. Fibrosis is characterized by an increased density of collagen resulting 
from an inflammatory response associated with a number of conditions (e.g., viral hepatitis, 
steatosis and liver cancer) and is often associated with organ dysfunction and, ultimately, 
failure. Sun et al. [190] characterized the changes in the distribution and quantity of collagen in 
a rat model of induced liver fibrosis using SHG microscopy. An automated segmentation 
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approach to quantify large collagen colonies with high connectivity (aggregated collagen) was 
compared with conventional histological stains, such as Masson’s trichrome, showing good 
correlation with pathology. 
2.6.4 Optical Coherence Tomography 
Optical coherence tomography (OCT) is a high speed (~4 frames per second [191]) vertical 
plane imaging modality combining confocal scanning capability with low coherence 
interferometry, resulting in excellent rejection of scattered light and deep tissue penetration. 
The use of near-infrared light (from about 800 nm to 2500 nm) allows it to penetrate into 
scattering media more deeply (up to 4 mm, depending on tissue type) than confocal microscopy, 
with typical lateral and axial resolution of 15 μm and 10 μm respectively, although research 
systems have demonstrated axial resolutions on the order of 1 μm [191,192]. 
OCT is the optical equivalent of ultrasound imaging where ultrasound waves are replace by light 
[193]. As with endoscopic ultrasound (EUS), two main OCT imaging are available, linear and 
radial. 
The basic components of an OCT system are a low-coherent light source and a beam splitter, 
which splits the light into two identical beams, one directed to the tissue and the other to a 
mirror. The signals coming back from the tissue and the mirror are combined using an 
interferometer, which, following signal processing steps allows cross-sectional images to be 
obtained. Contrast in OCT is essentially due to reflected or simply back scattered light from 
refractive index mismatches within tissue. 
Clinical experience 
Optical discrimination of the GI tissue layers was first described in a landmark paper by 
Tearney et al. [194] in normal and diseased tissues collected post-mortem and imaged using 
OCT. 
Zuccaro et al. [195] showed that OCT was able to discriminate normal oesophageal mucosa from 
cancer. However, this novel technique has the intrinsic potential to reach the muscularis 
mucosae and thus discriminate non-invasive from invasive neoplasia. In a comparative study in 
normal tissue, Das et al. [196] have shown that OCT has a higher resolution than high-frequency 
(20-30 MHz) EUS for imaging this layer with accuracy. Accurate delineation of this layer would 
in fact assist clinicians in determining whether endoscopic therapy rather than surgery should 
be indicated. 
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In vivo endoscopic OCT was also used to assess the efficacy of radiofrequency ablation (RFA) in 
treating persistent rectal bleeding from radiation proctitis unresponsive to conventional 
therapy [197]. 
A form of OCT, termed comprehensive volumetric microscopy, has been proposed that acquires 
a 3D microscopic image of the full thickness distal oesophagus [198,199]. In a preliminary study 
by Suter et al. [200], volumetric microscopy of the distal oesophagus was performed in 66 
patients referred for Barrett’s oesophagus screening using a custom balloon catheter (2.5 cm 
diameter) that enabled spiral cross-sectional optical frequency domain imaging (OFDI), a high 
speed 2nd generation embodiment of OCT. Using histopathology as the gold standard, OFDI 
showed increased sensitivity for detection of specialized intestinal metaplasia compared to 
standard endoscopy. 
Columnar and squamous epithelium in a region of heterotopic gastric mucosa (cervical inlet 
patch) in the upper oesophagus were clearly distinguished using a through-the-scope 3D OCT 
prototype probe. En face images were acquired up to 400 µm depth underneath the tissue 
surface and were compared with histology. Biopsies taken from the imaged lesion confirmed 
the endoscopic finding [201]. 
2.6.5 Future potential clinical optical imaging modalities 
Raman spectroscopy 
The Raman effect was first described in 1928 [202]. Since then, Raman spectroscopy has been 
used to probe the biochemical signatures of a multitude of biological molecules. The Raman 
effect results from energy exchange between incident light and scattering molecules within the 
tissue. It is also referred to as inelastic scattering as Stokes Raman scattered light has less 
energy than the incident light. Compared to Stokes Raman scattering, in anti-Stokes Raman 
scattering, the scattered photon has a higher energy than the absorbed photon. 
Raman signals have typical narrow peaks generally associated with the vibration of a particular 
chemical bond in a molecule. As the bond stretches and shrinks, a shift in frequency, which is 
characteristic of a particular molecule, is indicated in the spectrum. 
Therefore, Raman spectroscopy can provide highly specific molecular fingerprint information, 
which is chemically sensitive and label-free. Raman spectroscopy can be integrated with 
confocal microscopy for high spatial resolution. However, Raman signals are usually weak 
(cross-section typically 1000 times lower than fluorescence) and images require high laser 
power (typically >10 mW), ultrasensitive detectors and long acquisition times (>30 min), which 
are unsuitable for in vivo clinical use.  
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Clinical experience 
The feasibility of in vivo Raman spectroscopy for in vivo use in GI endoscopy was first 
demonstrated in 2000 [203]. Raman spectra were obtained from various GI tract organs, 
including oesophagus and colon, during endoscopy using a custom built fibre-optic near-
infrared Raman spectroscopic system at 785 nm excitation, but due to the limited set of data, 
only subtle differences were observed between normal and pathological states. Later on, 
distinctive in vivo Raman spectra were shown by the same group between 10 adenomas and 9 
hyperplastic colon polyps with 95% accuracy [204]. Principal component and linear 
discriminant analyses were used to develop a diagnostic prediction model for classifying colon 
polyps based on their spectral emission. Raman spectra were also analysed from 20 
hyperplastic and 34 adenomatous polyps, showing similar accuracy (93%) to the in vivo 
measurements. 
Microscopy based Raman spectroscopy at 830 nm excitation, was used to classify and 
discriminate between normal and pathological states, with a particular focus on early epithelial 
malignancies, in a variety of organs, including larynx, oesophagus, and bladder [205]. Tissues 
were obtained during endoscopic or surgical procedures and immediately snap frozen. 
Histological assessment preceded the spectral measurements so that only samples with clearly 
defined pathologies and blind unanimous agreement from three expert histopathologists were 
measured. In the oesophagus study, Raman spectra were measured from 50 samples classified 
in eight different tissue states: normal squamous epithelium, cardiac BO, fundic BO, intestinal 
metaplasia, HGD, adenocarcinoma, squamous dysplasia, and SCC. No agreement was achieved 
on samples with LGD so this group was excluded from the analysis. Multivariate linear 
discriminant analysis was performed on the 8 groups, and by combining the spectra into three 
clinically significant groups: normal; BO; and BO neoplasia. 93.2% and 88.6% of cases were 
correctly predicted by the three and eight-group models, respectively. The development of a 
custom built confocal Raman fibre optic probe for endoscopic use was then presented by the 
same group [206]. Raman spectra were obtained from 58 oesophageal biopsy specimens and 
the probe performance was compared to a conventional spectrometer at both 2 and 10 s 
acquisition times. Subsequent ex vivo work using this probe at 830 nm excitation in 72 
oesophageal samples from 35 patients, with acquisition periods of 10 and 2 s, reported a 73% 
overall correct classification in spectrally separating histological diagnoses into three clinically 
significant groups: normal, low risk (BO) and high risk (dysplasia and cancer) [207]. Recent ex 
vivo work using the probe in 298 fresh and 39 snap frozen oesophageal specimens collected 
during surgery or endoscopy from 28 patients, confirmed the ability of this system to 
discriminate BO and neoplasia with high levels of sensitivity and specificity (88% and 87% 
respectively [208]. 
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Using a fibre-optic Raman endoscopy system under trimodal imaging guidance (WLE+NBI+AFI), 
an in vivo pilot study was recently conducted in 27 patients with suspected oesophageal cancer 
[209]. A non-negativity constrained least squares minimization (NNCLSM) biomolecular 
modelling and linear discriminant analysis were used to develop a diagnostic algorithm for 
separating normal oesophageal mucosa from cancer with 97% sensitivity and 95% a specificity. 
Impressively, the full promising potential of moving the Raman spectroscopy into real-time 
during routine endoscopy, has been recently realized in the context of a national gastric cancer 
screening programme in Singapore, where a large number of Raman spectra (2465 normal and 
283 gastric cancer) were acquired at 785 nm excitation from 305 patients [210]. The algorithm 
analysis developed had modest overall diagnostic accuracy but, most importantly, the study 
showed that real time acquisition per measurement (< 0.5 s) with a reasonably low power 
(1.5 W/cm2) can be achieved, which is critical for in vivo clinical applications. Previous in vivo 
work published by the same group, combining NIR AF (Near-infrared autofluorescence) and 
Raman spectroscopy, revealed significant differences in both the spectral intensities and Raman 
peaks of different colonic tissues, including normal colon, hyperplastic and adenomatous polyps 
[211]. Intensities of adenomatous polyps were significantly lower than hyperplastic polyps, and 
normal tissue (p = < 0.001). The spectral shapes from different types of colonic tissues showed 
different decreasing trends from 810 to 1050 nm. Based on previous experience [212], they 
assumed porphyrins to be the major endogenous fluorophores responsible for NIR AF emission 
in tissue, particularly in proliferative lesions [213]. Increased contents of porphyrins for the 
adenomatous polyps as compared to hyperplastic polyps and normal colonic tissue were found 
using the NNCLSM biochemical modelling. 
As anticipated in pioneering studies [204,214], with further development this technique has the 
ambitious potential to distinguish adenomas from hyperplastic or inflammatory colonic polyps, 
and low grade from high grade dysplasia within Barrett’s oesophagus, which still remain the 
major controversial issues in GI pathology. 
Coherent anti-Stokes Raman scattering (CARS) microscopy 
Based on contrast derived from molecular vibration, CARS has the potential to provide fast 
imaging on a molecular level label-free and with 3D sectioning capability. 
Unlike Stokes Raman spectroscopy, CARS employs multiple photons to probe the molecular 
vibrations, and produces a signal in which the emitted waves are coherent with one another. As 
a result, the CARS signal is orders of magnitude stronger than spontaneous Raman emission 
and, hence, can provide much faster imaging. 
101 
 
A detailed comparison of Raman imaging and CARS microscopy was carried out by Krafft et al. 
[69] on ex vivo colon tissue sections, offering the intriguing prospects of a combined 
complimentary method for label-free live-cell imaging at video-rate speed, which is ideal for 
most clinical applications. 
Although prototype endoscopes capable to collect CARS signals have been developed [215,216], 
progress toward delivering in vivo CARS imaging in GI endoscopy is still awaited. 
Diffuse reflectance spectroscopy 
Diffuse reflectance spectroscopy – also known as elastic scattering spectroscopy (ESS) – is used 
to study the diffuse component of the reflected light that has been scattered multiple times 
within the tissue sample to be investigated. 
A white light source, rather than a laser, is typically used to illuminate the sample and the 
reflected light is collected and transmitted by optical fibres to the analysing spectrometer. 
Delivery and collection fibres are usually separated by a set distance in order to allow the 
spectrometer to preferentially detect diffuse (rather than specular) reflections. The resulting 
data then consist of the diffuse reflectance of the sample as a function of wavelength. 
As the propagation of light through a biological specimen depends on its intrinsic absorptive 
and scattering properties, the light elastically scattered can report on architectural changes at 
both cellular and subcellular level associated with disease, such as cellular and nuclear 
enlargement and crowding, and increased nucleus-to-cytoplasm ratio [217,218]. 
Diffuse reflectance spectroscopy has been widely used in clinical studies of skin cancer [219-
221], cervix [222,223], and bladder [224,225]. A number of clinical studies have also been 
performed in the GI tract, demonstrating that diffuse reflectance spectra contain diagnostically 
useful information. 
Clinical experience 
Pioneering work with ESS was conducted by Mourant et al. in 1996 [226]. Reflectance spectra 
were taken in vivo from the colon of 15 patients and the stomach of 17 patients. The ratio of the 
area under the reflectance curve between 540 and 580 nm to that under that between 400 and 
420 nm was used to discriminate neoplastic from non-neoplastic colon tissue. The slope of the 
spectrum in the 435 to 440 nm range was used to reasonably separate active colitis from 
quiescent colitis and normal colon mucosa. Gastric dysplasia was found in only one case, and 
this was separated from normal and inflamed gastric epithelia using the ratio between 355 and 
360 nm to that between 630 to 635 nm. 
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Using multiple linear regression for spectral classification, adenomatous polyps were 
distinguished from hyperplastic polyps with sensitivity and specificity of 89 and 75%, 
respectively [227]. 
Zonios et al. [71] collected diffuse reflectance spectra in vivo on adenomatous polyps and 
adjacent normal colon in 13 patients undergoing colonoscopy. Significant spectral differences 
were observed, especially around 420 nm (Hb absorption valley), and these were attributed to 
the increased Hb concentration (6 times higher) of polyps relative to normal colon. In contrast, 
oxygen saturation was found to be similar in both normal and adenomatous tissue. 
Wallace et al. measured diffuse reflectance spectra in 13 patients with a diagnosis of Barrett’s 
oesophagus or suspected oesophageal cancer. The sites measured were subsequently excised 
and submitted for pathological assessment. The data were analysed by a model in which a site 
was classified as dysplastic if more than 30% of the nuclei were enlarged, with ‘enlarged’ 
defined as greater than 10 µm in diameter. Based on this model, the samples were correctly 
classified with high sensitivity and specificity (90 and 90%, respectively) for detecting either 
the presence of high grade or low grade dysplasia. 
In a study by Lovat et al. [72], ESS measurements were collected in vivo from 81 patients with 
HGD or early cancer within Barrett oesophagus, and matched with histological specimens taken 
from identical sites within the segment of BO. All biopsies were reviewed by three GI 
pathologists and classified as low risk (non-dysplastic or low grade dysplasia) or high risk (high 
grade dysplasia or cancer). ESS detected high risk sites with a high sensitivity 92% but the 
specificity was only 60%. The specificity increased to 79% when ESS was used to discriminate 
high risk sites from areas of inflammation. A concurrent study from the same group, conducted 
on 45 patients undergoing colonoscopy, showed that ESS was able to discriminate with 84% 
sensitivity and 84% specificity between adenomatous and hyperplastic polyps, 80% sensitivity 
and 75% specificity between cancers and adenomas, 77% sensitivity and 82% specificity 
between IBD and normal colon, and 85% sensitivity and 88% specificity between dysplastic 
polyps and IBD [228]. 
Low-coherence enhanced backscattering (LEBS) spectroscopy, a variant of ESS, was recently 
proposed as an endoscopic pre-screening method for colorectal cancer (CRC) screening. Based 
on the concept of field carcinogenesis, micro-scale spectral changes were measured in biopsies 
of endoscopically normal rectum obtained from 219 patients undergoing colonoscopy to predict 
whether their colon harboured cancer or advanced adenomas elsewhere [229]. LEBS-detectable 
alterations in endoscopically normal rectum were seen to mirror neoplasia progression from 
patients with no neoplasia, to 5 to 9 mm adenoma and to advanced adenomas. For advanced 
adenomas, the LEBS signals had a sensitivity of 100% and a specificity of 80%. Further studies 
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with an endoscopically compatible fibre-optic probe are under way for validation of these 
results in vivo. 
Angle-resolved low coherence interferometry 
Changes in density and size of cell nuclei are considered characteristic biomarkers of dysplasia. 
By analyzing the angular distribution of the backscattered light from a sample at different 
depths, this technique enables the measurement of cellular and nuclear morphology and offers 
the potential to assess cellular structure and organization in vivo. 
Pyhtila et al. [230] developed a probe-based frequency-domain angle resolved low-coherence 
interferometry (fa/LCI) system with sub-second acquisition time to make depth-resolved (up to 
150 µm) quantitative measurements of changes in the size and texture of cell nuclei in tissue 
samples. Three oesophageal specimens from 3 patients, who underwent oesophagectomy for 
Barrett’s neoplasia, were measured to examine the average nuclear size and density in healthy 
and dysplastic tissue, and findings were in complete concordance with histology. 
Fluorescence Spectroscopy 
Optical spectroscopy involves the study of the interactions of photons with biological tissue. The 
technique can be used either as point spectroscopy or as spectroscopic imaging. In point 
spectroscopy, a fibre probe is brought into contact with the tissue. Point by point measurements 
typically take 1-5 seconds for their execution and make it possible to take many more samples 
than can be currently achieved by conventional biopsies for histology, providing real time 
results. With point spectroscopy it is also possible to combine different optical techniques e.g. 
diffuse reflectance, time-resolved autofluorescence and light scattering spectroscopy, in one 
optical biopsy. 
Fluorescence spectroscopy is an attractive technique for clinical use as it can be developed into 
a real-time adjunct for endoscopic examinations. Although prospective comparative studies of 
this technique and white light endoscopy have not yet been reported, it may well be envisaged 
that it may help in picking up early changes invisible to standard visualization by WLE. 
Studies of autofluorescence spectroscopy and imaging, which provided useful guidance and 
reference material for the investigations conducted in this thesis, will be presented in chapter 3. 
2.6.6 Summary 
The aim of this section was to introduce the latest technologies that have the potential to change 
the way GI diseases are currently detected and characterised at endoscopy. They offer improved 
image resolution, contrast, and tissue penetration, and may report on biochemical and 
molecular changes beyond the discrimination of existing endoscopic methods. 
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Virtual chromoendoscopy and fluorescence endoscopy may be used in combination with 
magnification and high definition endoscopy for enhanced visualization of mucosal structures. 
Confocal endomicroscopy and endocytoscopy may allow for in situ disease characterization at 
cellular and sub-cellular level. Moreover, detailed morphological and molecular information 
may be achieved with light-scattering, autofluorescence and Raman spectroscopy. Furthermore, 
OCT may offer the visualization beyond the mucosa extending the view of the endoscopist to the 
deeper layer of the GI wall. 
However, the adoption of any of these techniques in clinical practice still requires further 
extensive evaluation.  
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2.7 Unmet clinical needs in GI endoscopy 
The diagnostic accuracy of both conventional and advanced endoscopy is still not satisfactory 
[160,169,231-233]. Despite all the recently achieved technological advances described in this 
chapter, easy and accurate detection of dysplasia, early detection of malignancies and accurate 
discrimination of inflammatory disease from neoplasia remain the main challenges in GI 
endoscopy. There are at least five main domains where the clinical needs are still not met, which 
are: 
1. Polyps 
2. Early stage neoplastic lesions 
3. Flat and elevated dysplasia in inflammatory bowel disease (IBD) 
4. Dysplasia in Barrett’s oesophagus (BO) 
5. Inflammatory conditions characterised by macroscopically inconspicuous mucosa such 
as eosinophilic oesophagitis and microscopic colitis. 
In these conditions, the ability to detect and discriminate dysplasia or neoplasia from 
regenerative, inflammatory or hyperplastic changes would be of great interest to the 
endoscopist and benefit to the patient. 
Ideally, endoscopists should be able to detect, characterise and confirm the nature of a lesion at 
the bedside, minimising uncertainties and targeting biopsies and resections only where 
necessary. However, under conventional WLE inspection, at present the sole established 
technique available to most of humanity, premalignant conditions and early cancers with 
minimal or absent mucosal abnormalities can frequently escape detection. 
For colonic polyps, miss rates of up to 25% during colonoscopy have been reported [234-236]. 
Interval cancers have also been found in patients with a history of adenomatous (premalignant) 
polyps, despite regular colonoscopy surveillance [237,238]. As discussed in section 2.1.2, 
adenomas usually originate as diminutive polyps. However, only two thirds of colorectal cancer 
seems to develop through the stage of adenoma, the other third growing de novo from normal 
epithelium [43]. Aberrant crypt foci, defined as colonic crypts with a larger diameter and a 
thicker epithelium than normal mucosa, have been proposed as one of the earliest stages of 
malignant transformation. However, these changes are too subtle to be visualised with a 
standard endoscope [239]. Similarly, detection of flat polyps, which are characterised by a high 
malignant potential compared to sessile and pedunculated polyps [45,46], can be extremely 
difficult because of the less well-defined subtle findings. 
Detection of early stage neoplastic lesions of the GI tract is still a grey area in clinical endoscopy 
due to the minute changes such as faint mucosal irregularities or discoloration, which can be 
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easily overlooked. For instance, apart from Japan, only 10% of gastric cancers are detected at an 
early stage in most of the world [19]. Although chromoendoscopy is increasingly employed, the 
identification of early cancer remains poor unless an obvious abnormality such as an ulcer or 
mass is found. 
Dysplasia and malignant transformation represent the most important complication in patients 
with IBD. At present, annual endoscopic surveillance is recommended after 8-10 years of 
disease. In patients with UC, if no lesions are observed, four biopsy specimens are taken 
randomly at every 10 cm between the rectum and the caecum for a total of 40-50 biopsies per 
colonoscopy [38]. However, even this massive sampling regimen examines less than 1% of the 
total colonic mucosa surface. In addition, the natural history of dysplasia in the context of IBD is 
poorly understood. Dysplasia in IBD can be flat (endoscopically invisible) or elevated 
(endoscopically detectable)[240]. Elevated lesions are referred to as dysplasia-associated 
lesions or masses (DALMs), and are broadly separated into adenoma-like and non-adenoma-like 
depending on whether they resemble or not endoscopically to sporadic adenomas unrelated to 
IBD. It is still unclear if all elevated dysplastic lesions begin as flat endoscopically invisible 
dysplasia, and it is extremely difficult if not impossible to discriminate dysplasia from 
regenerative or inflammatory changes both in presence or absence of a visible lesion (i.e. 
pseudopolyps, DALM, raised or depressed areas of mucosa). One of the major problems faced by 
clinicians during endoscopic surveillance for cancer in patients with IBD is the histological 
finding of dysplasia detected in random (non-targeted) biopsies of diffusely inflamed mucosa as 
well as of macroscopically normal mucosa, and not in those targeted to a visible lesion. 
In Barrett’s oesophagus, up to 40% of high grade dysplasia was found to be associated with 
inconspicuous synchronous occult foci of adenocarcinoma after oesophagectomy [241,242]. 
Standard videoendoscopy identifies BO and obvious mucosal abnormalities (e.g. nodules, raised 
and depressed areas) but cannot distinguish intestinal metaplasia from dysplasia or other types 
of metaplasia (cardiac, oxyntic) not at risk of malignancy. Moreover, the current standard 
method for detecting dysplasia in patients with BO is a random 4 quadrant biopsies protocol, 
but dysplasia can easily be missed as only a small fraction of the Barrett's segment (less than 
3.5% of the total surface of a 2-cm-long segment) is sampled [32]. 
Finally, in frequently encountered benign conditions like eosinophilic oesophagitis and 
microscopic colitis, whose incidence has rapidly increased over the last few decades, there is no 
sign of inflammation on the mucosal surface during the endoscopic examination, and therefore 
multiple random biopsies are necessary for the diagnosis. However, the diagnostic yield of 
random biopsies is often low and incurs a high cost [243,244]. 
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Beside these considerations, another important emerging need is the increasing demand for 
endoscopy arising from screening and symptomatic work in an era of increasingly finite 
resources. This poses the difficult question of how to maintain and advance achievements in 
research and education, whilst meeting the rising demand on endoscopy services and 
constrained capacity.  
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Chapter 3: Introduction to fluorescence, fluorescence 
lifetime and autofluorescence spectroscopy and imaging 
This chapter provides an introduction to the principles, techniques and prior knowledge that 
directly relate to the experiments described in this thesis. The first section will introduce the 
principles and properties of fluorescence and fluorescence lifetime, and the methods used for 
their measurement will be discussed. Relevant definitions and examples will be provided to 
clarify the terminology used throughout this thesis. It will also review the current knowledge 
relating to the interaction of light with biological tissue and the origins of tissue 
autofluorescence. Autofluorescence is a complex phenomenon that has been studied widely, but 
its origins are still not entirely known for many tissue types. The known endogenous 
fluorophores of biological tissue are then described in detail, followed by a discussion on the 
expected and possible fluorophores within the different structures of the gastrointestinal wall. 
The second section will give an overview of the state of the art of endoscopic instrumentation 
for fluorescence lifetime spectroscopy (FLS) and imaging (FLIM), with an emphasis on the 
systems in current development at Imperial College. 
In the third section, a comprehensive literature review of autofluorescence spectroscopy and 
imaging in the gastrointestinal tract, focusing on studies of premalignant and malignant 
conditions. Finally, a summary with the motivation for the work presented in this thesis is 
discussed. 
3.1 Introduction to fluorescence 
Fluorescence is defined as the emission of light by a medium (e.g. tissue) that has absorbed light 
of a different wavelength. In most cases, the emitted light has a longer wavelength, and 
therefore lower energy, than the absorbed radiation. Stokes coined the term “fluorescence” to 
describe this phenomenon in 1852 [245]. 
Fluorophores are molecules within tissue that spontaneously emit light when illuminated by 
light at appropriate wavelengths. When these molecules are illuminated they can absorb energy 
from the incident photons and an electron within the molecule may enter an excited state.  The 
absorption spectrum is characteristic of the absorbing species. An electronically excited 
molecule may remain in an excited state for a period of picoseconds to nanoseconds before 
subsequently returning to its ground state by the spontaneous emission of a photon. 
Because this process is not 100% energy efficient, the emitted photon will necessarily have less 
energy, and therefore a longer wavelength, than the absorbed photon. Thus fluorescence will 
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have a longer wavelength than the excitation light; this phenomenon is known as Stokes’ shift.  
A fluorophore in the excited electronic state may also return to the ground state by a number of 
non-radiative processes (i.e. without the emission of fluorescence). The likelihood that radiative 
or non-radiative decay occurs depends on the fluorophores’ physicochemical environment and 
may be sensitive to factors such as local pH or viscosity. 
It should be noted that while the excitation of a fluorophore molecule is usually by a single 
photon, it is possible for it to be excited by absorbing 2 lower energy photons at virtually the 
same time. The 2 photons will each have half the energy (and therefore double the wavelength) 
that a single exciting photon would have and so together provide the necessary total energy to 
promote an electron from the ground state to an excited electronic state. This two-photon 
excitation forms the basis of multiphoton microscopy [246]. 
When investigating fluorescence, one may consider the intensity, the wavelength of both the 
excitation light and the emitted fluorescent light, and the lifetime of the emitted fluorescent 
light. These values will be different for different fluorophores. Thus, a fluorophore may be 
characterised by its quantum yield, its excitation and emission spectra and its fluorescence 
lifetime [247]. 
3.1.1 Fluorescence Intensity and Quantum Yield 
The intensity of the fluorescence emitted by a fluorophore is a function of its concentration and 
its quantum yield. When a fluorophore absorbs photons, not all of the excited molecules will 
fluoresce as some may return to the ground state by non-radiative means. 
The quantum yield (Φ) of the fluorophore may be defined as the number of molecules that emit 
fluorescence divided by the total number of molecules excited (equation 3-1). 
   
                         
                          
 Equation 3-1 
It may also be expressed in terms of the radiative (Γ) and non-radiative (k) decay rates of the 
excited fluorophore (equation 3-2). 
   
 
     
 Equation 3-2 
Absolute values of quantum yield for a fluorophore are very difficult to determine as they 
require knowledge of both the absorbed and emitted radiation fluxes and the fluorophore 
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concentration. This is particularly difficult in biological tissues, where a number of light-matter 
interactions such as scattering and absorption complicate the measurement. 
3.1.2 Fluorescence Spectra 
For each fluorophore there is a range of vibrational energy levels in the excited electronic state 
into which the fluorophore can be excited from the ground state by absorbing a photon. 
Consequently, photons of different amounts of energy (i.e. light of different wavelengths) may 
excite a fluorophore and generate fluorescence. The range of wavelengths of light that can excite 
a fluorophore is referred to as the fluorophore’s excitation spectrum. Similarly, a fluorophore in 
the excited state can undergo radiative electronic transition to a range of vibrational energy 
levels in the ground state. Thus the emitted photons from a fluorophore will have varying 
amounts of energy and so the emitted fluorescent light will be of a range of different 
wavelengths. The range of wavelengths of light that can be emitted following excitation of a 
fluorophore is known as the fluorophore’s emission spectrum. Because of the Stokes’ shift the 
emission spectrum of a fluorophore will always be red-shifted with respect to the excitation 
spectrum. As different fluorophores have different fluorescence spectra, the spectral resolution 
of fluorescence from a heterogeneous sample may help discriminate between different 
fluorophores. 
3.1.3 Fluorescence Lifetime 
Following light absorption, a fluorophore will remain in an excited electronic energy state for a 
very short period of time before returning to their ground state via emission of fluorescent light, 
in a manner somewhat similar to the radioactive decay of an unstable atom. 
Thus, fluorescent light from a sample does not instantaneously cease the moment that the 
excitation light is extinguished; rather, it decays away over a period of nanoseconds as excited 
fluorophore molecules in the sample return to their ground state (figure 3-1). 
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Figure 3-1: Illustration of the decay of fluorescence from a sample over a period of picoseconds after 
removal of the excitation light. Adapted and reproduced with permission from [248,249]. 
This period is referred as to fluorescence lifetime (FL) and the energy transfer is schematically 
illustrated with the classical Jablonski diagram (figure 3-2 (a)). 
Thus, fluorescence lifetime is the average time a fluorophore takes to radiatively decay after 
having been excited from its ground energy level, and, like the quantum yield, is also a function 
of the radiative and non-radiative decay rates and so can provide quantitative fluorescence 
based molecular contrast. The key point is that different fluorophores decay at different rates, 
and this parameter can be mapped at every pixel in an image in order to produce a fluorescence 
lifetime image (figure 3-2 (b)).  
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Figure 3-2: (a) Jablonski diagram showing electronic energy levels of ground (E0) and excited (E1) 
states and both radiative (Γ) and non-radiative (κ) decay pathways in a fluorescent molecule. (b) After a 
short pulse of light, fluorescence emitted from the sample decays away over a period of nanoseconds as 
excited molecules return to their ground state. FLIM produces images using the fluorescence lifetime 
determined at each pixel to provide image contrast, displayed through a false-colour scale, between tissues 
or different components within the tissue with different fluorescence decays. 
The rate of this decay is dependent on the fluorescence lifetime (τ) of the sample, which is 
defined as the average time that a fluorophore molecule remains in the excited state before 
returning to the ground state. Typical fluorescence lifetimes are of the order of picoseconds 
(10-12 s) to nanoseconds (10-9 s). The fluorescence decay is approximately exponential for a 
single fluorescent species. A mathematical description of this single exponential decay in 
fluorescence intensity from such a fluorophore following cessation of the excitation light is 
shown in equation 3-3: 
       
 
 
  Equation 3-3 
where It is the fluorescence intensity from the sample at time t after the excitation light has 
ceased, I0 is the fluorescence intensity at time 0 (i.e. at the instant the excitation light is 
removed) and e is the exponential constant (e = 2.718281…). Thus, unlike quantum efficiency, 
fluorescence lifetimes can be determined from relative intensity measurements without the 
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requirement for knowledge of fluorophore concentrations and radiation fluxes. Just as 
fluorophores have characteristic fluorescence spectra, they also have different fluorescence 
lifetimes. The temporal resolution of fluorescence adds an extra dimension of contrast to 
distinguish and contrast between different fluorophores in a heterogeneous medium. 
The lifetime of a fluorophore depends on the rate of decay from the excited electronic state back 
to the ground state by both radiative ( ) and non-radiative ( ) means (equation 3-4): 
   
 
   
 Equation 3-4 
The radiative decay rate ( ) is essentially a function of the fluorophore and is relatively 
unaffected by its surrounding environment. Conversely, the non-radiative decay rate ( ) 
depends on the fluorophores’ local physicochemical environment. It may be sensitive to a 
number of different parameters such as viscosity, temperature, pH and oxygen concentration as 
all these factors may impact on the intermolecular events that account for the non-radiative 
transition of an excited fluorophore to its ground state. Therefore, fluorescence lifetime can be 
influenced by, and so can be used as an indicator of, a certain fluorophore’s local environment.  
Thus, the measurement of temporally resolved fluorescence affords the possibility of obtaining 
functional as well as structural information. 
A single exponential decay model provides an accurate description of fluorescence decay only if 
a single fluorescent species is present in the sample being excited.  If more than one fluorophore 
or fluorescent species is present the various fluorophores will each contribute to the sample’s 
fluorescent decay. In heterogeneous samples such as tissue a mixture of fluorescent 
components in a variety of environments would be expected resulting in a very large number of 
separate decays. For example, a protein may contain a large number of residues of the 
fluorescent amino acid tryptophan; the different positions of the tryptophan moieties within the 
protein and the different conformations of the protein will all affect the fluorescence lifetimes 
[250]. A multiexponential decay rather than a single exponential may then be more appropriate 
model, where the intensity profile of a fluorescent sample with n exponential decay components 
is expressed by the following equation [251,252]: 
      ∑   
    ⁄
 
   
 Equation 3-5 
where τi represent the decay constants and αi the pre-exponential factors. 
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Having recorded the fluorescence decay and extracted the decay constants τi and pre-
exponential factors αi, the sample under investigation can therefore be parameterised using a 
single value obtained calculating the intensity weighted mean fluorescence lifetime according to 
equation 3-6: 
       
∑     
  
   
∑     
 
   
 Equation 3-6 
An alternative way to parameterise the sample is to calculate the amplitude weighted mean 
fluorescence lifetime and this can be achieved according to equation 3-7: 
        
         
     
 Equation 3-7 
An important characteristic of the fluorescence lifetime is that it is an inherently ratiometric 
quantity as it depends on the intensity decay as a function of time and not on the absolute 
intensity [252]. As such, unlike measurements with the intensity signal alone, measurements of 
the fluorescence lifetime do not suffer from uncertainties due to variations in fluorophore 
concentration or excitation power [253,254]. For this reason, considerable research efforts have 
been directed towards the development of instruments for time-resolved fluorescence 
spectroscopy and imaging [255-259]. Additionally, the fluorescence lifetime has been shown to 
be sensitive to the local environment of a fluorophore, reporting on factors such as pH [260], 
ionic concentration [261], viscosity [262] and temperature [263,264]. Most importantly from 
the perspective of this thesis, the fluorescence lifetime has been shown to help discriminate 
between healthy and diseased tissue [265-273]. 
3.1.4 Autofluorescence of biological tissue 
When studying autofluorescence of biological tissue, the molecular composition is often 
unknown and so tissue autofluorescence can present a complex signal resulting from an 
unknown number of endogenous fluorophores with unknown relative concentrations.  
Interpretation of autofluorescence data is therefore highly challenging, typically requiring a 
priori knowledge of tissue structure and physiological function to yield quantitative 
information.  Nevertheless, the potential for label-free contrast as a diagnostic tool is compelling 
and empirical autofluorescence contrast is finding its way into clinical practice while an 
increasing number of ex vivo and in vivo studies, including this thesis, are directed at 
understanding the molecular origins of tissue autofluorescence and the contrast available. 
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In biological tissue, autofluorescence can provide a source of label-free optical contrast, offering 
the potential to discriminate between healthy and diseased tissue. The prospect of detecting 
molecular changes associated with the early manifestations of diseases such as cancer is 
particularly exciting. For example, accurate and early detection of cancer allows earlier 
treatment and significantly improves prognosis [274]. 
The autofluorescence signal excited in biological tissue will depend on the concentration and 
the distribution of the fluorophores present, on the presence of chromophores (principally 
haemoglobin) that absorb excitation and fluorescence light, and on the degree of light scattering 
that occurs within the tissue [275]. Autofluorescence therefore reflects the biochemical and 
structural composition of the tissue, and consequently is altered when tissue composition is 
changed by disease states such as inflammation or cancer. In order to exploit autofluorescence 
for clinical applications, it is first necessary to investigate the autofluorescence “signatures” of 
normal and diseased tissue states. 
The interactions of light with biological tissue 
Biological tissue is a complex optically turbid medium and only a small fraction of incident light 
is returned as fluorescence. When incident light reaches the surface of a tissue it may be directly 
reflected or it may enter the tissue. Light is scattered within the tissue due to small differences 
in the refractive index caused by cell nuclei and cell organelles [276]. It may then exit the tissue 
surface as diffusely reflected light or be absorbed by molecules within the tissue. If the light is 
absorbed by a fluorophore it may be converted to fluorescence. This fluorescence light is again 
scattered within the tissue and may be reabsorbed by another molecule or may exit the tissue 
(figure 3-3). Thus the measurement of tissue fluorescence is complicated by the tissue 
scattering and absorption of both the excitation and the fluorescence emission light. It follows 
that the fluorescence intensity and excitation and emission spectra of the tissue may be altered. 
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Figure 3-3: Schematic diagram illustrating the interactions of light with biological tissue. Adapted and 
reproduced with permission from [277]. 
Fluorescence lifetime values are less affected by the effects of absorption and scattering in 
tissue [278]. The principal absorber of excitation and emission light in the UV and visible 
wavelengths in biological tissue is haemoglobin [279]. Its absorption is wavelength dependent 
and generally decreases with increasing wavelength, with maximal absorption at around 420 
nm. As a result, the penetration depth of light into biological tissue ranges from a few hundred 
micrometres for UV light to several centimetres for near-infrared as light absorption by 
haemoglobin decreases [280]. Only those fluorophores contained in the tissue layers to which 
the excitation light penetrates and from which emitted light can reach the tissue surface will 
contribute to the tissue fluorescence measured at the surface.  
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The origins of tissue autofluorescence 
Biological tissue contains a number of fluorophore molecules. These endogenous fluorophores 
account for the autofluorescence observed from biological tissue on illumination with an 
appropriate wavelength of excitation light. Analysis of tissue autofluorescence provides insights 
into the structure, composition and metabolic status of tissue. 
The main tissue fluorophores include collagen and elastin (crosslinks), reduced nicotinamide 
adenine dinucleotide (NADH), oxidized flavins (FAD and FMN), and porphyrins.  As shown in 
figure 3-4, these fluorophores have their excitation maxima in the UVA or the blue (325-
450 nm) spectral region and emit fluorescence in the near-UV to the visible (390-700 nm) 
region of the spectrum. 
 
Figure 3-4: Excitation and emission spectra of main endogenous tissue fluorophores. Adapted and 
reproduced with permission from [213]. 
The excitation and emission spectra of the main tissue fluorophores are reported in table 3-1. 
Unfortunately, many of the endogenous fluorophores found in biological tissue have similar or 
overlapping emission spectra (e.g. collagen, elastin and NADH). This necessarily limits the 
contrast that can be achieved by imaging spectrally-resolved fluorescence at a single excitation 
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wavelength. Investigators using point measurement techniques of spectrally-resolved 
fluorescence usually compare the emission spectra at two or three excitation wavelengths to 
help differentiate between the different fluorophores present.  Fluorescence lifetimes can help 
differentiate between the different biological fluorophores. 
The main endogenous fluorophores fall into three categories: the aromatic amino acids 
(tryptophan, tyrosine and phenylalanine); molecules involved in tissue metabolism (NADH and 
flavins); structural matrix proteins (elastin and collagen). In addition, other fluorophores that, 
depending on their concentrations, may contribute to tissue autofluorescence are porphyrins, 
vitamin A, vitamin B6 and lipoproteins. 
Fluorophore  Optimal Excitation (nm) Emission Spectra (nm)  Lifetime (ns)  
Tyrosine 250-290 300 2.5 
Phenylalanine 240-270 280 7.5 
Tryptophan 250-310 350 3.03 
NAD(P)H free 300-380  450-500  0.3 
NAD(P)H protein bound 300-380 450-500 2.0-2.3 
FAD  290-520  520-570  2.91 
FAD protein bound 420-500 520-570 <0.01-1 
FMN 420-500 520-570 4.27-4.67 
Riboflavin (Vitamin B2) 420-500 520-570 4.12 
Elastin  300-370  420-460  ≤ 2.3 
Collagen  280-350 370-440  ≤ 5.3 
Melanin  300-800 440, 520, 575  0.1/1.9/8  
Keratin  290 525  1.4  
Protoporphyrin IX 400-450 635-710 up to 15 
Lipofuscin 340-395 430-460, 540 1.34 
Table 3-1: Spectral characteristics and absolute lifetime values of the main endogenous tissue 
fluorophores reported in literature [280-282].  
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Aromatic amino acids 
The aromatic amino acids tryptophan, tyrosine and phenylalanine are all fluorescent [275] and 
proteins containing these amino acids are found throughout all biological tissues. However, they 
require UV-B or UV-C light for excitation as the excitation maxima of all 3 amino acids are below 
300 nm [275]; UV-B and UV-C light are both potentially harmful to living tissue and have 
extremely poor tissue penetration.  It is unlikely that aromatic amino acid fluorescence accounts 
for any of the tissue fluorescence measured in the experiments reported in this thesis. 
Pyridine nucleotides and flavins 
The pyridine nucleotides and the flavoproteins are intracellular molecules found predominantly 
within mitochondria. They play an important role as electron carrier co-enzymes in the electron 
transport chain of aerobic cellular metabolism for ATP production [283]. 
NADH derives from the nicotinamic acid and was discovered from deproteinised yeast extracts 
by Harden and Young in 1904 [284]. 
NADH and NAD(P)H are the reduced forms of the two nucleotides Nicotinamide adenine 
dinucleotide (NAD+) and nicotinamide adenine dinucleotide phosphate (NADP+). The 
difference between NADH and NAD(P)H in terms of their structure is a single phosphate group. 
The oxidised form NAD+ normally prevails over the one reduced. In contrast to NADH, the 
reduced form NAD(P)H predominates. However, NADH is found in greater concentrations than 
NAD(P)H within the cell and the fluorescence of NADH prevails over that of NAD(P)H [285]. 
Flavins are co-enzymes derived from riboflavin and were first isolated from egg white by Kuhn 
and Karrer in 1935 [286]. The most common forms of flavins are flavin mononucleotide (FMN) 
and flavin adenine dinucleotide (FAD). An isoalloxazine ring is responsible for the fluorescence 
emitted from their oxidised forms. 
Nicotinamide adenine dinucleotide is fluorescent in its reduced form (NADH) but only 
minimally so in its oxidised form (NAD+) [287]. The opposite is true for flavin adenine 
dinucleotide (FAD) and flavin mononucleotide (FMN); their reduced form does not fluoresce 
whereas their oxidised forms are fluorescent [287]. Because of this difference, measuring the 
fluorescence from tissue NADH and flavins can report on the ratio of oxidised and reduced 
electron carriers (“redox ratio”) and hence yield information on the tissue metabolic activity 
[287,288]. NADH fluorescence is maximal at excitation wavelengths of around 340 nm and little 
fluorescence occurs with excitation at wavelengths longer than 400 nm; the peak of its emission 
spectrum is at 460 nm [287]. Most intracellular NADH is found in the mitochondria, where it is 
usually bound to enzymes [289]. Protein binding increases the fluorescence quantum yield of 
NADH, affects its emission maximum and lengthens its fluorescence lifetime from 0.4 ns to 1.0-
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4.0 ns [290,291]. Skala et al. [292] recently demonstrated a decrease in protein-bound NADH 
lifetimes measured in vivo from severe dysplasia in the hamster cheek pouch model of oral 
carcinogenesis. 
FMN fluorescence quantum yield is roughly 10 times greater than that of FAD [293]. The flavins 
have excitation maxima of around 450 nm and emission maxima of 515-530 nm. The flavins 
have a broad absorption spectrum between 200 and 500 nm with an emission peak at 525 nm 
[293,294]. The fluorescence lifetime of FAD is around 4.7 ns; that of FMN is around 5 ns but 
becomes much shorter with protein binding [275,293,295,296]. 
Structural extracellular proteins 
Collagens are one of the most important contributors to tissue autofluorescence. They are found 
in extracellular matrix throughout the body [297]; tissues such as connective tissue, cartilage 
and bone are particularly rich in collagen. A large fraction of collagen autofluorescence is 
attributable to the cross-linkages that form between collagen molecules [298], although there is 
also some contribution from aromatic amino acids and from other fluorescent residues within 
collagen monomers [299]. 
At least 6 different types of fluorescent collagen cross-linkages have been described [298,300] 
and excitation and emission spectra have been measured for each of these crosslinks. These 
spectra, together with the spectra of the aromatic amino acids found within the collagen 
molecules, contribute to the excitation and emission spectra of the different collagen proteins. 
Collagen type IV (the principal component of basement membranes) has emission peaks at 
344 nm, 365 nm, 392 nm and 430 nm, with corresponding optimal excitation wavelengths of 
280-310 nm, 310-350 nm, 340-350 nm, and 320-380 nm [301]. In general, most collagens have 
excitation maxima of around 320-330 nm and emission maxima of around 400 nm. The 
fluorescence decays of collagen are similarly complex due to the contributions of different 
crosslinks and other fluorescent components [302]. 
Elastin is another insoluble polymeric structural protein found particularly in elastic tissue such 
as arterial wall, lung parenchyma and skin. Like collagen, elastin autofluorescence is believed to 
be partly due to its cross-linkages. As elastin autofluorescence is due to several fluorophores, its 
fluorescence decay profile is complex, with a mean lifetime of around 2.2 ns [302,303]. 
Porphyrins 
The porphyrins consist of a family of proteins derived from the tetrapyrrole molecule- 
porphyrin. They are found as intermediate metabolic products during the synthesis of haem. 
Protoporphyrin IX is the more studied type of porphyrin. Normally the concentration of these 
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molecules is low, and once haem is bound to iron in haemoglobin, their fluorescence is 
quenched and cannot be detected. 
The absorption spectrum of porphyrins consists of 4 peaks, the Soret absorption maximum at 
~405 nm and four smaller Q-bands ranging from 500-630 nm. Their fluorescence emission 
spectra peak between 624-633 nm, depending on the porphyrin. When excited at this 
wavelength, protoporphyrin IX was found to have a fluorescence peak at 633 nm [304]. 
Porphyrins are known to exhibit long fluorescence lifetimes up to 17 ns [305] [280-282]. 
Lipofuscin 
Lipofuscin is an intracellular pigment that has been found in a number of tissues, including the 
skin, brain, heart, liver and retina [282] [306]. In the colon, the presence of lipofuscin has been 
associated with melanosis coli and the use of anthraquinone laxatives [307,308]. It is found in 
histiocytes or macrophages and is considered to represent a cellular degradation product from 
cells undergoing apoptosis. It consists of aggregates of granules arising from the phagocytosis of 
degraded lipid from organelles of apoptotic cells. Lipofuscin accumulation is documented to be 
reversible if intake of the offending agent is suspended. Within the colon, the pigment is only 
found in the lamina propria sparing the crypts. 
Lipofuscin has an excitation spectrum between 440-470 nm, with an emission spectrum 
between 510-700 nm [309]. This falls within the excitation wavelength range used for the 
experiments of this thesis. However, its contribution to GI tissue autofluorescence is considered 
to be minimal [310] and has not been widely investigated. 
Schweitzer et al. [309] reported a fluorescence lifetime of 190 ps for the pigmented retinal 
epithelium, which is rich in lipofuscin, in a healthy volunteer using 468 nm excitation and 510-
700 nm emission. 
Origin of the intrinsic autofluorescence contrast in the GI tract 
The GI tract wall is composed by a complex combination of known and unknown fluorophores 
that occur in different concentrations, states (e.g. free/bound, oxidised/reduced) and at 
different depths. Each layer has a distinct fluorophore composition, so that even though each 
fluorophore has distinct fluorescence properties (e.g. lifetime), the fluorescence measured at the 
tissue surface results from the contributions of the fluorophores in each layer. 
Figure 3-5 shows a schematic diagram of the GI structure wall and the fluorophores expected to 
be contained in each layer based on a priori anatomical knowledge of the GI tissue composition.  
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Epithelium 
As discussed above, aromatic amino acids are ubiquitous constituents of biological tissue and 
are all fluorescent. However, their excitation maxima fall outside the wavelengths typically 
employed for autofluorescence studies. 
The more studied intracellular fluorophores are NADH, FAD and FMN. Stringari et al. [311] have 
recently postulated a free/bound NADH gradient along the epithelial cells associated with 
cellular proliferation and differentiation along the axis of small intestine crypt-villi. According to 
their study, proliferative cells at the base of the crypt are characterized by a glycolytic metabolic 
phenotype, thus they exhibit predominantly free NADH, while differentiated cells at the surface 
of the crypts have an oxidative phosphorylation phenotype and exhibit primarily protein bound 
NADH. 
Although not as widely investigated as NADH and flavins, mucins, which are found 
predominantly in the goblet cells, could also represent another possible source of intracellular 
fluorescence [312]. 
 
Figure 3-5: Cartoon showing the various layers making up the GI wall and the expected fluorophores 
contained in each layer.  
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Basement membrane 
Collagen type IV is primarily found in the basement membrane (linings surrounding the crypts – 
see figure 2.3) and it is considered to be the source of autofluorescence emitted from this layer 
[301].  
Lamina propria 
The predominant fluorophores found in the stroma of the lamina propria are collagen types I-III 
and V [7,313]. In normal colon, collagen type I was found to be the major collagen type in 
normal intestine (68%), followed by types III (20%) and V (12%) [314]. 
Contributions from porphyrins within erythrocytes have been recently suggested by Stringari et 
al. [311], although this was based on fluorescence lifetime values and no spectral evidence of 
porphyrins identification was provided. Normally, the concentration of porphyrins within 
erythrocytes is low (< 50-100 µg/dL [315,316]), and haemoglobin predominates [317] (free 
erythrocyte porphyrins/haemoglobin ratio = 1.69 µg ± 0.67 µg per gram of haemoglobin [318]). 
Haemoglobin fluorescence has also been reported in measurements of normal blood cells at 
457.9 nm [319] and of human lyophilized ferrous haemoglobin powder using two-photon 
microscopy [320]. However, it is still not clear the extent to which these molecules contribute to 
the fluorescence of this layer and further research is needed. 
Contributions from lipofuscin within lymphocytes and macrophages may also be expected [321-
323], although it does not generally contribute greatly to GI tissues fluorescence emission [310], 
especially in normal (non melanotic) mucosa. Interestingly, lipopigments are reportedly absent 
in both neoplastic and hyperplastic colonic polyps [324]. 
Contributions from NADH and flavins within myofibroblasts, lymphocytes and macrophages are 
also possible. 
The lamina propria contains a vascular network of blood vessels which drain into larger vessels 
in the submucosal layer. The walls of small arteries have multiple layers of smooth muscle cells 
and as they penetrate within the lamina propria become thinner and composed of less collagen 
and elastin. Veins are known to have smooth muscle only and no elastic fibres. 
Banerjee et al. [301] used excitation wavelengths between 280 and 350 nm to characterize the 
autofluorescence signatures of normal, dysplastic and neoplastic colon tissue ex vivo. Elastin did 
not appear to contribute to any of the autofluorescence peaks observed. 
Muscularis mucosae 
This thin layer consists of smooth muscle fibres and myofibroblasts. Contribution from 
myofibroblasts intracellular fluorophores may be possible. 
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Submucosa 
As for the lamina propria, contributions from collagen I-III and V are expected to be prominent. 
Type V collagen is produced in relatively large amounts by smooth muscle cells and was found 
to increase in Crohn’s disease [314]. Other contributions may arise from erythrocyte 
porphyrins, intracellular NADH and flavins within myofibroblasts and lymphocytes, and 
lipofuscin in macrophages. Arterioles may also contain a small amount of elastin. 
 Muscularis propria 
The intrinsic fluorescence from the muscularis propria is weak as this layer is essentially 
composed of muscle fibres, although minor contributions from myofibroblasts intracellular 
fluorophores might still be possible. However, the muscularis propria is a deep layer (~1000 
µm in normal colon [325]), often beyond the depths reachable by UV and blue light excitation 
wavelengths. 
Serosa 
Serosa is the deepest layer, consisting of simple squamous epithelium (mesothelium) and a 
small amount of underlying loose connective tissue composed of mainly collagen type I. The 
oesophagus is not lined by a serosa. 
3.1.5 Fluorescence lifetime imaging and spectroscopy 
As discussed in section 3.1.1, fluorescence lifetime (FL), is defined as the average time a 
fluorophore takes to decay after having been excited from its ground energy level. Different 
fluorophores decay at different rates, and this parameter can be mapped at every pixel in an 
image in order to produce a fluorescence lifetime image (figure 3-2(b)). 
Fluorescence Lifetime Imaging Microscopy (FLIM) is a powerful means to map the decay rate of 
fluorescence emitted from tissue samples, providing quantitative contrast. It can be achieved for 
a variety of fluorescence imaging instruments including wide field imaging, confocal 
microscopy, and two-photon microscopy. 
Optical fibre probe-based fluorescence lifetime spectroscopy (FLS), can resolve the fluorescence 
emission spectrum and fluorescence decay rate to provide a wealth of label-free information 
from biological tissue. 
The measurement of fluorescence lifetimes 
As mentioned in section 3.1, fluorescence lifetime can report on fluorophore type and its local 
refractive index as well as its chemical environment, and can therefore be a useful contrast 
parameter. There are two main ways of performing FLIM: time domain, and frequency domain. 
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Time-Domain FLIM 
The measurement of fluorescence lifetime in the time domain is performed by recording the 
intensity decay of fluorescence after excitation with a very short pulse of light, and can be done 
either by time-gating, as is used in wide-field microscopes, or by time-correlated single photon 
counting (TCSPC) as is used in confocal microscopes and spectroscopy systems.  Time-domain 
measurements are the most intuitive as they involve directly measuring the decay of 
fluorescence intensity over time. 
Time-Gating 
Time-gated FLIM is a technology most widely used in wide-field microscopes, and involves 
acquiring a number of images with very short exposure times at a number of delay times after 
the arrival of an excitation light pulse, as shown in figure 3-6. By comparing the relative 
intensities in the different time “gates” a profile of the decay can be built up to which a decay 
can then be fitted. 
 
Figure 3-6: The principle of time-gated detection for FLIM. The excitation light pulse is shown in purple 
with the fluorescence emission in green. Three detection time gates (t1, t2 and t3) are also shown. 
Time-Correlated Single-Photon Counting 
TCSPC is the gold-standard of fluorescence lifetime detection.  In this method the arrival time of 
each detected photon relative to the excitation light pulse is measured, therefore giving an 
accurate picture of the decay profile. 
When a fluorescence photon is detected, typically by a “photomultiplier tube (PMT)”, an 
electronic signal is sent to a “time to amplitude converter (TAC)”, which starts to linearly charge 
a capacitor that is subsequently stopped when the laser next emits a light pulse. The charge on 
the capacitor is then fed into an “analogue to digital converter (ADC)” and the time recorded in 
memory. Repetition of this process for many detected photons allows a histogram of photon 
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arrival times to be built up, and decay models can then be fitted to these data. A summary of the 
recording steps is given in figure 3-7. As TCSPC relies on point detectors it is used mainly in 
confocal, multiphoton and point spectroscopic systems [326]. TCSPC has the advantage of light 
efficiency as all detected photons are recorded, and accuracy, as the time-precision of the 
system can be very fine. 
 
Figure 3-7: Schematic diagram of the TCSPC acquisition procedure. 
Frequency Domain FLIM 
Frequency domain FLIM uses sinusoidally varying (or otherwise modulated) excitation light. 
The resultant fluorescence is then also sinusoidally modulated but with a reduction in the 
modulation depth (and average intensity) and a shift in phase, as shown in figure 3-8. 
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Figure 3-8: Phase shift and demodulation seen in frequency domain FLIM when exciting with 
sinusoidally modulated light. The phase shift, φ, is labelled as are the amplitudes of the excitation light, Aex 
and emitted light Aem and the respective average intensities, Iex and Iem. 
Instrument Response Function 
When a fluorescence decay measurement is performed, it should be noted that the signal 
received depends not only on the sample being analysed, but also on the response of the 
measuring system. No fluorescence lifetime measurement apparatus is perfect and as such there 
is a finite temporal extent of both the excitation light pulse and a limited resolution of the 
detection system. These factors combine to form an instrument response function (IRF) that 
must be taken into account when fitting fluorescence decays.  The method used to obtain the 
IRF depends on the system being used, but usually involves measuring the time response of a 
fluorophore with a short lifetime (e.g. erythrosin B, daspi) or a scatterer (e.g. Ludox). 
Displaying FLIM Images 
Once a decay model has been fitted to every pixel within an image, it is then necessary to display 
those data in an accessible and informative manner. The most straightforward way to do this is 
to make a false-colour image, in this manner an 8-bit colour image is formed where typically 
blue represents shorter lifetimes and red is for longer lifetimes, corresponding to a lifetime 
scale specified by the user. This display strategy takes no account of intensity though and 
therefore some important structural information may be lost; this may be remedied by merging 
the FLIM map with the integrated intensity image.  In this way the structural information is 
maintained and pixels with low signals which may have less accurate lifetime fits are given less 
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emphasis.  Images are merged in LabVIEW (National Instruments, USA). An example of FLIM 
map, intensity image and merge are shown in figure 3-9. 
 
Figure 3-9: Matched white light, fluorescence intensity and FLIM images of a fresh haemicolectomy 
specimen containing a moderately differentiated colonic adenocarcinoma. (a) white light image; (b) 
fluorescence integrated intensity image; (c) false colour FLIM map; (d) FLIM merge image showing clear 
visual contrast between areas of normal and malignant tissue. Adapted and reproduced with permission 
from [273].  
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3.2 Development of endoscopic instrumentation to utilise 
autofluorescence lifetime for the study and diagnosis of 
gastrointestinal disease 
Fluorescence lifetime technology can be used to detect changes in tissue state caused by 
diseases such as cancer [273], atheroma [327] and osteoarticular arthritis [328,329]. This is due 
to changes in the environment or changes in the relative concentration, both of which may affect 
the fluorescence lifetime of endogenous fluorophores such as collagen, elastin, reduced 
nicotinamide adenine dinucleotide (NADH), oxidized flavin adenine dinucleotide (FAD) and 
flavin mononucleotide (FMN), and porphyrins. It is also possible to use exogenous probes to 
distinguish disease states, which holds promise for minimally invasive tissue analysis. Whilst 
there have previously been a few demonstrations of fluorescence lifetime applied to endoscopy, 
which are discussed in detail below, there is still a significant amount of technological 
development and clinical study required before it can become a clinically viable method. 
The development and implementation of fluorescence lifetime measurement capability in 
endoscopic instruments for clinical use has provided the fundamental motivation for the studies 
described in this thesis. 
During this PhD, three endoscopic instruments consisting of a single point fibre-probe FLS 
system, a FLIM confocal endomicroscope and a wide-field FLIM fibre-optic endoscope have been 
developed for ex vivo and in vivo studies of fluorescence lifetime of tissue autofluorescence as a 
result of multidisciplinary team working. A novel compact FLS fibre-optic probe system was 
constructed ex novo and a full characterisation is presented in chapter 7.  The contrivance of this 
instrument is demonstrated through its application to both ex vivo and in vivo measurements. 
The FLIM confocal endomicroscope and the wide-field fibre optic FLIM endoscope were not 
used in the studies presented in this thesis as further refinements and developments of these 
instruments are still ongoing. 
3.2.1 Single point fluorescence lifetime spectroscopy (FLS) instrumentation 
Single point spectroscopic measurements for studying tissue autofluorescence are typically 
obtained using a spectrofluorometer and a fibre-optic based probe to deliver the excitation light 
and collect the resulting fluorescence from a sample, often combined with a spectrograph to 
capture fluorescence emission spectra and also reflected light spectra [330]. With broadband 
illumination, reflected light spectra can provide information concerning the elastic scattering 
properties of tissue samples and this has been used to identify diseased tissue [225]. 
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Fluorescence spectral measurements have been combined with fluorescence lifetime 
measurements in spectrofluorometers and fibre-optic probe instruments [255,256,266,303]. 
Multispectral fluorescence lifetime measurements are often realized using dichroic filters with 
multiple time-resolved detection channels or using a scanning spectrometer with a single time-
resolved detector [303] and spectrographs have been used with array detectors, including gated 
intensified CCDs [256], streak cameras [255] and time-correlated single photon counting 
(TCSPC) [331], e.g. [332]. 
Fluorescence lifetime spectroscopy (FLS) in the GI tract was pioneered by Mycek et al., whose in 
vivo study [265] on 24 polyps (13 adenomas, 11 non-adenomas) from 17 patients, using an 
excitation wavelength of 337 nm and detection in the range 530-570 nm, demonstrated shorter 
average lifetimes for adenomas compared to non-neoplastic polyps (9300 ± 400 ps vs. 10500 ± 
700 ps). They deployed a portable spectrometer specifically designed for use during endoscopy 
utilizing a nitrogen laser as excitation source to provide UV radiation with pulse durations of 4 
ns at 20 Hz repetition rate. The laser pulses were attenuated by neutral density (ND) filters and 
coupled by a lens into a 600 m diameter optical fibre. Tissue exposure was less than 0.5 J of 
excitation energy per pulse. The same fibre was used to collect AF emission from the tissue and 
directed through a bandpass filter with a centre wavelength of 550 nm. An avalanche 
photodiode was used to detect the decay signal, which was then recorded by a digitizing 
oscilloscope and finally transferred to a computer running LabVIEW software. 
FLS was further developed to measure fluorescence spectra and lifetime decays simultaneously, 
using a spectrograph-coupled intensified charge coupled device (ICCD) to collect the 
fluorescence emission in a single-shot with data acquisition times less than 1 s. The system was 
housed in a compact, portable three-shelf cart for clinical use and applied to the study of several 
human tissues in vivo including normal skin [256] and Barrett’s oesophagus [266]. 
FLS systems have then been implemented using a scanning monochromator with single channel 
lifetime measurement, two pulsed lasers providing excitation at 337 nm and 391 nm, and a 
sterilizable custom-made bifurcated probe [303], and applied to studies of ex vivo human 
glioblastoma [333] and in vivo atherosclerotic plaque disruption in animal model [334]. 
A streak camera-based FLS system was used by Glanzmann et al. [255] to acquire in vivo time-
resolved spectra of diseased and surrounding normal bladder, bronchi, and oesophagus, from 9 
patients during endoscopy. They also investigated the fluorescence decay of photosensitizers 
Hexyl-ALA and mTHPC in patients undergoing PDT for early cancers of the bladder and the 
oesophagus, respectively. This instrument utilized a nitrogen laser providing 337 nm excitation 
pulses at a repetition rate between 1 and 50 Hz, a high speed streak camera in “analog mode” 
that allowed short acquisition times (15 s total measurement time per location) with 
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subnoanosecond resolution, and a 4 m long fibre probe (core diameter 550 µm, outer diameter 
630 µm, NA = 0.22) specifically designed to be inserted into the biopsy channel of a 
conventional endoscope. The nitrogen laser was enclosed in a Faraday cage and the whole 
system mounted on a mobile trolley. 
3.2.2 Single point fluorescence lifetime spectroscopy (FLS) instrumentation designed 
and built by the Photonics Group at Imperial College London 
In 2007, De Beule et al. [258] developed a fibre probe-based fluorimeter capable of 
simultaneously measuring spectrally and time resolved fluorescence with dual excitation 
wavelength, 355 and 440 nm, designed to excite both NADH and flavoproteins. This instrument 
employed two compact pulsed laser sources operating at 37.1-40 MHz together with a 
multichannel time-correlated single photon counting (TCSPC) detection system to provide 
parallel fluorescence lifetime measurement in 16 spectrally resolved channels. This laser 
radiation was coupled into the excitation channel of a custom built fibre-optic probe that 
housed seven optical fibres, each with a diameter of 200 µm and a numerical aperture of 0.22, 
six of which served to collect fluorescence and one to deliver the excitation. This system was 
used to excite 23 freshly excised skin specimens with an average output power up to 200 mW 
for the 355-nm-laser diode and up to 1 mW for the 445 nm laser source, respectively. The whole 
instrument was mounted on a 60 x 60 cm2 breadboard to facilitate transportation, and was fully 
enclosed for safe use in clinical settings. The laser beams were combined using a dichroic mirror 
and subsequently coupled into a 200 µm diameter multimode fibre using a 10x microscope 
objective. Data acquisition was controlled using the Becker-Hickl “SPCM” software package. 
Later on, the initial blue laser diode was replaced by a high power laser diode providing 3.7 mW 
average output power at 445 nm excitation and the acquisition was controlled by a custom-
written LabVIEW program. Further development of this system has led to the FLS instrument 
that has been used for the experiments described in chapter 6, chapter 7 and 8 of this thesis. 
3.2.3 Fluorescence lifetime imaging (FLIM) instrumentation 
Wide-field FLIM is usually implemented with gated imaging detectors that sample the 
fluorescence signal. Crucial to the translation of fluorescence lifetime technology to endoscopy 
is the development of compact and real time systems that are suitable for in vivo clinical 
applications. Since the end of the '90s, several FLIM endoscope designs have been proposed [66-
68,335-338], and current efforts are directed to implement and validate this technology for 
modern endoscopy. 
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In 2005, Munro et al. [68] reported the first flexible FLIM  fibre-optic endoscope design, based 
on a wide field time gated FLIM for real time FLIM endoscopy. Excitation was provided by a 
frequency tripled Nd:YVO4 laser producing 10 ps pulses at a repetition rate of 80 MHz and a 
wavelength of 355 nm with up to 350 mW average power, was used as excitation source. The 
excitation light was coupled into a multimode fibre and introduced through the working 
channel of the endoscope. Proof of principle was shown on fresh human stomach and lamb’s 
kidney tissue. 
A multispectral FLIM flexible side-view endoscope, which was built around a flexible imaging 
fibre bundle, was then presented by Elson et al. [335]. The excitation source was a nitrogen 
laser providing 700 ps pulses at 20 Hz and a wavelength of 337 nm. The illumination was 
delivered using a separate adjacent multimode fibre. This set up was used in vivo in a hamster 
cheek pouch oral pre-cancer model, and in three patients undergoing surgery for glioblastoma 
multiforme [339,340]. 
Recently, Cheng et al. [338] presented the design of a small diameter flexible wide field FLIM 
endoscope capable of simultaneous multispectral FLIM imaging, which was built around an 
imaging fibre bundle. A frequency-tripled Nd:YAG laser was used as the excitation source 
(355 nm). Wide-field time-gated FLIM was implemented using an intensified charge-coupled 
device (ICCD) camera. The system was validated on a hamster cheeck pouch model of oral 
cancer. 
3.2.4 Confocal FLIM endomicroscopy instrumentation designed and built by the 
Photonics Group at Imperial College London 
The FLIM confocal endomicroscope (figure 3-10) is based on a commercially available probe 
based confocal laser endomicroscope (pCLE, Cellvizio GI, Mauna Kea Technologies, France), 
which is licensed for clinical use in the GI tract and for bronchoscopy [341]. This instrument is a 
laser scanning single-photon fluorescence fibre bundle endomicroscope that is capable of 
recording optically sectioned images with a variety of fibre probes using an excitation 
wavelength of 488 nm. The system has been adapted to also incorporate a Mai Tai Ti:Sapphire 
pulsed laser (Newport Spectra-Physics Ltd, United Kingdom) to generate shorter wavelength 
pulsed excitation light for FLIM acquisitions.  
The infrared output is frequency doubled to produce ~100 fs pulses of 355-495 nm light at a 
repetition rate of 80 MHz. The probe has a lateral resolution of ~1.4 μm, a working distance of 
60 μm and a field of view of 240 μm. The diameter of the distal tip is 2.6 mm, which is 
compatible with any endoscope/laparoscope having a working channel of 2.8 mm diameter or 
greater. The set-up was configured to change between FLIM and the standard fluorescence 
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intensity imaging [336]. Fluorescence from the sample is collected by the fibre probe and 
descanned by the laser scanning unit. The whole system is portable and is mounted on a 
breadboard fixed on a robust trolley specifically designed and built by the Photonics Group. 
This is the first microconfocal FLIM endoscope employing a fibre bundle probe and time 
correlated single photon counting in a clinically viable instrument. 
 
Figure 3-10: (a) Configuration of the modified TCSPC FLIM confocal endomicroscope. Adapted and 
reproduced with permission from [336]. (b) The FLIM confocal endomicroscope based on a commercially 
available confocal laser endomicroscope (Cellvizio GI, Mauna Kea Technologies, France). 
The greatest technological barrier to overcome is the background fluorescence from the fibre 
probes. At wavelengths typically used for autofluorescence studies (310 and 420 nm) [275,280], 
the fluorescence from the fibres occurs over the whole 3 m length, is very strong and completely 
masks the fluorescence arising from the few µm thick sample section to investigate. This limit 
fixed at 420 nm the shortest excitation wavelength currently exploitable with this 
implementation. One possible way to overcome this limitation is the construction of lower 
background fluorescence fibres prototypes. 
This limitation prompted the design of experiments using a bench confocal FLIM microscope to 
explore the potential for contrast available at 420 nm excitation in freshly excised GI tissue from 
patients undergoing endoscopic procedures. This work will be presented in chapter 4. 
However, it should be noted that when applied to Forster resonance energy transfer (FRET) 
imaging of live COS-7 cells in culture transfected with fluorescent proteins (EGFP and EGFP–
mCherry tandem FRET construct) this system showed a clear decrease in the lifetime of the 
EGFP donor expected for FRET in the tandem construct. The optically sectioned FLIM images 
(a) (b)
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were acquired in 2 s, which approaches the acquisition time required for investigating in vivo 
spatiotemporal dynamics of cell-signalling processes in animal models [342]. 
3.2.5 Wide field FLIM endoscopy instrumentation designed and built by the Photonics 
Group at Imperial College London 
The wide field FLIM system (figure 3-11(a)) has been used previously for wide field imaging of 
large pieces of biological tissue [270,273]. A Vanguard frequency-tripled Nd:YVO4 laser 
(Newport Spectra-Physics Ltd, United Kingdom) is used to generate excitation light.  This is a 
compact laser with a relatively small footprint. Its combination of high laser powers (up to 
350 mW) and relative portability make it useful for future in vivo FLIM endoscopy applications. 
It provides picosecond pulsed 355 nm ultraviolet excitation at an 80 MHz repetition rate. This 
wide-field FLIM setup is currently being adapted for endoscopy e.g. using a flexible 
ureteroscope (Flex X ureteroscope, Karl Storz GmbH, Germany) as shown in figure 3-11(b). This 
instrument has the exciting potential to rapidly screen fields of view of several square 
centimetres and plus provide a “red-flag” screening tool, at the expense of optical sectioning 
capacity. Ultimately, this system could be used to guide the subsequent use of probe-based 
optical techniques such as FLS to provide complementary spectral and lifetime measurements, 
with the ultimate goal of reducing or eliminating the need for tissue removal, processing and 
evaluation. 
 
 
Figure 3-11: (a) Schematic diagram illustrating the wide field FLIM endoscope set-up. Excitation light 
(dark grey) is directed onto the sample. Emitted fluorescent light (light grey) is collected by the endoscope 
and imaged onto the GOI. Adapted and reproduced with permission from [67]. (b) Photograph of the flexible 
ureteroscope (Flex X ureteroscope, Karl Storz GmbH, Germany) being adapted for wide field FLIM endoscopy. 
Aside from this flexible endoscopy setup, a handheld wide filed imaging rigid arthroscope is also 
currently under development for arthroscopic/surgical applications. This system implements 
(a) (b)
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rapid wide field time-gated imaging (6 gates per 0.2 s, 1.2 s total acquisition time) using a fibre-
taper coupled CCD and gated optical image intensifiers from Kentech Instruments Ltd (figure 
3-12). 
 
Figure 3-12: The wide field FLIM portable handheld rigid arthroscope for arthroscopic/surgical 
applications.  
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3.3 Review of research and clinical experience with autofluorescence 
spectroscopy and imaging 
One of the first reports on the use of quantitative fluorescence diagnostic techniques to 
discriminate between normal and diseased tissue appeared in 1965 [343]. The authors found 
that the fluorescence intensities of ex vivo cancerous tissue from oesophagus, stomach, breast 
and thyroid were less than that of normal tissue using excitation at 330 nm. Since then, there 
have been a large number of studies regarding the utility of fluorescence diagnostic techniques 
in the detection of disease and several comprehensive reviews have been published on the 
progress in this field [213,275,280,282,330]. The majority of these studies claim the potential of 
fluorescence techniques to detect early neoplastic changes, particularly in epithelial surfaces. 
Nowadays, there is an increasing interest in exploiting spectroscopic readouts of tissue 
autofluorescence and a number of groups have shown that GI disorders, including cancer, 
exhibit different autofluorescent signals from those of normal tissue.  Results are reviewed here 
by organ site. 
Oral cavity 
Evaluation of oral cavity, pharynx and larynx using AF imaging systems has become an essential 
tool for the screening of head and neck squamous cell cancers as a result of pioneering ex vivo 
studies [344,345].  Fluorescence spectroscopy and imaging of oral mucosa have been evaluated 
by several groups with the aim to detect malignant or premalignant conditions using excitation 
wavelengths in the UV [280,346] and for a wide range of UV and visible wavelengths (250-500 
nm) [345]. 
Uppal and Gupta [347] carried out enzymic measurements of NAD(P)H concentration on 
samples from nine patients with oral squamous cell carcinoma. All measurements were carried 
out on malignant tissue and normal appearing mucosa adjacent to the lesion from the same 
patient.  They showed that the concentrations of NAD(P)H in malignant sites of oral cavity 
tissue were significantly lower than in the healthy mucosa. 
Oesophagus 
A number of important papers published in the 1990s presented AF emission spectra that were 
collected in vivo from Barrett's oesophagus, malignant and normal tissue at 410 nm excitation 
[348-351]. These results showed that fluorescence of normal oesophageal mucosa and non-
dysplastic Barrett's epithelium could be distinguished from that of dysplasia and cancer in 
patients with Barrett's oesophagus.  
Mayinger et al. [352] used an innovative optical system delivering either white or violet-blue 
light for excitation of tissue AF during routine endoscopy. Nine patients displayed a 
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spinocellular carcinoma and 4 had an adenocarcinoma of the oesophagus. As a result, both types 
of cancer exhibited different emission spectra compared to those of normal oesophagus. 
The combined use of three different spectroscopic techniques (reflectance, fluorescence and 
light-scattering spectroscopy) has been shown to provide useful complementary information in 
patients with dysplastic Barrett’s oesophagus [70]. At 337 and 397 nm excitation, the 
progression from non-dysplastic, to low-grade, to high-grade dysplasia was accompanied by a 
broadening of the spectral lineshape together with a shift toward longer wavelengths (600–
750 nm). In a subsequent study from the same group, the fluorescence spectra of NADH and 
collagen in dysplastic tissue appeared considerably different from non-dysplastic mucosa [353]; 
dysplastic epithelium was characterized by low collagen and high NADH fluorescence intensity 
compared to normal oesophagus. This study advanced the concept of tissue fluorophores as 
quantitative biochemical markers of dysplastic change. 
Pfefer et al. [266] used excitation wavelengths of 337 and 400 nm and compared the 
measurement of fluorescence emission spectra to fluorescence decay profiles acquired at 
550 nm in vivo in 37 patients undergoing routine endoscopic surveillance for BO. In this study 
time-resolved fluorescence was unable to achieve sensitivity and specificity values above 60% 
for discriminating high risk (carcinoma, high grade dysplasia) from low risk (low grade 
dysplasia, non-dysplastic or indefinite for dysplasia) tissue, whereas moderate overall accuracy 
was achieved using steady-state fluorescence only. 
Further work to investigate the differences in the metabolic pathway between normal tissue 
and cancer was made using FLIM to measure intracellular oxygen concentration with a 
ruthenium based fluorescent probe (RTDP) in cultured normal and adenocarcinoma cells (from 
Barrett’s epithelium) of human oesophagus [354]. Higher intracellular levels of oxygen and 
NADH fluorescence intensity were sensed in the adenocarcinoma cells, while there was no 
significant variation in NADH lifetime between normal and neoplastic cell lines. 
The clinical diagnosis of adenocarcinoma in patients with short-segment Barrett's oesophagus 
(which is defined as intestinal metaplasia occurring in columnar epithelium <3 cm in length) is 
often challenging and controversial. Niepsuj et al. [355] used an adapted laser-induced 
fluorescence endoscopy device (LIFE, Xillix Technologies Corp., Canada) with blue light 
excitation (425-455 nm) in 34 patients with documented short-segment Barrett's oesophagus.  
In this study, a red-shift (to longer wavelengths) of the fluorescence emission was observed in 
metaplastic Barrett’s mucosa compared to normal oesophagus, and autofluorescence endoscopy 
increased the detection rate of high-grade dysplasia when compared with WLE. 
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Lin et al. [356] studied ex vivo biopsy specimens from 30 patients with Barrett’s oesophagus 
using high resolution AFI under 266 nm, 355 nm, and 408 nm excitation along with an image 
acquired using the same set-up under white light illumination. Distinct cellular organization and 
morphology related to disease progression could be identified and the pathological evaluation 
was confirmed by expert pathologists. 
More recently, AFI with blue light excitation has been combined with high-definition white light 
endoscopy and NBI in a single endoscope with two charge-coupled devices. This technology is 
referred as to as “trimodal imaging” and has been applied to identify inconspicuous Barrett's 
neoplasia [357] and assist endoscopic mucosal resection (EMR) of early neoplasia in Barrett's 
oesophagus [358]. In an international multicentre study involving 84 patients with Barrett’s 
oesophagus, the addition of AFI to high-resolution endoscopy increased the detection rate of 
early neoplasia within the Barrett segment, and additional viewing with NBI increased the 
overall specificity [357]. However, as with AFI alone, the increased detection of dysplasia was 
only marginal (11%), and did not translate into a real benefit for the patients. Moreover, AFI 
alone was associated with a high false positive rate (81%); therefore, the authors used NBI with 
optical magnification to further characterize areas detected by AFI, reducing the false positive 
rate to 26% (at the expense of misclassifying two lesions as falsely negative). 
Another large multicentre randomized trial with patients affected by Barrett’s oesophagus 
compared the diagnostic accuracy of surveillance with AFI-targeted biopsies plus 4-quadrant 
biopsies in comparison with the conventional Seattle protocol only. The investigators suggested 
that the AFI-guided biopsies improved the diagnostic accuracy for neoplasia in comparison with 
the conventional approach when using four quadrant biopsies.  However, because of decreased 
sensitivity, they concluded that AFI alone was not suitable for replacing the standard Seattle 
protocol [359]. 
Endoscopic molecular imaging using fluorescently labelled targeted peptides is being 
increasingly investigated for detection of inconspicuous dysplasia in BO. For example, glycans 
have been shown to be altered in GI cancers [175,360-362]. They have the potential to be used 
as a molecular target for fluorescence endoscopic imaging of GI mucosa. Glycan changes can be 
detected using lectins, which have specific affinity for particular glycans. AFI and a fluorescently 
labelled lectin, Tritiicum vulgare agglutinin (WGA), have been used to detect changes in glycan 
expression on the epithelial cell surface associated with the transition from BO through 
dysplasia to ADC [363]. In particular, AFI was used to image WGA in four oesophagectomy 
specimens obtained immediately after surgery. The specimens were intubated from the 
proximal end and both baseline WL and AFI images were acquired. Fluorescein-labelled WGA 
was sprayed over the oesophageal mucosa and imaged with 395-475 nm excitation. Specimens 
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were then opened along their vertical axis and imaged using an IVIS camera (Caliper Life 
Sciences), to enable quantification of fluorescence and registration with histology. A highly 
significant statistical correlation between WGA fluorescence and the degree of dysplasia was 
found (p = 0.0002), with areas of HGD and cancer showing lower fluorescence intensity and 
WGA binding relative to areas of non-dysplastic BO and normal oesophageal mucosa. 
Stomach 
Chwirot et al. [364] reported the first study on AF imaging of gastric cancers ex vivo. In 
particular, they imaged 21 surgically resected specimens using excitation at 325 nm and 
442 nm, and measured the fluorescence emission in six regions of the visible spectrum.  In all 
the spectral channels, the AF intensity of neoplastic tissue was found to be lower than that of 
areas of normal stomach in the same specimen. 
Immediately after surgery, Abe et al. [365] applied laser-induced fluorescence endoscopy 
(LIFE), which employs endoscopic AF imaging with excitation at 442 nm and emission detected 
in two bands around 520 nm and > 630 nm, to 61 gastric cancers resected from 50 patients.  
Comparison of these data with the histopathological diagnosis showed that depth of infiltration 
and mucosal thickening were correlated with differentiated cancers but not with 
undifferentiated cancers, which displayed a scattered pattern of tumour infiltration without 
altering the mucosal thickness. 
Silveira et al. [366] used fluorescence spectroscopy with excitation at 488 nm to detect benign 
and malignant lesions of ex vivo human gastric mucosa. Biopsies with endoscopic diagnosis of 
gastritis and gastric cancer of the antrum were collected from 35 patients during the endoscopic 
examination. On each biopsy fragment the AF spectrum was collected at 2 random points via a 
fibre-optic catheter coupled to the excitation laser. Analysis of fluorescence spectra was able to 
identify the normal tissue from neoplastic lesions with 100% of sensitivity and specificity. 
Ohkawa et al. [367] found that LIFE applied to 79 patients with gastric cancer, provided high 
sensitivity but poor specificity with limited clinical utility. Also, only a small degree of 
correlation was observed between histopathology and AF findings. 
Ito et al. [368] stained and imaged biopsy specimens of freshly resected gastric cancers from 
three patients with gastric cancer using an antibody anti-carcinoembryonic antigen (CEA) and 
tagged with a novel fluorescent label (ICG-sulpho-OSu), and an infrared fluorescence endoscope. 
They found that there was a good correlation between the intensity of the infrared fluorescent 
signal and the cancerous sites, suggesting that this technique can spot cancer cells and generate 
a relatively strong fluorescent signal to detect small cancers. 
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Xiao et al. [369] acquired AF images of gastric cancer ex vivo using a laser scanning confocal 
microscope with two detection channels in the green (505-530 nm) and red (> 580 nm). The 
two spectrally resolved image channels were then merged and presented to the clinician. 
Sixteen gastric cancer specimens and corresponding normal gastric tissue were imaged using 
both 488 and 543 nm excitation wavelengths. Normal stomach appeared green whereas a red-
brown image was found to be characteristic of all neoplastic specimens. Subsequently, the same 
group used a helium–cadmium laser system (Liconix 4240) at 442 nm excitation to acquire 
spectra in vivo from 38 patients with various gastric diseases, including cancer [370]. 
Interestingly, all spectra showed one major peak at 510 nm and three minor peaks at 590, 670 
and 710 nm. The intensity and shape of the spectra at 510 nm were found to be significantly 
different between cancer and normal gastric mucosa, and dysplasia and normal mucosa, but not 
between cancer and dysplasia. 
Mayinger et al. [371] used light-induced AF spectroscopy for in vivo diagnosis of gastric cancer 
studying normal and cancerous gastric mucosa in 15 patients with adenocarcinoma and 16 
patients with signet-ring cell gastric carcinoma. A system capable of exciting tissue AF 
alternately with white or violet-blue light was used. Endogenous fluorescence spectra emitted 
by the tissue were collected with a fibre-optic probe and analysed with a spectrograph. Both 
types of cancers emitted a less intense signal compared to normal tissue (2300 vs. 3700 a.u. 
approximately), with a lower total intensity between 480 and 570 nm. A higher red-to-green 
ratio was also observed in cancers compared to normal gastric mucosa. The sensitivity of 
fluorescence spectroscopy for the diagnosis of carcinoma decreased by 30% with the presence 
of signet-ring cells, which may be explained by the scattered and frequently submucosal 
infiltration of this subtype of adenocarcinoma (diffuse type according to the Lauren 
classification [372]). 
Kim et al. [373] performed preoperative AFI in 20 patients with early gastric cancers and then 
compared the endoscopic characteristics with histology after endoscopic submucosal 
dissection (ESD). Categorization of AFI images of gastric cancers into four patterns proved to be 
useful to delineate the dissection margins in the majority of cases. 
Liver and Pancreas 
Izuishi et al. [131] published the first pilot study using AF endoscopy in cancer of the biliary 
tract. They performed percutaneous transhepatic AF cholangioscopy in 9 patients with bile duct 
cancer using LIFE. Normal mucosa appeared as light blue whereas cancerous legions displayed 
a dark red fluorescence and also a white fluorescence in the majority of cases suggesting an 
additional contrast parameter for the diagnosis of bile duct cancer by AF endoscopy. 
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Chandra et al. [374] observed significant differences between the fluorescence and reflectance 
properties of normal, pancreatitis, and adenocarcinoma tissues. Measurements were associated 
with a larger collagen content detected in adenocarcinoma and pancreatitis than in normal 
tissue. Reflectance data indicated that adenocarcinoma had higher reflectance in the 430 to 
500 nm range compared to normal and only inflamed tissues. Subsequently [375], they used a 
fibre optic probe-based spectroscope to assess the diagnostic accuracy in 50 freshly-resected 
specimens of pancreatic adenocarcinoma and chronic pancreatitis. They developed a 
classification algorithm - the spectral areas and ratios classifier (SpARC) - which they showed 
could discriminate between healthy and diseased tissue and identify cancer with reasonable 
sensitivity and specificity (85% and 89% respectively). 
Liang et al. [376] evaluated the ability of two-photon microscopy (TPM) to detect the number of 
hepatitis C virus (HCV) infected cells in frozen sections of liver biopsy specimens from 9 
patients with chronic HCV-related hepatitis. TPM was able to determine the number of infected 
hepatocytes with considerably higher sensitivity than that achieved by biochemical detection of 
HCV proteins or viral RNA. 
Preliminary data from our group have shown AF lifetime contrast between cancerous and 
healthy tissue in one specimen of unfixed ex vivo liver containing metastatic colorectal 
carcinoma and in one unfixed pancreas containing an area of pancreatic adenocarcinoma. This 
was achieved using wide-field FLIM and the lifetime of neoplastic tissue AF induced by 355 nm 
excitation was shorter than AF from surrounding non-neoplastic tissue [273]. 
In a recent study conducted on freshly-excised GI tissue from 10 normal and 5 transgenic mice, 
excitation spectral signatures of epithelium, lamina propria, collagen, and lymphatic tissue were 
determined using hyperspectral two-photon microscopy with 740 nm excitation and three 
emission channels (350–505 nm, 505–560 nm, and 560–650 nm). Based on the 3D sectioned 
two photon images acquired, the morphology of these four main components was clearly 
visualized and compared to cross-sectional histology with a high degree of concordance [323]. 
Colon 
A large body of literature exists on the use of AF spectroscopy to investigate colonic polyps and 
adenocarcinomas. Typically, colonic neoplasms have shown decreased AF intensity compared to 
that of normal colon.  This can be attributed to the decrease with neoplasia of mucosal collagen, 
which is the dominant fluorophore, as a consequence of the enlargement of crypts that 
progressively displace the lamina propria. In addition, the submucosal contribution to the 
fluorescence in adenomatous tissue is reduced compared to that in normal colon due to the 
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increased thickness of the polyp and absorption by haemoglobin, as a result of increased intra-
tumoural microvessel density. 
The fluorescent architecture of normal colon, colonic adenoma and adenocarcinoma was 
studied by fluorescence microscopy in frozen tissue sections excited in the range 351 to 364 nm 
[377-379]. Collagen, present in all the layers of the GI wall, was responsible for the blue 
fluorescence emitted from normal tissues and adenomas, whereas the yellow-amber 
fluorescence was mainly attributed to the lamina propria.  Interestingly, adenomas displayed 
cytoplasmic blue-green fluorescence increasing with the degree of epithelial dysplasia.  This 
cytoplasmic fluorescence was not emitted from normal mucosal cells. The lamina propria of 
adenomas exhibited less fluorescence from collagen and was richer in blue-green fluorescent 
eosinophilic granules than that of normal colon [377]. Dysplastic adenomas displayed higher 
fluorescence intensity than normal tissue and lower fluorescence intensity than 
adenocarcinomas [379]. Conversely, Fiarman et al. [380], using confocal microscopy in frozen 
tissue sections with 488 nm excitation, claimed that the fluorescence from normal colonic 
mucosa arises primarily from the lamina propria, whereas the epithelium is the main source of 
fluorescence in adenomas and hyperplastic polyps. In normal tissue, the epithelium/lamina 
propria fluorescence intensity ratio was significantly lower than that of adenomas and 
hyperplastic polyps, and no statistically significant difference was seen between the ratios of 
both types of polyps. 
Izuishi et al. [381] did not observe any significant differences between the fluorescence 
intensities of frozen sections of normal, adenomatous and cancerous tissue obtained using 400 
to 440 nm excitation and 520 nm emission. Likewise, the concentration of flavins measured by 
high-performance liquid chromatography was not significantly different between normal and 
diseased tissue. Interestingly, the invasion of the submucosal layer was associated with a 
decreased fluorescence emission, in agreement with the hypothesis that collagen is the main 
source of colon AF. The screening effect of mucosal thickening and replacement of submucosa 
by cancer cells was proposed as a reason for the decreased fluorescence observed in cancerous 
tissue. 
Bottiroli et al. [322] identified different patterns of fluorescence intensity and spectra of AF 
emission between neoplastic and non-neoplastic tissue using a micro-spectrofluorometer with 
366 nm excitation.  The different patterns were related to distinct layers of the GI wall, and in 
the 480-580 nm band in particular, the spectra of neoplastic epithelia displayed higher intensity 
than those of normal colon epithelia, suggesting the role of different arrangements in the 
neoplastic stromal compartment as a possible explanation for the differences observed. 
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Using 370 nm excitation, Manoharan et al. [382] showed spectral differences between 
adenomas and normal mucosa, and proposed a model to extract quantitative contributions from 
different tissue structures like mucosal collagen, submucosa and dysplastic cells. 
Kapadia et al. [383] obtained fluorescence emission spectra from 35 normal specimens and 35 
adenomatous polyps of the colon at 325 nm excitation. They used multivariate linear regression 
analysis of the spectra and a binary classification scheme to develop and optimize an algorithm 
that differentiates adenomatous polyps from normal mucosa and hyperplastic polyps, 
retrospectively. The algorithm prospectively discriminated 16 adenomatous polyps from 16 
hyperplastic polyps and 34 normal tissues, with a sensitivity of 100% and specificity of 98%. 
A similar study was conducted in vivo by Cothren et al. [384] at 370 nm excitation from 31 
adenomas, 4 hyperplastic polyps and 32 normal sites of the colon. Following the sequence 
normal to hyperplasia to adenoma, they identified a characteristic decrease in the maximum 
fluorescence intensity at 460 nm and a relative increase in the fluorescence intensity at 680 nm. 
Using these spectral features, each tissue state was differentiated with high sensitivity and 
specificity. Later on, they also used an algorithm that was able to detect dysplasia in vivo during 
endoscopy with 90% sensitivity and 95% specificity [385]. 
Richards-Kortum et al. [386] measured fluorescence emission spectra from normal colon 
tissues and adenomatous colonic polyps, in vitro at a range of excitation wavelengths, spanning 
the ultraviolet and visible spectrum. They found that the spectral differences between normal 
and adenomatous colon tissues were greatest at 330, 370 and 430 nm excitation. Furthermore, 
at an excitation wavelength of 370 nm, fluorescence intensities at 404, 480 and 680 nm were 
found to be most useful for differentiating adenomas from normal colon tissues. 
In two consecutive studies by Schomacker et al. [387,388], emission spectra from normal sites 
(n = 86), hyperplastic (n = 35), adenomatous polyps (n = 49), and adenocarcinomas (n = 7) were 
collected both in vivo and ex vivo at 337 nm excitation. The spectra of neoplastic and 
non-neoplastic tissue were differentiated with a diagnostic accuracy of 87%, which is about the 
same as that of routine clinical pathology. Interestingly, the spectra emitted from ex vivo and in 
vivo tissues were also different and this change was attributed primarily to NADH, whose 
fluorescence was shown to decay with a half-life of approximately 100 minutes after resection. 
Yang et al. [389] excited fresh biopsies of normal (n = 39) and malignant colonic tissue (n = 35) 
using a range of excitation (290 to 340 nm) and emission (360-450 nm) wavelengths.  They 
then evaluated the ratio of the fluorescence emission intensities at 360 nm to 380 nm for 
excitation at 325 nm, and the ratio of the fluorescence emission intensities measured at 450 nm 
with excitation at 290 nm to 340 nm. An algorithm based on the ratio of these fluorescence 
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intensities separated adenocarcinomas from normal tissues with 94% sensitivity and 92% 
specificity. 
Chwirot et al. [390] observed that the intensity of AF emission at 325 nm excitation from 50 
surgically-resected specimens of neoplastic and premalignant conditions was lower than that of 
contiguous normal colon. The spectral bands centred at around 440 nm and 475 nm seemed to 
be most promising in terms of possible future clinical applications. 
Distinctive fluorescence emission spectra have also been shown in vivo from 32 adenomas and 
114 hyperplastic polyps at 337 nm excitation [129]. 
Mycek et al. [265] performed time-resolved AF spectroscopy in vivo on 24 polyps (13 adenomas, 
11 non-adenomas) from 17 patients. This was the first study in the colon that demonstrated 
differences in fluorescence lifetime decay between normal and dysplastic tissue. Adenomas 
showed faster average decays than those of non-adenomas (9.3 ± 0.4 ns vs. 10.5 ± 0.7 ns). 
Statistically significant AF lifetime contrast was observed between cancerous and healthy colon 
tissue in a series of 16 unstained ex vivo colonic tumours surgically resected, using wide-field 
FLIM. In this study, the lifetime of neoplastic tissue AF induced by 355 nm UV excitation was 
longer than AF from surrounding non-neoplastic tissue [273]. 
In a randomized trial on 100 patients undergoing screening colonoscopy, AFI was not able to 
significantly improve the diagnostic accuracy, with adenoma miss-rates similar to WLE [391]. 
In a multicentre prospective randomized controlled study, the use of trimodal imaging did not 
improve the detection rate for adenomas compared with standard endoscopy. NBI and AFI 
showed very little accuracy and specificity in differentiating adenomas from non-adenomas 
(63%, 75%, and 37%, 62% respectively) [233]. Also, differentiation of adenomas from 
hyperplastic polyps by using trimodal imaging in patients with patients with hyperplastic 
polyposis was unsatisfactory [392]. 
Another study from Japan showed that the fluorescence intensity of images aquired using an 
AFI system is inversely proportional to the degree of dysplasia in colonic adenomas [393]. This 
study suggested that the dysplastic changes, including an increased number and density of cells 
and crypts, and the enlargement of nuclei and crypts, might somehow alter the tissue 
permeabilty and thus jeopardise the way back to the surface of the emitted fluorescence.  
Since the assessment of AFI images is strictly dependant on colour presented to the clinician by 
the image processing system usedintensity, quantifying the intensity of the colour “magenta” by 
calculating a fluorescence index, has been proposed as a method to discriminate lymphomas 
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from reactive lymphoid hyperplasia [394], and to evaluate the degree of dysplasia in colonic 
neoplasms [393]. 
The ratio between AF signal intensities in colonic adenomas and normal specimens, obtained at 
365 and 405 nm excitation wavelength, has also been used to discriminate adenomas from 
normal colon mucosa, and neoplastic from non-neoplastic polyps [395]. The excitation 
wavelengths were targeted to detect NADH fluorescence. Reflected ligth images at 550 and 
610 nm excitation were also acquired to evaluate the haemoglobin concentration of the 
samples, which was shown not to influence on the overall fluorescence intensity detected. 
3.4 Summary 
Recent advances in GI endoscopy constitute an unprecedented leap forward in basic and clinical 
research for both patients and clinicians. 
High-definition and magnifying endoscopy have contributed to higher detection rates compared 
to standard white light endoscopy alone and are expected to prospectively replace conventional 
equipment in daily practice. Contrast enhancement techniques, whether dye-based or 
computed, have been combined with conventional WLE to further improve its accuracy during 
routine endoscopy, especially in detecting early cancers, but histology is still required to clarify 
the diagnosis. 
New developments have brought the optical resolution down to a few micrometres enabling for 
the first time in vivo tissue microscopy during endoscopy. However, although of invaluable 
assistance for tissue characterisation, techniques such as CLE and EC have not yet made 
transition between research and clinical use. In addition, these techniques can only infer 
structural aspects but they do not provide functional information about the tissue. 
None of the currently available techniques has been able to provide a red flag technique for easy 
and rapid detection of early changes of disease. In this respect, autofluorescence spectroscopy 
and imaging, either incorporated into an endoscope or to be used via the endoscope working 
channel, seem promising and further research is awaited. 
There appear to be two separate research communities, one working with sophisticated 
endoscopic technology and the other with disease biomarkers, who seemingly tend to work 
independently. It would seem sensible to integrate these two approaches to identify risk 
predictors and determine which modality is best for different patient populations. 
It is still unknown which technique or combination of techniques offers the best potential. The 
optimal method will probably entail the ability to survey wide areas of tissue in concert with the 
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ability to obtain the degree of detailed information provided by point measurements. This 
would be possible by coupling a wide field modality to a mode of single point measurement. 
Raman spectroscopy offers the exciting prospect of revealing highly specific biochemical 
changes before morphological differences between normal and diseased tissue become 
detectable. However, it cannot be readily extended to provide a wide-field screening tool that 
can image fields of view of several centimetres. 
One optical technology potentially capable of this is FLIM. Nevertheless, to date FLIM has only 
been investigated in the GI tract ex vivo on a relatively small number of samples and further 
studies are required to establish these initial findings. Systematic studies of the fluorescence 
lifetime signatures in normal and diseased tissue in vivo are crucial for a complete 
understanding of the origin of the autofluorescence contrast observed, and for assessing the 
ability of fluorescence lifetime technology for accurate clinical diagnosis. 
Amongst the unmet clinical needs discussed in section 2.7, enhanced detection and 
discrimination of neoplastic polyps together with assisting with the implementation of novel 
time-resolved endoscopic instruments for in vivo clinical use provided the motivation for the 
studies described in this thesis. 
Polyps are undoubtedly of greatest interest to the endoscopist because of their high prevalence 
in the general population, and, if neoplastic, for their established role in the stepwise process 
that results in colorectal cancer. Clearly, endoscopists spend a lot of time and emotional energy 
searching for polyps, and worry about the potential impact of cancer on their patients. Optical 
biopsy techniques, which interrogate the mucosal surface with light without the need to 
physically remove tissue, would be highly desirable as they could facilitate clinical decision 
making in ambiguous situations reducing time to diagnosis. This would bring accurate and 
reliable information directly at the point of service, circumventing the cost and time required 
for histology, reducing uncertainty for patients and the attendant psychological morbidity, and 
therefore improving the overall quality of care. 
The overarching hypothesis for all the experiments described in this thesis was that 
fluorescence lifetime imaging/metrology is able to generate contrast between different 
types and states of human tissue (GI, skin, bladder), including between normal and 
neoplastic tissue.  
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The general aims of this work were: 
 To explore the origin of the fluorescence signals and characterize the potential 
origins of fluorescence lifetime contrast associated with normal and diseased tissue 
using the excitation and emission wavelengths compatible with the FLIM/FLS 
endoscopes developed during the project. 
 To translate fluorescence lifetime technologies from the optical bench to the bedside 
and from ex vivo to in vivo applications. 
 To try and determine whether in vivo FLIM/FLS is possible, practicable and clinically 
useful and what can add to the existing techniques.  
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Chapter 4: Fluorescence Lifetime Imaging (FLIM) of 
human gastrointestinal tissues: a pilot observational 
study conducted on ex vivo endoscopically resected 
specimens. 
This chapter describes the results obtained by imaging a number of fresh, unfixed, unstained 
tissues collected from patients undergoing GI endoscopy as part of their clinical investigations, 
with a confocal FLIM microscope. These initial observational experiments were performed on a 
spectrum of tissue types containing a wide range of structures and potential fluorophores in 
order to try and determine the potential origins of the contrast generated by FLIM and the 
relative contributions to tissue autofluorescence from the different areas and structures within 
the tissue. This observational study is a another step towards testing the hypothesis that 
fluorescence lifetime imaging/metrology is able to generate contrast between different types 
and states of human GI tissue and is a necessary step towards exploring the potential 
applications of FLIM both for ex vivo tissue FLIM analysis and in vivo tissue imaging. 
The FLIM confocal microscope represents a convenient platform for initial systematic 
observations due to its inherent capacity for optical sectioning, relative ease of use and a fast 
and clinician-friendly interface for image acquisition and processing. Although this microscope 
offers great versatility in terms of excitation and emission wavelengths, the excitation 
wavelength of 420 nm was chosen because of its compatibility with the clinically deployable 
confocal FLIM endomicroscope that has been developed by the Photonics Group. The system 
and the experimental protocol are described here as well as the experiments with synthetic 
fluorophores in solution, and the immunohistochemistry assays and selective stains that have 
been performed on selected cases to enable histopathological correlation of the fluorescence 
lifetime contrast observed. 
The work presented in this chapter shows that confocal fluorescence lifetime imaging has the 
potential to provide useful diagnostic information in a range of GI tissue types and states of 
disease. Particularly, this was seen to be the case in colonic polyps and inflammatory bowel 
disease, where a statistically significant decrease in fluorescence lifetime was found between 
lesional and normal specimens (p = 0.024 and 0.015 for polyps and IBD, respectively). 
As discussed in chapter 3, data on the diagnostic potential of fluorescence lifetime 
measurements have already been observed in previous studies [265-268,270,271,273,396,397] 
and it is opportune to investigate the application of FLIM to other tissue types and diseases, 
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including pre-neoplastic conditions. However, it is important to draw a distinction between 
wide field FLIM, where the entire sample is illuminated and, depending on sample scattering 
and absorption, fluorescence emission is indistinctly collected from all layers, and confocal 
FLIM, where the sample is illuminated with a focussed beam of light, and although other parts of 
the sample are also illuminated, the fluorescence detected comes only from the tissue layer in 
focus. 
4.1 Introduction 
The medical conditions relevant to this chapter have been introduced in chapter 2. Some 
summary of the most relevant parts of this chapter are provided here together with further 
relevant work in this area. 
Prevention in endoscopy is based on early detection of potentially curable cancers or precursor 
conditions that have a significant risk of progression to malignancy. Thus, early diagnosis is the 
critical goal since it allows endoscopic or surgical intervention on a localised disease without 
lymph node involvement, which greatly improves patient survival. 
Traditionally, white light endoscopy (WLE) has been used to evaluate the mucosal surface of the 
GI tract but inflammatory disorders, dysplasia and early stage cancers are frequently invisible 
or difficult to visualise. Diagnosis of early and premalignant lesions is indeed difficult even for 
experienced endoscopists because they appear similar to benign lesions and normal mucosa. 
Although several novel imaging techniques that can be operated in conjunction with standard 
WLE have recently become available in the clinical arena – such as narrow-band imaging (NBI) 
[59], autofluorescence imaging (AFI) [61] and more recently confocal endomicroscopy (CLE) 
[62,398] – there is still no “red flag” technique for detection of GI pre-malignant lesions that can 
progress into cancer. Furthermore, there is currently no reliable technology that can indicate 
when it is safe and appropriate not to biopsy. Thus, the current clinical best practice in GI 
endoscopy is for tissue abnormalities to be biopsied and sent for histological assessment and 
interpretation, which confers a significant burden on healthcare systems [2,399]. 
In most cases, multiple random biopsies are still required to confirm or reject the endoscopic 
diagnosis. For example, diagnosis of benign conditions like eosinophilic esophagitis and 
microscopic colitis is only possible by random biopsy as on endoscopy the mucosa typically 
looks normal or shows only very subtle signs of disease. However, the diagnostic yield of 
random biopsies is often low and incurs a high cost [243,244]. 
Another point to consider is that although histopathological assessment is quoted as a “gold 
standard”, it is not. For instance, the accuracy of routine clinical pathology in colonic polyp 
differentiation is only approximately 87% [265]. It is also accepted that histopathology suffers 
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from subjectivity on grading low and high grade dysplasia in Barrett’s oesophagus [400]. In fact, 
the differences between inflammatory regenerative changes, low-grade and high-grade 
dysplasia and cancers are difficult to classify because of overlapping morphological features. 
There is a need for more objective assessment as the histopathologist is disadvantaged by 
reviewing material out of context and with demonstrable levels of poor to moderate inter-
observer agreement at best about what constitutes “dysplasia”. 
Sampling error combined with the delay in obtaining histological confirmation of disease can 
place a patient at risk of progression of the disease that precludes endoscopic/surgical 
resection, and often causes psychological distress. In addition, the inability to confirm whether a 
tissue is benign or malignant at the time of endoscopic examination leads to unnecessary 
biopsies, repeat endoscopies and imaging and treatments. There is therefore a need to develop 
diagnostic endoscopic imaging technologies to interrogate tissue and identify lesions that 
cannot be detected using existing techniques. 
A non-invasive method of diagnosis would remove the need for a physical biopsy and could 
provide improvements in diagnostic accuracy for a number of conditions. 
The advent of novel imaging technologies is creating important new opportunities for contrast.  
One such example is fluorescence imaging, which can be implemented in endoscopes and can 
use endogenous (AFI) or exogenous fluorophores (PDD) to achieve contrast. 
However, the reason for the difference in fluorescence between normal and diseased tissue 
observed with AFI is still unclear and intensity-based contrast is often not sufficiently specific 
[135-137]. Only a few clinical studies have been performed, showing mixed results [391,401] a 
high false positive rate [357] or an overall sensitivity inferior to standard WLE 
[233,359,392,402]. 
The development of endoscopic Fluorescence Lifetime Imaging (FLIM) offers the opportunity to 
add an additional contrast parameter to the clinical environment. As the FLIM signal is 
generated by endogenous fluorescent molecules it can provide both histological and 
biochemical information. It has therefore the potential to provide an in vivo label-free “optical 
biopsy” avoiding multiple unnecessary and/or random biopsies. 
Wide-field FLIM has been shown to provide intrinsic contrast between benign and neoplastic GI 
tissue ex vivo [273] and single point fluorescence lifetime measurements have been successfully 
applied in vivo to colonic polyps [265] and skin cancer [403], and ex vivo to skin [258,270] and 
GI endoscopic biopsy samples [404]. 
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A number of other translational label-free optical techniques are currently being investigated 
owing to their potential to acquire non-invasive biochemical information and to image with sub-
cellular resolution but the published experience is limited. 
Near-infrared diffuse reflectance imaging offers another potential source of optical contrast, and 
has been applied to detecting colon cancer [73] but further miniaturization of the imaging 
system is still required for clinical application. Optical coherence tomography (OCT) allows 
imaging at greater depths within tissue but typically does not supply functional information. 
Raman spectroscopy and coherent anti-Stokes Raman scattering (CARS) microscopy can be 
used to obtain highly detailed spectroscopic information [69] but usually require long data 
acquisition times and cannot be readily extended to wide-field imaging modalities. Point 
spectroscopy with probes inserted through the working channel of conventional endoscopes 
has been able to differentiate non-neoplastic from neoplastic tissues [70]. 
In this chapter, preliminary observational work performed using excitation at 420 nm with 
detection by a time-resolved fluorescence lifetime imaging confocal microscope to investigate 
FLIM contrast in GI tissue that has been freshly biopsied/resected from patients undergoing 
endoscopy is described. 
The aim of this study was to image a relatively large number of GI endoscopic specimens in 
order to explore the origin of the fluorescence signals and characterize the potential origins of 
fluorescence lifetime contrast associated with normal and diseased tissue morphology using 
confocal FLIM at 420 nm excitation. This excitation wavelength was chosen to be compatible 
with FLIM confocal endoscopes that are expected to utilise excitation in the blue spectral region 
(~405-445 nm) where there is an optimal balance between excited tissue autofluorescence and 
unwanted background fluorescence, e.g. from glass fibre bundles.  
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4.2 Materials and methods 
4.2.1 Overview 
Between May 2010 and December 2011, a total of 71 endoscopic samples from different GI sites 
were collected from 35 patients undergoing either upper or lower GI endoscopy at Charing 
Cross Hospital, Imperial College Healthcare NHS Trust. All samples were imaged using a 
confocal FLIM microscope with 420 nm excitation. Fluorescence was detected using time 
correlated single photon counting (TCSPC) over the range 450-680 nm. 
A total of 481 confocal images were acquired (mean 6 images per sample; minimum = 1, 
maximum = 19). FLIM image processing was performed using commercially available software 
SPC-Image 3.1 (Becker & Hickl GmbH, Germany). This was done manually and in many steps, 
becoming often a laborious and time-consuming process which is prone to error. Therefore, 
given the large number of images acquired, it was necessary to introduce a selection strategy 
based on objective criteria in order to reduce the workload to a reasonable level. 
Criteria for image selection were: 
1. Number of photons per pixel above 1000, as a number below this threshold would 
prevent accurate determination of the fluorescence lifetime using a double exponential 
decay fitting model. 
2. Presence of recognisable histological structures based on resemblance to corresponding 
histological and representative confocal microscopy images. 
3. Easy orientation of mucosal side. 
4. Plane of the mucosa imaged at a depth of 100 ± 30 μm, in order to simulate the fixed 
imaging plane depth of the probe based confocal laser endomicroscope. 
This selection considerably reduced the number of images to manually process. Finally, only 
two images (1 normal, 1 disease) per patient data set were selected according to the highest 
fidelity to histological structures, best image quality and resolution, and the highest number of 
photons per pixel. 
Data from each diseased sample were compared to data from normal sample taken from an 
endoscopically normal area near the lesion, fitting the fluorescence decay to a double-
exponential decay model and analysing the resulting mean fluorescence lifetime. Only paired 
samples were included in the analysis. All samples were submitted for histopathology following 
the imaging and measurements. Normal tissue and some of the most common GI diseases - 
including colonic polyps and cancer, inflammatory bowel disease (IBD) and Barrett’s 
oesophagus (BO) - were investigated (table 4-1).  
153 
 
Tissue group Histological diagnosis No. of samples 
Colonic polyps 11 adenomas with LGD 
2 mixed hyperplastic adenomatous polyp with LGD 
1 hyperplastic polyp 
1 nonspecific reactive changes 
15 
IBD 5 active chronic ulcerative colitis 
1 severe chronic ulcerative colitis with multifocal LGD 
1 ischaemic colitis 
1 active chronic Crohn’s disease 
8 
Colon cancer 4 adenocarcinoma 4 
Gastric disease 2 chronic gastritis 
1 adenocarcinoma 
3 
Oesophageal disease 2 BO with LGD 7 
 3 BO  
 2 reflux oesophagitis  
Other (polypectomy scar) 1 stromal fibrosis 1 
Normal colon tissue 20 normal colonic mucosa 
1 lymphocytic colitis 
1 severe chronic ulcerative colitis 
22 
Normal stomach tissue 1 normal gastric mucosa 
1 intestinal metaplasia and mild dysplasia 
2 
Normal oesophageal tissue 6 normal oesophageal mucosa 
1 papillary hyperplasia 
1 parakeratotic achantotic squamous epithelium 
8 
Normal duodenal tissue 1 normal duodenal mucosa 1 
Total number of normal tissue specimens 33  
Total number of diseased tissue specimens 38  
Total number of specimens 71  
Table 4-1: Summary showing the histological diagnoses of all the ex vivo samples investigated with the 
confocal FLIM microscope. Note that the group “gastric disease” incorporates gastric cancer, gastritis and 
portal hypertensive gastropathy. “Oesophageal disease” incorporates Barrett’s oesophagus and oesophagitis. 
LGD = low grade dysplasia; IBD = inflammatory bowel disease; BO = Barrett’s oesophagus. 
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4.2.2 Patient enrolment 
Patients were recruited from those attending the Endoscopy Unit at Imperial College Healthcare 
NHS Trust’s Charing Cross Hospital Site. 
Patients who participated in the research were recruited by the clinical team and gave their 
informed written consent to participate. The study was carried out with the approval of the 
National Research Ethics Service (REC reference number 09/H0706/28). 
The use of human tissue in this research complied with the requirements of the Human Tissue 
Act (2004). Patients agreed to the collection of an additional normal biopsy and the use of tissue 
samples not needed for histopathology for research. 
Inclusion Criteria 
Patients were recruited if clinically diagnosed with one of the following conditions and if they 
required biopsy or endoscopic resection: Barrett’s oesophagus; atrophic gastritis and intestinal 
metaplasia; gastric cancer; biliary reflux disease or portal gastropathy; small intestinal 
enteropathies; duodenal ampullary disease and pancreatobiliary benign and malignant 
strictures; inflammatory bowel diseases; colorectal cancers and polyps. 
Exclusion Criteria 
The following exclusion criteria were used: 
• Unable to give informed consent 
• Under 18 years old 
• Prisoner 
• Having a blood borne infection e.g. Hepatitis, HIV. 
Pseudo-anonymisation 
All recorded data was tagged using a linked anonymised identifier for each patient.  Data 
analysis and correlation with histology was also anonymous. The clinical researchers (SC, KLR & 
AVT) held the link but did not disclose this to the research group and maintained patient 
confidentiality as part of their normal medical duty. This link was electronically stored on an 
encrypted standalone electronic storage medium that is stored on College property and its 
access is also restricted physically by storage in locked cupboard in a room with restricted 
access. These data will be kept for 10 years as per the Imperial College policy. 
Minimum Data Set  
A minimum data set was collected from each participant as follows: 
 Patient data (potentially relevant data was collected from the patient/medical records 
including patient demographics). 
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 Lesional data (clinical diagnosis, site of lesion, size). 
 FLIM data (duration of imaging, imaging parameters). 
 Histological data (histological diagnosis, images of histology slides). 
4.2.3 Fluorescence lifetime imaging instrumentation 
The bench-top FLIM system used for this study was an inverted Leica SP5 confocal microscope 
(Figure 4-1). At least one FLIM image was acquired using a 40x 0.75 NA objective from all 
specimens. An additional image or images were acquired over a larger field of view (FOV) in 
some cases using a 20x 0.75 NA objective. The confocal pinhole was set at 1 Airy unit for all 
imaging. 
The size of the scanned image was chosen according to the structures observed in the sample 
and therefore a digital zoom of 1, corresponding to a FOV of 387.5 x 387.5 µm, was selected. 
This ensured that the same area of tissue was sampled in all cases in a consistent way with a 
field of view large enough to allow for averaging over many crypts. 
All samples were excited at 420 nm excitation. This wavelength was chosen because of its 
compatibility with the FLIM endomicroscopes that are being developed by our group for 
potential in vivo clinical applications. This wavelength falls within the excitation spectra of a 
number of important tissue fluorophores, such as flavins, porphyrins, collagen and elastin. 
Typical excitation wavelengths used by other investigators for studying the autofluorescence 
characteristics of different types of tissue lie between 310 and 420 nm [275,280]. Fluorescence 
was detected over the range 450-680 nm. 
Excitation light was generated using a Mai Tai Ti:Sapphire laser (Newport Spectra-Physics).  
The infrared output was tuned to 840 nm and frequency doubled to produce ~100 fs pulses of 
420 nm light at a repetition rate of 80 MHz. Fluorescence lifetimes were measured using TCSPC 
(SPC830 card, Becker and Hickl GmbH, Germany). 
As discussed in section 3.1.5, in TCSPC, high gain photomultiplier tubes are used to measure the 
arrival times of single fluorescence photons. The excitation light is set to be sufficiently weak so 
that less than one fluorescence photon is detected per excitation pulse. Therefore, after many 
thousands of excitation pulses a histogram of photon arrival times can be built up. The 
distribution of the arrival times of emitted photons relative to the excitation pulse reflects the 
fluorescence decay from the point being measured. The excitation beam is scanned across the 
sample to produce a photon arrival histogram for each pixel in the image. 
For TCSPC, image acquisition and data processing is performed using the commercially 
available software SPCM and SPC-Image respectively (Becker & Hickl GmbH, Germany). 
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The optical average power was restricted to a maximum of 1 mW in the sample plane. Typically 
used excitation powers were 0.5 mW. 
 
Figure 4-1: (a, b) Experimental set up for ex vivo imaging using the inverted Leica SP5 confocal FLIM 
microscope. (c) Graphic of the estimated image section of a tissue sample (in light blue). Adapted and 
reproduced with permission from [405]. 
Additionally, fluorescence from the sample could be directed into a fibre-coupled spectrometer 
(HR4000, Ocean Optics Inc., B.V., The Netherlands) allowing the emission spectrum averaged 
over the whole scan field to be measured. 
Lifetime calibration 
For each imaging session an instrumental response function for the system was taken using 
fluorescence from a drop of erythrosin B solution (10-40 µM), which has a single exponential 
decay with a lifetime of 89 ps [406]. 
4.2.4 Sample preparation and protocol 
During routine endoscopy, pinch biopsy samples were taken by endoscopic “jumbo” biopsy 
forceps (Radial Jaw 3 LC forceps, Boston Scientific) or superficial lesions removed with cold or 
hot snare (Captivator single-use snares, Boston Scientific) according to standard patient care 
(Figure 4-2a). Care was taken to avoid contamination of the accessory devices (e.g. forceps, 
snares, etc.) with formalin. Samples were 5-15 mm in diameter. Where clinically possible, at 
least one biopsy of healthy tissue was also taken from each patient with a suspicious region. The 
healthy biopsy was taken as close as possible to the suspicious region. 
The freshly-excised samples were placed in a pot with chilled tissue culture medium (phenol 
red-free DMEM, Invitrogen-Gibco, USA) and packaged for transport to the Physics FLIM 
laboratory (Blackett laboratories 623-628) immediately after excision. All tissues were confined 
using tertiary containment and taken to the Physics department by taxi. 
Prior to imaging, the samples were removed from the container and rinsed with fresh buffer 
solution (HBBS, Invitrogen-Gibco, USA) to remove DMEM, blood and excess mucus. 
(b) (c)(a)
Mucosa
Submucosa
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The samples were then placed in a plastic culture dish with a glass coverslip base (Figure 4-2b). 
For larger specimens (polyps), the tissue was kept moist by placing it onto gauze, soaked in the 
buffer solution, which had been previously cut with a hole in the middle to allow imaging and 
tailored to accommodate the sample. 
 
Figure 4-2: (a) Endoscopic biopsy during endoscopy. (b) Sample placed in a plastic culture dish with a 
glass coverslip base for imaging. 
The samples were first examined with either a 10x or a 20x objective in transillumination mode 
to determine the correct orientation so that they could be imaged with the epithelial surfaces 
facing down the microscope objective. Polyps, in contrast, could be easily orientated with visual 
inspection only. Subsequently, the 40x objective was selected and focused onto the surface of 
the specimen, which was assigned as a nominal depth of 0 µm. Finally, the acquisition of a 
fluorescence intensity image using a 10 s exposure allowed the presence of a clear fluorescence 
signal to be collected. 
The acquisition time for each FLIM image was set at 120 seconds. Images were acquired at 
increasing epithelial depths from the surface until tissue details were no longer resolvable, 
typically every 7-10 µm (figure 4-3). 
(b)(a)
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Figure 4-3: (a) Transverse histological image (H&E, original magnification 40x) and corresponding en 
face confocal intensity (b) and FLIM (c) images obtained at different depths beneath the epithelial surface 
from a polyp of the sigmoid colon. Brightness, crypt size, tissue architecture, as well as the mean fluoresce 
lifetime, change as the depth of the focal plane increases from 0 to 40 μm beneath the epithelial surface. Note 
that no exact registration exists between histology and FLIM images; the figure serves solely to illustrate the 
relative geometric orientation of the histological section and the stack of FLIM images from the same sample. 
To prevent deterioration, samples were kept moist during imaging and handled minimally. 
There were no visible changes in the texture, thickness or appearance of the samples over the 
duration of the measurements. All samples were imaged in the FLIM laboratory within 60-
120 minutes of resection. Following imaging, the tissue was removed from the dish and 
transferred to a hospital prefilled container with 10% formaldehyde solution. The samples were 
then sent to the hospital histopathology laboratory at Charing Cross Hospital for diagnostic 
assessment. 
The tissue slices were then subjected to histopathological examination after paraffin embedding 
as per current clinical practice. All samples were sectioned at 4-µm-thickness and stained with 
0 µm
τmean = 1248 ps
10 µm
τmean = 1203 ps
20 µm
τmean = 1151 ps
30 µm
τmean = 1148 ps
40 µm
τmean = 1059 ps
(a)
(c)(b)
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haematoxylin and eosin (H&E). The histopathological classification of mucosal lesions was made 
according to the World Health Organization classification. 
Correlation with histopathological analysis 
After histological assessment, the H&E-stained tissue sections were requested and reviewed by 
two experienced histopathologists (GWS & MAEl-B) to correlate the histological findings with 
the FLIM images. Specific staining and immunohistochemistry were also performed in selected 
cases to help correlate and evaluate the structures observed. 
Tissue crush and diathermy artefacts 
Images presenting tissue curling or crush artefacts caused by the biopsy forceps were not 
processed. 
Thermal artefact after diathermy snare excision is a common artefact encountered in surgical 
histopathology. Polyps less than 10 mm in size are usually resected by cold snaring whereas for 
polyps greater than 10 mm or those that are stalked, diathermy polypectomy is generally 
preferable. Sometimes the presence of diathermy is such to render the histological diagnosis 
impossible, and the heating of tissue during diathermy would be expected to alter the 
fluorescence properties. However, all of the tissue specimens removed using hot snaring were 
sufficiently large that the area imaged using the optical system (the head of the polyp) was 
unaffected by any specimen heating. 
4.2.5 Data processing, lifetime calculation and FLIM map generation 
Time-Correlated Single-Photon Counting (TCSPC) is currently the gold-standard of fluorescence 
decay measurement. 
Data processing was performed using commercially available software SPC-Image 3.1 (Becker & 
Hickl GmbH, Germany). 
The fluorescence decay profiles were analysed using an instrumental response function 
obtained by imaging a single drop of erythrosin B solution (10-40 µM) prior to or following the 
experiments. During the data processing, if the IRF determined at the time of the experiments 
was found to be inaccurate (long decay, contamination, etc.) the option “auto IRF” was used to 
calculate an automatic IRF from the data trace with an estimation method provided by the SPC-
Image software. The recourse to this method was necessary in only a few cases. 
Fluorescence decay fitting model 
The autofluorescence of biological tissue tends to show a complex exponential decay profile due 
to the multiplicity of fluorophores present and their different states e.g. oxidised/reduced and 
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free/protein bound. It can be described using a multi-exponential model i.e. the sum of a 
number of single exponential decays as expressed in equation 3.5. 
As the number of lifetime decay components to be fitted increases, so must the fluorescence 
intensity emitted from the tissue, for the model to fit accurately. A double-exponential decay 
model is commonly used when imaging biological tissue, and often expressed as a weighted 
mean of the two lifetime components. 
Thus, given the nature of the samples investigated in this study, a double exponential decay 
analysis in each individual pixel of the image was routinely performed and the mean lifetime 
was calculated using equation 3.7. 
Data processing with Becker & Hickl SPC-Image 3.1 software 
Once the data was imported, an intensity image was displayed in the top left quadrant of the 
software package’s window (see figure 4-4). This image is calculated from the integrated 
number of counts for each pixel and is autoscaled by default. The IRF was then loaded as 
“instrumental response” and appeared in the decay box at the bottom of the screen. 
In the decay graph (Figure 4-4(c)), the blue points show the measured photon decay data trace 
for a particular pixel in the image, the red line is the fit to the data, and the IRF is shown by the 
green line. Deviations between photon data and fit are shown at the bottom as weighted 
residuals. The two vertical black cursor lines (T1 and T2) indicate the time channels defining 
the range of data used for the fit process [407]. 
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Figure 4-4: (a) Screenshot from SPC-Image software fitting the fluorescence decay from images taken 
from a specimen of normal colonic mucosa (caecum) excited at an excitation wavelength of 420 nm excitation 
wavelength. (b) Inset showing the lifetime distribution histogram (top panel) and the multiexponential decay 
fitting parameters (lower panel). (c) Inset showing the decay graph for the pixel indicated by the blue 
crosshair. The double exponential fit to the data (blue points) can be seen (red line), with associated 
residuals in the bottom panel (black line). T1 = start of fit; T2 = end of fit; TMax = temporal bin corresponding 
to peak of decay; Bin = binning; Thld = threshold; Pos = position of selected pixel; tm = weighted average 
lifetime of selected pixel; χ2r = reduced Chi-Square. 
The fit model “incomplete multiexponential” option, with a maximum number of 20 iterations, 
was applied to account for incomplete decays and prevent distortions in the lifetime values that 
are caused by fluorescence photons generated by the previous excitation pulse. 
The binning value indicates the number of surrounding pixels which are summed into each 
decay trace. Therefore, increasing the binning value will increase the number of photons in each 
decay trace, though at the cost of loss in spatial resolution in the resulting FLIM map. 
(a)
(c)
(b)
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We chose to fit a double exponential decay model, and therefore binning factor 2 in the SPC-
Image software (equivalent to 5 x 5 pixel smoothing) was used for the analysis of all images. 
The threshold value allows the user to select the minimum number of photons in the peak of a 
fluorescence curve required in a pixel in order for the decay to be fitted. The value of this 
threshold was set by eye depending on the brightness of the sample to reject dark featureless 
regions. 
The shift parameter determines how the instrumental response function is located relative to 
the peak of the fluorescent signal. The scatter parameter allows directly scattered excitation 
light to be included in the fit model and this was fixed to zero for all fits. 
The software also allows a vertical offset to be included to compensate for background 
fluorescence or detector dark noise. As both of these were low compared to the fluorescence 
signal from the sample, this offset was fixed to zero for all fits. 
For the paired samples (normal and diseased) within the same patient, the temporal shift of the 
IRF was fixed to the same value for both samples according to the best χ2r (reduced Chi-Square) 
obtained in the normal sample. The χ2r measures the goodness of the fit, and a low χ2r 
(approaching to 1) generally indicates that the fitting model is appropriate. 
For the final calculation of the fluorescence lifetime histogram, intensity weighting was used. 
This means that bright pixels with greater lifetime accuracy were given greater weight than dim 
pixels with poor lifetime accuracy. This also served to minimise the effect of the manually 
determined threshold chosen on the resulting lifetime values. 
At the end of the fitting, the lifetime and the distribution histogram were displayed next to the 
intensity image (see right hand side of figure 4-4(a) and inset (b)). The final FLIM map is a 
composite of the fluorescence intensity (encoded image brightness) and lifetime (encoded using 
colour). 
The software calculates the average value of the lifetime (“Cross value”) within the image and 
the range of the standard deviation (“Left” and “Right” cursors), which includes 66% of all 
values found within the region of interest (33% on each side of the mean value). 
4.2.6 Statistical analysis of paired lifetime measurements 
Since the data presented here is not normally distributed, a nonparametric test was selected to 
statistically test the significance of the differences observed. 
The Wilcoxon signed-rank test was used to confirm the hypothesis that when comparing two 
matched samples, healthy and diseased, their median fluorescence lifetime ranks differed. This 
was calculated using the MATLAB function “signrank” (MATLAB Statistical toolbox, MathWorks, 
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USA), which performs a two-sided signed rank test of the null hypothesis that data comes from a 
continuous, symmetric distribution with zero median, against the alternative that the 
distribution does not have zero median. 
4.2.7 Criteria for interpretation of confocal images 
The criteria applied to interpret endoscopic microscope images were based on histological 
characteristics of tissue. These include well-established features and structures seen on 
microscopy of standard histological sections [8,9,408] and recently published criteria for 
confocal laser endomicroscopy [62,151,409-411]. These criteria were used to identify the tissue 
types and describe the morphological alterations. 
Equally, the terminology used to describe the structures observed is based on both standard 
histopathological nomenclature and the confocal endomicroscopy criteria for classification of e-
CLE and pCLE patterns of normal, regenerative, and neoplastic tissue based on evaluation of 
crypts and vascular architecture, named, respectively, the Mainz [62] and Miami [412] criteria. 
A comprehensive online video library of pCLE images with training and testing sections –
Cellvizio.net, Mauna Kea Technologies [413], and attendance to national and international 
training workshops, have also provided invaluable reference and assistance for the 
understanding and interpretation of the images acquired. 
For each image, analysis and interpretation was supported by two experienced GI pathologists 
(GWS & MAEl-B). 
4.3 Results 
All analysis was performed based on the histological diagnosis for each sample. Samples were 
excluded if microscopic analysis revealed normal large bowel mucosa in abnormal samples or 
histological abnormalities in normal specimens. The laser used for fluorescence excitation 
caused no tissue damage that could be detected at the microscopic level. 
 Table 4-2 summarises the demographic details of patients undergoing GI endoscopy whose 
tissue has been imaged. 
No. of patients Male Female Age range 
35 23 12 22-95 
Table 4-2: Demographic details of patients. 
TCSPC FLIM data was acquired over a FOV of 387.5 x 387.5 µm. Paired representative images 
from normal and diseased tissues are shown in each of the following specific result sub-
sections. A paired analysis approach was used when calculating the shift in the mean 
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fluorescence lifetime (i.e. relative to the normal tissue obtained from the same patient) and 
when performing tests on statistical significance. This approach was motivated by the high 
inter-patient variability observed in normal specimens from different patients (see figure 
4-8(a)). 
Although excluded from the paired analysis, unpaired samples, for which it was not clinically 
possible to obtain an associated normal or diseased specimen, were also processed and 
characterized. 
The diagnostic groups are shown in table 4-1. The following gallery of images summarizes the 
findings seen in some of the different types of tissue examined. 
4.3.1 Colonic polyps 
As discussed in section 2.1.2, polyps are normally classified into 2 groups: neoplastic (consisting 
of adenomas with low grade or high grade dysplasia, and carcinomas) and non-neoplastic 
(hyperplastic, inflammatory pseudopolyps, hamartomas). Neoplastic polyps are of greatest 
clinical significance because of their established role in the process that results in colorectal 
cancer. However, macroscopic discrimination between neoplastic and non-neoplastic polyps 
during endoscopy is extremely difficult. 
Of the total of 23 specimens measured (13 polyps and 10 normal) from 10 patients, 4 specimens 
were excluded from the analysis: 1 polyp and 1 normal sample from 1 patient as the normal 
specimen was found to be abnormal by histopathology (lymphocytic colitis); 1 polyp and 1 
normal from the same patient as the clinically identified polyp was not confirmed at the 
histopathological assessment. The polyp specimens included in the analysis are summarised in 
table 4-3-3. 
No. of patients 8 
No. of polyps 11 
 Neoplastic 
10 
 Non-neoplastic 
1 
No. of normal specimens 8 
Total number of specimens 19 
Table 4-3: Summary of colonic polyp and normal specimens included in study. 
Paired representative images from normal and pre-neoplastic (adenoma) tissues are illustrated 
in figure 4-5 and figure 4-7, and obvious morphological differences are apparent with neoplastic 
progression. The normal colon sample shows a symmetric arrangement of regular and uniform 
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crypts. The crypts are almost equidistant and present circular openings in a symmetric 
arrangement. One representative crypt opening is shown with an asterisk in each fluorescence 
intensity figure. Goblet cells are known to surround the crypts and are orientated with their 
long axis perpendicular to the inner ring of the crypt. In the figures, cellular structures are 
apparent with large dark inclusions, which are therefore identified as goblet cells. At this 
excitation wavelength, the main intracellular fluorophore is expected to be due to flavins (see 
section 3.1.4), and mucin filled vacuoles would be expected to exclude intracellular flavins and 
so appear darker. Examples of identified goblet cells are shown in the figures by red arrows.  
In contrast, a solid structure with aberrant crypts with almost no openings and no apparent 
gland formation is observed in the polyp specimen. The crypts appear condensed and displaced 
by large dense branching bands of interstitial space mostly free of cells. Crypts are distorted and 
elongated (asterisk), and significantly fewer goblet cells can be observed, which are now 
replaced by crowded elongated cells with large dark regions, which are assumed to be the 
nuclei, pointing toward the exterior rim of the crypts (red arrowheads). This change in cell 
orientation is consistent with that observed in histopathology of adenomatous polyps. 
The polyp sample shows a net decrease of the average lifetime values compared to normal 
mucosa. In addition, within each sample, irrespective of healthy or diseased status, crypts and 
surrounding stroma (lamina propria) exhibit a fluorescence lifetime separation: longer 
fluorescence lifetime values (red in the colour scale) are found at the edge and, in the case of the 
normal sample, in the centre (luminal openings) of the crypts (see inset in figure 4-5(b)), while 
the stroma surrounding the crypts is instead characterised by a shorter lifetime (blue). It is 
worth noting that, in the centre of the crypt lumen, which would be expected to be empty, 
fluorescence is observed, with mean fluorescence lifetime longer than that of the surrounding 
structures (see inset of figure 4-5(b)). Goblet cells are known to produce mucous that passes 
into the crypt lumen and eventually flows into the colon lumen to facilitate the movement of the 
faecal mass along the colon. This fluorescence was therefore attributed to the presence of 
mucous residues within the crypts lumen. 
The FLIM images therefore seem to provide some functional information in addition to the 
morphological features seen in the fluorescence intensity images. 
The lifetime shift observed may be attributed to the different tissue fluorophore composition of 
these structures, which was shown schematically in figure 2-3. Crypts are lined by an epithelium 
consisting of a single layer of goblet and columnar cells that sit on the basement membrane. 
Underneath this structure, the lamina propria is a thin vascular layer of connective tissue. The 
basement membrane is made of proteins held together by type IV collagen, and the lamina 
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propria is mainly composed of loose connective tissue containing mainly collagens I-III, 
lymphocytes, myofibroblasts and a network of capillaries and lymphatics. 
Intracellular fluorophores such as flavins (NAD(P)H fluorescence is unlikely given the excitation 
wavelength used) and mucins may be responsible of the longer mean fluorescence lifetimes 
observed at the edge and in the lumina of the crypts. In contrast, collagen type I-III and collagen 
type IV may be responsible of the shorter lifetimes in the pixels corresponding areas such the 
lamina propria and the external rim of the crypts (basement membrane). 
Mucin depletion can be seen in the polyp specimen, where only a few goblet cells can be 
distinguished and the crypts openings appear void. Interestingly, this finding is accompanied by 
a shortening of the lifetime at the edge of the crypts, and particularly, in the lumina. Differences 
in mucins content has been further confirmed for this pair of samples using a mucin-specific 
staining (see section Colonic polyps – selective staining and figure 4-10(i-l)). 
In the polyp, the mean fluorescence intensity, averaged across all the pixels of the intensity 
images, was higher than that of the normal specimen (879 ± 390 vs. 421 ± 158 mean detected 
photons per pixel), measured using identical image acquisition parameters for both normal and 
polyp specimen and similar image depths. 
The spatially averaged fluorescence emission spectra acquired using the spectrometer show 
similar spectra for the normal and polyp specimens, see figure 4-5(f), with a peak at 
approximately 520 nm. This is in reasonable agreement with the emission maxima of flavins 
(515-530 nm). 
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Figure 4-5: Matched intensity (a, c) and FLIM images (b, d) of a freshly resected adenomatous polyp (c, 
d) and contiguous normal colonic mucosa obtained from an adjacent region in the same patient (a, b). The 
inset in (b) shows the decay graph from the centre of the crypt lumen in the normal sample. (e) Mean lifetime 
distribution histogram calculated from the FLIM data. Subverted architecture with highly atypical crypts can 
be seen in the polyp (c, d) and a separation of the FLIM histograms is clear (e). (f) Spatially averaged 
fluorescence intensity emission spectra collected from the samples with a spectrometer. See text for 
description of arrows, arrowheads, and asterisks. 
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The emission spectra were compared to spectra of purified flavins in solution (Flavin adenine 
dinucleotide disodium salt hydrate, Sigma-Aldrich, USA) obtained using a spectrofluorometer at 
420 nm excitation and 540 nm emission wavelength (figure 4-6). A 2.5 µM solution of FAD 
dissolved in MilliQ water was made up immediately prior to the measurement. The spectra 
were acquired at room temperature (21 °C) from 440 nm to 730 nm (10 nm steps) at 40 s 
acquisition per wavelength (Figure 4-6 (b)). The black dashed rectangle in figure 4-6(b) shows 
the overlap between the emission spectra of the polyp and normal specimen, collected with a 
fibre-coupled spectrometer, and the emission spectra of purified flavins in solution. As 
expected, the peak and the line shape of the emission spectra appeared to be similar to that 
observed for flavins, with a minor contribution from another fluorophore, e.g. NADH or 
collagen, sub-optimally excited at 420 nm excitation. Contribution from lipopigments is usually 
not expected in normal (non melanotic) mucosa and colonic polyps [324], and elastin does not 
significantly contribute to colon tissue autofluorescence [301]. 
 
Figure 4-6: (a) Emission spectra of main endogenous tissue fluorophores (adapted from [213]). (b) Graph 
showing the overlap (black dashed rectangle) of the intensity spectra from fresh biopsy specimens of rectal 
polyp and adjacent normal rectal mucosa (shown in figure 4-5) collected with a fibre-coupled spectrometer, 
and the emission spectra of flavins (FAD) in solution (2.5 µM) obtained using a spectrofluorometer [414] at 
room temperature (21 °C), λex = 420 nm, λem = 540 nm. 
In figure 4-7(a, b), the normal specimen shows a regular crypt architecture, and again, the 
interior rim of the crypts and the lumina (asterisks) exhibit longer lifetime values compared to 
the surrounding stroma. In contrast, the adenoma shows crowded tubulovillous crypts with 
openings almost entirely obliterated, which exhibit longer lifetime values at the edge but 
shorter in the centre of the crypt and in the surrounding stroma. Elongated cigar-shaped cells 
with small bright structures and dark vacuoles (red arrowheads) line the crypt openings. 
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It should be noted that in this case the quality of the image for the normal sample was poorer 
than that seen in Figure 4-5(a) and this may be due to a greater imaging depth. 
Overall, the polyp shows a brighter surface in contrast to that more opaque of the normal 
mucosa. The polyp again emitted a slightly higher intensity spectrum compared to the normal 
sample (figure 4-7(f)), with peaks similar to the previous samples (approximately 520-530 nm). 
Accordingly, the mean fluorescence intensity for the polyp specimen, averaged across all the 
pixel of the intensity images, was also found to be higher than that of the normal specimen 
(133 ± 50 vs. 55 ± 32 mean detected photons per pixel). 
The mean fluorescence emission wavelength was also slightly longer for the polyp compared to 
that of the normal specimen (566 nm vs. 562 nm). The mean fluorescence lifetime values 
observed seem again in line with the range of lifetimes reported for protein-bound flavins (see 
section 4.3.1). 
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Figure 4-7: Matched intensity (a, c) and FLIM images (b, d) of a freshly resected adenomatous polyp (c, 
d) and contiguous normal colonic mucosa (a, b). Numerous merging crypts with distorted orifices can be seen 
in the polyp (c, d). (e) Mean lifetime distribution histogram calculated from the FLIM data. (f) Spatially 
averaged fluorescence intensity emission spectra collected from the samples with a spectrometer. 
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Figure 4-8(a) shows a summary of results for all the polyp specimens included in the paired 
analysis. It is evident from this chart that there is considerable inter-patient variation in the 
measured lifetimes of the normal specimens. The analysis of paired lifetime shifts within 
individual patients should circumvent any potential problems that this variation could cause. 
Figure 4-8(b) shows the shift in the intensity-weighted mean fluorescence lifetime (t) for each 
normal-polyp pair. The mean fluorescence lifetimes for polyps were shorter than those 
observed in normal tissue and this trend was observed in all polyps but one (sample 49, a 
recurrent adenoma with LGD). It should be noted that sample 29 was a hyperplastic polyp, 
sample 86 was a mixed adenomatous-hyperplastic polyp, and all the remainders were 
adenomatous polyps. 
 
Figure 4-8: (a) Bar graphs showing the mean fluorescence lifetime observed in all polyps relative to a 
sample of healthy tissue from the same region of the colon. (b) Shift in the mean fluorescence lifetime of all 
polyp specimens included in the paired analysis. Lifetime shifts are calculated using a measurement of 
normal tissue obtained from the same or nearest region of colon. 
The ratio of mean fluorescence intensity, averaged across all the pixels of the intensity images to 
the corresponding value for the polyp specimen, was found to be greater than 1 for all polyps 
(n = 11) indicating that the fluorescence intensity from the polyp specimens was always greater 
than the paired normal specimen. Figure 4-9 shows the paired ratio (polyp/normal) of the 
fluorescence intensity for all the polyps relative to a specimen of healthy colon from the same 
patient. 
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Figure 4-9: Bar graph showing the ratio (polyp/normal) in the mean fluorescence intensity observed in 
all the polyp specimens relative to a specimen of healthy tissue from the same patient. The mean intensity for 
all the samples was obtained calculating the mean number of photons detected per pixel, across all the pixels 
of the intensity image. The error bars represent ± 1 standard deviation and were calculated via error 
propagation from the fluorescence intensity distribution in the normal and polyp images. 
Colonic polyps - selective staining 
In addition to the standard Haematoxylin and eosin (H&E) stain for conventional 
histopathological assessment, a number of immunochemistry assays and selective stains have 
been performed on selected cases in order to enhance the different structural contrast derived 
from epithelia and connective tissue, and compare this with the fluorescence lifetime contrast 
obtained using the confocal FLIM microscope. 
This correlation was performed in an attempt to aid our understanding of the fluorophores that 
are prevalent in structures, such crypts and connective tissue. 
The following types of staining methods were used: epithelial membrane antigen (EMA); 
Masson trichrome; Alcian Blue (AB); Collagen IV; Vimentin. Each of them has a specific 
molecular target to highlight different components of the intestinal wall. 
EMA highlights epithelium for thickness and crypt architecture, and separates clearly epithelial 
cells and glands from stroma. EMA stains normal and neoplastic epithelium including 
adenocarcinomas from a range of sites. Strong staining of the apical portion of duct lining cells 
in glandular epithelia is seen. Staining with this antibody was chosen to identify any correlation 
with fluorescence of intracellular origin. 
In Masson trichrome staining (MTS), three dyes are employed to highlight selectively collagen 
fibres, muscle, fibrin, and erythrocytes. As a result, the collagen fibres are stained blue, the 
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nuclei will be stained black, cytoplasm, muscle and erythrocytes red, and fibrin pink. Masson's 
Trichrome is most useful to differentiate collagen from other fibres, particularly smooth muscle 
and elastin, and to identify an increase in collagen. 
AB is a specific stain for acid mucins of epithelial origin (sulphomucins and sialomucins), which 
are found in the goblet cells located in the intestine. AB does not stain neutral mucins, which are 
found primarily in the surface epithelia of stomach and duodenum. AB provides good contrast 
between normal and diseased samples. For example, mucin and numerous goblet cells are 
commonly seen in normal samples, while they are almost invariably lacking in polyps or 
cancers. 
Collagen IV staining highlights basal membranes, muscle and vessels. This antibody reacts 
selectively with collagen type IV, which is the major constituent of the basement membranes. 
Adenomas have less type IV collagen in their basement membranes, leading to sparser, 
trabecular staining in neoplasms versus a more rigid meshwork pattern in normal glands. 
Vimentin staining highlights primarily collagen type I, and therefore selectively stains stroma. 
Figure 4-10 shows a gallery of images obtained using these stains to differentiate the tissue 
structure of the same specimens of figure 4-5 (freshly resected adenomatous polyp and adjacent 
normal colonic mucosa), with the aim to establish a correlation between the fluorescence 
lifetime contrast observed and the different tissue components selectively highlighted. 
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Figure 4-10: Haematoxylin and eosin (H&E) stain of a biopsy sample of normal colon (a) and 
adenomatous polyp from the same patient (autofluorescence intensity and FLIM images from this patient are 
shown in Figure 4-5). Numerous normal goblet cells can be seen in (a), while only a few goblet cells are 
visible in the tubular adenoma dysplastic epithelium (b). The epithelial membrane antigen (EMA) highlights 
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epithelial cells and glands from stroma in the normal colon specimen (c, e) and in the polyp (d, f). Masson's 
Trichrome staining (MTS) highlights fibromuscular tissue in both the normal colon (g) and the polyp (h). 
Alcian Blue (AB) highlights intracellular mucins in goblet cells, and mucins discharged  into the gland lumina, 
showing good contrast between normal colon mucosa (i, k) and adenoma (j, l). Collagen IV highlights the 
basal membrane, muscle and blood vessels in normal colon (m) and in the polyp (n). The distribution of 
mucosal collagen appears altered between the samples, with remarkably reduced stain uptake in the polyp, 
where only scant amounts of collagen IV can be seen in the basal membranes and around the adenomatous 
crypts. Vimentin shows fairly selective staining of stroma both in normal colon mucosa (o), and the polyp (p), 
confirming the presence of stromal distortion within the irregular and overwhelmed (squeezed) 
adenomatous glands. 
These staining methods have been able to differentially stain epithelial crypts from connective 
tissue and intracellular mucins, confirming the structures recognized in the FLIM images. 
Interestingly, mucins are well represented in normal colon, while they are hardly seen in 
dysplastic or neoplastic tissue (see figure 4-10(i-l)). Mucins could therefore represent another 
possible cause for the AF contrast observed, although they have not been as widely investigated 
as the more common fluorophores such as NADH, flavins and collagen.  
Another important finding is that collagen is found in large amounts in the mucosal layer (see 
figure 4-10(g-h, m-p). This seems in contrast with the general assumption that collagen is 
predominantly located in the submucosal layer. For 420 nm excitation we expect the dominant 
tissue fluorophores within the mucosa to be intracellular flavins, and collagen types I-IV. 
Collagen type IV is primarily found in the linings surrounding the colonic crypts (basal 
membranes, see figure 4-10(m-n)), whereas collagen types I-III are predominant in the stroma 
of the lamina propria figure 4-10(g-h, o-p). 
4.3.2 Colon cancer 
Colorectal cancer develops within pre-existing foci of adenomatous tissue. This occurs usually, 
but not always, in a polypoid lesion. Colorectal carcinoma is composed of irregularly infiltrating 
malignant glands. The cells are columnar and have elongated “cigar-shaped” nuclei with 
coarsely granular chromatin pattern. The invasive tumour is usually surrounded by a 
desmoplastic response and focal necrosis is common. 
All of the 8 specimens measured (4 cancer and 4 normal) from 4 patients, were included in the 
paired analysis ( table 4-4). Interestingly, at the histopathological assessment, 1 cancer 
specimen was found to be not a primary colon cancer but the secondary localisation of a 
metastatic undifferentiated non-small cell lung adenocarcinoma.  
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No. of patients 4 
No. of cancer 4 
No. of normal specimens 4 
Total number of specimens 8 
Table 4-4: Summary of colon cancer specimens included in the study. 
Paired representative images from normal and neoplastic colon tissues are illustrated in figure 
4-11. Figure 4-11 shows the fluorescence intensity and FLIM images of 2 biopsy samples (1 
normal, 1 diseased) from the same patient diagnosed with stenosing rectal adenocarcinoma. 
The normal sample (figure 4-11(a, c)) shows a honeycomb arrangement of crypts of uniform 
shape and size, and each crypt has a central circular opening. Goblet cells can be identified (red 
arrows) due to the presence of dark vacuoles containing mucin, and the crypts are separated by 
an interstitial tissue exhibiting a higher fluorescence intensity and shorter fluorescence lifetime 
than the epithelium. 
The cancerous specimen (figure 4-11(b, d)) shows an irregular cribriform structure without 
significant gland formation and back-to-back arrangement of crowded cells with very little 
intervening stroma. The crypts visible in normal colon are missing and there are no goblet cells, 
but crowded and highly disorganized nests of fusing cells with large and dark regions, which are 
assumed to be the nuclei, are present (red arrows). In these dark regions, surrounded by 
smaller and brighter white dots (indicated by red arrowheads) a granular pattern can be seen. 
This feature is consistent with the coarse granular chromatin pattern observed in 
histopathology (“salt-and-pepper” or stippled chromatin pattern), typically associated with 
neoplastic diagnosis. At this excitation wavelength, the main intracellular fluorophores are 
expected to be flavins, which are found predominantly within mitochondria. In malignant cells, 
mitochondria show variable shape and volume, and large mitochondria can be sometimes 
observed. Degenerative changes also lead to the formation of cytoplasmic inclusions, such as 
apoptotic bodies and lipofuscin granules. These intracellular changes might be causing the small 
and bright dots with higher fluorescence intensity than the surrounding structures. 
The lifetime histogram (figure 4-11(e)) shows a net lifetime shift between normal and 
cancerous tissue, with an increased average lifetime value for the cancer sample. 
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Figure 4-11: Matched intensity and FLIM images of fresh biopsy specimens of normal rectal mucosa (a, 
b) and rectal cancer (c, d). (e) Mean lifetime distribution histograms calculated from the FLIM data. (f) 
Intensity spectra collected from the samples with a spectrometer. 
In addition to comparing morphological differences, the emission spectra from normal and 
neoplastic tissue were also analysed. The mean fluorescence intensity from the cancer specimen 
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was lower than that of normal rectum (104 ± 43 vs. 114 ± 84 mean detected photons per pixel). 
It should be noted that the cancer emitted a lower intensity spectrum compared to the normal 
sample, which is contrast with what seen in polyps (figure 4-7). In the discussion, it is 
speculated that the reason for this difference may be possibly due to the different amount and 
distribution of interstitial space and connective tissue between these two different tissue states. 
However, interestingly, the shapes of the two spectra were similar (figure 4-11(f)). In addition, 
the peak and the line shape of the emission spectra, again appeared to be similar to that 
observed for flavins by us (figure 4-6) and other investigators [213,287,415]. 
The mean fluorescence emission wavelength was longer for the cancer compared to that of the 
normal specimen (585 nm vs. 566 nm). 
Figure 4-12(a) shows a summary of results for all the colon cancer specimens included in the 
paired analysis. Figure 4-12(b) shows the shift in the intensity-weighted mean fluorescence 
lifetime (t) for each normal colon-cancer pair. All of these cancers were shown to be invasive 
adenocarcinomas at the histological assessment. The mean fluorescence lifetimes for cancer 
were all longer than those observed in the corresponding normal tissue. 
No difference in lifetime trend was observed between the metastatic (sample 104) and the 
primary cancer specimens (the remainder three). 
 
Figure 4-12: (a) Bar graphs showing the mean fluorescence lifetime observed in all colon cancers 
relative to a sample of healthy tissue from the same region of the colon. (b) Shift in the mean fluorescence 
lifetime of all colon cancer specimens included in the paired analysis. Lifetime shifts are calculated using a 
measurement of normal tissue obtained from the same or nearest region of colon. 
Figure 4-13 shows the paired ratio (cancer/normal) of the fluorescence intensity for all the 
cancer specimens relative to a specimen of healthy colon from the same patient. 
The ratio of mean fluorescence intensity, averaged across all the pixels of the intensity images to 
the corresponding value for the cancer specimen, was found to be less than 1 in three out of four 
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cases, indicating that the fluorescence intensity from the cancer specimen was lower than the 
paired normal specimen in 3 patients and higher in 1 patient (sample 37). 
 
Figure 4-13: Bar graph showing the ratio (cancer/normal) in the mean fluorescence intensity observed 
in all the cancer specimens relative to a specimen of healthy tissue from the same patient. The mean intensity 
for all the samples was obtained calculating the mean number of photons detected per pixel, across all the 
pixels of the intensity image. The error bars represent ± 1 standard deviation and were calculated via error 
propagation from the fluorescence intensity distribution in the normal and cancerous images. 
4.3.3 Inflammatory bowel disease 
Clinical conditions characterised by chronic or recurring immune response and inflammation of 
the gastrointestinal tract are typically referred to as inflammatory bowel diseases (IBD). The 
two most common IBDs are ulcerative colitis and Crohn’s disease. Surveillance for colorectal 
cancer is necessary for patients with IBD as they have an increased risk of developing dysplasia 
and cancer. The risk of cancer is influenced by the duration and extent of disease and is also 
linked to the endoscopic appearance at colonoscopy [35-37]. 
Of the total of 16 specimens measured (8 inflamed samples and 8 normal) in 8 patients, 2 
specimens (1 normal, 1 diseased) from 1 patient were excluded from the analysis as the normal 
specimen was found to be histologically abnormal (severe chronic ulcerative colitis with mild to 
moderate activity). The IBD specimens included in the analysis are summarised in table 4-5.  
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No. of patients 7 
No. of IBD specimens 7 
 UC 6  
 CD 1 
No. of normal specimens 7 
Total number of specimens 14 
Table 4-5: Summary of IBD and normal specimens included in study. IBD = inflammatory bowel 
disease; UC = ulcerative colitis; CD = Crohn’s disease. 
Paired representative images from normal and IBD specimens are illustrated in figure 4-14 and 
figure 4-15 for ulcerative colitis, and figure 4-16 for Crohn’s disease. 
Ulcerative colitis 
Ulcerative colitis (UC) is an idiopathic IBD that almost always begins in the rectum and extends 
proximally into the colon in a contiguous manner. Based on the amount of colon involved, three 
types of disease distribution are recognized; (1) ulcerative proctitis; (2) left-sided colitis; (3) 
pancolitis. 
Dysplasia and malignant transformation represent the most important complication of this 
disease and the risk begins to rise at 8-10 years after onset. At present, annual endoscopic 
surveillance is recommended after 8-10 years of illness.  If no lesions are observed, four biopsy 
specimens are taken randomly at every 10 cm between the rectum and the caecum for a total of 
40-50 biopsies per colonoscopy. However, even this massive sampling examines less than 1% of 
the total colonic mucosa surface. Thus, there is a strong interest in developing techniques that 
may be able to guide targeted biopsies and assist in discriminating between normal and 
dysplastic areas. 
Figure 4-14 and figure 4-15 show the fluorescence intensity and FLIM images of biopsy 
specimens (normal, diseased) taken from two patients affected by chronic active distal UC. 
Regular crypt architecture can be seen in the uninflamed mucosa (figure 4-14(a, b)) showing 
numerous mucin rich goblet cells assorted around the inner rim of the crypt openings (arrows). 
In contrast, both intensity and FLIM images of the inflamed tissue (figure 4-14(c, d)) show 
distanced crypts surrounded by an interstitial matrix fully infiltrated by small circular bright 
cells (arrowheads) containing dark dots in their centres (nuclei). This morphology is reflected 
histologically, where a loosening of the interstitial space is observed, and the mucosa is 
chronically infiltrated by inflammatory cells (neutrophils, lymphocytes and plasma cells). 
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Erythrocytes extravasated from capillaries of the lamina propria may also be present [411,416]. 
Goblet cell depletion and small crypt openings are also visible (asterisk), as a consequence of 
severe crypt destruction. This would be expected to increase the contribution of mucosal 
collagen fluorescence in the diseased sample. 
A decrease in lifetime is observed for the inflamed sample with a bimodal distribution of the 
average lifetime values compared to the normal counterpart, suggesting that at least two 
predominant fluorophores are involved in this sample figure 4-14(e). 
The mean fluorescence intensity was lower for the inflamed specimen compared to that of 
normal colon (706 ± 261 vs. 1021 ± 316 mean detected photons per pixel). 
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Figure 4-14: Matched intensity (a, c), and FLIM (b, d) images of fresh colon biopsy samples of normal 
mucosa (a, b) and ulcerative colitis (c, d). (e) Mean lifetime distribution histograms calculated from the FLIM 
data. 
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In figure 4-15(c, d), a nearly sagittal view of the inflamed sample was obtained, showing almost 
the full length of a crypt duct replete with extravasated mucous and cellular infiltration, 
possibly representing a crypt abscess (asterisk). According to the exhibited mean lifetime values 
in the FLIM images, cells with very short fluorescence lifetime values (blue on false colour scale) 
can be seen (white arrowheads) and regions of longer fluorescence lifetime (red on false colour 
scale) can also be seen (white arrows), which may be due to accumulation of mucin. 
In comparison with figure 4-14(e), a more clear separation in the mean lifetime histograms is 
shown in Figure 4-15(e), and the trend towards shorter lifetimes is repeated for the inflamed 
tissue. The mean fluorescence intensity was again lower for the inflamed specimen compared to 
that of normal colon (762 ± 190 vs. 778 ± 175 mean detected photons per pixel). 
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Figure 4-15: Matched intensity (a, c) and FLIM (b, d) images of fresh colon biopsy samples of normal 
mucosa (a, b) and ulcerative colitis (c, d). (e) Mean lifetime distribution histograms calculated from the FLIM 
data.  
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Crohn’s disease 
Crohn’s disease (CD) is a chronic idiopathic disorder characterized by a typically transmural 
inflammation that can affect any part of the GI tract. 
Figure 4-16 shows the fluorescence intensity and FLIM images of two biopsy specimens (1 
normal, 1 diseased) taken from the same patient affected by CD. 
The normal specimen (figure 4-16(a, b)) shows a regular crypt architecture and numerous 
cellular structures with large dark inclusions, which are therefore identified as goblet cells. 
The intensity and FLIM images of the inflamed tissue figure 4-16(c, d) show irregular crypt 
architecture, with aggregates of small circular bright cells containing dark dots in their centres 
(nuclei), indicated by red and white dotted circles in figure 4-16(c) and figure 4-16(d), 
respectively). This morphology is reflected histologically by the presence of nodules consisting 
of inflammatory cells (neutrophils, lymphocytes and plasma cells) as well as extracellular 
matrix, and lymphoid aggregates. These nodules are referred to as “non-caseating granulomata” 
and are characteristic of CD. According to the exhibited mean lifetime values in the FLIM images, 
these aggregates are composed of a mixture of cells with very short (blue on false colour scale) 
and relatively longer (green on false colour scale) fluorescence lifetime values. 
A decrease in mean fluorescence lifetime is observed for the inflamed sample compared to the 
normal colon (figure 4-16(e)). 
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Figure 4-16: Matched intensity (a, c) and FLIM (b, d) images of fresh colon biopsy samples of normal 
mucosa (a, b) and Crohn disease (c, d). (e) Mean lifetime distribution histograms calculated from the FLIM 
data. (f) Spatially averaged intensity spectra collected from the samples with a spectrometer. 
It is worth noting that although no difference can be seen in the emission spectra from the two 
samples, the mean fluorescence intensity for the inflamed sample was higher than that of the 
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normal colon (877 ± 273 vs. 596 ± 257 mean detected photons per pixel), and, once again, the 
peak and the line shape of the emission spectra appeared to be similar to that observed for 
flavins. 
Figure 4-17(a) shows a summary of results for all the IBD specimens included in the paired 
analysis. Figure 4-17(b) shows the shift in the intensity-weighted mean fluorescence lifetime 
(t) for each normal colon-IBD pair. Despite the considerable inter-patient variation for both 
normal and diseased specimens, the mean fluorescence lifetimes for IBD were all found to be 
shorter than those observed in normal colon. 
No difference in lifetime trend was observed between Crohn’s disease (sample 41) and 
ulcerative colitis (all the remainders). 
 
Figure 4-17: Bar graphs showing the mean fluorescence lifetime observed in all IBD specimens relative 
to a sample of healthy tissue from the same or nearest region of the colon. (b) Shift in the mean fluorescence 
lifetime of all IBD specimens included in the paired analysis. Lifetime shifts are calculated using a 
measurement of normal tissue obtained from the same or nearest region of colon. 
Figure 4-18 shows the paired ratio (IBD/normal) of the fluorescence intensity for all the IBD 
specimens relative to a specimen of healthy colon from the same patient. 
The ratio of mean fluorescence intensity, averaged across all the pixels of the intensity images to 
the corresponding value for the inflamed specimen, was found to be less than 1 in four out of 
seven cases, indicating that the fluorescence intensity from the inflamed specimen was lower 
than the paired normal specimen in four cases and higher in three cases. 
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Figure 4-18: Bar graph showing the ratio (IBD/normal) in the mean fluorescence intensity observed in 
all the IBD specimens relative to a specimen of healthy tissue from the same patient. The mean intensity for 
all the samples was obtained calculating the mean number of photons detected per pixel, across all the pixels 
of the intensity image. The error bars represent ± 1 standard deviation and were calculated via error 
propagation from the fluorescence intensity distribution in the normal and inflamed images. 
4.3.4 Oesophageal disease 
Barrett’s oesophagus 
Barrett’s oesophagus (BO) is a condition in which squamous mucosa is replaced by columnar 
epithelium as a result of gastric (and probably duodenal) content reflux. This replacement is 
referred to as intestinal metaplasia, histologically defined as the presence of goblet cells. 
Goblet cells are essential for the diagnosis of BO. Their distinct mucus vacuoles confer to these 
cells the characteristic appearance of wine goblets. Foveolar mucus cells are insufficient for the 
diagnosis. 
Increased epithelial proliferation, atypical mitoses, hyperchromatic nuclei, irregular 
distribution of chromatin, and high nucleus-cytoplasm ratio can be observed in both low (LGD) 
and high grade dysplasia (HGD). Gland architecture is subverted, showing irregular gland 
shapes, abnormal cellular and nuclear orientation and crowded clusters of cells (e.g. gland-
within-gland). 
Barrett’s oesophagus is associated with an increased risk of oesophageal adenocarcinoma, 
particularly when dysplasia arises within its epithelium. To date, dysplasia can be detected only 
histologically. Therefore, when BO is identified, a protocol consisting of 4 quadrant biopsies 
every 1 to 2 cm with biopsies of mucosal abnormalities (Seattle protocol) should be taken above 
the level of the lower oesophageal sphincter. Although it has never been validated, this protocol 
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is currently the standard method for detecting dysplasia in patients with BO. Standard 
videoendoscopy identifies BO but cannot distinguish intestinal metaplasia from dysplasia. This 
underscores the need for novel imaging techniques that may help target areas of dysplasia, thus 
assisting in the early diagnosis of dysplasia and cancer and allow for their timely treatment. 
All of the measured specimens (5 diseased and 5 normal) in patients with BO were included in 
the analysis and are summarised in table 4-6. 
No. of patients 5 
BO 5 
No. of normal specimens 5 
Total number of specimens 10 
Table 4-6: Summary of Barrett’s and normal oesophagus specimens included in study. BO = Barrett’s 
oesophagus. 
Paired representative images from normal and Barrett’s oesophagus are illustrated in figure 
4-19. Figure 4-19 shows the fluorescence intensity and FLIM images of two biopsy specimens (1 
normal, 1 diseased) taken from the same patient affected by Barrett’s oesophagus complicated 
by focal LGD. In normal oesophagus, the outlets of the submucosal mucous glands, which drain 
to the surface via ducts that are frequently squamous-lined, can be recognized (red asterisks). In 
pathology, these glands provide evidence that the location of the biopsy is the oesophagus, 
because such ducts are not present in the stomach. Normal squamous oesophageal epithelium 
(a, b) appears as flattened “scale-like” [417] tiles (red dotted rectangle), whereas a “villous-like” 
(intestinal) tissue architecture can be seen in the columnar-lined mucosa (c, d) with distorted 
and elongated appearance of glands and numerous dark goblet cells (red solid rectangle). An 
increase in the number of dark cells with an irregular border along the epithelium has been 
reported in Barrett’s-associated dysplasia using confocal endomicroscopy. Furthermore, the 
loss of the regular basement membrane integrity and the disruption of the villous epithelial 
structure are strongly suggestive of high-grade dysplasia and/or early carcinoma [149]. The 
H&E-stained histological sections (20x original magnification) of the normal and the BO 
specimens for this patient are shown in the upper and lower left insets respectively. Although 
they do not correspond precisely to the tissue slices observed, there is similarity of the confocal 
images with histology. For example, flat, thin “scale-like” squamous cells and the outlets of the 
submucosal mucous glands can be seen in the normal specimen (figure 4-19(a) and upper left 
inset), as opposed to the columnar epithelium with numerous goblet cells lining the ducts of the 
metaplastic mucosal glands (similar to the intestinal glands) in the BO specimen (figure 4-19(c) 
and lower left inset). 
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The mean lifetime histograms (e) show a narrower distribution of lifetimes for the Barrett’s 
epithelium and a tendency to shorter lifetime values compared to the normal mucosa. 
The mean fluorescence intensity was lower for the metaplastic epithelium compared to that of 
normal oesophagus (172 ± 47 vs. 133 ± 55 mean detected photons per pixel).  
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Figure 4-19: Matched intensity and FLIM images of fresh oesophageal biopsy specimens of normal 
mucosa (a, b) and Barrett’s oesophagus with low grade dysplasia (c, d). (e) Lifetime histograms calculated 
from the FLIM data. The upper and lower left insets provide magnified views (20x original magnification) of 
the H&E-stained histological sections of the normal and the BO specimen, respectively. Note that no exact 
registration exists between histology and FLIM images; the insets serve solely to illustrate the similarity of 
the confocal images with histology. 
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Figure 4-20(a) shows a summary of results for all the BO specimens included in the paired 
analysis. Figure 4-20(b) shows the shift in the intensity-weighted mean fluorescence lifetime 
(t) for each normal oesophagus-BO pair. The mean fluorescence lifetimes for BO were longer 
than those observed in normal tissue in three of five specimens. 
 
Figure 4-20: Bar graphs showing the mean fluorescence lifetime observed in all BO specimens relative to 
a sample of healthy oesophageal tissue. (b) Shift in the mean fluorescence lifetime of all BO specimens 
included in the paired analysis. 
Figure 4-21 shows the paired ratio (BO/normal) of the fluorescence intensity for all the BO 
specimens relative to a specimen of healthy oesophagus from the same patient. The 
fluorescence intensity from the BO specimens was higher than that of the correspondent normal 
specimen in all cases (n = 5). 
 
Figure 4-21: Bar graph showing the ratio (BO/normal) in the mean fluorescence intensity observed in all 
the Barrett’s oesophagus specimens relative to a specimen of healthy tissue from the same patient. The mean 
intensity for all the samples was obtained calculating the mean number of photons detected per pixel, across 
all the pixels of the intensity image. The error bars represent ± 1 standard deviation and were calculated via 
error propagation from the fluorescence intensity distribution in the normal and Barrett’s oesophagus 
images. 
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Reflux oesophagitis 
Gastro-oesophageal reflux disease (GORD) is a common disorder of the GI tract, affecting up to 
20% of the population in Western countries [418]. 
Endoscopic changes in reflux disease may present as non-erosive abnormalities such as 
erythema, friability and granularity of the mucosa, or, most commonly, as erosive oesophagitis, 
with the presence of erosions or ulcerations as described in section 2.1.2. 
Histologically, erosive esophagitis is characterized by epithelial injury and active inflammation. 
Epithelial injury is represented by oedema, which appears as a widening of the intercellular 
spaces, loss of cell cohesion, necrosis and sloughing [3]. Regenerative changes may occur in the 
epithelium adjacent to the eroded area. The presence of neutrophil infiltrate in both the 
epithelium and lamina propria is the hallmark of active inflammation. Occasionally eosinophils 
may predominate. The intensity of cellular infiltrate usually correlates with the degree of 
epithelial injury. 
Figure 4-22 shows the fluorescence intensity and FLIM images of two biopsy specimens (1 
normal, 1 diseased) taken from the same patient affected by grade D erosive oesophagitis – 
according to the Los Angeles endoscopic classification of GORD (see section 2.1.2)- which has 
caused a severe narrowing (stricture) of the lower oesophagus. 
As seen above in the normal oesophageal epithelium, a uniform pattern of flat and scale-like 
polygonal cells can be observed (red dotted rectangle in figure 4-22(a)). In contrast, the 
mucosal damage in the inflamed sample (figure 4-22 (c, d)) is testified by a dense cellular 
infiltration into the squamous epithelium (arrowheads in the intensity images, small “blue cells” 
in the FLIM images as opposed to normal “green-yellow” squamous cells in the upper right 
region of figure 4-22(d)) and numerous fibrous bands of connective tissue (arrows) which 
confer to the tissue a finely granular appearance (red solid rectangle in figure 4-22(c)). 
The histograms show a net lifetime shift between normal and inflamed tissue. In particular, 
decreased average lifetime values can be observed for the inflamed sample. It is interesting to 
note that the distribution of at least two components of the mean fluorescence lifetime vary 
asymmetrically across the 2 samples, possibly reflecting changes in the proportion of 
fluorophores involved in the emitted fluorescence. A shift in binding partners of flavins or 
changes in the ratio of free:protein-bound flavin fluorescence in the “blue cells” (assumed to be 
inflammatory cells) might be responsible of their shorter lifetime values. 
The mean fluorescence emission wavelength was longer for the inflamed specimen compared to 
that of normal oesophagus (555 nm vs. 401 nm). The mean fluorescence intensity for the 
195 
 
inflamed sample was higher than that of normal oesophagus (450 ± 171 vs. 285 ± 115 mean 
detected photons per pixel). 
 
Figure 4-22: Matched intensity and FLIM images of fresh oesophageal biopsy specimens of normal 
mucosa (a, b) and reflux oesophagitis (c, d). (e) Lifetime histograms calculated from the FLIM data. (f) 
Intensity spectra collected from the samples with a spectrometer. 
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Carditis 
The term cardia refers to the point where the oesophagus becomes the stomach. It is unclear 
whether the cardia is present from birth or rather arises as a metaplastic mucosa in the distal 
oesophagus as a consequence of gastro-oesophageal reflux disease [419]. When sampling at or 
just below the squamocolumnar junction (SCJ), cardiac mucosa often occurs in biopsy 
specimens taken. 
Figure 4-23 shows the fluorescence intensity and FLIM images of two biopsy specimens (1 
normal, 1 diseased) taken from the same patient affected by grade D erosive oesophagitis – 
according to the Los Angeles endoscopic classification of GORD - which has caused a severe 
narrowing (stricture) of the lower oesophagus. In this case, the diseased sample was taken at 
the level of the gastro-oesophageal junction, where the disease appeared to be more severe. 
The pattern of flat and scale-like polygonal cells can be observed in figure 4-23(a) and figure 
4-23(b). Uniform and homogeneous squamous cells with scattered outlets of submucosal 
mucous glands (asterisks) can be discerned, confirming the evidence that the location of the 
biopsy is the oesophagus. 
In the sample from cardia, “fundic-like” tissue architecture can be seen (figure 4-23 (c, d)) with 
tortuous foveolar pits and numerous dark goblet cells (red arrows). The presence of 
intraepithelial inflammation is identified by small bright round cells (red arrowheads in the 
intensity images, cells with a short fluorescence lifetime (blue on false colour scale) in the FLIM 
images) which are haphazardly distributed in the epithelium and may represent inflammatory 
cells, as seen by other investigators [410,420]. 
The mean lifetime histograms (figure 4-23(e)) show a narrower distribution of lifetimes for the 
inflamed epithelium and a tendency to shorter lifetime values compared to the normal mucosa. 
As an aside, it is interesting to note that longer lifetime values can be observed in proximity and 
at the mouth of the mucous glands (asterisks) in the normal oesophagus specimen, where 
mucin-rich cells are usually located. 
The mean fluorescence intensity was remarkably higher for the inflamed epithelium compared 
to that of normal oesophagus (237 ± 150 vs. 64 ± 20 mean detected photons per pixel). 
197 
 
 
Figure 4-23: Intensity and FLIM images of fresh oesophageal biopsy specimens of normal oesophageal 
mucosa (a, b) and inflamed cardiac mucosa (c, d). (e) Lifetime histograms calculated from the FLIM data.  
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4.3.5 Summary 
Our preliminary data is summarised in table 4-7 and reveals that the mean fluorescence lifetime 
of dysplastic or neoplastic samples may be either shorter or longer than that of normal tissue 
depending on the disease considered. The quoted errors are the standard deviation of the 
values across all specimens for each tissue group. 
Diagnostic group Mean τ disease  SD 
(ps) 
Mean τ normal  SD 
(ps) 
Δτ  (lesion - normal)  SD 
(ps) 
P 
value 
Colon polyps (n=11) 655  302 706  336 -191  234 0.024 
Colon cancer (n=4) 754  105 534  168 220  187 0.125 
IBD (n=7) 619  284 832  345 -213  101 0.015 
BO (n=5) 544  238 622  375 -77  262 1 
Table 4-7: Mean fluorescence lifetime shift for all samples included in paired analysis. Tau = 
fluorescence lifetime; SD = standard deviation; IBD = inflammatory bowel disease, BO = Barrett’s 
oesophagus. 
There is a statistically significant contrast between the lesion and normal tissue for polyps 
(p = 0.024) and IBD (p = 0.015), with the general trend being that the lesions present a decrease 
in fluorescence lifetime. In contrast, the mean fluorescence lifetime of colon cancer was longer 
than that of normal tissue with a mean delta tau shift of 220  187 ps, but this shift was not 
found to be statistically significant using the Wilcoxon signed rank test (p = 0.125) possibly due 
to the small number of specimens collected for this disease type. The lack of statistical 
significance for the Barrett’s oesophagus group is due to the small number of specimens imaged, 
the relatively large standard deviations on the lifetime shifts, and the small mean shift in 
fluorescence lifetime observed. 
Given the excitation wavelength used, we have attributed FLIM contrast primarily to 
contributions from intracellular fluorescence from flavins (FAD, FMN) in the epithelium, and to 
a lesser extent to mucosal collagen, which are also supported by histopathology studies. 
Although the limited number of samples, together these results suggest that label-free single 
photon FLIM imaging is feasible and effective to discern normal from pre-cancer, cancer, and 
inflammatory disease by providing both biochemical and structural details label-free in fresh, 
unfixed, unstained specimens. However, clearly more samples are required to confirm and 
quantify this result.  
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4.4 Discussion 
In this observational study, autofluorescence from a number of GI tissue specimens was excited 
using a confocal FLIM microscope at 420 nm. 
As discussed in section 3.1.5, FLIM is a potential new clinical imaging technique. UV and blue 
light generate measurable AF but have very limited tissue penetration, measured to be typically 
<1 mm in skin [421]. Consequently, excitation at these wavelengths would be unable to induce 
fluorescence from within solid organs by external illumination. 
Single photon-excited FLIM is therefore best suited to imaging tissues from endoscopically 
accessible surfaces such as the luminal lining of the GI tract, the bladder, and the skin, or during 
surgery where the tissue surface of an organ is exposed. 
FLIM images are normally presented by merging the false-colour FLIM maps with the 
corresponding fluorescence intensity images.  These intensity-weighted FLIM maps combine 
the biochemical information provided with FLIM with the structural information provided by 
the fluorescence intensity images. 
This preliminary work presents the experimental observation that the fluorescence lifetime of 
diseased tissue autofluorescence induced by 420 nm visible excitation may be either shorter 
(e.g. polyps, IBD and BO) or longer (colon cancer) than AF from adjacent normal tissue.  
In a paired analysis using the Wilcoxon signed rank test, a statistically significant lifetime 
contrast between normal and lesional tissue was found for polyps and IBD. In contrast, the shift 
in fluorescence lifetime was found not significant in colon cancer and BO. Further 
measurements would be needed to establish if the trends observed for these disease types are 
significant. 
4.4.1 Fluorescence lifetime changes with time following endoscopic excision 
All the specimens were imaged within 60-120 minutes of biopsy/resection. Although the AF of 
fresh tissue ex vivo shows similar intensity and spectral line shapes to that of in vivo tissue 
[422], some physical and metabolic changes may inevitably occur. For instance, AF from 
intracellular fluorophores such as NAD(P)H has been reported to decay ex vivo over a time scale 
of 118 minutes due to tissue deoxygenation, while the fluorescence from collagen and flavins 
remained relatively constant [388]. The haemoglobin content may also change, altering the 
absorption properties of the tissue. 
All the samples were kept in chilled tissue culture medium to minimize this degradation and to 
preserve tissue viability for as long as possible. However, it is likely that any change to ex vivo 
tissue fluorescence would affect all areas of a sample without distinction and so would be 
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unlikely to alter the lifetime contrast between normal and neoplastic tissue [273]. Interestingly, 
in a recent study from our group using multiphoton excitation conducted on four repeatedly 
imaged samples of freshly excised normal skin at the same field of view over a three hour 
period, which is the same timescale of hours pertinent to our study, the decrease in mean 
fluorescence lifetime was shown to be only marginal (less than 5% from the initial value 
averaged over four spectral channels) [423]. 
4.4.2 Characteristics of the GI mucosal tissue 
Tissue biopsy samples from GI tract are essentially composed of epithelia. This is because it is 
unlikely (but not impossible) to reach the submucosal layer of the GI wall with biopsy forceps.   
As discussed in chapter 2, the GI tract from the cardia to the rectum is lined by a simple 
columnar epithelium. The cells forming a simple columnar epithelium are tall. The nuclei of cells 
within the epithelium are usually located at the same height within the cells, close to the base. In 
contrast, the oesophagus is lined by a stratified squamous epithelium consisting of many cell 
layers. Basal cells often form a well-defined layer at the interface of the epithelium with the 
underlying connective tissue. 
The connective tissue and the epithelium are separated by a basement membrane. As 
mentioned above, though an endoscopic biopsy is unlikely to reach the submucosal layer, it is 
sometimes possible to find a component of submucosa in samples resected by cold snaring 
(polyps) or when biopsy is taken from atrophic areas or ulcerated lesion. The submucosa is the 
layer of connective tissue that supports the mucosa and contains blood vessels, lymphatic 
vessels, and nerves. 
Another important point to consider is the average thickness of the mucosal layer in the GI tract, 
which is about 500 µm in normal mucosa and almost the double in cancer [325], and the 
average thickness of an endoscopic biopsy sample, which may vary from 2 to 10 mm. However, 
in confocal microscopy, the thickness of the optical section (i.e. the thickness of sample slice 
from which emitted light is collected by the detector) is determined by the numerical aperture 
of the objective, wavelength used and size of the confocal pinhole aperture and not by the 
sample thickness. Therefore, in contrast to wide field microscopy or single point spectroscopy 
of biopsy samples, here the samples have theoretically the same optical section thickness, 
regardless of their original thickness. However, in thicker samples such as large polyps or 
cancers, deeper focal planes may show reduced signal intensity due to absorption and scatter. In 
our experiments, an imaging depth of 200 µm was reached.  
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4.4.3 Colonic polyps and cancer 
Previous work in our group using wide field FLIM with excitation at 355 nm has shown 
statistically significant contrast between cancerous and healthy colon tissue in a series of 18 
unfixed colonic samples following surgical resection, with 16 colonic adenocarcinomas showing  
longer lifetime values compared to surrounding normal tissue, and 2 serrated adenoma 
showing a decrease in fluorescence lifetime [273]. Shorter AF lifetime values have been 
reported in colonic adenomas using time-resolved spectroscopy at an excitation wavelength of 
337 nm [265]. The findings with 420 nm excitation reported in this chapter seem in accordance 
with these studies, though undoubtedly more samples are required to build a more statistically 
significant sample size. 
In cancer-associated changes there are a number of factors that would be expected to alter the 
tissue AF and fluorescence lifetime. These include changes in: a) the metabolic state of cells (e.g. 
intracellular NADH and flavin concentrations, and protein binding state [278,424,425]); b) 
tissue architecture and morphology (e.g. mucosal expansion displacing submucosal type I 
collagen away from the tissue surface; epithelial destruction and regeneration; tumour 
degradation of extracellular matrix or new matrix formation; inflammatory infiltrate) [426]; c) 
tissue oxygenation and pH. 
It has been previously ascertained that dysplasia and cancers favour a metabolic pathway 
different from normal tissue. One of the biochemical hallmarks of carcinogenesis is the shift 
from oxidative phosphorylation to glycolysis. This observation is known as the Warburg effect 
[427]. It is also widely accepted that there is an increase in metabolic activity in cancer cells, 
which finds its basis in altered tumour vascularisation and imbalance between oxygen demand 
and supply [428]. Based on these assumptions, changes in the redox ratio NADH/FAD with 
cancer development have been investigated in ex vivo human fresh bladder [272], cervix [429], 
colon [430] and in the animal model of oral carcinogenesis in vivo [292,431]. 
Using multiphoton microscopy at 800 nm excitation, a quantitative analysis of the redox ratio 
NADH/FAD was performed by Zhuo et al. [430] to quantitatively monitor colonic cancer 
progression. The redox ratio was shown to increase with progression from dysplasia to cancer.  
Skala et al. [292] demonstrated a decrease in protein-bound NAD(P)H and flavins lifetimes 
measured in vivo from severe dysplasia in the hamster cheek pouch model of oral 
carcinogenesis. Our measurements show that dysplastic adenomas and cancer display opposite 
lifetime trends, which may be due to differences between the concentration and distribution of 
the most prevalent GI tissue fluorophores involved (e.g. flavins, collagen). 
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It is widely accepted that morphological changes in dysplasia include mucosal thickening, crypt 
enlargement, “back to back” aspect of dysplastic cells, and lamina propria displacement. In 
cancer, a highly disorganised architecture, abundant and unregulated epithelial proliferation, 
and contraction of epithelial interstitial space are common findings. The progressive 
enlargement and obliteration of the crypts may be responsible for displacing the underlying 
lamina propria, thus decreasing the total amount of mucosal collagen fluorescence [353,432]. It 
is reasonable to assume that the fluorescence emitted from cancer and neoplastic polyps, at the 
wavelength used in this study, may be due more to contributions of flavins, rather than from 
collagen and elastin, which is reinforced by the measurements of fluorescence emission 
spectrum presented. 
However, in addition to the enlargement of the crypts, in neoplastic polyps we also observed 
large bands of interstitial matrix, with only sparse cellular infiltrate, and this, together with the 
observations made using immunochemistry assays and selective stains, may support the 
assumption that collagen, although here sub-optimally excited, may be another principal 
contributor to the changes in AF lifetime observed. 
In normal colon specimens excited at 735 nm using MPM, peak fluorescence emission intensity 
in the 410-490 nm wavelength range has been reported [433]. It was suggested that this 
fluorescence at relatively longer wavelengths could be attributed to flavins and possibly 
lipofuscin, which are respectively found in cells within the interstitial space and leukocytes 
within the lamina propria. Also, lipopigments have emission spectra similar to flavins [213]. 
4.4.4 Inflammatory bowel disease 
The picture is less clear in inflammatory conditions, whose metabolic pathway is still not 
completely understood due to differences in in disease states (acute, chronic, active, quiescent) 
and the wide variation of both metabolic and structural factors involved such as cytokines 
secretion, epithelia destruction and regeneration, inflammatory cells infiltrates, autophagy, etc. 
In contrast to normal cervix and cervical intraepithelial neoplasia (CIN) at different grades, 
reduced epithelial redox ratios have been shown in inflammatory cervical epithelial tissues. 
However, both inflammatory and dysplastic tissues displayed a large decrease in stromal 
quantity, indicating a marked loss of collagen [429]. 
Possible explanations include cytokine-induced inflammatory response and apoptosis, resulting 
in reduced proliferation rate of epithelial cells. Collagen fibres are replaced by the infiltrating 
lymphocytes, which promote further degradation of collagen [280,434] 
These observations may support the significant difference in the mean fluorescence lifetime 
values observed between inflammatory and polyp specimens.  
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4.4.5 Barrett's oesophagus and oesophageal disease 
Barrett's oesophagus represents a highly heterogeneous clinical entity, whose histochemical 
characteristics vary considerably among biopsies and patients. This may also partly explain the 
mixed results obtained in this particular disease group. 
Interestingly, in the cases of reflux oesophagitis and carditis, presumed inflammatory cell 
infiltrates showed shorter fluorescence lifetime than normal epithelium. It is speculated that a 
shift in binding partners of flavins or changes in the ratio of free:protein-bound flavin 
fluorescence might explain this finding. 
4.4.6 Known and unknown fluorophores in GI mucosal tissues 
For 420 nm excitation we expect the dominant fluorescence signal to be due to intracellular 
flavins within the mucosa with perhaps some additional signal from mucosal collagen in the 
lamina propria, which can be excited at this wavelength [309]. Data from a previous study in our 
laboratory also showed that fluorescence from lyophilised collagen powders from various 
anatomical sources could be excited at 420 nm (Figure 4-24)[435]. 
 
Figure 4-24: Model excitation-emission matrix (EEM) of lyophilised collagen powder from type I collagen 
from bovine Achilles tendon (C9879, Sigma-Aldrich). λ = wavelength. Reproduced with permission from 
[426]. 
204 
 
Contributions from lipopigments might also be expected [321,322], although they do not 
generally contribute greatly to tissues fluorescence emission [310], especially in non melanotic 
mucosa, and are reportedly absent in both neoplastic and hyperplastic colonic polyps [324]. 
The fluorescence emission spectra peak measured in the paired specimens of colon polyp 
(figure 4-7(f)) and cancer (figure 4-11(f)) at ~530 nm is broadly consistent with the emission 
spectra of flavins [436] and collagen [309]. 
Flavins have a mean fluorescence lifetime of around 4.7 ns for FAD and 5 ns for FMN, and 
shorter decay components typically in the range ~0.01-1 ns when protein bound [275]. 
Collagen type IV is primarily found in the linings surrounding the colonic crypts (basal 
membranes), whereas collagen types I-III are predominant in the stroma of the lamina propria 
[7,313]. In our samples, large amounts of mucosal collagen were indeed highlighted by the 
selective stains presented. Collagen fluorescence is particularly complex and a range of values 
are reported in the literature, e.g. 1.05-5.3 ns [302,437]. 
The fluorescence lifetime measured in this study in the range 0.1-1.4 ns is also broadly 
consistent with a combination of the longer decay components found for collagen and those of 
free and protein-bound flavins. 
In our study, it is speculated that there are at least three central players responsible of the 
changes in AF intensity and lifetime observed: flavins, collagen, and mucins. 
Fluorescence emission spectra were measured from 5 pairs of specimens in an attempt to 
identify by observing the resultant peak and line shape the most prevalent fluorophores 
involved in producing the fluorescence decay signatures. 
Each pair included one normal and one diseased specimen excised from 3 different locations of 
the GI tract (oesophagus, colon and rectum) and representative of the three main disease 
categories investigated (inflammation, pre-cancer, cancer). In all cases, especially for the normal 
samples, the peak and the line shape of the emission spectra, appeared to be similar to that 
observed for flavins [213,287,415]. The emission spectra were also compared to spectra of 
synthetic flavins in solution obtained using a spectrofluorometer at 420 nm excitation to 
reinforce this assumption. 
Mucins are a family of glycosylated proteins produced by epithelial tissues and discharged 
through a duct opening on an internal or external surface. They form secretions which serve to 
lubricate, enhance or inhibit cell signaling, and offer a chemical barrier to microbes and toxics.  
To date, we have found no previous studies that investigated mucin fluorescence and its relative 
contribution to changes in normal and disease autofluorescence. As mucin often takes an 
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inhibitory role, from a clinical perspective, it is often perceived as an extraneous and 
confounding constituent of glandular tissues, something that needs to be discarded to unmask 
more relevant information beneath. 
However, it must be noted that the role of mucin secretion in Barrett’s oesophagus is well 
known in histochemistry, where the relative proportions of different types of mucins (neutral, 
sialomucins, or sulfomucins) are often invoked to discriminate between intestinal metaplasia 
from other types of epithelium such as columnar non metaplastic oesophageal epithelium and 
gastric metaplasia (fundic epithelium)[438,439]. 
In one study by Adur et al. [312], higher fluorescence lifetime values in mucinous ovarian 
epithelium were found in cells with abundant mucin content. Also in our study, where mucin 
can be reliably located - essentially in the crypts openings lumina - longer lifetime values can be 
observed in the corresponding pixels in contrast with mucin-devoid areas such the stroma or 
the external rim of the crypts. 
In our images, mucin depletion has been observed in polyps and cancer compared to their 
paired normal specimens. Differences in mucins content have been further confirmed using 
mucin-specific staining such as AB, showing good contrast between the normal and diseased 
samples. 
As mentioned in section 4.2.4, prior to imaging, samples were thoroughly rinsed with fresh 
buffer solution. Nevertheless, although unlikely, the presence of small sources of contamination 
(e.g. residues of the tissue culture medium used to transport the specimens between the 
campuses, blood, excess mucus, and for the colon specimens, any residues of bowel cleansing 
preparation) cannot be excluded. Thus, when interpreting the findings, this aspect should also 
be considered but it is unlikely to be the cause of contrast seen between normal and diseased 
samples as they were all treated in the same way. 
4.4.7 Fluorescence intensity 
In general, in vivo studies of tissue AF describe reduced fluorescence measured at the tissue 
surface from cancerous and dysplastic areas compared to normal tissue [275,280,381]. 
In this study, a decrease in mean fluorescence intensity was seen in the cancer and the IBD 
specimens compared to adjacent samples of healthy mucosa, whereas the contrary was seen for 
polyps and IBD. However, unlike fluorescence lifetime, fluorescence intensity measurements are 
affected by sample scattering and absorption, which increase with imaging depth, making 
quantitative measurements more difficult. 
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Izuishi et al. [381] hypothesized that under blue light excitation the main source of tissue 
fluorescence is submucosal collagen and that the reason for the decreased fluorescence in colon 
cancer is a decrease in collagen fluorescence as a consequence of a screening effect of the 
thickened mucosa overlying the submucosal layer or replacement of the submucosa by cancer 
cell infiltration. Also, the increased blood volume in neoplastic tissues migth explain a decrease 
in fluorescence intensity due to haemoglobin absorption. 
4.4.8 Future work 
The results of this chapter show that confocal FLIM with excitation at 420 nm can be used to 
characterize the main tissue components and compartments, and help discriminate normal 
from inflammatory, dysplastic and neoplastic tissue in fresh human GI biopsy specimens, 
without the addition of exogenous contrast agents. 
It is envisaged that in the future, confocal FLIM may have an important role in the study of GI 
disease since it is able to provide evidence of non-endoscopically evident mucosal damage, 
which could only be confirmed by histopathology. For instance, in this study, changes in mean 
fluorescence lifetime were observed in specimens endoscopically classified as “normal”, which 
eventually showed abnormalities on histological examination. 
The difference in mean lifetimes as measured by delta tau is encouraging, particularly when 
applied to colonic polyps. Proven colon cancers display a negative lifetime shift, but clearly 
many more samples need to be studied to confirm and quantify these initial findings. 
Based on this experience, the following improvements for future research work have been 
proposed: 
• Increase the sample size. 
• Reduce the excision/imaging interval. This could be achieved by moving the confocal 
FLIM microscope to the hospital. The images were acquired within 60-120 minutes after 
removal of samples by forceps biopsy or polypectomy snare.  How lifetime changes over 
this time period is unknown. However, imaging time for normal/diseased pairs in this 
study was always reasonably well-matched. 
• Better registration between confocal and histological images. 
• Simultaneous image acquisition and data processing, and simultaneous processing of 
entire data sets (batch fitting). This would significantly reduce the time required to 
complete the analysis of a high number of images. In this study, only two images (1 
normal, 1 disease) per patient data set were selected. Data processing was performed 
manually for each individual image selected, a laborious and time-consuming process 
which is prone to error. 
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• Sample orientation; there is no ideal method to ensure that the epithelial surfaces are 
correctly positioned facing the objective lens. Nevertheless, the method developed in 
this study enabled to clearly distinguish mucosal from submucosal side in most cases. 
• Inherent contrast available; use of contrast dyes may help to enhance nuclear contrast 
(acetic acid to contrast nuclei, glucose to energise cells). 
We are encouraged by other reports that have shown some of the features that we have 
observed [156,323,440]. Similarly, Professor Hillman’s group have presented hyperspectral 
two-photon microscopy (TPM) paired images and emission spectra from normal and transgenic 
mouse GI tissue [323]. However, their study involved freshly excised small intestine and colon 
from 15 (10 normal and 5 transgenic APC Min/+) mice, and was mainly carried out to determine 
the TPM excitation spectral properties of the four layers of the normal GI tract wall. 
To the best of our knowledge, our study represents the most comprehensive survey of 
fluorescence lifetime images in normal and diseased human gastrointestinal mucosal tissues 
and the only study to use confocal FLIM at 420 nm excitation to image autofluorescence from 
freshly-resected specimens from patients undergoing endoscopic procedures.  
Further work is warranted to identify the optimum fluorescence imaging parameters for 
contrasting a given disease and tissue type, including the optimization of the excitation and 
emission wavelengths. 
4.5 Conclusions 
We have presented an observational study of time-resolved confocal FLIM of gastrointestinal 
samples collected from patients undergoing endoscopy as part of their clinical investigations. 
Utilizing a FLIM confocal microscope, we have studied the autofluorescence signatures of fresh 
endoscopically resected GI tissue. We found that FLIM imaging allows the visualization of tissue 
details in some of the most common GI diseases. 
FLIM contrast can be generated within and between biological tissues.  Of particular interest, is 
the preliminary data that suggest FLIM is able to contrast between normal and dysplastic tissue. 
In fresh tissue, and by analogy in vivo, this contrast may be primarily attributed to the different 
fluorescence lifetimes of flavins and collagen [435] at the excitation wavelength used.  The 
ability to generate this contrast suggests potential clinical applications for confocal FLIM 
including the in vivo detection and characterisation of dysplasia and early GI cancers, and the 
discrimination with inflammatory diseases. Currently, the application of the confocal FLIM 
endomicroscope in ex vivo and in vivo studies of tissue autofluorescence is still limited by the 
background fluorescence from the fibre probes. However, further refinement of this endoscope 
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is ongoing and in the future, the construction of lower background fluorescence fibres 
prototypes may overcome this barrier. 
Future work is more likely to involve the collection of a larger, more significant data set to allow 
confirmation of the observations made in the results section of this chapter. 
Firstly, this will allow us to build a bank of ex vivo data to permit detailed investigation of the 
optical signatures of other GI disease types meaning that the worth of confocal FLIM can be 
assessed over a wider range of GI conditions, including liver, biliary and pancreatic disorders. 
Secondly, an increased database of information would also facilitate the development and 
implementation of FLIM in endoscopic instruments for clinical use. Once the observed changes 
have been confirmed to a higher degree of significance and the best opportunities for contrast 
between healthy and diseased tissue have been assessed, the development of imaging 
instrumentation could be accelerated.  
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Chapter 5: Fluorescence Lifetime Imaging (FLIM) of 
bladder cancer: a pilot study conducted on human 
bladder specimens collected under Hexvix induced 
endoscopic fluorescence guidance 
The work reported in this chapter used the FLIM confocal microscope described in the previous 
chapter to analyse the autofluorescence from ex vivo “cold-cut” tissue samples of human 
bladder. The specimens were excised from patients undergoing cystoscopy as part of their 
clinical investigations. 
In this series, autofluorescence imaging, with or without instillation of a photosensitising agent 
into the bladder prior to cystoscopy, was performed and a consistently longer overall lifetime 
for biopsies of bladder cancer was observed. Fluorescence emission spectra were also 
compared with pure solutions of protoporphyrin IX (PpIX) in an attempt to detect the 
fluorescence signature of this important fluorophore, which accumulates preferentially in 
malignant tissue. 
The aim of the work described in this chapter was to assess whether the fluorescence patterns 
seen could report on the disease state of the tissue. These observations were directed at 
understanding the fluorescence contrast available, especially when associated with the artificial 
enhancement of the fluorescent signal resulting from abnormal accumulation of PpIX. 
As for the GI specimens, the FLIM confocal microscope served as a very convenient platform for 
systematic observations due to its inherent optical sectioning capability, wide wavelength 
tunability, relative ease of use, and a fast and clinician-friendly interface both for image 
acquisition and processing. 
5.1 Introduction 
Bladder cancer (BC) is the fourth commonest cancer affecting men. Cancer research UK has 
recently reported that 10,090 people were diagnosed with bladder cancer in 2007 in the UK 
[441]. With over 150,000 people dying worldwide from this illness, BC has the highest lifetime 
treatment costs per patient of all cancers. The high recurrence rates and continuous invasive 
surveillance required are the key contributors to the economical and human toll of the disease. 
The majority of bladder cancers arises from the transitional layer and are called transitional cell 
carcinoma (TTC). The most common type of TCC is the papillary form. On cystoscopy, it is often 
obvious and appears as an anemone-like series of fronds, or digitations, frequently on a stalk, 
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protruding in the lumen of the bladder. However, the sessile type and the carcinoma in situ (CIS) 
are flat and almost invisible cancers, which are usually found only on biopsy. 
As for the GI tract, early detection and subsequent immediate treatment in patients with 
superficial tumours confers an overall 90% survival rate [441], whereas once the muscularis 
propria is invaded, there is a 30% mortality rate at 5 years after diagnosis [442]. 
Current endoscopic techniques rely on the clinician taking biopsies using white light cystoscopy 
(WLC) from areas of abnormal tissue for histological diagnosis of suspected bladder cancer, 
enabling further treatment and management. Urinary cytology and conventional white light 
cystoscopy with bladder mapping have therefore represented the gold standard diagnostic tool 
for many years but these are not without their limitations. While WLC can easily detect 
macroscopic lesions, flat and early cancers such as CIS and dysplasia with minimal/absent or 
nonspecific urothelial abnormalities can escape detection [443]. Significantly, WLC light 
cystoscopy can miss lesions not visible to the naked eye, and has poor overall sensitivity (56-
68%) [444,445]. Furthermore, given that up to 83% of patients with CIS can develop invasive 
cancer, achieving the optimal inspection of the bladder wall remains a principle obstacle in the 
early detection and precise staging of bladder cancer [446]. 
The advent of novel imaging technologies is creating important new opportunities for the 
progression in tumour identification and characteristics. One such example is fluorescence 
cystoscopy; often referred to as blue light photodynamic diagnosis (PDD). This offers the 
opportunity to improve the quality of the endoscopic diagnosis and treatment of bladder 
cancers by enhancing the visual contrast between benign and malignant tissue by inducing a 
photodynamic process, resulting in selective emission of fluorescence from cancer cells. 
PDD (see section 2.4.3) relies on the administration of a photosensitising agent (typically 5-
Aminolevulinic Acid (5-ALA), to induce the accumulation of protoporphyrin IX (PpIX), a 
fluorescent by-product involved in the haem cycle, which has been shown to build up in rapidly 
proliferating and therefore neoplastic cells [447]. 
ALA-induced PpIX fluorescence for detection of bladder cancer was first described by 
Baumgartner et al. in 1993 [448]. ALA was instilled intravescically in 56 patients and after a 
period of 2-4 hours, a strong red fluorescence was exclusively emitted by the epithelial tumours. 
In a cohort of 104 patients with suspected primary or recurrent bladder cancer, Kriegmair et al. 
[119] reported a higher sensitivity for blue light cystoscopy compared to WLC (97% vs. 73%) in 
detecting dysplasia and early bladder cancers. 
Work by Jichlinski et al. [449] using topically administered PpIX in 34 patients with known 
bladder cancer reported a good correlation between the PpIX fluorescence and the 
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histopathological diagnosis. In addition, PpIX permitted the detection of 47 unsuspected lesions 
that were overlooked by WLC in 18 patients, 40% of which were early cancers. 
A study by Lange et al. [450] showed that topical application of an ester form of ALA resulted in 
a twofold increase of PpIX fluorescence intensity at a considerably lower concentration 
compared to ALA. 
Intravenous injection of photosensitizers (Photofrin) has also shown promise as a way to 
differentiate malignant lesions from normal bladder mucosa when applied in 21 patients at 
337 and 405 nm excitation [451]. 
A blue light PDD system has been recently introduced by Karl Storz (D-LIGHT C system, Karl 
Storz GmbH & Co. KG, Germany) for endoscopic tissue characterization during cystoscopy in 
combination with hexaminolevulinate hydrochloride, an ester of 5-ALA (Hexvix, PhotoCure, 
Norway) administered via intravescical instillation. Following administration of the 
fluorescence marker, in the fluorescence mode (blue light), malignant tissue can be 
differentiated from benign tissue as tumorous areas fluoresce in red, while normal tissue 
exhibits a blue colour. The false colours are generated by the image display software, with blue 
representing low and red representing a high fluorescence intensity. 
PDD of bladder cancer has recently been shown in large case series to improve detection of 
small papillary tumours, CIS and satellite lesions from previously resected tumours [452]. 
Evidence that PDD outperforms the gold standard white light in diagnosis of bladder cancer has 
been provided [119,449,453]. However, PDD appears to be not enough sensitive at 
differentiating between inflamed and cancerous tissue, offering low specificity (41.4-98.5%) 
and giving a high false positive rate, limiting its clinical uptake [454]. Thus, the development of 
PDD aims at increasing the specificity by discriminating neoplasms from inflammatory lesions. 
Hence, the integration of PDD with an emerging technology that has the potential to provide 
more specific contrast on the basis of the tissue fluorophore composition would be highly 
desirable. As described in section 3.1.5, fluorescent lifetime imaging microscopy (FLIM) is a 
novel technique that measures the characteristic decay of molecules (fluorophores) rather than 
solely the fluorescent intensity [273]. 
5.1.1 FLIM of PDD agents in bladder cancer 
There are relatively few reports in the literature on FLIM of bladder cancer [65,272,273,455]. 
Mizeret et al. [65,456] presented the development of instrumentation for time-resolved 
fluorescence imaging in 1997. Results obtained on a single freshly resected human bladder were 
contextually presented to illustrate the potential of the technique. At 417 nm excitation, an area 
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corresponding to erythematous urothelium exhibited a shorter mean fluorescence lifetime than 
the surrounding normal mucosa (1.65 ± 0.4 ns vs. 2.6 ± 0.2 ns). 
Cicchi et al. [272,455] used a combination of 4 different systems - two photon intrinsic 
fluorescence (TPE), second harmonic generation microscopy (SHG), fluorescence lifetime 
imaging microscopy (FLIM), and multispectral two photon emission detection (MTPE) - to 
investigate different states of ex vivo fresh biopsies of bladder. They focused on normal mucosa 
and carcinoma in situ (CIS), reporting significant morphological and spectroscopic differences, 
and both in spectral emission and fluorescence lifetime distribution. In particular, using two-
photon excitation at 740 nm and 890 nm, and emission filters centered at 460 nm and 510 nm 
to selectively detect NADH and FAD fluorescence respectively, they found differences in the 
fluorescence lifetime components ratio of NADH and FAD with a higher concentration of 
protein-bound NADH and of free FAD in CIS compared to normal bladder. 
Previous work in our group using wide-field time-gated FLIM at 355 nm excitation showed a 
decreased fluorescence lifetime in bladder exhibiting squamous cell carcinoma relative to 
surrounding healthy transitional mucosa (one surgical specimen) [273]. 
In terms of time-resolved measurements of ALA induced PpIX fluorescence, pioneering work 
has been done by Konig et al. [305]. Decay times of 230 ps (weak component) and 17 ns (main 
component) were obtained in mice with subcutaneous grafts of human bladder cancer 3 hours 
after intravenous administration of 5-ALA. Control measurements of PpIX in dimethylsulfoxide 
confirmed the experimental findings showing decay times of approximately 17 ns for the main 
component, whereas the weak component exhibited a decay time of around 3 ns. The authors 
did not explain the difference between the two weak components. 
In a study by Glanzmann et al. [255], the in vivo ﬂuorescence lifetime of PpIX excited at 418 nm 
in three patients with bladder cancer was found to be 1590 ± 120 ps. The photosensitizing agent 
Hexyl-ALA was instilled into the patient’s bladder during 4 hours prior to the measurements. 
This value was close to the value found in vitro for PpIX in organic solution (1700 ± 600 ps) and 
higher than that found for PpIX in ethanol (1250 ± 500 ps). They also reported a longer AF mean 
lifetime at 337 nm excitation in bladder cancer (invasive papillary carcinoma) compared to 
surrounding normal tissue (4250 ± 55 ps vs. 5410 ± 150 ps), in a patient undergoing 
cystoscopy. 
5.1.2 FLIM of PDD in other tissues 
Cubeddu et al. [457] reported a long lifetime for PpIX of 1500-1800 ps using FLIM with a gated 
(two gates) intensified camera at 405 nm excitation in five patients with basal cell carcinomas 
or squamous cell carcinomas of the skin (total of 6 lesions). Delta-aminolevulinic acid was 
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topically administered to the patients 1 hour before the measurement, and all tumours were 
localised on the basis of the longer decay time detected in neoplastic tissues due to the stronger 
emission of PpIX. Furthermore, two fluorescence methods, fluorescence lifetime imaging at 
405 nm and multicolour imaging at 390 nm, were used by Andersson-Engels et al. [458] to 
identify and separate basal cell carcinomas from normal surrounding skin from two patients, 2 
hours after topical application of 20% ALA ointment. High ratios of mean lifetime and amplitude 
between tumour and surrounding healthy tissue were observed in all of the 5 lesions, as a result 
of the longer lifetime decay of the exogenous neoplastic fluorescence compared to the natural 
endogenous fluorescence of normal skin. 
Kantelhardt et al. [459] used FLIM in vivo at 750 nm excitation in mice with  intracranial grafts 
of human glioma cell lines in mouse after intraperitoneal administration of 5-ALA. They found 
significantly longer mean fluorescence lifetimes of 5-ALA induced PpIX fluorescence in the 
tumour areas compared to contralateral normal brain (3240 ps vs. 1810 ps, respectively) [460]. 
In vivo time resolved spectral measurements at excitation-emission range specific for PpIX 
detection (410 nm-633 nm), were applied by Chang et al. [461] to discriminate normal oral 
mucosa from premalignant oral lesions such as leukoplakia and erythroleukoplakia and 
squamous cell carcinoma. Significantly longer lifetime values were reported in oral 
premalignant and malignant lesions relative to normal oral mucosa (10000 ps vs. 3500 ps). It 
was assumed that the wide lifetime shift was caused by abnormal accumulation of PpIX in 
cancerous tissue. Similarly, Chen et al. [268] using a 2-component decay model, found that the 
average lifetime for dysplastic samples was longer than that for normal mucosa, and the longer 
lifetime (component 2) was recognized to be from PpIX. 
5.1.3 Summary of previous work and aims 
It is therefore proposed in this study that there are differences in the fluorescence lifetime 
signatures between various bladder tissue states. Showing that FLIM can differentiate between 
normal, inflamed and cancerous ex vivo human bladder tissue samples and validating the 
molecules contributing to differences in the fluorescence lifetime would aid in developing a 
novel endoscopic system to give a real-time optical tissue diagnosis during cystoscopy. 
The hypothesis of the experiments described in this chapter was that FLIM is able to detect the 
lifetime signature of PpIX, which is used in PDD of bladder cancer after the application of 
hexaminolevulinate (Hexvix). 
The aim was to assess whether confocal FLIM at 405 nm excitation is able to contrast normal 
from neoplastic bladder in virtue of the differences in both natural and PpIX induced 
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fluorescence, which are expected to lengthen the measured fluorescence lifetime in cancer 
compared to normal tissue. 
5.1.4 Normal bladder histology 
The wall of the bladder consists of three layers (mucosa, muscularis propria, and adventitia). 
The mucosa is composed of urothelium and lamina propria and has either no or often only a 
discontinuous muscularis mucosae. Therefore, the lamina propria and the submucosa tend to 
merge and a well delineated submucosa is not identifiable. The urothelium (inner layer) is lined 
by the so called transitional cells (i.e. between nonkeratinizing squamous and pseudostratified 
columnar epithelium), which represent the most common source of bladder cancer. 
The urothelium is composed of three layers: superficial, intermediate, and basal. 
 The superficial layer is a single layer of “umbrella cells”, which are large and elliptical 
with abundant eosinophilic cytoplasm and often binucleated. One umbrella cell covers 
several underlying cells. 
 The intermediate layer contains small cuboidal cells with well-defined borders and 
cytoplasm rich in glycogen. 
 In the basal layer, cells are more cylindrical and lie on the basal membrane. 
The lamina propria is located between the basal membrane and the muscularis propria, and 
contains dense connective tissue, blood vessels lymphatics, and adipose tissue. 
The muscularis propria consists of a trabecolature of circular and longitudinal muscle bundles. 
The adventitia (outer layer) separates the bladder from other organs. 
A transverse section through the urinary bladder wall is shown in figure 5-1. When the bladder 
empties, the mucosa folds in ridges called rugae (dotted circle). Vice versa, the rugae are effaced 
when the bladder fills. The transitional epithelium allows the bladder to expand as it fills [6]. 
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Figure 5-1: Light micrograph of the wall of the urinary bladder in transverse section. The mucosa 
appears corrugated in folds called rugae (dotted circle). Adapted and reproduced with permission from 
[462]. 
Recently, Sonn et al. [463] reported the first in vivo microscopic evaluation of human bladder 
urothelium using a confocal laser endomicroscope (Cellvizio, Mauna Kea Technologies, France). 
A comparison of H&E and confocal endomicroscopy (pCLE) images of normal bladder mucosa is 
illustrated in figure 5-2. 
 
Figure 5-2: Comparison of H&E and pCLE images of normal bladder mucosa with fluorescein staining. 
(A) Large, polygonal superficial cells consistent with umbrella cells. (B) Smaller, deeper urothelial cells 
consistent with intermediate cells. (C) Lamina propria containing blood vessels filled with erythrocytes. 
Reproduced with permission from [463]. 
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5.1.5 Bladder cancer pathology 
The transitional cells represent the most common source of bladder cancer. Other bladder 
cancers, such as sarcomas, adenocarcinomas and squamous and small cell carcinomas are 
relatively rare. 
The histological patterns of bladder cancer vary from papillary, to nodular, or completely flat 
(CIS). Endoscopically, papillary cancers usually appear as red raised excrescences with variable 
size from 1 to 5 cm. Early or flat types appear as areas of reddening, granularity, and thickened 
lining. Low grade papillary cancers show an overall orderly architecture and only cytological 
features (e.g. atypical and hyperchromatic nuclei, mitotic figures, variation in nuclear size and 
shape, loss of polarity) can help to make a precise diagnosis. High grade forms are characterised 
by increased thickness of the urothelium, lack of cohesiveness (i.e. presence of loosely jointed, 
dyscohesive cells), increased cells shedding, infiltration of the deeper layers, and “pagetoid” 
spread of malignant cells. 
Comparison of H&E and confocal endomicroscopy (pCLE) images of bladder cancer mucosa is 
given in figure 5-3. In low grade papillary tumours (figure 5-3(a, b)), densely arranged small 
and uniformly shaped cells (homogeneous and monomorphic) were observed. High grade 
carcinoma (figure 5-3(c, d)) showed a more pleomorphic population of cells with irregular 
shape and presence of fibrovascular stalks (due to neoangiogenesis) [464]. 
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Figure 5-3: Comparison of in vivo confocal endomicroscopy images with fluorescein staining of low (a) 
and high grade urothelial carcinoma compared with corresponding H&E sections (c) and (d). (a, b) Crowding 
of uniform-appearing cells in low grade cancer cells. (c, d) Pleomorphic and distorted sheet of cells in high 
grade carcinoma. Adapted and reproduced with permission from [464].  
(b)
(c)(a)
(d)
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5.2 Materials and methods 
5.2.1 Overview 
Between August 2010 and February 2012, a total of 23 non diagnostic (not submitted for 
histopathological examination) bladder samples were obtained as “tru-cut” biopsies from 13 
patients undergoing rigid cystoscopy at St Mary’s Hospital for suspected cancer. 
Adjacent tissue was biopsied from normal and lesional areas, and submitted for 
histopathological evaluation during a process called bladder mapping, where multiple biopsies 
are taken from several different locations in the bladder to better determine the extent of 
cancer or dysplasia. 
The true histological diagnoses of the tru-cut specimens studied were later confirmed on the 
basis of the diagnostic samples collected during the bladder mapping. 
All samples were imaged using a confocal FLIM microscope (Leica SP5 confocal microscope, 
Leica Microsystems) - see section 4.2.3 - with 405 nm excitation provided by a frequency-
doubled Ti:Sapphire laser oscillator (BB Mai Tai, Newport Spectra-Physics). Fluorescence was 
detected over the range 432-750 nm using time-correlated single photon counting (TCSPC). 
A total of 120 confocal images were acquired (mean 5 images per sample; minimum = 1, 
maximum = 27), 36 of which were selected and manually processed using the Becker & Hickl 
SPC-Image 3.1 software (see section 4.2.5). 
Data processing and image selection was performed as described in section 4.2.1. Each diseased 
sample was compared to a normal sample taken from an endoscopically normal area near the 
lesion, fitting the fluorescence decay to a double-exponential decay model and analysing the 
resulting mean fluorescence lifetime. Only paired samples were included in the analysis. 
5.2.2 Patient enrolment 
Patients were consented for the use of excess tissue in medical research. All cold-cut bladder 
tissue biopsies in these experiments were obtained in accordance with Outer West London 
Research Ethics Committee approval number 08/H0719/37. The use of human tissue in this 
study complied with the requirements of the Human Tissue Act (2004). 
Patients agreed to the collection of an additional normal biopsy and the use of tissue samples 
not needed for histopathology for research. 
Inclusion Criteria 
Patients were recruited if clinically diagnosed with bladder cancer and if they required biopsy 
or cystoscopic resection. 
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Exclusion Criteria 
The following exclusion criteria were used: 
• Unable to give informed consent 
• Under 18 years old 
• Prisoner 
• Having a blood borne infection e.g. Hepatitis, HIV. 
Pseudo-anonymisation 
All recorded data was tagged using a linked anonymised identifier for each patient. Data 
analysis and subsequent correlation with histology was also anonymous. 
The clinical care team (DC, AK & EM) held the link but did not disclose this to the research group 
and maintained patient confidentiality as part of their normal medical duty at all times. 
5.2.3 Fluorescence lifetime imaging instrumentation 
The FLIM confocal microscope has been described in section 4.2.3. All samples were excited at 
405 nm because porphyrins have their Soret absorption maximum at this wavelength. Their 
fluorescence emission spectra peak between 624-633 nm, depending on the porphyrin. When 
excited at this wavelength, protoporphyrin IX was found to have a fluorescence peak at 633 nm 
[304]. 
When relatively larger bladder cancer specimens were obtained (dates 15/12/2010, 
24/05/11), fluorescence lifetimes were further measured either using time-gated wide field 
imaging or confocal endomicroscopy to contribute towards the development of a wide field 
FLIM flexible ureteroscope prototype (Karl Storz GmbH, Germany) and a FLIM confocal 
endomicroscope respectively, for future in vivo clinical application – see section 3.2. 
Lifetime calibration 
As for the GI specimens, the instrumental response functions were obtained by imaging a drop 
of Erythrosin B solution (10-40 μM), which has a single exponential decay with a lifetime of 
89 ps [406]. 
5.2.4 Sample preparation and protocol 
In patients undergoing cystoscopy that were suitable candidates for in vivo Hexvix instillation 
and surveillance using blue light cystoscopy, Hexvix (50 ml at concentration of 8 mmol/l) was 
instilled into bladder tissue in vivo for an hour, before being washed out prior to blue light 
cystoscopy. This “incubation” period is known to induce the accumulation of PpIX in rapidly 
proliferating cells. PpIX is a fluorescent by-product involved in the haem cycle and therefore 
requires respiration in order to accumulate in vivo before the fluorescent properties of the 
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tissue are measured. Samples were extracted with the guidance of the Storz D-light system, and 
then brought to the Photonics Group laboratory for spectral and fluorescence lifetime analysis. 
A summary of the clinical and histological diagnoses of all the ex vivo samples investigated is 
given in Table 5-1. 
Tissue type   
Cystoscopic diagnosis Histological diagnosis Number of samples 
Bladder neoplasia 10 TCC 
1 papilloma 
11 
Normal bladder tissue 12 normal bladder 12 
Total number of normal tissue specimens 12  
Total number of diseased tissue specimens 11  
Total number of specimens instilled with Hexvix  10  
Total number of specimens not instilled 13  
Total number of specimens 23  
Table 5-1:  Summary showing the clinical diagnoses of all the ex vivo non diagnostic samples 
investigated with the confocal FLIM microscope. Note that the histological diagnoses correspond to the 
diagnostic samples collected during the bladder mapping. 
Each sample was excised by transurethral endoscopic resection. Following excision, the 
specimens instilled in vivo were kept in physiological Hartmann’s solution warmed to 37 °C and 
transported immediately after resection to the Photonics Group FLIM laboratory. 
Sample preparation and imaging was then performed as described in the section 4.2. Particular 
care was taken to image the mucosal side of the biopsies as we expected the majority of relevant 
fluorescence (especially PpIX) to originate from there. 
Fluorescence emission spectra for bladder tissue samples were also measured (QE65000, Ocean 
Optics Inc., B.V., The Netherlands) to validate the molecules involved in producing the 
fluorescence decay signatures, and compared to spectra obtained from pure solutions of flavins 
and PpIX. 
5.2.5 Criteria for interpretation of confocal images 
The criteria applied to interpret endoscopic microscope images were based on histological 
characteristics of tissue. These include well-established features and structures seen on 
microscopy of standard histological sections [8,9,408,465-467] and recently published criteria 
for confocal laser endomicroscopy of the urinary tract [463,464,468,469]. 
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5.3 Results 
All analysis was performed based on the histological correlation achieved for all samples with 
the adjacent diagnostic specimens collected during the bladder mapping. Samples were 
excluded if histological analysis of their diagnostic pair revealed normal tissue in clinically 
abnormal samples or histological abnormalities in clinically normal specimens. 
Before presenting the images and the results for the bladder specimens instilled with Hexvix 
included in the analysis, it is considered necessary to illustrate the fluorescence intensity and 
FLIM images of two biopsy specimens (1 normal, 1 diseased) taken from a patient affected by 
bladder cancer, who did not receive Hexvix instillation. In this way, the autofluorescence 
contrast arising from the two tissue states (in this pair of specimens) is presented, along with a 
description of the morphological differences observed. 
In figure 5-4(a, b), a layer of cells (red arrows) can be seen. The cellular fluorescence intensity is 
higher in some regions (red dotted circles), which may align with the rugae. Most cells have a 
well-defined nucleus, as seen from the absence of cellular autofluorescence in the centre of the 
cell, which is consistent with flavin (or possibly NAD(P)H) fluorescence. Some cells appear 
much smaller (red arrowheads), which may be deeper intermediate or basal cells (see figure 
5-2), with the majority of larger cells likely corresponding to umbrella cells (also see figure 5-2). 
This seems consistent with the known size difference between umbrella and the deeper 
intermediate or basal cells on histology, and with the observations made by several 
investigators [463,464,468]. The ridges and slopes within the tissue, coupled with the increased 
brightness of the (assumed) umbrella cells, may also be responsible for the presence of areas of 
different brightness in the images. 
In contrast, in figure 5-4(c, d), an almost flat and uniform villous pattern (red solid square) of 
smaller and densely packed urothelial cells is seen in the cancerous sample. This is also in 
accordance with both histological [8,9,408,465-467] and confocal endomicroscopy features 
[463,464,468,469]. 
In the cancer specimen, the mean fluorescence intensity was higher than in the normal bladder 
(54 ± 19 vs. 46 ± 20 mean detected photons per pixel). 
The lifetime histograms (figure 5-4(e)) show a slightly broader distribution of lifetimes for the 
normal tissue, but otherwise the histograms are similar. 
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Figure 5-4: Matched intensity (a, c) and FLIM images (b, d) of tissue autofluorescence in freshly 
resected normal bladder (a, b) and bladder cancer (c, d) obtained from the same patient undergoing 
cystoscopy at St Mary's Hospital, London. The normal specimen (a, b) shows large umbrella cells (red 
arrows) organized in rugae (red dotted circles), and a smaller subtype of cells which may correspond to 
intermediate or basal cells (red arrowheads). The cancerous specimen (c, d) shows a villous pattern with 
small and uniform cells and no umbrella cells can be seen. (e) Mean lifetime distribution histogram 
calculated from the FLIM data. 
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Of the total of 23 specimens imaged (11 cancers and 12 normal) from 13 patients, 13 specimens 
were excluded from the paired analysis because it was not possible to obtain a normal or a 
cancerous specimen (7), because Hexvix was not administered (2), and because a good image of 
the mucosal side could not be obtained despite repeated attempts (4). Therefore, 10 specimens 
(5 cancers, 5 normal) from 5 patients, who received intravescical instillation of Hexvix prior to 
cystoscopy, are included in the paired analysis presented in this section. 
Figure 5-5 shows two paired representative images from normal and diseased tissues instilled 
intravescically prior to cystoscopy, resection and imaging. Figure 5-5(e) shows the histograms 
of the intensity-weighted mean fluorescence lifetimes (t mean) for a normal-cancer pair. Figure 
5-5(f) shows the fluorescence emission spectra collected over the entire fields of view. 
In figure 5-5(c), a compact layer of small densely packed monomorphic cells can be seen, which 
is different from the architecture of normal urothelium shown in Figure 5-5(a) and previously 
described for Figure 5-4(a). The cancer sample exhibited a broader and longer distribution of 
fluorescence lifetime values compared to the normal sample (Figure 5-5(e)). 
Again, compared to the bladder cancer specimen, in normal bladder there appear to be 
considerably more cell size heterogeneity, with a prominent population of cells exhibiting 
shorter fluorescence lifetime values (blue on false colour scale). This seems consistent with the 
known size difference between umbrella and the deeper intermediate or basal cells on histology 
for the normal bladder. 
The rather homogeneous appearance of small and uniform cells seen in the bladder cancer 
specimen is also consistent with histology. The change in fluorescence lifetime between the two 
populations of cells in normal and neoplastic tissue could be attributed to the different ratio of 
NAD(P)H/flavins, and to their different distribution of free/protein bound states as it is known 
that neoplastic metabolism is associated with changes in the relative concentrations of NADH 
and FAD [278,470]. In the cancer cells, an increase in protein bound NAD(P)H and free flavins 
might be responsible of their longer lifetime distribution  
It is interesting to note that the cancer specimen emitted a higher mean fluorescence intensity 
than the normal bladder (160 ± 38 vs. 125 ± 41 mean detected photons per pixel) with a peak 
fluorescence emission wavelength of approximately 500 nm that is consistent with the emission 
maxima of flavins and NAD(P)H (Figure 5-5(f)) [213,287,415]. Normally, as seen with in vivo 
blue light cystoscopy, higher fluorescence intensity in the cancer specimen would be expected 
because of the preferential accumulation of PpIX in neoplastic tissue. In addition to the emission 
peak at 500 nm, the characteristic double-peaked emission spectrum of PpIX at 630 and 700 nm 
was also seen in both specimens (Figure 5-6(a, b)). 
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PpIX was also shown in separate solution phase experiments (Figure 5-6(c)) to have a peak 
emission spectrum at ~630 nm when measuring purified PpIX in solution with a 
spectrofluorometer [414]. A 25 µM solution of synthetic PpIX (Protoporphyrin IX, Sigma-
Aldrich, USA) in dimethylsulfoxide (DMSO, Molecular probes, Life Technologies, USA) was made 
up immediately prior to the measurement. The spectra were acquired at room temperature 
(21 °C) from 580 nm to 750 nm using 405 nm excitation. 
The longer fluorescence lifetime in the cancerous specimen is consistent with a greater 
concentration of PpIX in this specimen compared to normal tissue and with the longer 
fluorescence lifetime of PpIX compared to tissue autofluorescence, c.f. figure 5-4. 
Emission spectra showed a peak at ~500 nm and at ~630 nm, both consistent with the 
fluorescence peak of flavins and PpIX respectively. 
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Figure 5-5: Matched intensity (a, c) and FLIM images (b, d) of a freshly resected bladder cancer (c, d) 
and normal bladder tissue (a, b) obtained from an adjacent region in the same patient. (e) Mean lifetime 
distribution histogram calculated from the FLIM data. (f) Intensity spectra collected from the samples with a 
spectrometer. 
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Figure 5-6: (a) Emission spectra of main endogenous tissue fluorophores (Adapted from [213]). (b) 
Graph showing the overlap (black dashed rectangle) of the intensity spectra from a fresh biopsy specimen of 
bladder cancer (shown in figure 5-5) collected with a fibre-coupled spectrometer, and the emission spectra 
of PpIX in DMSO (25 µM) obtained using a spectrofluorometer [414] at room temperature (21 °C), λex = 
405 nm, λem = 580-750 nm. 
Figure 5-7 shows the fluorescence intensity and FLIM images of two biopsy specimens (1 
normal, 1 diseased) taken from the same patient affected by a bladder papilloma. Papilloma is a 
rare form of bladder tumour and is usually found in younger patients. It appears as a delicate 
anemone-like exophytic structure with a stalk and multiple finger-like digitations on the top. 
The typical papillary fronds [442], or cloves, lined by normal appearing urothelium (red dotted 
ovals) can be seen almost in cross section in the papilloma specimen (figure 5-7(c, d)), in 
contrast with the structure of the normal specimen (figure 5-7(a, b)). As for the other tumours 
in this study, the papilloma showed a longer mean fluorescence lifetime compared to normal 
bladder (figure 5-7(e)); however its mean fluorescence lifetime decay was by far the longest 
amongst all diseased specimens. 
Substantially similar emission spectra (figure 5-7(f)) and mean fluorescence intensities were 
displayed by both papilloma and normal bladder (14 ± 3 vs. 13 ± 3 mean detected photons per 
pixel). It is worth noting, however, that the peak and the line shape of the emission spectra 
appeared once again to be similar to those observed for flavins (at 520 nm) and porphyrins 
(double peak at 630 and 700 nm). 
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Figure 5-7: Matched intensity (a, c) and FLIM images (b, d) of a freshly resected bladder papilloma (c, d) 
and normal bladder tissue (a, b) obtained from an adjacent region in the same patient. (e) Mean lifetime 
distribution histogram calculated from the FLIM data. (f) Intensity spectra collected from the samples with a 
spectrometer.  
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5.3.1 Summary 
The data for all samples included in the paired analysis is summarised in Table 5-2. 
Mean τ disease  SD (ps) Mean τ normal  SD (ps) Δτ  (disease - normal)  SD (ps) P value 
895  246 707  250 189  158 0.0625 
Table 5-2: Mean fluorescence lifetime shift for all samples included in paired analysis (n = 5). τ (tau) = 
fluorescence lifetime, SD = standard deviation. 
Figure 5-8 (a) shows a summary of results for all the cancer specimens included in the paired 
analysis. Figure 5-8(b) shows the shift in the intensity-weighted mean fluorescence lifetime (t) 
for each normal-cancer pair. The mean fluorescence lifetime for the cancer specimen was longer 
than that observed in normal tissue and this trend was observed in all cases. However, this 
difference was not found to be statistically significant (p = 0.06). It is interesting to note that the 
longest mean lifetime value was observed in the papilloma sample, (sample No. 22), which has 
low malignant potential compared to TCC (Figure 5-7). 
 
Figure 5-8: (a) Bar graphs showing the mean fluorescence lifetime observed in all cancers relative to a 
sample of healthy tissue from an adjacent region of bladder. (b) Shift in the mean fluorescence lifetime of all 
cancers specimens included in the paired analysis (n = 5). 
Figure 5-9 shows the paired ratio (disease/normal) of the fluorescence intensity for all the 
cancer specimens (n = 5) relative to a sample of healthy bladder tissue from the same patient. 
The ratio of mean fluorescence intensity, averaged across all the pixels of the intensity images to 
the corresponding value for the cancer specimen, was found to be greater than 1 in three out of 
five cases, indicating that the fluorescence intensity from the cancer specimen was higher than 
the paired normal specimen in 3 patients and lower in 2 patients (samples 10 and 16). 
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Figure 5-9: Bar graph showing the ratio (bladder cancer/normal) in the mean fluorescence intensity 
observed in all the cancer samples relative to a sample of healthy tissue from the same patient. The mean 
intensity for all the samples was obtained calculating the mean number of photons detected per pixel, across 
all the pixels of the intensity image. The error bars represent ± 1 standard deviation and were calculated via 
error propagation from the fluorescence intensity distribution in the normal and cancerous images. 
5.3.2 Wide field FLIM imaging 
As mentioned above, when relatively larger bladder cancer specimens were obtained, 
fluorescence lifetimes were further measured using time-gated wide field imaging to contribute 
towards the development of a wide field FLIM flexible ureteroscope prototype (Flex X 
ureteroscope, Karl Storz GmbH, Germany), for future in vivo clinical application. The wide field 
FLIM endoscope setup is described in section 3.2.5. 
In these experiments, the specimens were excited at 405 nm using a separate multimode fibre 
and the resulting fluorescence collected through the endoscope coupled to a GOI. In the future, 
following further development of this FLIM endoscopy system, the excitation light will be 
delivered using an additional fibre that is integrated into the same endoscope. 
Figure 5-10 shows the wide field FLIM images of two biopsy specimens (1 cancer, 1 normal) 
taken from a patient affected by bladder cancer, who did not receive Hexvix instillation. 
Macroscopically, the cancerous sample had a red papillary growth rising from the mucosal 
layer, consisting of finger-like epithelial projections and villi. 
Neoplastic tissue had visibly less intense fluorescence than the normal specimen, and exhibited 
a shorter mean fluorescence lifetime compared to normal bladder. 
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Figure 5-10: Wide field FLIM images of normal bladder (a) and bladder cancer (b) obtained from the 
same patient. Fluorescence lifetime distribution histogram calculated from the FLIM data, fitting the mean 
lifetime to a double-exponential decay model. The field of view of the ureteroscope is 3.29 mm x 2.51 mm. 
5.4 Discussion 
The objective of this study was to investigate the potential for FLIM when applied to induced 
PpIX fluorescence in the bladder. These observations might help develop a FLIM endoscope that 
may be used to detect the lifetime signature of PpIX in vivo during cystoscopy, and increase the 
detection rates and the specificity over standard fluorescence intensity imaging alone, e.g. with 
the Storz blue light system. 
PpIX is a fluorescent by-product involved in the haem cycle, which is used in PDD of bladder 
cancer after the instillation of products such as Hexaminolevulinate (Hexvix). Previous studies 
suggested that the combination of natural and PpIX induced fluorescence lengthens the 
measured lifetime, and makes it possible to differentiate between normal, inflamed and 
cancerous tissues [457,458,471]. 
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These results suggest that the combination of autofluorescence and PpIX induced fluorescence, 
which were both measured by the broad detection band employed, lengthens the fluorescence 
lifetime in cancer compared to normal. 
Based on this limited set of data it appears that the mean fluorescence lifetime of bladder cancer 
biopsies are consistently longer than the healthy biopsies for intra patient comparisons, 
although this difference was not found to be statistically significant (p = 0.06). 
The increase in the mean fluorescence lifetime for the cancerous specimens could be due to 
there being a larger proportion of PpIX in neoplastic tissue when compared with normal tissue 
as it is well known that PpIX has a long mean lifetime (up to 15 ns) [280-282]. 
In our study, we have not observed very long values of fluorescence lifetime as it would be 
normally expected in presence of PpIX accumulation. However, previous studies have shown 
that PpIX fluorescence lifetime goes through significant changes when bound to intracellular 
partners. For example, the fluorescence lifetimes of photosensitizers such as Photofrin, 5-ALA, 
and mTHPC were all shortened compared to those in solution [472,473]. 
In addition, the spectral analysis of each cancer biopsy revealed spectral peaks that are 
consistent with published values for the emission spectrum of flavins and PpIX fluorescence 
[213,255,287,415]. This result is also in good agreement with those obtained from Glanzmann 
et al. [255], where a strong emission band between 510 and 560 nm, corresponding to the 
tissue autofluorescence only, was distinguished both spectrally and temporally at 418 nm 
excitation from the 5-ALA induced PpIX fluorescence with its characteristic emission peak at 
633 nm. A longer AF mean lifetime was also reported at 337 nm excitation for bladder cancer 
compared to surrounding normal tissue (4250 ± 55 ps vs. 5410 ± 150 ps). 
Notwithstanding the obvious differences, longer fluorescence lifetimes induced by exogenous 
administration of PpIX relative to adjacent healthy tissue have also been reported in skin cancer 
[457,458], oral dysplasia and cancer [268,461], and in a number of tumour-bearing animal 
model studies [459,460,474], including chick chorioallantoic membrane [475], rat prostate 
adenocarcinoma cells in organic solution [476], and rat epithelial cells incubated with 5-ALA 
[477]. 
This chapter also reports preliminary work using wide field FLIM to study bladder 
autofluorescence. Shorter mean fluorescence lifetime for cancer relative to adjacent normal 
bladder was found in two paired specimens. This contrast is similar to that observed in previous 
work from our group using wide field time domain FLIM instrumentation at 355 nm excitation 
[273], showing a decreased fluorescence lifetime in a freshly resected bladder containing a 
moderately differentiated squamous cell carcinoma. This result is also in agreement with an 
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earlier study employing frequency-domain FLIM at 363 nm excitation, showing a decreased 
fluorescence lifetime in bladder exhibiting an erythematous urothelium [65]. Further work is 
required to investigate this more thoroughly. 
In this study, an increase in mean fluorescence intensity (mean ratio bladder cancer/normal = 
1.26) was seen in the cancer specimens compared to adjacent samples of healthy mucosa. 
However, unlike fluorescence lifetime, fluorescence intensity measurements are known to be 
affected by a number of factors, including the relative difference in the focal plane for each 
individual sample measured, the different depth of penetration reached by the excitation light, 
and scattering of emitted fluorescence as it propagates back through the sample. 
The detection bandwidth used in our study enabled to measure both AF and PpIX intensity 
together. It is therefore difficult to separate their relative contributions to the resulting 
fluorescence intensity detected. For example, it is possible that PpIX fluorescence increased for 
cancer relative to autofluorescence and this masked the lower fluorescence intensity compared 
to the normal specimen. The observation here in two sample pairs that AF intensity decreases in 
cancer is consistent with earlier reports of autofluorescence studies [478,479]. Koenig et al. 
[478] studied 53 patients with bladder cancer undergoing cystoscopy with mucosal biopsies or 
transurethral resection of a bladder tumour. Tissue was excited at 337 nm using a fibre-optic 
probe inserted through the working channel of the cystoscope. Cancer exhibited lower 
fluorescence intensity compared to healthy bladder mucosa. Importantly, in non-malignant 
tissue, including normal and inflamed mucosa, a peak at 385 nm was consistently seen, which 
instead was not observed in malignant lesions. Based on this observation, they developed an 
algorithm to distinguish malignant from non-malignant tissue, with 97% sensitivity and 98% 
specificity. 
A decrease in autofluorescence intensity for bladder cancer, independent of grade and stage of 
tumour, was also observed by Anidjar et al. [479] at different excitation wavelengths (308, 337 
and 480 nm). 
In our study, other than in fluorescence lifetime and intensity, morphological differences were 
also observed between the two tissue states although these differences were not quantified. The 
patterns provided by confocal FLIM in freshly excised bladder specimens were found to be 
similar to those characterised by pCLE [463,464], and to those of conventional H&E 
histopathology. The tissue morphology observed in our images was also similar to that shown 
by Cicchi et al. [272] using a combination of two-photon excitation fluorescence, second 
harmonic generation (SHG) and FLIM microscopy at 740 nm and 840 nm excitation. 
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The fluorescence spectrum and lifetime trends observed (greater 630 nm emission peak and 
longer fluorescence lifetime) support the idea that Hexvix induced PpIX in the bladder 
preferentially accumulates in cancerous tissue and also demonstrates the potential for FLIM to 
differentiate normal and diseased tissue based on Hexvix induced lifetime contrast in the 
bladder. Intensity measurements were confusing due to the wide spectral detection band 
employed detecting both AF and PpIX fluorescence. Future work is more likely to involve the 
spectral separation of AF and PpIX contributions using narrower detection bands. However, a 
larger data set is required to confirm this promising result. 
5.5 Conclusions 
Our data, although based on only a small number of ex vivo specimens, suggests that FLIM is 
able to differentiate between normal and neoplastic tissue, confirmed on histological diagnosis, 
with a consistently longer overall lifetime for biopsies of bladder cancer compared to paired 
normal specimens. Our AF emission spectra suggest that this may be due to the different 
lifetimes of flavins in combination with PpIX when bladder tissue is excited at 405 nm. Further 
study to characterize bladder biopsies obtained during PDD using blue light cystoscopy using 
FLIM ex vivo is necessary before a novel endoscopic system can be used for in vivo optical 
biopsy. Our work suggests that FLIM may become a useful adjunct to blue light PDD, and can 
possibly offer a novel technological solution to the challenge of accurate diagnosis of bladder 
cancer.  
234 
 
Chapter 6: In vivo time-resolved fluorescence lifetime 
spectroscopy of skin cancer 
This chapter presents results from an in vivo a clinical investigation conducted at Lund 
University Hospital using a novel, compact, multidimensional, clinically deployable fluorescence 
lifetime spectrometer. A cohort of 25 patients with suspected skin cancer was studied 
immediately before surgical excision of their lesions. 
Particular emphasis was given to basal cell carcinoma (BCC), which was the most prevalent 
lesion type in the group of patients recruited in the study. 
In the first part of this chapter, a brief introduction to skin cancer, novel optical techniques 
applied to the diagnosis of skin cancer, and to the anatomy of normal human skin is provided. 
The design, construction and application of the spectrometer are then described along with the 
experimental protocol, the clinical procedure and the main results. A statistically significant 
decrease in the fluorescence lifetime of BCCs compared to neighbouring healthy tissue was 
observed. 
This was the first in vivo study of autofluorescence lifetime using an instrument developed by 
the Photonics Group and was published in the Journal of Biophotonics, Vol. 5, February 2012 
[403]. The article was also highlighted as the Editor’s Choice and publicised by the journal in a 
press release. 
This study served not only to illustrate the clinical applicability of optical spectroscopy for the 
diagnosis of skin cancer but, more importantly, preceded and pioneered the application of the 
same technology and instrumentation for use in the gastrointestinal tract. 
6.1 Introduction 
Malignant tumours of the skin include cutaneous melanoma, basal cell carcinoma (BCC) and 
squamous cell carcinoma (SCC). Melanoma is the type of skin cancer that develops from 
melanocytes (nevi), whereas BCC and SCC develop from basal cells and keratinocytes 
respectively. 
BCC and SCC, collectively known as non-melanoma skin cancer (NMSC), account for 90% of all 
skin malignancies and represent a significant health problem worldwide. Despite the extended 
survival prognosis of these diseases compared to malignant melanoma, their incidence appears 
to be increasing. In the UK and the USA respectively, there are approximately 100,000 and 
1,000,000 new cases reported every year [480,481]. 
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For instance, amongst white populations in Europe, the USA, Canada and Australia the average 
increase in NMSC has been between 3 and 8% per year since the 1960s [482,483]. 
Basal cells are found in the deepest layer of the epidermis and around the hair follicles. BCCs are 
predominantly found on areas of skin exposed to the sun (i.e. face, nose, forehead, cheeks, back, 
and legs), and are often diagnosed in middle or old age. Lesions start typically as a small lump 
with shiny edges and a depressed or sunken centre. They then tend to grow upwards and 
become crusty and ulcerated, infiltrating the epidermis, the dermis and other neighbouring 
types of tissue such as cartilage or bone, although, unlike melanomas, they rarely metastasise to 
other parts of the body. A synchronous or metachronous development of a BCC is possible, and 
once affected, the risk of being re-affected by another BCC increases in turn. 
Squamous cell skin cancers are responsible for about 20% of all skin cancers. They arise in 
areas of direct exposure to the sun, or can also develop in scarred, burnt or ulcerated areas of 
skin. 
SCCs affect predominantly older people and present as shallow ulcers, often with a scaly crust 
and elevated and hardened edges, which tend to infiltrate to the deeper layers of the skin if left 
untreated. The spreading of SCCs to regional lymph nodes and metastases is uncommon. 
Diagnosis of skin cancer is currently based on a patient’s anamnesis and on visual inspection of 
the suspected lesion. However, in many cases the diagnosis still remains unclear and a biopsy, 
followed by histopathological assessment of the excised tissue, is often required for 
confirmation. Nonetheless, non-melanoma skin cancers are occasionally difficult to classify 
because of overlapping morphological features or ambiguous differentiation. In these 
circumstances pathologists have to recourse to immunohistochemistry. 
Taking a skin biopsy is quite an invasive procedure, which is not devoid of risks and 
complications (pain, bleeding, scarring). This method often leads to unnecessary excision of 
benign lesions [484,485] and, additionally, the delineation of the margins of the lesion can be 
extremely difficult so, a significant section of surrounding healthy tissue is usually resected to 
ensure that no cancerous tissue remains.  Another point to consider is that the histopathological 
analysis is an expensive and time consuming process that ideally should be left only for selected 
cases. Clearly, a non-invasive method of assessing skin lesions, capable of avoiding unnecessary 
biopsies and reducing uncertainties for patients and clinicians would be desirable. 
Skin offers the advantage of being the largest and most easily accessible organ of the body, 
which makes it particularly attractive for optical diagnostic methods. 
A number of non-invasive technologies based on autofluorescence imaging and spectroscopy 
have been investigated for the detection and delineation of skin diseases over the last decades. 
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These include diffuse reflectance measurements [219,225,397], polarisation-resolved 
reflectance spectroscopy and imaging [486-488], steady state fluorescence spectroscopy [489], 
time-resolved fluorescence spectroscopy [490,491] and imaging [270,423,492], confocal 
reflectance microscopy [493-495], optical coherence tomography (OCT) [496,497], Raman 
spectroscopy [498], and multiphoton microscopy (MPM) [490,499-501]. 
Rajaram et al. studied non-melanoma skin cancer in vivo using a combination of diffuse 
reflectance and fluorescence spectroscopy [397] at 337 nm excitation, while Blackwell et al. 
used an instrument recording fluorescence decays in four spectral channels to compare the 
fluorescence signature of human skin from diabetic and non-diabetic subjects in vivo [491]. 
Using a single-point spectroscopy probe, Brancaleon et al. [489] measured the emission spectra 
collected in vivo and from fresh frozen samples of both BCC and SCC excited at four different 
wavelengths (350, 360, 390 and 420 nm). Interestingly, a loss of autofluorescence from a region 
surrounding the malignant tissue was reported, and this area corresponded to a visible loss of 
collagen and elastin at the histological assessment. 
The spectroscopic data suggest that NAD(P)H, flavins, keratin, collagen and elastin 
[298,490,502] constitute the principal contributors of skin autofluorescence, and the spectral 
and temporal properties of the emission from these fluorophores reflect changes in tissue 
metabolism and environment due to the presence of disease. There is therefore a compelling 
need to develop instruments that can probe these subtle changes measuring the 
autofluorescence properties of skin (and other organs) for early and enhanced diagnosis of 
early stage cancers [397,485,503-507]. A number of instruments have been presented that are 
capable of monitoring both the fluorescence lifetime and emission spectrum of a sample 
[255,256,258,508], and significant differences between the fluorescence lifetimes of healthy and 
diseased tissue in NMSC have been shown in both ex vivo [258,270] and in vivo studies 
[397,491]. 
The recent emergence of a clinically licensed and commercially available two photon 
microscope [509], has prompted the application of multiphoton microscopy to studies of skin 
disease [499-501]. 
Using step-wise two-photon microscopy (TPM) at 810 nm excitation, Eichhorn et al. [500] 
measured the spectra from fresh skin (n = 150) and formalin fixed, unstained sections (n = 27) 
of melanocytic lesions. They observed a single spectral emission peak at 490 nm in benign nevi 
and at 600 nm in nodular melanomas, with both peaks appearing in dysplastic nevi. 
Two photon microscopy has also been used to study the morphological features of skin 
malignancies and been reported to show good correlation with histology. Ex vivo studies of non-
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melanoma skin cancer samples excited at 780 nm [499] showed irregularly distributed 
keratinocytes with dilated intercellular gaps. Higher cytoplasmic fluorescence intensity was 
found in pleomorphic cells and dyskeratotic cells compared to the surrounding cells.  Nests of 
BCC cells were found in a third of the BCC specimens. 
Although most researchers have focused on skin cancers, investigations have also been 
extended to non-cancer applications such as skin aging [510], inflammatory conditions such as 
atopic dermatitis [511] and hypertrophic scars [512]. The application of fluorescent precursors 
as exogenous source of contrast (induced fluorescence) to skin imaging, such as protoporphyrin 
IX, is also being increasingly investigated [513]. 
Most recently, due to the improvement of FLIM instrumentation, fluorescence lifetime contrast 
of skin lesions has also been reported. Previous work from our group [270], using a wide field 
FLIM system to excite freshly-resected specimens of BCC at 355 nm, revealed a significant 
lifetime difference between cancers and normal perilesional skin (1.40 ns vs. 1.55 ns 
respectively). 
Conversely, using TPM with excitation at 740 nm, another group has reported longer lifetime 
values for BCC compared to normal tissue [492]. 
Recent ex and in vivo work in our group [423] using multispectral multiphoton FLIM to 
differentiate BCC cells from normal keratinocytes showed statistically significant increases in 
the fluorescence lifetimes of neoplastic cells. In addition to differences in fluorescence and 
morphology, the new parameter of “merging cells” was proposed, which together with existing 
criteria [514] provided a good sensitivity (79%) and specificity (93%) for identifying BCCs from 
FLIM images using a visual architectural analysis. It is important to consider this work in the 
context of current and past work on MPM and FLIM of autofluorescence of human skin. 
Seidenari et al. [514] combining multiphoton intensity imaging and FLIM for the diagnosis of 
BCC, cells with a longer fluorescence lifetime were always observed for BCCs and this 
morphological descriptor provided the highest sensitivity (100%) and specificity (70%) of all of 
the descriptors identified. An overall sensitivity for the diagnosis of BCC from other lesions and 
normal skin of 97% was obtained when two or more descriptors were considered and a 
specificity of 100% with five descriptors or more.  A number of studies have also described 
criteria for diagnosis of BCC, using reflectance confocal laser scanning microscopy showing high 
sensitivity (91.6-100%) and specificity (88.5-97%). These morphological descriptors included: 
polarised elongated nuclei; linear telangiectasia-like horizontal vessels; basaloid cord and 
nodules; nests of cells tightly packed in palisading structures; and peritumoural clefting [515-
519]. In a recent in vivo study comparing reflectance confocal microscopy and a multiphoton 
tomography for BCC diagnosis, elongated cells and palisading structures were recognised, and 
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the nucleus of elongated BCC cells was found to be significantly longer than other measured 
normal skin cells, whereas no significant discrimination was possible using the cell density and 
nucleus/cytoplasm ratio of BCC as morphological descriptors [520]. 
Melanomas have also been studied both ex vivo and in vivo with excitation at 760 nm [501,521], 
and, when fitted to a double exponential decay model, keratinocytes and melanocytes could be 
differentiated according to their fluorescence lifetimes, although no difference was observed 
between benign and malignant tissue. 
The work presented here is a clinical investigation of autofluorescence lifetime of non-
melanoma skin cancer performed using a fibre probe based time-resolved spectrometer 
utilising single photon dual fluorescence excitation at 355 and 445 nm. 
The hypothesis was that measurements of fluorescence lifetime and diffuse reflectance spectra 
permitted normal and diseased skin to be distinguished, particularly when applied to basal cell 
carcinomas and surrounding health skin prior to surgical excision. The aim was to apply for the 
first time in vivo a fluorescence lifetime spectrometer developed by the Photonics Group and 
demonstrate its potential for clinical diagnosis.  
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6.1.1 Normal Skin 
The skin is composed of three main layers: the epidermis; dermis; and subcutaneous tissue. 
 
Figure 6-1: Annotated H&E stained section of the epidermis and dermis of normal skin. Adapted and 
reproduced with permission from [522]. 
The epidermis is the most superficial layer of the skin and is organised into four distinct layers 
defined by their histological appearance as stratum corneum, stratum granulosum, stratum 
spinosum, and stratum basale (see figure 6-1). Keratinocytes constitute 90% of the cells found in 
this layer, and undergo changes in cellular morphology (terminal differentiation) as they 
progress from the stratum basale to the stratum corneum. The epidermis is separated from the 
dermis by the basement membrane (blue line in figure 6-1) and varies in thickness depending 
on age and region of the body (typically 60-100 µm [523]). The basement membrane is mainly 
composed of collagen type IV, and adheres to the stratum basale by means of large glycoprotein 
molecules called laminins. 
Melanocytes are usually found in the lower part of the epidermis and in the papillary dermis. 
Their primary role is to produce and distribute melanin to the surrounding keratinocytes to 
protect their nuclei from UV photodamage. Langerhans dendritic cells are found in the stratum 
spinosum of the epidermis and have immune surveillance function. Merkel cells are involved in 
sensory perception and are located in the basal layer near associated sensory nerve endings. 
The dermis lies underneath the basement membrane, providing physical support and nutrition 
for the epidermis above. The dermis is divided into two layers: a superficial layer adjacent to the 
epidermis, called the papillary dermis; and a deep layer, the reticular dermis, which can be 
distinguished by a change in the orientation of the collagen fibres. The papillary dermis forms 
protrusions, called dermal papillae, which interdigitate with the epidermal ridges (see figure 
6-1). Various structures are located within the dermis, including the pilosebaceous unit (hair 
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and sebaceous gland), nerves, sweat glands, sensory receptors and blood vessels. The dermis is 
composed of a matrix of proteoglycan macromolecules, type I and III collagen and elastin. 
The subcutaneous tissue lies under the dermis and contains loose connective tissue and 
approximately 80% of all body fat [524]. Regional variation can be found in normal skin 
depending on body site e.g. thicker on the palms and soles. 
6.2 Materials and methods 
This study was carried out in collaboration with researchers from the departments of Oncology, 
Dermatology and Atomic Physics at Lund University, Sweden, as part of a European research 
network (Photonics4Life). The study involved the use of two spectrometers, one of which was a 
time-resolved spectrometer built at Imperial College London [258], and the other was a steady 
state spectrometer developed at Lund University [525]. 
The Imperial instrument is a time-resolved fluorescence spectrometer utilising a fibre-optic 
probe to deliver excitation and collect autofluorescence decay profiles in multiple spectral 
channels [403]. The Lund system is a compact steady state spectrometer, which combines 
measurements of spectrally resolved fluorescence for four excitation wavelengths, and 
measurements of diffuse reflectance obtained using a white LED source. 
It should be noted that the description of the steady state spectrometer developed by the Lund 
investigators is beyond the scope of this thesis, but more detailed information on this 
instrument can be found in references [328,403,525]. 
The time-resolved fluorescence spectrofluorometer was transported in a van from London to 
Lund by the Imperial investigators, including myself, taking a ferry across the North Sea from 
Harwich (UK) to Esbjerg (Denmark). The compact steady-state spectrometer developed by the 
Swedish team was available on site. 
Both spectrometers were set up in a room in the dermatology clinic at Lund University Hospital, 
where all measurements took place. 
A total of 27 lesions on 25 patients at Lund University Hospital were investigated in vivo before 
surgical excision of the irradiated region. Patients were all of skin phototypes I-III according to 
the Fitzpatrick scale [413]. 
The experiments were performed by a multidisciplinary team of both clinicians and non-clinical 
researchers from the University of Lund and Imperial College London. 
Patients were assessed and recruited from the local team of physicians during dermatology 
outpatient clinics. The study was conducted with the approval of the local Ethics Committee and 
in accordance with the ethical principles of the Declaration of Helsinki. 
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The lesion characteristics with clinical (pre-excision) and histological diagnoses are 
summarised in table 6-1. 
Lesion Patient Location Size (mm) Clinical diagnosis Histological diagnosis 
1 1 R cheek 10x10 BCC BCC 
2 2 Back 6 Lentigo melanoma Benign pigmented naevus 
3 3 R cheek 9 Ulcerated BCC BCC 
4 4 L abdomen 12 BCC or melanoma Melanoma (superficial spreading) 
5 5 L forearm 10x14 Morbus of Bowen SCC in situ 
6 6 L leg 10x12 BCC BCC 
7 7 R arm 18x15 BCC Melanoma (naevoid type) 
8 8 Head 25 SCC Highly diff. SCC 
9 9 Head 10x10 Actinic Keratosis Actinic Keratosis 
10 9 R chest 30 Nodular BCC Nodular BCC 
11 10 Back 50x40 Invasive BCC Invasive BCC, focal spinocellular diff. 
12 11 R foot 40x60 Kaposi's sarcoma Kaposi's sarcoma 
13 12 L back 12x7 Melanoma Melanoma (superficial spreading) 
14 13 R thigh 10x10 Unknown Keratoacanthoma 
15 14 R cheek 15x15 Unknown Highly diff SCC 
16 15 R ear 10x10 Unknown SCC 
17 16 R thigh 7x7 Dysplastic naevus Pigmented naevus with dysplasia 
18 17 Back 15x30 BCC BCC 
19 18 L cheek 6x7 Nodular BCC Nodular BCC 
20 19 L shin 12x12 BCC BCC 
21 20 L shoulder 7x8 Unknown Nodular BCC 
22 21 R shoulder 3x3 Dysplastic naevus Blue naevus 
23 22 R index finger 15x15 Pyogenic granuloma Pyogenic granuloma 
24 23 R elbow 12x10 Arsenic keratosis SCC in situ 
25 24 Back 3x4 Actinic keratosis Actinic keratosis 
26 25 upper back 10x8 Actinic keratosis Actinic keratosis 
27 25 lower back 6x6 BCC BCC 
Table 6-1: Summary of the skin lesion characteristics with clinical and histological diagnoses. 
R = right, L = left, BCC = Basal Cell Carcinoma, SCC = Squamous Cell Carcinoma.  
242 
 
6.2.1 Time-resolved fibre-optic probe fluorescence lifetime spectrometer 
The time-resolved fluorescence spectrometer was configured as shown in figure 6-2(a). 
 
Figure 6-2: (a) Optical layout of the time-resolved fluorescence spectrometer. (b) An example of the 
raw data acquired with this system. The graph shows 16 spectrally resolved fluorescence decays obtained 
from human skin in vivo using an excitation wavelength of 355 nm. Reproduced with permission from [403]. 
Excitation was provided by two pulsed laser sources: a frequency tripled ultrafast UV fibre laser 
(UVPower355, Fianium Ltd., UK), which provided 10 ps pulses at 355 nm with a repetition rate 
of 37.1 MHz; and a blue diode laser (LDH-P-C-440B, PicoQuant GmbH, Germany), which emitted 
50-150 ps pulses at 445 nm with an adjustable repetition rate of up to 40 MHz. 
The optical arrangement of the time-resolved spectrometer and the fibre probe are shown in 
figure 6-3. 
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Figure 6-3: (a) Photograph illustrating the optical arrangement of the time-resolved spectrometer with 
the lid removed. (b) The custom built fibre probe (FiberTech Optica, Canada). 
A maximum power of 10 µW for UV irradiation and 50 µW for blue irradiation was set to ensure 
that no photodamage could be potentially caused as these power levels were below the 
maximum permissible exposure (MPE) for skin for exposure times as long as 1000 s. 
This laser radiation was coupled into the excitation channel of a custom built fibre-optic probe 
(FiberTech Optica, Canada, figure 6-3(b)) that housed seven optical fibres, each with a diameter 
of 200 µm and a numerical aperture (NA) of 0.22, six of which served to collect fluorescence and 
one to deliver the excitation. 
At the distal end of the probe, the fibres are arranged with the central excitation fibre 
surrounded by the six collection fibres (inset at bottom left of figure 6-2(a)). This arrangement 
was designed to optimise the illumination and collection efficiency while maintaining a 
relatively small probe size. The distal branch of the probe (common to all optical fibres) was 
1 m in length. 
(a)
(b)
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Spectral band pass filters were employed to narrow the emission of the laser diode and to reject 
residual light at other wavelengths emitted by the frequency tripled fibre laser. 
Variable neutral density (ND) filters limited the optical power at the sample to 10 μW for UV 
light and 50 μW for blue light. 
Computer controlled mechanical shutters in the two excitation beam paths were used to switch 
between the two sources. The output from the excitation optical fibre was directed onto the 
sample over an area of approximately 0.2 mm2 and the resulting fluorescence was collected by 
the six multimode collection fibres which surround the central excitation optical fibre in the 
FiberTech probe. 
The output from these collection optical fibres was then imaged onto the input slit of a grating 
spectrometer (MS125 1/8m, Lot-Oriel, UK) which was attached to a 16 channel multi-anode 
photomultiplier tube (PMT) detector (PML-16-C, Becker-Hickl GmbH, Germany). The PMT was 
linked to a computer with a SPC-730 time correlated single photon counting (TCSPC) card 
running SPCM software (Becker-Hickl GmbH, Germany) so that fluorescence decay profiles 
could be recorded in 16 spectral channels spanning a wavelength range of 400-600 nm. At the 
fibre probe output, the 6 collection fibres were aligned vertically in order to maximise the 
coupling into the input slit of the spectrograph (see inset at top centre of figure 6-2(a)). 
A motorised filter wheel was placed in the detection beam path between the fibre probe output 
and the spectrometer to prevent any stray scattered laser light from reaching the 16 channel 
detector. The whole system was mounted on a 60 x 60 cm2 breadboard to facilitate 
transportation and fully enclosed for safe use in clinical settings. 
A single data set acquired using this instrument consisted of two sets of 16 spectrally resolved 
fluorescence decays, one for 355 nm excitation and one for 445 nm excitation. Typically, for 
each sample we made three identical measurements with each laser with exposure times of 
around 5 s per measurement, thus for a total acquisition time is ~30 s. An example of the raw 
data obtained when exciting human skin with 355 nm excitation is shown in figure 6-2(b). 
The raw data is then corrected to account for the instrument response function of the 
spectrometer and the non-uniform channel sensitivity of the 16 channel PMT as described in 
[258,328,403]. First, the distal end of the fibre probe was illuminated with white light passed 
through a calibrated monochromator, which allowed the spectral centre and bandwidth of each 
detection channel to be determined. Second, the relative sensitivity of each PMT element was 
found by recording the emission from a calibrated white light source (LS-1-CAL, Ocean Optics, 
The Netherlands) and this information was then used to correct the fluorescence intensity 
measured in each spectral channel. 
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6.2.2 Experimental protocol 
Following the clinical consultation, each patient was conducted to the experimental room and 
prepared for the experiments. 
As a prophylactic measure, all patients (and investigators) were asked to wear laser safety 
goggles for protection against UV and blue wavelengths (figure 6-4) during the procedure. 
Prior to the measurements, a plastic spacer was attached and secured to the distal end of the 
fibre probe. This was used to ensure a consistent fixed distance of 1.5 mm between the tip of the 
fibre bundle and the skin surface. This resulted in the excitation lasers illuminating an area of 
skin of approximately 0.2 mm2. 
Before use on each patient, thorough disinfection of the spacer and the distal face of the fibre 
bundle was performed with high level disinfectant Trigene Advanced wipes (Tristel Solutions 
Ltd) for non-critical devices. Following this, further disinfection of the spacer was obtained by 
immersion in a 70% ethanol solution for 15 minutes. Specific advice on this aspect was 
provided by the host clinical team at Lund University Hospital. 
The probe was then placed on a clinical trolley and, when required, passed to the clinical 
investigator carrying out the measurements. 
During the procedure, the probe was held by hand at approximately ~4 cm from the distal end, 
and placed into contact via the spacer with the area of skin to be studied, exerting constant 
gentle pressure throughout the measurements. 
A circular area of ~2 mm was covered by the probe during the measurements and pictures of 
the lesion were recorded before and after the measurement. The total time required for each 
individual measurement was approximately 30 s. 
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Figure 6-4: Illustration of the experimental measurements. Photograph reproduced with kind 
permission of patient and investigators. 
Using the time-resolved system, and depending on the lesion size, between one and four 
measurements were taken from the lesion, and two measurements were performed on the 
perilesional healthy skin surrounding the lesion. Whereas, with the steady state system, only 
two measurements were taken in each case – one on the lesion and one on the neighbouring 
normal tissue. 
Figure 6-5 shows images of two example lesions with the small solid black circles showing the 
locations of the time-resolved fluorescence measurements and the large white dotted circles 
those of the steady state spectrometer. The insets in the figure illustrate how the individual 
experiments were planned. 
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Figure 6-5: The images show how the fluorescence measurements were planned (in the inset) and 
performed (main image) prior to the surgical excision. The small black solid circles indicate the sites of the 
single-point fluorescence lifetime measurements, and the large dotted white circles the sites of the wide-field 
steady state measurements. (a) Nodular BCC of the left shoulder (lesion 21, patient 20). (b) Actinic keratosis 
of the back (lesion 25, patient 24). 
During the measurements, the room lights were temporarily switched off to reduce the 
background on the fluorescence measurements. 
Once the measurements had been performed, the entire region irradiated with the time-
resolved spectrometer was excised and sent for histopathological assessment. 
All used work surfaces were wiped with Trigene Advance wipes after each session. 
In table 6-2, a summary of the lesion types and the number of measurements performed is 
reported. 
Lesion type (histopathology) Number of lesions 
BCC 10 
SCC 3 
Benign naevus 2 
Dysplastic naevus 1 
Malignant melanoma 3 
Actinic keratosis 3 
Other 5 
Total number of lesions 27 
Total number of normal skin sites 27 
Total number of measurements 54 
Table 6-2: Summary of the skin lesions studied with the FLS system, reporting the histological 
diagnoses. 
(a) (b)
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6.2.3 Fluorescence decay analysis 
As discussed in section 3.1.4, autofluorescence from biological tissue displays a 
multiexponential decay profile due to the vast array of known (and possibly unknown) 
fluorophores present, and their different chemical states (e.g. oxidised/reduced and 
free/protein bound). 
Two sets of 16 spectrally resolved fluorescence decays were collected and, given the nature of 
the tissue examined, it is highly probable that each decay reflected the contribution from a 
number of different fluorophores. 
However, as only a limited number of photons were collected in each spectral channel, a double 
exponential model was considered appropriate and fitted to the fluorescence decay curves. This 
was performed according to equation 6-1: 
           (
  
  
)       (
  
  
) Equation 6-1 
where τ1 and τ2 are the two lifetimes, and a1 and a2 are the two pre-exponential amplitudes. 
The mean fluorescence lifetime in each spectral channel was calculated using in-house software 
written in Matlab® (MathWorks™). 
In order to accurately fit an exponential model to observed fluorescence decay data it is 
essential to account for the instrument response function (IRF), which essentially describes how 
the system responds to an infinitely short pulse of light. 
In these experiments, the IRF was determined by measuring a solution of the dye DASPI (2-(p-
dimethylaminostyryl)-pyridylmethyl iodide, Radiant Dyes Laser Accessories GmbH, Germany) 
in water. DASPI is a fluorophore that has a fluorescence lifetime of less than 50 ps, which is 
significantly shorter than the instrument response time and, therefore, provides a good estimate 
of the IRF. As the emission spectrum of DASPI does not cover the entire collection range of the 
spectrometer, one representative spectral channel was selected and used for fitting all the 
spectral channels. This approach was believed to be reasonable as the variation in the shape of 
the IRF between different spectral channels is low [526]. 
An adjustable temporal offset was introduced into the exponential fitting model to compensate 
the variable temporal shift in the IRF across the different spectral channels. 
The mean fluorescence lifetime (τmean) was then calculated in each spectral channel according to 
equation 6-2. 
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 Equation 6-2 
Since the fluorescence lifetime (and the contrast in fluorescence lifetime between healthy and 
diseased regions of tissue) did not vary significantly with emission wavelength, a spectrally 
averaged mean fluorescence lifetime was calculated according to equation 6-3 to summarise the 
fluorescence decay data from each measurement site. This was achieved by averaging the 
spectrally resolved mean lifetime values and weighting them according to the fluorescence 
intensity recorded in each channel. Thus, for each measurement site a single intensity-weighted 
average fluorescence lifetime was obtained. 
  ̅          
∑     
 
   
∑   
 
   
 Equation 6-3 
Here, τspectral is the spectrally averaged mean lifetime, n is the number of spectral channels 
included in the average and Ii and τi are respectively the intensity and mean lifetime recorded in 
each of the spectral detection channels. 
For each lesion, the difference between these spectrally averaged mean lifetimes was then 
calculated for the normal and lesional tissue measured on each patient (i.e. lesion normalt t t   ) 
in order to investigate the diagnostic potential of the fluorescence lifetime data. In this way, the 
interpatient variation in the fluorescence lifetime measured from normal tissue is compensated 
for by the paired comparison.  
The Wilcoxon signed rank test was performed on the paired differences in the spectrally 
averaged fluorescence lifetime (Δτ) and the mean emission wavelength (Δλ) to determine 
whether any significant differences existed between the healthy and diseased tissues measured. 
The null hypothesis was that the mean shift in the mean emission wavelength or spectrally 
averaged fluorescence lifetime difference was equal to zero.  
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6.3 Results 
6.3.1 Steady state spectral analysis 
Figure 6-6 shows the steady state fluorescence spectra acquired from two patients diagnosed 
with BCC (lesion numbers 11 and 18 respectively). The two graphs show the data from the 
time-resolved spectrometer for healthy (figure 6-6a) and lesional (figure 6-6b) tissue. 
 
Figure 6-6: Graphs showing the steady state fluorescence emission spectra of healthy tissue (a) 
adjacent to a lesion, and lesional tissue (b) measurements acquired with the time-resolved spectrometer 
using 355 nm excitation from lesion numbers 11 and 18. 
It is clear from figure 6-6 that there are spectral differences between the 2 BCCs and their 
adjacent perilesional tissue. However, as expected, there was considerable inter-patient 
variability in the acquired spectra. For instance, opposite trends can be seen for the two healthy 
tissues relative to the lesions 11 and 18. 
This variation in the measured spectra can be attributed to inter-patient differences in factors 
such as skin photo-type, level of sun exposure, age and the location of the measurement site on 
the body [403]. 
As the analysis of the steady state spectra focussed mainly on the data collected with the 
spectrometer developed by the Lund investigators, which is, as mentioned above, beyond the 
scope of this thesis, the interested reader is referred to reference [403]. In summary, the steady 
state data obtained with the Lund spectrometer showed that the diffuse reflectance and 
fluorescence intensity excited at 355, 375 and 395 nm were lower in BCCs than on surrounding 
healthy tissue. 
6.3.2 Time-resolved autofluorescence measurements 
Figure 6-7 shows the mean fluorescence lifetimes averaged over all BCC patients and recorded 
in each of spectral channel for healthy and diseased tissue under UV (a) and blue (b) excitation. 
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The peak fluorescent signal for UV excitation was within the 425-540 nm spectral range, while 
that for blue excitation was within 475-550 nm. 
The fluorescence lifetime and the contrast observed did not vary significantly with emission 
wavelength over the spectral ranges containing the peak fluorescent signal. Therefore, in order 
to increase the accuracy of the lifetime information obtained from the data sets, a spectrally 
integrated, intensity weighted mean fluorescence lifetime was determined for each 
measurement site for both excitation wavelengths.  This enabled the incorporation of a higher 
number of photons in the decay analysis, while providing a single simple parameter to compare 
the measurement sites. 
It should be noted that, within the spectral range containing the peak fluorescent signal, a slight 
increase, although not significant, in mean fluorescence lifetime with emission wavelength can 
be observed for BCCs at 355 nm excitation (figure 6-7(a)), whereas at 445 nm excitation, the 
mean lifetimes remain nearly constant across the range 477-550 nm (figure 6-7(b)). 
 
Figure 6-7: Graphs showing the mean fluorescence lifetime in all spectral channels for healthy (blue 
columns) and lesional tissue (red columns) for (a) 355 nm and (b) 445 nm excitation. The mean values were 
calculated over all BCC patients and the error bars represent the standard deviation of the measurements. 
6.3.3 Paired analysis of normal tissue measurements 
Using the spectrally integrated mean lifetime values, the intra-patient variability was first 
quantified by comparing the lifetimes obtained from the two “normal” perilesional sites 
measured on each patient. 
The mean lifetime shifts in the spectrally averaged mean lifetime (i.e. 1 2normal normalt t t   ) for 
each lesion are shown in figure 6-9. 
For both 355 nm and 445 nm excitation, the differences are evenly distributed on both sides of 
the horizontal axis (zero) with mean values of -18 ps and 19 ps respectively. 
0
500
1000
1500
2000
2500
3000
3500
4000
375 388 399 412 426 438 451 464 477 489 502 514 526 539 550 562
M
e
a
n
 L
if
e
ti
m
e
 (
p
s)
Wavelength (nm)
(a)
0
500
1000
1500
2000
2500
3000
3500
451 464 477 489 502 514 526 539 550 562
M
e
a
n
 L
if
e
ti
m
e
 (
p
s)
Wavelength (nm)
(b)
Healthy
Lesion
252 
 
Lesion 6 shows the highest excursion in mean lifetime difference between the two normal sites 
for both excitation wavelengths, and this was probably due to the presence of scar tissue near 
both perilesional measurement sites (figure 6-8, sites No. 1 and 4). 
 
Figure 6-8: Lesion No. 6: Basal cell carcinoma (12 x 10 mm) located on the left shin. A total of 4 
measurements (2 on the lesion, 2 on normal surrounding skin) were performed. 
As an estimate of the error on the fluorescence lifetime, the mean standard deviations of the 
normal tissue measurements were also calculated and these were found to be 75 ps with 
355 nm excitation and 175 ps with 445 nm excitation. 
Significant variations in the measured lifetimes were also observed between patients, and this is 
evident in figure 6-7, where the error bars indicate a considerable spread in fluorescence 
lifetime across different patients. Skin photo-type, level of sun exposure, age and body location, 
may all be responsible of the high inter-patient variability observed. 
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Figure 6-9: Graphs showing the lifetime shifts between the two measurements of the healthy tissue 
surrounding each lesion (i.e. Δτ = τnormal 1 – τnormal 2) for (a) 355 nm and (b) 445 nm excitation. Figure 
adapted, with permission, from reference [403]. 
Ten of 25 patients presented with BCC. Figure 6-9 shows the spectrally resolved fluorescence 
lifetimes for BCC compared to the normal tissue for each patient after excitation with UV light 
(355 nm, left panel) and blue light (445 nm, right panel). 
The spectrally weighted healthy and lesional lifetimes, averaged across all BCC patients and 
including all spectral channels, were respectively 2770 ± 250 ps and 2880 ± 409 ps with UV 
excitation and 3130 ± 413 ps and 2240 ± 480 ps with blue excitation. 
Figure 6-10 shows the shift in the spectrally weighted lifetime (i.e. lesion normalt t t   ) 
observed for all patients with BCC. Again, there is no clear trend in the lifetime shifts of BCCs 
observed with UV excitation. For blue (445 nm) excitation (Figure 6-10b), on the other hand, 
the fluorescence lifetimes of BCCs are consistently shorter than those of the surrounding 
perilesional skin (indicated by negative lifetime shifts for all lesions). The mean lifetime 
decrease was calculated as 886 ± 655 ps and the lifetime shifts observed in all but one case 
(lesion 1) were also seen to exceed the estimate of the mean intra-patient variability reported 
above (175 ps). 
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Figure 6-10: Graphs showing the lifetime shifts for all BCC lesions (i.e. Δτ = τlesion – τnormal) with (a) UV 
and (b) blue excitation. Figure adapted and reproduced with permission from [403]. 
The mean emission wavelength was also calculated for each BCC measurement site and for both 
excitation wavelengths. However, no significant difference was observed in the mean emission 
wavelength of healthy skin and BCCs for either excitation wavelength. 
In general, the trends observed for BCCs were also seen to hold for all other lesion types. 
Therefore, in order to test for statistical significance, Wilcoxon signed rank tests were 
performed on the lifetime shifts for each individual lesion type and for all lesion types 
combined. The null hypothesis in these significance tests was that, for each lesion type 
examined, the lifetime shifts had a mean value of zero. 
For individual lesion types other than BCCs, there were not enough measurements to reject the 
null hypothesis and attribute statistical significance to the observed trends. For BCCs alone, 
however, with 445 nm excitation there was a consistent decrease in fluorescence lifetime (i.e. 
lesion normalt t ) and this was statistically significant with a p-value of 0.002. Furthermore, when 
investigating all the skin lesions included in this study as an ensemble (i.e. when considering all 
lesion types together) the same trend was observed, this time with a p-value of 5.6 x 10-6. 
In summary, when using 445-nm-excitation, statistically significant differences have been 
observed between the fluorescence lifetime of healthy tissue and skin cancer. This was shown to 
be valid for all of the skin neoplasms included in this study all together, and, particularly, when 
considering only the BCCs. 
6.4 Discussion 
This chapter has described the application of a fibre-optic coupled time-resolved spectrometer 
to an in vivo investigation of the optical signatures of skin cancer in order to evaluate its 
potential for use in clinical diagnosis. 
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The data from the steady state spectrometer developed by the Lund investigators has not been 
shown in this chapter, but for completeness it should be mentioned that the diffuse reflectance 
and fluorescence intensity excited at 355 nm, 375 nm and 395 nm were found to be all lower in 
BCC lesions compared to those of surrounding healthy tissue. These data were in agreement 
with the observations made by Rajaram [397] and Brancaleon [489]. 
The data acquired with our instrument (time-resolved spectrometer) show that BCCs exhibit a 
statistically significant (p = 0.002) decrease in their mean fluorescence lifetime relative to 
neighbouring healthy tissue when excited with 445 nm light (figure 6-10). In addition, the 
contrast in fluorescence lifetime between healthy and diseased tissue did not vary substantially 
with emission wavelength (figure 6-7). 
The results are also in accordance with previous ex vivo measurements made with same system 
on freshly resected (< 2 hours) NMSC tissue samples [258] and, using the blue excitation source, 
the absolute values observed in vivo are in reasonably good agreement with those seen ex vivo 
for both BCCs and normal skin. 
In general, in vivo studies of tissue autofluorescence describe reduced fluorescence measured at 
the tissue surface from cancerous and dysplastic areas compared to normal tissue 
[275,280,381,397]. Our findings seem in accordance with these studies. 
The results are also consistent with prior imaging work using wide field FLIM with 355 nm 
excitation, where BCCs exhibited shorter mean lifetime values than the surrounding uninvolved 
skin irrespective of the decay model selected to fit decay data (single vs. stretched exponential) 
or the long-pass filter used to collect the emitted autofluorescence (375 vs. 455 nm)[270]. 
Conversely, longer lifetime values for BCC compared to normal skin have been recently reported 
using TPM at 740 nm excitation ex vivo [492]. Additionally, manually segmented BCC cells 
excited at 760 nm by multispectral multiphoton FLIM tomography were also found to have 
higher mean fluorescence lifetime values than normal keratinocytes [423]. 
The main advantage of imaging modalities over point probe spectroscopic measurements is 
undoubtedly the spatial resolution and the morphological information provided. However, our 
time-resolved spectrometer has the potential to provide highly accurate combined knowledge 
of fluorescence emission spectra and fluorescence lifetimes and can provide a convenient and 
safer route into the clinic for in vivo use (a lower total exposure is required compared to 
equivalent imaging systems). 
The time-resolved spectrometer is relatively compact and in the future may be able to be 
constructed using relatively inexpensive components. The excitation wavelengths used are able 
to excite a number of tissue fluorophores to generate measurable tissue autofluorescence. 
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Notably, the instrument described here has been subsequently implemented and adapted for 
use in hollow organs such as the GI tract and the bladder. The system has been mounted on a 
small portable optical bench and moved on a compact wheeled trolley. This newly developed 
version of the spectrometer has been applied to ex vivo and in vivo fluorescence lifetime 
measurements of gastrointestinal mucosa during endoscopy. These results will be presented in 
the next two chapters. 
6.5 Conclusions 
In summary, the spectrometer described in this study has been shown to provide useful 
contrast between skin lesions and the neighbouring unaffected tissue, particularly for BCCs. 
To the best of our knowledge, this is the first in vivo clinical study using a time-resolved fibre-
optic spectrofluorometer with dual wavelength laser diode excitation source to investigate the 
autofluorescence lifetime signatures of skin cancer. 
In all the BCCs investigated, with excitation at 445 nm, the fluorescence lifetime was seen to be 
lower than that of the surrounding healthy tissue and, importantly, in 9 out of 10 cases the 
decrease in lifetime was greater than the mean intra-patient variation in the measured lifetimes. 
Future work in this area should now be driven toward the collection of more in vivo data. The 
collection of more data, and a multicentre extension of this trial, would be desirable to confirm 
the results obtained on a larger scale, and to investigate more lesion types, such as SCC and 
melanoma. 
Another important aim of the future extension of this study will be to ascertain whether the 
fluorescence lifetime can be used to differentiate between different lesion types other than 
between healthy and unhealthy tissue. If the observed trends will be confirmed, the 
development of wide-field imaging instrumentation could then be guided by the spectroscopic 
signatures obtained with this instrument.  
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Chapter 7: Fluorescence lifetime spectroscopy (FLS) of 
tissue autofluorescence in normal and diseased 
gastrointestinal tissue measured ex vivo using a fibre-
optic probe 
The work presented in the previous chapter showed that measurements of the fluorescence 
lifetime emitted from tissue can provide useful information to recognise basal cell carcinomas 
from normal surrounding skin. 
This chapter describes an investigation of temporally and spectrally resolved autofluorescence 
in 60 GI endoscopic excisional biopsy/resection specimens measured ex vivo using a custom 
built fibre-optic probe. Autofluorescence was quantified immediately following endoscopic 
biopsy using a fibre-optic-coupled multispectral time-resolved spectrofluorometer with pulsed 
excitation laser sources operating at two separate excitation wavelengths. The development of 
the system beyond that used in the previous chapter, the experimental design and protocol, and 
the procedures adopted to meet safety, disinfection and ethical considerations for use in the 
hospital setting are also described. The new system was redesigned to make it more compact, 
portable, and clinically compatible with flexible endoscopes. The software was also simplified to 
provide easy-to-operate user interface and more intuitive control over all the system. 
7.1 Introduction 
Neoplasms of the gastrointestinal (GI) tract account for approximately a quarter of worldwide 
cancer mortality, equivalent to an incidence of about 2 million new cases each year [527,528]. 
Prevention is based on early detection and excision of premalignant changes (e.g. dysplasia, 
adenomas) and early stage cancers during endoscopic examination. This significantly increases 
patient survival while reducing disease progression and direct medical costs [529]. However, 
early stage lesions are often invisible or difficult to visualise under inspection with white light 
endoscopy (WLE) alone even for expert endoscopists. In addition, it is often difficult to 
distinguish between benign and early or pre-malignant lesions, such as between inflammatory 
disorders and adenomas. Neoplastic polyps are of particular clinical significance because of 
their established role in the stepwise process that results in colorectal cancer (adenoma-
carcinoma sequence) [39]. However, macroscopic discrimination between neoplastic 
(consisting of adenomas with low grade or high grade dysplasia, and carcinomas) and 
non-neoplastic (hyperplastic, inflammatory pseudopolyps, hamartomas) polyps during WLE is 
extremely difficult. Thus, they are all removed when detected. This leads to unnecessary 
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removal of benign lesions, such as diminutive unimportant polyps, and a considerable  number 
of tissue biopsies, which impose a significant burden on the healthcare system [530] and can be 
coupled with a low diagnostic yield [243,244]. In addition, removing diminutive polyps is not 
without some risk, particularly when using polypectomy with cautery, which has repeatedly 
been shown to be the greatest risk factor for complications such as perforation, bleeding, and 
post-polypectomy syndrome [531]. 
Although several adjunct techniques for enhancing contrast have recently become available in 
the clinical environment, this contrast essentially shows alteration in tissue morphology and 
architecture, which are unfortunately not always specific and may not reflect (or do so only 
minimally) the real presence of disease. As a result, despite the use of advanced imaging, in 
most cases multiple biopsies are still required to confirm or reject the endoscopic diagnosis. In 
the absence of objective and self-evident findings, the endoscopist has only to rely on his ability, 
experience, judgement, and a sort of sixth sense. 
As discussed in section 2.4, various other optical approaches are being investigated for their 
potential to provide an in vivo label-free “optical biopsy” to aid diagnosis of GI disease, with the 
ultimate aim of allowing clinicians to avoid multiple unnecessary and/or random biopsies and 
instead permit targeting of both biopsies and resections. Examples include point probe-based 
diffuse reflectance spectroscopy [70,71,532], which has been applied to in vivo detection of 
dysplasia in Barrett’s oesophagus (BO) [72] and to ex vivo surgical specimens of colon cancer 
[73]. Another example is Raman spectroscopy [203], which has recently been applied in a large 
study of 305 patients [210]. In this work, it was decided to focus on autofluorescence 
spectroscopy and lifetime measurements as they can be readily extended from point-based 
measurements to wide-field imaging once the spectroscopic features presenting the greatest 
contrast between normal and diseased tissue have been identified. 
As discussed in detail in section 3.1.4, tissue autofluorescence arises from intra- and 
extracellular endogenous fluorophores such as collagen, elastin, pyridine nucleotides and 
flavins, and the fluorescent signature of these substances – along with their local distributions – 
have the ability to report on tissue disease state [213]. Further information can be obtained 
from the fluorescence excitation and emission spectra [213,533] and the fluorescence decay 
rate (or fluorescence lifetime) [258,265,280,403,534,535]. 
A number of previous studies have investigated differences in autofluorescence emission 
spectra between healthy and diseased colonic tissue. Such investigations have demonstrated 
contrast in a variety of tissue types. For example: between normal tissue and adenomatous (i.e. 
neoplastic) polyps ex vivo [383] [386] [536]; between normal tissue and adenomas in vivo 
[129]; between normal tissue or hyperplastic polyps and adenomas [384]; between 
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hyperplastic polyps and adenomas [387,388]; and between all three of the above tissue groups 
[385] [47]. Cancers in the upper GI tract (oesophagus and stomach) have also been investigated 
[352,371,537]. 
In addition to measurements of autofluorescence emission spectra, there have also been a 
number of applications of autofluorescence imaging (AFI) modalities to the study of GI tissue 
[364,370,390] [356]. AFI has been combined with high-definition video-endoscopy (HDE) [538] 
and also with NBI in so-called “trimodal imaging”, which has been applied to the study of 
Barrett's neoplasia [357]. 
Mycek et al. [265] performed pioneering work using time-resolved autofluorescence 
spectroscopy in vivo on 24 polyps (13 adenomas, 11 non-adenomas) from 17 patients using an 
excitation wavelength of 337 nm and detection in the range 530-570 nm. This study 
demonstrated shorter average lifetimes for pre-neoplastic polyps (adenomas) compared to 
non-neoplastic polyps (9300 ± 400 ps vs. 10500 ± 700 ps). In work by Li et al. in ex vivo tissue, 
longer AF lifetimes were found in cancerous colonic tissues using excitation at 397 nm and 
detecting at 635 nm compared to normal colon (18,450 vs. 4320 ps). This was attributed to the 
contribution of protoporphyrin IX (PpIX), which is known to both accumulate in neoplasia and 
have a long fluorescence lifetime [539]. Pfefer et al. [266] used excitation wavelengths of 337 
and 400 nm and compared the measurement of fluorescence emission spectra to fluorescence 
decay profiles acquired at 550 nm in vivo in 37 patients undergoing routine endoscopic 
surveillance for BO. In this study time-resolved fluorescence was unable to achieve sensitivity 
and specificity values above 60% for discriminating high risk (carcinoma, high grade dysplasia) 
from low risk (low grade dysplasia, non-dysplastic or indefinite for dysplasia) tissue, whereas 
moderate overall accuracy was achieved using steady-state fluorescence only. 
A small number of studies have applied fluorescence lifetime imaging (FLIM) to the study of GI 
tissue ex vivo. Mizeret et al. reported an increased fluorescence lifetime in ex vivo human oral 
carcinoma compared to surrounding uninvolved tissue [65]. This was achieved using a 
frequency domain technique with 417-nm-excitation and an emission band ranging from 
470 nm to 650 nm. Wide-field time-gated FLIM with 355 nm excitation demonstrated a 
statistically significant increase in the fluorescence lifetime of invasive colonic adenocarcinomas 
(16 specimens) relative to the surrounding healthy tissue, while a decrease in fluorescence 
lifetime was observed in two serrated adenomas with focal high grade dysplasia [273]. 
Despite all of the studies discussed in chapter 3, further research is still required in order to 
better determine the spectroscopic parameters that will provide the greatest contrast between 
healthy and diseased GI tissue, in particular for colonic polyps. This is most easily accomplished 
using point spectroscopy, which discards spatial information and can provide both spectral and 
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temporal resolution. The resulting data can then be used to guide the development of new 
autofluorescence based endoscopic devices that aim to rapidly screen large areas of tissue. 
The hypothesis was that time-resolved measurements of autofluorescence enable the 
discrimination of normal and diseased specimens of human GI mucosa. 
The aim of this study was to investigate the clinical diagnostic potential of measurements of the 
fluorescence lifetime and emission spectrum using two separate excitation wavelengths 
(375 nm and 435 nm) and detection by a time-resolved fluorescence spectrometer in GI tissue 
that has been freshly biopsied/resected from patients undergoing endoscopy. 
7.2 Materials and methods 
7.2.1 Patient enrolment 
A total of 60 endoscopic samples from different GI sites were collected from 23 patients 
undergoing GI endoscopy at Charing Cross Hospital, Imperial College Healthcare NHS Trust. 
Each of these samples was then studied with the point-probe FLS system described below. All 
samples were submitted for histopathology following the optical measurements. Normal tissue 
and the following diseases were investigated: colonic polyps, inflammatory bowel disease (IBD), 
gastric diseases (including cancer, gastritis and polyps) and oesophageal diseases (including 
reflux oesophagitis and Barrett’s oesophagus (BO)). 
Patients who participated in the research were recruited by the clinical team and gave their 
informed consent to participate. The study was carried out with the approval of the National 
Research Ethics Service (REC reference number 09/H0706/28). In 21 patients who had given 
their consent to participate in the study, no specimens were taken as there was no indication to 
biopsy; however, copy of their consent was retained for hospital audit purposes. None of the 
patients approached for seeking consent refused to participate in the study. 
7.2.2 Fluorescence lifetime spectroscopy (FLS) instrumentation 
The spectrofluorometer used in this study provided measurements of time-resolved 
fluorescence spectra (16 spectral detection channels) using two excitation wavelengths. The 
optical system is similar to that described in section 6.2.1 and references [258,328,403] and is 
shown in figure 7-1. However, some redesign was needed to make the system more compact 
and portable, and to ensure full compatibility of the fibre-probe with most endoscopes in terms 
of length, size, flexibility, and high level disinfectability. 
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Figure 7-1: (a) Optical configuration of the fibre-optic probe fluorescence lifetime spectroscopy system. 
Figure (b) shows the proximal end of the excitation branch; figures (c) and (d) respectively show side and 
face views of the common distal end; and figure (e) shows the proximal end of the fluorescence detection 
branch. Cores shown in green are fluorescence detection fibres; fibres coloured blue are used to deliver the 
laser excitation. The red and orange fibres are respectively the delivery and collection cores for the diffuse 
reflectance measurements; they were unused in this study. 
Two pulsed diode lasers were used as excitation sources with central emission wavelengths of 
375 nm and 435 nm (LDH-P-C-375B and LDH-P-C-440B respectively, PicoQuant GmbH, 
Germany). Hereafter, the two laser sources are referred to as the UV and the blue laser. 
The 375 nm diode laser replaced the previously used frequency tripled Nd fibre laser, which is 
significantly more compact and stable, making it more suitable for clinical applications. Both 
lasers emit pulses of 50-150 ps duration and were configured to operate at 20 MHz, The outputs 
from the two lasers were first combined and are then coupled into the fluorescence excitation 
channel of a custom-built optical fibre probe (Fibertech GmbH, Germany). This custom fibre 
probe comprised 19 multimode optical fibres (all of 0.22 NA and 200 μm diameter), of which 3 
were used to deliver the laser excitation to the sample and 14 were used to collect the resulting 
fluorescence. Two fibres in the bundle were reserved for measurements of diffuse reflectance 
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spectra. However, the sensitivity of the spectrometer was found to be too low to reach the signal 
available from GI tissue. 
The distal branch of the probe (common to all optical fibres) was 3 m in length. The inset (b) in 
figure 7-1 illustrates the arrangement of the fibres in the excitation branch of the proximal end 
of the bundle, where the sagittal (side) and the cross sectional (face) view of the probe are 
shown. At the distal end of the probe the fibres were arranged as shown in the insets (c) and (d) 
of figure 7-1. The individual fibres are hexagonally packed and secured using epoxy inside a 
medical grade stainless steel ferrule which is 6 mm long. The ferrule protrudes 1.5 mm beyond 
the distal face of the fibre bundle and acts as a spacer to ensure that the sample under 
investigation is always held at a set distance from the output of the fibre probe (figure 7-1 (c)). 
This results in the excitation lasers illuminating an area of tissue of approximately 0.9 mm2. In 
cross section (face view), the fibres are configured as shown in figure 7-1(d) where the 
excitation fibres are coloured blue, the fluorescence collection fibres are green and the white 
light illumination and detection fibres are shown in red and orange, respectively. Figure 7-1(e) 
shows the fluorescence detection branch of the proximal end, where the 14 collection fibres are 
aligned vertically in order to maximise the coupling into the input slit of the spectrograph. 
Figure 7-2 shows a photograph of the optical setup (a) and the fibre-optic probe (b, c). 
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Figure 7-2: (a) Annotated high angle photograph illustrating the optical arrangement of the time-
resolved spectrometer with the lid removed. (b, c) The custom built fibre probe for use in GI endoscopy 
(Fibertech GmbH, Germany). 
It is worth noting that the fibre probe has been manufactured by Fibertech GmbH (Berlin, 
Germany), whose main business is the manufacture of clinical fibre optic probes consisting of a 
single fibre optic cable for laser lithotripsy. Therefore, all of the materials used in the 
construction of the probe are thoroughly tested for biocompatibility. 
A neutral density (ND 0.7) filter was placed in the path of the 375 nm laser in order to limit the 
average optical power at the sample to 35 μW. A bandpass filter (Z440/20x, Chroma 
Technology, USA) was used to narrow the spectrum of the 435 nm laser, which provided a 
maximum average power of 200 μW at the sample. 
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It should be emphasised that the power was limited in this way to permit in vivo use of this 
system during routine endoscopic examinations - see chapter 8. The use of maximum power 
levels below those stated above minimises the risk of photodamage as the quoted values are 
below the maximum permissible exposure (MPE) for skin for exposure times as long as 1000 s 
(there is no accepted MPE for GI tissue). 
The outputs of the two laser sources were controlled via computer and used to illuminate the 
specimen sequentially. The resulting fluorescence was collected by the 14 fluorescence 
detection fibres that relayed the collected light to the fluorescence detection arm of the 
spectrofluorometer (figure 7-1(e)). The output from the collection fibres was imaged onto a 16 
channel PMT detector as described in section 6.2.1. 
A motorised filter wheel was placed between the fibre probe output and the grating 
spectrometer. This filter wheel contained two emission filters (E400LPv2 and E475LPv2, 
Chroma Technology, USA), that were used in combination with the 375 and 435 nm excitation 
lasers respectively to ensure that no scattered laser radiation reached the PMT detector. 
Compared to the study presented in chapter 6, all optical components were mounted on a 
smaller 30 x 45 cm2 breadboard, and the breadboard and all electrical components were now 
housed and enclosed within a compact (182 x 70 x 55 cm3) wheeled trolley, making clinical 
measurements within the endoscopy suite possible. The entire system is controlled through 
software written in LabVIEW 7.1 (National Instruments, USA) meaning that the 
spectrofluorometer can be used within a clinical environment in a safe and practical manner. 
As in the previous study, each measurement consisted of 5 s fluorescence data acquisition with 
each laser, repeated three times, for a total acquisition time of approximately 30 s. Similarly, 
two sets of 16 spectrally resolved fluorescence decays (one for each excitation wavelength, with 
three identical measurements performed in each case) were obtained. In order to analyse the 
raw fluorescence data it was necessary to determine the wavelength range collected by each 
PMT element and to determine its relative sensitivity. This was performed in an identical 
manner to that described in section 6.2.1 and references [258,403]. 
The computer contains a TCSPC card (SPC-730, Becker-Hickl GmbH, Germany) which is used to 
control the 16 channel PMT detector and permits the collection of the spectrally-resolved 
fluorescence decays. The filter wheel is also linked to the computer (using an RS-232 cable) and, 
thus, the entire system can be controlled through software. 
The system (figure 7-3) is fully enclosed using a stainless steel lid and front, back and side 
panels made from a black, optically absorbent, rigid foam PVC sheet material (Foamalux, Robert 
Horne Group, UK). It also has a hinged panel (stainless steel) at the front of the optical setup to 
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allow easy connection and containment of the proximal ends of the fibre probe. This front panel 
includes a small opening near the centre where the proximal fibres emerge and the fibre probe 
splitter (the section of the probe in which the individual optical fibres are routed to the 
appropriate proximal branches) is clamped in place just below this opening. Having the system 
enclosed in this way means that the optical system is safe for use in a clinic and that the 
electrical components cannot be accessed. It also permits easy cleaning of the system in the case 
of any spillage of clinical liquids. The computer also incorporates a medical grade “wipe-clean” 
keyboard and touchpad, again to allow easy cleaning of all external components. 
The panels on the side of the trolley have ventilation holes drilled in to them and two fans are 
installed on the back. The fans run at all times that the system is turned on and create a constant 
air flow through the instrument. This air flow acts to cool the interior of the trolley and ensures 
that no problems arise due to overheating. 
 
Figure 7-3: Photograph of the transportable trolley which houses the entire spectrometer, showing 
some important features of the system. 
With the optical setup fully enclosed, the only point at which laser radiation is emitted from the 
system is at the distal end of the fibre probe. As mentioned above, ND filters in the beam paths 
of the lasers limit the maximum optical power at the distal end of the probe to 35 μW of UV and 
200 μW of blue light. Two interlock switches are also located on the trolley to ensure that the 
lasers cannot be operated when the lid to the optical enclosure is open. Thus, the system as a 
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whole has been classified as a Class 1 laser product (by Aurora Radiation Protection Services, 
UK) and, hence, no protective eyewear is required when the system is in normal use. 
All electrical elements contained within the trolley are connected to the isolating medical 
transformer. Hence, the only electrical outlet from the system is the connection of the medical 
transformer to the mains electricity. This isolating transformer provides an ungrounded 
“floating” power supply for the system which reduces the leakage current and minimises the 
risk of electrocution. The medical transformer is connected directly to the mains and, hence, 
provides power for the entire instrument. There is also an earthing point on the transformer 
and this is connected to mains earth via an earth bonding cable which provides a low resistance 
route to ground in the case of any short circuit fault condition. Additionally, a 7 A surge/radio 
frequency interference (RFI) filter (FA7-RS, RS Components Ltd., UK) is located between the 
mains power and the medical transformer and this is used to protect all the electrical 
equipment from the unwanted effects of any power surges. 
The computer monitor (also connected to the isolating medical transformer) is mounted on a 
metal post fixed in place at the back of the trolley. The dimensions of the fully assembled system 
are as follows: height – 182 cm, width – 70 cm, depth – 55 cm. Thus, the trolley mounted system 
is relatively compact and can be easily stored, transported and used within a clinical setting. 
Control software 
The system is controlled exclusively through software. In fact, the powers and repetition rates 
of the lasers are already set and fixed using the commercial software provided with the laser 
control unit. Beyond this, the entire system is controlled by software written in-house using 
LabVIEW 7.1 (National Instruments, USA). This software comprises a single program which 
regulates the detectors, light sources (using the USB-DAQ device), filter wheel and all 
acquisition parameters, and a screenshot of the user interface of the software is shown in figure 
7-4. 
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Figure 7-4: Screenshot of the user interface of the LabVIEW software used to control the spectrometer. 
The software can be used to control each component in the system individually and also allows 
the user to automatically acquire data in one of three ways: a single fluorescence acquisition 
(exciting once with both lasers); a single diffuse reflectance acquisition; or a time series 
acquisition in which both fluorescence and reflectance data are recorded. In a time series 
acquisition, time-resolved fluorescence spectra are first recorded using each excitation source 
in sequence and a chosen number of repeat measurements are made. Secondly, the white light 
source is used for illumination and a single reflectance spectrum is acquired. In all cases data 
are recorded as text files showing the fluorescence or reflectance intensity as a function of time 
and/or wavelength. 
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A medical grade pedal (Texas Instruments, USA) is connected to the computer (indicated in 
figure 7-3) and is incorporated into the LabVIEW software. The footswitch is programmed such 
that depression of the switch creates a new save folder and begins a time series acquisition, 
saving all data to the newly created folder. This enables a single clinician to operate the system 
easily while carrying out the endoscopic procedure. 
The spectrofluorometer was assembled in the endoscopy unit of Charing Cross Hospital, where 
it was used to make clinical measurements of human GI tissue ex vivo and subsequently in vivo. 
A simple safety instruction document was created for clinical users in order to operate the 
system safely and effectively. A troubleshooting guide was also prepared to help with software 
errors or unforeseen technical difficulties. 
7.2.3 Experimental procedure 
For the ex vivo tissue measurements the spectrometer remained in a private lockable room 
(with black-out curtains) within the endoscopy unit, while endoscopic procedures were carried 
out in the neighbouring endoscopy suite. 
During routine endoscopy, pinch biopsy samples of any suspicious regions of tissue were taken 
with “jumbo” biopsy forceps (Radial Jaw 3 LC forceps, Boston Scientific, figure 7-5(a)) and any 
superficial lesions (i.e. polyps) were removed with either a cold or a hot snare (Captivator 
single-use snares, Boston Scientific, figure 7-5(b)) according to standard patient care. Polyps 
removed by hot snare polypectomy were sufficiently large that the area measured using the 
optical system was unaffected by any specimen heating. Samples were 4-15 mm in diameter. 
 
Figure 7-5: (a) Endoscopic biopsy forceps (Radial Jaw 3 LC forceps, Boston Scientific) and (b) 
polypectomy snares (Captivator single-use snares, Boston Scientific) in use at Charing Cross Hospital. Images 
adapted and reproduced with permission from [540]. 
Where clinically possible, at least one biopsy of healthy tissue was also taken from each patient 
with a suspicious region and the healthy biopsy was taken as close as possible to the suspicious 
(a) (b)
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region. After completion of an endoscopic examination, any tissue samples obtained were 
immediately delivered to the adjacent spectroscopy room and measured with the FLS system. 
All samples were measured within approximately 10 minutes of excision. Once removed, the 
biopsy samples or excised polyps were carefully teased onto gauze with sterile disposable 
tweezers, keeping the mucosal surface facing upward. 
All samples were washed gently by dripping Hanks' Balanced Salt Solution (HBSS) onto them 
using a 1 ml syringe (with no needle) and then placed in a plastic culture dish with a glass 
coverslip base. 
The distal tip of the optical fibre probe was then placed en face in contact with the sample and 
data acquisition was performed as described in the previous section. To ensure that the sample 
was not damaged by mechanical stress and to simulate in vivo probing, the distal end of the 
probe was held by hand, exerting constant gentle pressure throughout the measurements. 
To prevent deterioration, samples were kept moist during the measurements and handled 
minimally. There were no visible changes in the texture or appearance of the samples over the 
duration of the measurements and the sample thickness always remained consistent (compared 
to the original condition). Following measurements with the FLS system, all tissue samples were 
sent for histopathology. 
All haematoxylin and eosin (H&E) stained tissue sections were reviewed by an experienced 
histopathologist (GWS) in order to correlate the histological findings with the fluorescence 
measurements. Finally, each sample was assigned a unique number for identification purposes 
and the characteristics of the specimens investigated in this study are summarised in table 4-1.  
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Tissue type No. of 
samples 
Endoscopic diagnosis Histological diagnosis  
Colonic polyps 12 tubular adenomas with LGD 
2 mixed hyperplastic adenomatous polyp with LGD 
2 hyperplastic polyp 
1 serrated polyp 
3 inflammatory polyp 
1 nonspecific reactive changes 
1 normal colonic mucosa 
22 
IBD 1 active chronic inflammation 
2 severe chronic ulcerative colitis 
2 moderate chronic colitis 
1 basal inflammation 
6 
Gastric disease 1 chronic gastritis Hp+ 
1 chronic gastritis 
1 invasive poorly differentiated adenocarcinoma 
2 fundic gland polyps 
5 
Oesophageal disease 1 BO (intestinal metaplasia with no dysplasia) 
1 acute reflux oesophagitis 
2 
Total No. of diseased tissue meas.  35 
Normal colon tissue 18 normal colonic mucosa 
1 active chronic inflammation 
19 
Normal stomach tissue 3 normal gastric mucosa 
1 invasive poorly differentiated adenocarcinoma 
4 
Normal oesophageal tissue 2 normal oesophageal mucosa 2 
Total No. of normal tissue meas.  25 
Total No. of measurements  60 
Table 7-1: Summary showing the clinical diagnoses of all the ex vivo samples investigated with the 
endoscopic spectrometer. LGD, low grade dysplasia; IBD, inflammatory bowel disease; Hp+, Helicobacter 
pylori positive; BO, Barrett’s oesophagus. 
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7.3 Data analysis 
7.3.1 Exponential fitting of fluorescence decays 
As discussed in sections 3.1.3 and 6.2.3, a single exponential decay model only provides an 
accurate description of a fluorescence decay in the case that only a single fluorescent species 
(with a single radiative decay pathway) is present in the sample being excited. Autofluorescence 
from biological tissue typically exhibits a complex exponential decay profile as tissue contains 
several fluorescent species each with a number of possible states (e.g. oxidised/reduced and 
free/protein bound). Thus, it is appropriate to fit a multi-exponential decay model to the 
recorded tissue data. As only a limited number of photons are collected in each of the 16 
spectral channels, a double exponential model was chosen. Hence, fitting was performed 
according to equation 6.1. 
In order to measure the instrument response function (IRF) in all spectral channels of the 16 
channel PMT detector, reflected light IRFs were recorded by placing a diffusely reflecting 
sample at a short distance (approximately 10 cm) from the distal end of the probe and then 
adjusting the angle of the grating in the grating spectrometer to direct light onto each PMT 
element in sequence. This method provides an IRF in all spectral channels, however, it cannot 
be performed regularly as the calibration of the spectral locations of the 16 PMT elements 
requires that the grating remains fixed. Thus, this approach relies on the assumption that the 
IRFs do not vary considerably over time. Additionally, the diffusely reflecting sample was 
located at a distance from the distal end of the probe and was not in contact with the end of the 
ferrule as the sample would be in a typical experiment. This introduced a temporal offset 
between the IRF and the measured data.  
To account for the temporal shift of the IRF with respect to the data, the tissue data was 
therefore fitted with an adjustable temporal offset for each spectral channel. 
7.3.2 Fluorescence data analysis 
Having fitted the fluorescence decays according to equation 6.1, the mean fluorescence lifetime 
(τmean) in each spectral channel was calculated. This was achieved as shown in equation 6.2. 
For each tissue type (i.e. different diseases and different regions of healthy tissue), the variation 
in the mean lifetime was investigated as a function of emission wavelength. In order to 
summarise the fluorescence lifetime data from each sample in a simple manner, a spectrally 
averaged fluorescence lifetime was then calculated by averaging the spectrally resolved mean 
lifetime values and weighting the data according to the fluorescence intensity observed in each 
channel (see equation 6.3). 
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For 375 nm excitation, the spectrally averaged mean lifetime was calculated excluding the first 
and last spectral channels (i.e. over the range 418-582 nm), owing to the weak signal and poor 
decay fitting in these channels. For 435 nm excitation, the spectrally averaged mean lifetime 
was calculated over channels 7-15 (481-582 nm) for the same reason. Following the initial 
analysis, it was observed that the greatest lifetime contrast with 375 nm excitation for IBD was 
seen in spectral channels 8-13 (494-556 nm) and a 2nd spectrally averaged mean lifetime was 
therefore calculated over this narrower range. 
Finally, for each lesion, the difference between its spectrally averaged mean lifetime and that of 
a neighbouring healthy tissue sample (excised from the same patient) was calculated (i.e.
lesion normalt t t   ) in order to investigate the diagnostic potential of the fluorescence lifetime 
data. It is noted that this paired analysis of the fluorescence lifetime compensates for inter-
patient variation in the fluorescence lifetimes measured for normal tissue. 
The spectral properties of the samples were also investigated using fluorescence emission 
spectra where the area under the fluorescence emission spectrum was normalised to unity. The 
mean fluorescence emission wavelength was also calculated for each sample and for each 
excitation wavelength. 
Finally, Wilcoxon signed rank tests were performed on all sets of spectrally averaged lifetime or 
mean emission wavelength shifts in order to investigate whether any statistically significant 
differences had been observed between healthy and diseased tissue. In all cases, the null 
hypothesis being tested was simply that the mean shift in the mean emission wavelength or 
spectrally averaged fluorescence lifetime was equal to zero. 
7.4 Results 
All analysis was performed based on the histological diagnosis for each sample. Samples were 
excluded if microscopic analysis revealed normal large bowel mucosa in clinically abnormal 
samples or histological abnormalities in clinically normal specimens. As only a small number of 
measurements were made for gastric and oesophageal diseases, the data presented in this 
section focus solely on the fluorescence measurements performed on normal and diseased 
colonic specimens, in particular for patients with colonic polyps and IBD. 
Normal tissue characterization 
In the first part of this study, the measured fluorescence emission spectrum and fluorescence 
lifetime in histologically normal tissue were investigated, as segmental variations in normal 
colon morphology from proximal to distal segments – following the sequence caecum, right 
colon, transverse colon, left colon, rectum (figure 7-6)– are well known [5]. From the caecum to 
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the rectum there is a gradual significant decrease in the diameter of the crypts, the number of 
crypts per unit area and the inner intestinal circumference. There is also an increase in 
thickness of the mucosa from the caecum (0.5 mm) to the rectum (1 mm). Furthermore, crypts 
are deeper in the rectum and sigmoid colon than they are in the proximal part of the colon. In 
addition, it must also be considered that patients with IBD have been variably subjected to 
medical therapy with steroids, immunomodulators, antibiotics and biologics, which might be 
responsible for further changes in the mucosal layer thickness/permeability across the entire 
colon compared to that of untreated patients (i.e. those with polyps). 
 
Figure 7-6: Diagram illustrating the different regions of the human colon. Source: American Society for 
Gastrointestinal Endoscopy (ASGE) Anatomical Images, Colon & Rectum [541]. 
Figure 7-7(a, b) shows the mean fluorescence emission spectra from histologically normal colon 
obtained from patients diagnosed with a polyp or IBD. Normal colon from patients with IBD 
shows a slight shift to shorter emission wavelengths for 375 nm excitation compared to normal 
colon obtained from patients diagnosed with a polyp. There is also a slight shift to longer 
emission wavelengths for excitation at 435 nm. However, the change in mean emission 
wavelength was not found to be statistically significant for either excitation wavelength. The 
fluorescence lifetime recorded in each spectral channel for normal tissue from patients 
diagnosed with a polyp and IBD is plotted in figure 7-7(c, d). 
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For 375 nm excitation, the mean fluorescence lifetime varies slightly with emission wavelength, 
with a maximum at an emission wavelength of around 500 nm. For 435 nm excitation, the mean 
fluorescence lifetime is more consistent with emission wavelength. 
In order to get a better overview of the fluorescence lifetime, the spectrally averaged 
fluorescence lifetimes were calculated – see figure 7-7(e) – which shows that there is a higher 
mean fluorescence lifetime for normal tissue with 435 nm excitation for patients diagnosed with 
a polyp compared to patients diagnosed with IBD. However, this shift was not found to be 
statistically significant by two-way ANOVA (normal data was tested according to both diagnosis 
(p = 0.11) and region (p = 0.30), null hypothesis that all groups are drawn from populations 
with the same mean).  
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Figure 7-7: Summary of results from normal tissues grouped according to whether the patient was 
diagnosed with a polyp (n = 13) or IBD (n = 4). Figures (a) and (b) show the mean fluorescence emission 
spectra obtained with 375 and 435 nm excitation respectively. Figures (c) and (d) show the spectrally 
resolved fluorescence lifetimes for 375 and 435 nm excitation respectively. Figure (e) shows the spectrally 
averaged mean fluorescence lifetimes for both groups and for both excitation wavelengths. The error bars 
represent ± 1 standard deviation in all panels. 
The fluorescence lifetime data from all histologically normal samples were also grouped 
according to the region of colon from which they were obtained. 
Figure 7-8(a, b) shows that there is a slight blue shift in the fluorescence emission spectrum for 
the two specimens obtained from the rectum for 375 nm excitation, but the shift in mean 
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emission wavelength was not found to be significant by 2-way ANOVA (grouping data by both 
diagnosis and region) for either excitation wavelength. 
 
Figure 7-8: Summary of results from normal tissues grouped according to the location that the 
specimen was taken from. The number of specimens in each group was: rectum (n = 2), left (n = 8), 
transverse (n = 5), right (n = 3). Figures (a) and (b) show the mean fluorescence emission spectra obtained 
with 375 and 435 nm excitation respectively. Figure (c) shows the spectrally averaged mean fluorescence 
lifetimes for all four groups and for both excitation wavelengths. The error bars represent ± 1 standard 
deviation in all panels. 
The mean fluorescence lifetime obtained with 435 nm excitation from the two rectal specimens 
is longer than that obtained from the other three regions (see figure 7-8(c)). As reported above, 
a 2-way ANOVA was performed on the spectrally averaged mean fluorescence lifetimes from 
histologically normal colon grouped according to both diagnosis and region of colon and no 
statistically significant differences were obtained. 
A summary plot of all the normal samples grouped according to their location in the colon for 
both excitation wavelengths is shown in figure 7-9. 
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Figure 7-9: Summary of the measured absolute mean fluorescence emission wavelengths and 
spectrally averaged mean fluorescence lifetimes for all the normal samples divided according to their 
location in the colon for (a) 375 nm and (b) 435 nm excitation wavelengths.  
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Diseased vs. normal tissue 
Colonic polyps 
 Unpaired analysis Paired analysis 
No. of patients 12 11 
No. of polyps 21 18 
 Neoplastic 15 12 
 Non-neoplastic 6 6 
No. of normal specimens 13 12 
Table 7-2: Summary of colonic polyps included in study. 
Of the 22 clinically identified polyps (see table 4-1), one was excluded as it was found to be 
normal by histopathology, and the polyp specimens included in the analysis are summarised in 
table 7-2. Where possible, at least one specimen of normal colon was obtained from all patients. 
Figure 7-10(a, b) shows the normalised mean fluorescence spectra observed in normal colon 
tissue and in neoplastic (tubular adenomas with LGD and mixed hyperplastic adenomatous 
polyps) and non-neoplastic (hyperplastic and inflammatory) colonic polyps for both excitation 
wavelengths, and the spectra overlap within the error bars. No statistically significant difference 
was obtained when comparing the mean fluorescence emission wavelength for either excitation 
wavelength. 
Figure 7-10(c, d) shows the mean fluorescence lifetimes measured in each spectral channel for 
both 375 and 435 nm excitation. The mean fluorescence lifetimes for neoplastic polyps were 
shorter than those observed in normal tissue for both excitation wavelengths and this trend was 
observed in all spectral channels. The spectrally averaged mean fluorescence lifetime (weighted 
according to the intensity recorded in each spectral channel) for normal tissue, neoplastic and 
non-neoplastic polyps is shown in figure 7-10(e). 
As can be seen from the size of the error bars on fluorescence lifetime measurements in figure 
7-10, there is significant inter-patient variability in the measured mean fluorescence lifetime 
from both normal and diseased specimens. Therefore, in order to overcome this variability a 
paired analysis was conducted by calculating the difference in spectrally averaged mean 
fluorescence lifetime between normal and lesional specimens obtained from the same patient. 
This paired analysis was performed using a total of 30 specimens (see table 7-2). Three polyps 
obtained from one patient were excluded from the paired analysis as it was not clinically 
possible to obtain a normal specimen in this patient. In the one patient where two normal 
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specimens were obtained, the lesional specimens were compared to the anatomically closest 
normal specimen. 
 
Figure 7-10: Comparison of normal tissue versus neoplastic and non-neoplastic polyp specimens: figures 
(a) and (b) show the mean fluorescence emission spectra obtained with 375 and 435 nm excitation 
respectively. Figures (c) and (d) show the spectrally resolved fluorescence lifetimes with 375 and 435 nm 
excitation respectively. Figure (e) shows the spectrally averaged mean fluorescence lifetimes for all three 
groups (normal tissues, neoplastic and non-neoplastic polyps) and for both excitation wavelengths. The 
error bars represent ± 1 standard deviation in all panels. 
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For each normal-lesion pair, both the shift in mean fluorescence emission wavelength and the 
shift in spectrally averaged mean fluorescence lifetime were calculated for both excitation 
wavelengths. The measured shift in mean fluorescence emission wavelength was not found to 
be statistically significant for either excitation wavelength. 
Figure 7-11 shows the shift in the spectrally averaged fluorescence lifetime (t) for each 
normal-lesion pair. The mean values calculated over all pairs for neoplastic and non-neoplastic 
polyps are summarised in table 7-3. 
 Mean shift in spectrally averaged fluorescence lifetime of polyp 
compared to normal tissue from same or nearest region of colon (ps) 
 UV Blue 
Neoplastic -230  560 
 
-570  740 
Non-neoplastic 25  820 -160  780 
Table 7-3: Spectrally averaged fluorescence lifetime shift for neoplastic and non-neoplastic polyps. 
A Wilcoxon signed rank test was applied to all sets of paired difference values. The data 
obtained with 375 nm excitation showed no significant difference while the 435 nm excited data 
shows a statistically significant decrease in the fluorescence lifetime of neoplastic polyps with 
respect to healthy tissue (p = 0.021). The difference in spectrally averaged mean lifetime shift 
between neoplastic and non-neoplastic polyps for 435 nm excitation was not found to be 
statistically significant (Wilcoxon rank sum test). 
 
Figure 7-11: Shift in the spectrally averaged mean fluorescence lifetime for (a) 375 nm and (b) 435 nm 
excitation of neoplastic (red bars) and non-neoplastic (green bars) polyp specimens. Lifetime shifts are 
calculated using a measurement of normal tissue obtained from the same or nearest region of colon (paired 
analysis). 
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Specimen numbers 23, 33 and 34 correspond to patients where the normal sample was not 
taken from the same region of colon as the polyp. If these specimens are excluded from the 
analysis then for 435 nm excitation the shift in mean emission wavelength averaged over all 
specimen pairs becomes 2.6  3.1 nm (p = 0.019) and the shift in spectrally averaged mean 
lifetime averaged over all specimen pairs becomes -690  640 ps (p = 0.0049). The increase in 
mean emission wavelength at this excitation wavelength was found to be correlated with the 
decrease in fluorescence lifetime (R2 = 0.71), see figure 7-12. 
 
Figure 7-12: Correlation plot of the shift in mean emission wavelength (Δλ) vs. the shift in spectrally 
averaged mean lifetime averaged over all neoplastic polyp specimen pairs (polyp – normal), where the 
normal sample was taken from the same region of colon as the polyp, for 435 nm excitation wavelength. 
Inflammatory bowel disease 
A total of 11 specimens (6 diseased and 5 normal) were measured from 5 patients with IBD. One 
normal and one IBD specimen (from different patients) were excluded because the 
histopathological assessment revealed no difference between the normal and the diseased 
samples. Therefore, the numbers of specimens shown in table 7-4 were analysed. 
 Unpaired analysis Paired analysis 
No. of patients 5 3 
No. of IBD specimens 5 4 
No. of normal specimens 4 3 
Total No. of specimens 9 7 
Table 7-4: Summary of IBD (inflammatory bowel disease) specimens included in the study, divided by 
type of analysis performed. 
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Figure 7-13(a, b) shows the emission spectra obtained for normal and IBD specimens for both 
excitation wavelengths. For 375 nm excitation, the emission spectrum is shifted to the red for 
IBD specimens compared to normal, but the shift in mean emission wavelength was not found 
to be statistically significant (p = 0.06). The spectrally resolved mean fluorescence lifetimes are 
shown in figure 7-13(c, d). With 375 nm excitation the mean fluorescence lifetime observed in 
IBD was longer than that of normal tissue in all spectral channels and this difference appeared 
to be greater for longer emission wavelengths. Thus, the spectrally averaged mean fluorescence 
lifetime was calculated over a reduced spectral emission range of 494-556 nm as this gave the 
greatest contrast (see figure 7-13(e)).  
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Figure 7-13: Comparison of normal tissue and IBD specimens: figures (a) and (b) show the mean 
normalised fluorescence emission spectra obtained with 375 nm and 435 nm excitation respectively. Figures 
(c) and (d) show the spectrally resolved mean fluorescence lifetimes with 375 nm and 435 nm excitation, 
respectively. Figure (e) shows the mean fluorescence lifetime averaged over the emission spectral range 494-
556 nm for both groups and for both excitation wavelengths. The error bars represent ± 1 standard deviation 
in all panels. 
Figure 7-14 shows the shift observed in the spectrally averaged mean fluorescence lifetime for 
each IBD sample investigated measured with respect to normal tissue obtained from the same 
patient (paired analysis). With 375 nm excitation, the fluorescence lifetimes of all four IBD 
samples are longer than those of the nearby normal colon tissue (mean t = 983  289 ps) but 
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this shift was not found to be statistically significant using the Wilcoxon signed rank test 
(p = 0.125). 
 
Figure 7-14: Bar graphs showing the shift in the spectrally averaged mean fluorescence lifetime 
observed in all IBD samples relative to a sample of healthy tissue from the same patient. (a, b) show lifetime 
shifts obtained with 375 nm and 435 nm excitation respectively. The lifetime shift for 375 nm excitation was 
obtained using the spectrally averaged mean lifetime calculated over the emission spectral range 
494-556 nm. 
The paired shift in mean fluorescence emission wavelength between IBD and healthy tissue 
(mean  = 6.9  6.6 nm, p = 0.25) was investigated, which was also not statistically significant. 
The lack of statistical significance is due to the relatively large standard deviations on the 
spectral and lifetime shifts and the small number of measurements made for this disease type. 
Further measurements would be needed to establish if the trends observed are significant. It is 
also worth noting that the shifts in the mean fluorescence emission wavelength and the 
spectrally averaged mean fluorescence lifetime were correlated (R2 = 0.90), see figure 7-15. 
Additionally, the relative error for the mean shift in spectrally averaged mean lifetime was a 
factor of 3.4 times smaller than the relative error for the mean shift in mean emission 
wavelength. 
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Figure 7-15: Correlation plots of the shift in mean emission wavelength (Δλ) vs. the shift in spectrally 
averaged mean lifetime averaged over all IBD specimen pairs (IBD – normal) for 375 nm excitation 
wavelength. 
Figure 7-16 shows summary plots of all paired measurements of shift in mean fluorescence 
lifetime against shift in mean emission wavelength for both excitation wavelengths. Figure 
7-16(a) shows a summary plot of all paired measurements of shifts in mean emission 
wavelength and spectrally averaged mean fluorescence lifetime for 375 nm excitation 
wavelength. Paired measurements between two regions of normal tissue would be expected to 
cluster around the origin. However, it was not possible to obtain such specimens in this study 
and it was therefore not possible to compare the distribution of normal-normal tissue 
measurements with those obtained from normal-diseased tissue. Figure 7-16(b) shows the 
equivalent plot for the shift in mean emission wavelength and fluorescence lifetime where the 
shift in 435 nm excited mean fluorescence emission wavelength is plotted on the horizontal axis 
and the shift in 435 nm excited spectrally averaged mean fluorescence lifetime is shown on the 
vertical axis. Polyp specimens tend to show a decrease in the 435 nm excited spectrally 
averaged fluorescence lifetime and IBD specimens show an increase in the 375 nm excited 
spectrally averaged fluorescence lifetime as already discussed in the figures above. 
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Figure 7-16: Summary of all measured shifts in mean fluorescence emission wavelength and spectrally 
averaged mean fluorescence lifetime for (a) 375 nm and (b) 435 nm excitation wavelengths. The lifetime 
shift for 375 nm excitation was obtained using the spectrally averaged mean lifetime calculated over the 
emission spectral range 494-556 nm for all points. 
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Figure 7-17 shows summary plots of all measured absolute mean emission wavelengths and 
mean fluorescence lifetimes divided by tissue type (normal colon, neoplastic polyps, 
non-neoplastic polyps, and IBD) for both excitation wavelengths. 
 
Figure 7-17: Summary of all measured absolute mean fluorescence emission wavelengths and spectrally 
averaged mean fluorescence lifetimes for (a) 375 nm and (b) 435 nm excitation wavelengths. 
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7.5 Discussion 
In this study, no statistically significant variation was found in mean fluorescence emission 
wavelength or spectrally averaged mean fluorescence lifetime for normal colon according to 
type of disease (polyp or IBD) or region of the colon for either of the excitation wavelengths 
employed. Based on the known variations in these tissues (see text at beginning of results 
section), significant variation in contrast between regions of colon would have been expected. 
However, the number of specimens in each group was relatively small and a study on a larger 
number of specimens would be needed to investigate this further. 
For 375 nm excitation the dominant tissue fluorophores within the mucosa are expected to be 
collagen types I-IV and intracellular NAD(P)H. Collagen type IV is primarily found in the linings 
surrounding the colonic crypts (basal membranes), whereas collagen types I-III are 
predominant in the stroma of the lamina propria [7,313]. Collagen fluorescence is particularly 
complex and a range of values are reported in the literature, e.g. [302,437], and recent 
measurements of type II collagen obtained with an instrument similar to that used here showed 
a peak emission wavelength of 390-430 nm and a mean fluorescence lifetime of approximately 
10 ns for excitation at 355 nm [329]. NADH has a peak emission wavelength of 460 nm and a 
mean fluorescence lifetime of 440 ps in its free state [425] and longer decay components 
typically in the range ~2-2.5 ns when protein bound [542]. These results show a peak 
fluorescence emission wavelength of 470 nm that is broadly consistent with the fluorescent 
signal being a combination of collagen and NAD(P)H fluorescence. The fluorescence lifetime 
measured in this study in the range 3-3.5 ns is also broadly consistent with a combination of the 
longer decay components found for collagen and those of free and protein-bound NAD(P)H. 
In IBD the intestine is chronically infiltrated by inflammatory cells and in the presence of active 
disease the epithelium can be severely damaged and frayed (goblet cell depletion), leaving large 
exposed areas of underlying connective tissue. This would be expected to increase the 
contribution of mucosal collagen fluorescence measured by the fibre-probe for excitation at 
375 nm and therefore to produce a corresponding increase in the mean fluorescence lifetime 
(due to the longer mean fluorescence lifetime of collagen compared to NAD(P)H). An increase in 
the mean fluorescence lifetime was observed for IBD, see figure 7-13(e), although this was not 
found to be statistically significant. However, an increase in the contribution of collagen 
fluorescence to the signal might also be expected to decrease the mean fluorescence emission 
wavelength but instead an increase was observed (although again not statistically significant). 
For 435 nm excitation the dominant fluorescence signal is expected to be due to intracellular 
flavins within the mucosa with perhaps some additional signal from mucosal collagen, which 
can be excited at this wavelength [309]. The fluorescence emission spectra peak measured in 
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this study at ~530 nm is broadly consistent with the emission spectra of flavins [436] and 
collagen [309]. In a paired analysis of normal and lesional specimens obtained from the same 
region of colon, it was found that 435-nm-excitation of colonic polyps provides statistically 
significant differences in both the mean fluorescence emission wavelength (longer) and 
spectrally averaged mean fluorescence lifetime (shorter) compared to healthy tissue. This shift 
in mean emission wavelength was found to be correlated (R2 = 0.71) with the shift in mean 
fluorescence lifetime and the relative error on the mean shift in spectrally averaged mean 
fluorescence lifetime was lower than that for the shift in mean emission spectrum. The changes 
in fluorescence emission spectrum and lifetime might be explained by changes in the ratio of 
free:protein-bound flavin fluorescence [278,295] or by changes in the ratio of intracellular 
flavin fluorescence to collagen fluorescence. 
There are relatively few reports of autofluorescence lifetime (AFL) studies to date. Only one 
study – by Mycek et al. [265] – has investigated single point measurements of AFL on colonic 
polyps at 337 nm excitation. This was the first study in the human colon that demonstrated 
differences in fluorescence lifetime decay between normal and dysplastic tissue. However, the 
study was mainly carried out to assess the ability of time-resolved AF spectroscopy in 
distinguishing between adenomatous and non-adenomatous polyps and no measurements were 
obtained from normal tissue. Nevertheless, adenomas showed faster average decays than those 
of non-adenomas (9300 ± 400 ps vs. 10500 ± 700 ps), where non-adenomas comprised 6 
hyperplastic polyps, 3 mucosal prolapses, 1 lymphoid aggregate, and 1 aberrant crypt focus. In 
the study presented here, no statistically significant differences in the spectrally averaged 
lifetime between neoplastic and non-neoplastic polyps were found for either excitation 
wavelength. The shorter excitation wavelength (337 nm) used by Mycek et al. may explain 
differences between their work and that presented here.  
7.6 Conclusions 
Overall, these results suggest that it may be possible to discriminate polyps from normal tissue 
and IBD using 435 nm excited fluorescence lifetime measurements and IBD from normal tissue 
and polyps using the fluorescence lifetime measured with 375 nm excitation but more extensive 
work is required to confirm the observations made so far and to allow the investigation of 
additional disease types. While further research is certainly required, these results suggest that 
the combination of 375 nm and 435 nm excited fluorescence measurements might provide 
physicians with valuable information on whether the nature of a lesion is proliferative or 
inflamed during endoscopic procedures. In the future, this work will be extended to in vivo 
measurements and to wide-field FLIM endoscopy.  
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Chapter 8: Endoscopic fluorescence lifetime spectroscopy 
(FLS) of gastrointestinal disease: a translational 
investigation conducted in vivo during routine 
endoscopy 
This chapter presents the application of the system described in chapter 7 to an in vivo "bench 
to bedside" translational investigation. A feasibility trial was conducted at Charing Cross 
Hospital in a cohort of 17 patients clinically referred for endoscopic investigation for a variety of 
indications. The aim of this study was to investigate the clinical diagnostic potential of 
measurements of the fluorescence lifetime and emission spectrum in vivo in patients 
undergoing endoscopy, and to further test the hypothesis that fluorescence lifetime 
measurements can generate contrast between different tissue types. Indeed, the system was 
easily operated by the clinical investigators and integrated into the clinical process without 
interfering with service provision and delivery. 
However, in vivo measurements of fluorescence lifetime are challenging. A number of changes 
would be expected to vary between ex vivo ad in vivo measurements that could alter the tissue 
AF and fluorescence lifetime detected. These include: a) greater haemoglobin content and 
higher tissue oxygenation, altering the absorption properties of the tissue; b) changes in the 
metabolic state of cells (e.g. intracellular NADH and flavin concentrations; c) tissue pH; d) 
relative motion of the measured tissue with respect to the probe and movement artifacts (e.g. 
diaphragmatic motion, vascular pulsation, probe slipping, etc.). 
The initial data indicates that blue excitation of autofluorescence provides contrast broadly 
consistent with ex vivo measurements, although a study on a greater number of patients is 
clearly required. This study does demonstrate, however, that such in vivo measurements are 
practical. The experimental design and protocol along with the procedures adopted to meet 
safety, disinfection and ethical considerations for in situ clinical use are described before data 
are presented. 
8.1 Introduction 
Over the last ten years, fluorescence lifetime imaging (FLIM) and spectroscopy (FLS) have 
developed from techniques only available to leading instrumentation research laboratories into 
techniques that carry the potential to be commonly applied to study biological tissue and 
cellular interactions. Such a possibility has arisen because of the functional information that 
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becomes available when detecting the lifetime of fluorophores, partly due to the sensitivity of 
fluorescence lifetime to the local environment of the fluorescent molecules [543]. 
As discussed in the previous chapters, FLS has been used to detect changes in tissue state 
caused by diseases such as cancer [273], atheroma [327,544,545] and osteoarticular arthritis 
[328,546]. This is due to the fluorescence lifetime signature of endogenous fluorophores such as 
collagen, elastic, NADH, FAD and porphyrins. It is also possible to use exogenous probes to 
distinguish disease states, which holds promise for minimally invasive tissue analysis. Whilst 
there have previously been a few demonstrations of fluorescence lifetime imaging and 
spectroscopy used in endoscopy, the technique has not been developed into a clinically viable 
system. 
The virtues of a non-invasive method of optical biopsy have been already extolled in section 7.1. 
However, it is important to reiterate that the inability to distinguish benign or malignant tissue 
during endoscopic examination inevitably leads to unnecessary biopsies and repeat 
endoscopies, radiological imaging and treatments. There is an urgent need to improve 
diagnostic endoscopic imaging capabilities. It is therefore vital to evaluate new approaches to in 
situ optical diagnosis that would allow a legitimate focusing of the increasingly limited 
resources only on those that require preventative intervention. 
Fluorescence lifetime (FL) contrast could be used as a biomarker of tissue abnormalities for in 
vivo endoscopic applications [213,258,265,280,403,534,535] but, to date, we are aware of only a 
few reports of time-resolved spectroscopy and imaging applied in vivo in endoscopy 
[66,265,266]. 
Mizeret et al. [65] reported the development of instrumentation for time-resolved fluorescence 
imaging in 1997. Results obtained on a single freshly resected human oral carcinoma were 
contextually presented to illustrate the potential of the technique. At 417 nm excitation, an area 
corresponding to CIS exhibited a longer mean fluorescence lifetime than the surrounding 
uninvolved tissue (3440 ± 700 ns vs. 2500 ± 200 ps). This was achieved using frequency domain 
FLIM. However, this study was mainly focussed on the instrumentation and, as such, only a 
single oral mucosa tissue specimen was imaged. In a subsequent report, the feasibility of the 
imaging instrumentation developed was then demonstrated in vivo in the bronchi, displaying a 
fluorescence lifetime of 2500 ps for healthy bronchial mucosa excited at 514 nm. 
Mycek et al. [265] performed time-resolved AF spectroscopy in vivo on 24 polyps (13 adenomas, 
11 non-adenomas) from 17 patients.  This was the first study in the colon that demonstrated 
differences in fluorescence lifetime decay between normal and dysplastic tissue. Adenomas 
showed faster average decays than those of non-adenomas (9.3 ± 0.4 ns vs. 10.5 ± 0.7 ns). 
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In a study by Glanzmann et al. [255], FLS was applied in vivo in one patient with advanced 
oesophageal cancer with 337 nm excitation and an emission band ranging from 375 nm to 
515 nm. Interestingly, the decay profiles between the cancer and the surrounding healthy tissue 
appeared to change at different wavelength bands, i.e. the fluorescence lifetime for cancer was 
longer than that of normal mucosa between 375-400 nm (3740 ps vs. 3360 ps, respectively), 
and shorter between 465-485 nm (3270 ps vs. 3740 ps, respectively). Conversely, the spectra 
between the two conditions, although different, were not able to differentiate normal from 
neoplastic tissue. In the same study, they also investigated the use of the photosensitizer 
mTHPC in three patients with early SCC of the oesophagus undergoing PDT. The oesophagus 
was excited at 418 nm and fluorescence emission was collected between 580 and 720 nm. 
However, no significant difference was found between normal and neoplastic mucosa.  
Pfefer et al. [266] compared temporally- and spectrally-resolved fluorescence spectroscopy at 
337, 400 and 550 nm respectively in vivo in 37 patients undergoing routine endoscopic 
surveillance for BO. However, time-resolved fluorescence was unable to achieve sufficient 
sensitivity and specificity (values above 60%) in discriminating high risk (carcinoma, HGD) 
from low risk tissue (LGD, non-dysplastic or indefinite for dysplasia BO), whereas moderate 
overall accuracy was achieved using steady-state fluorescence only. 
Recently, Marcu et al. [339] demonstrated the feasibility of in vivo endoscopic FLIM using a 
flexible imaging probe at 337 nm excitation on a hamster model of oral carcinoma. 
In this chapter, the research question was whether the changes in fluorescence emission 
spectrum and lifetime observed ex vivo could be confirmed in vivo. The aim of this study was to 
investigate the origins of the autofluorescence lifetime contrast observed in vivo and to evaluate 
its potential for in vivo diagnosis of GI diseases or precursor conditions. 
8.2 Materials and methods 
8.2.1 Patient enrolment 
In the endoscopy unit of the Charing Cross Hospital, Imperial College Healthcare NHS Trust, the 
spectrometer was applied in vivo in an exploratory feasibility trial from December 2011 to June 
2012. A total of 42 measurements of different GI sites were performed in 17 patients 
undergoing GI endoscopy. Patients who participated in the research were recruited by the 
clinical investigators (SC, KLR & AVT) of the clinical care team at Charing Cross and the study 
was carried out with the approval of the National Research Ethics Service Committee London-
Stanmore (REC reference number: 11/LO/0728). 
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As per ethics recommendation, the information sheet about this research was sent to potential 
participants by post 4 weeks in advance of their appointment, together with the usual 
documentation about the endoscopy procedures and their risks. This allowed enough time to 
read and digest the information well in advance of their attendance for their procedures. In 6 
patients, who had given their consent to participate in the study, no specimens were taken as 
there was no indication to biopsy; copy of their consent was however retained for service audit 
purposes. Only 2 patients refused to participate. 
The trial was adopted and registered on the UK Clinical Research Network Study Portfolio 
(UKCRN ID 12378). 
A nonclinical investigator (AJT) of the Photonics Group, licensed with an NHS honorary contract, 
was present in the endoscopy suite for the majority of the measurements to operate the 
computer controlling the data acquisition and recording, but did not come into direct contact 
with the patient, and did not have a clinical role. 
8.2.2 Fluorescence lifetime spectroscopy (FLS) instrumentation 
The spectrofluorometer used in this study has been described in section 7.2.2. Figure 8-1 shows 
the experimental set up for in vivo measurements using the FLS point probe system in the 
Endoscopy suite at Charing Cross Hospital. 
 
Figure 8-1: Photograph showing the FLS point probe system in the Endoscopy suite at Charing Cross 
Hospital. 
Endoscopy trolley
FLS system
Endoscopy monitor
294 
 
8.2.3 Experimental procedure 
For in vivo measurements the experimental procedure differed slightly from that used in the ex 
vivo experiments. The spectrometer was moved into the endoscopy suite (Figure 8-1) and 
placed next to the patient’s bed. Then, during the endoscopic examination, measurements were 
made of any suspicious areas of tissue by inserting the optical fibre probe into the working 
channel of the endoscope. Figure 8-2 and Figure 8-3 show endoscopic images of the point probe 
being deployed in vivo. 
 
Figure 8-2: Endoscopic images showing the fluorescence lifetime fibre probe spectrometer being 
deployed in vivo to measure normal (a-d) and inflamed (e-h) regions of tissue in the colon. Both 
measurements were made in the same patient. Each site is illuminated for 10 s with the 375 nm and the 
435 nm laser source. During the data acquisition, the endoscope light source is temporarily switched off to 
avoid damaging to the fibre probe detector, and a semi-circular ring of blue light bleeding through from the 
outer edge of the fibre probe in contact with the tissue can be seen in figures (c) and (g). Each area of tissue 
examined with the probe (~0.9 mm2) was removed by subsequent excisional biopsy (d, h). Source of 
acquisition: Drs Coda & Thillainayagam, Endoscopy Unit, Charing Cross Hospital, Imperial College Healthcare 
NHS Trust. 
 
Figure 8-3: Endoscopic images showing the fluorescence lifetime fibre probe spectrometer being 
deployed in vivo to measure abnormal (a, b) and normal (c, d) regions of tissue in the gastric antrum (the 
distal section of the stomach). Both measurements were made in the same patient. Each areas of tissue 
examined with the probe (~0.9 mm2) was removed by subsequent biopsy (d) for histological assessment. 
Source of acquisition: Drs Coda & Thillainayagam, Endoscopy Unit, Charing Cross Hospital, Imperial College 
Healthcare NHS Trust. 
(a)
(e)
(c)(b)
(h)
(d)
(g)(f)
(c)(a) (d)(b)
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As for the ex vivo experiments, at least one measurement was also made of a complementary 
region of healthy tissue. After the measurements were complete, all the irradiated regions of 
tissue were excised (by endoscopic biopsy) and sent for histopathological analysis. 
The illumination site was easily identified by a red ring resulting from impression of the ferule 
on the mucosa and this was shown to be due solely to the pressure exerted by the probe (figure 
8-4). 
 
Figure 8-4: (a) Endoscopic image showing the florescence lifetime fibre probe spectrometer being 
deployed in vivo to measure a colon cancer (a) and a neighbouring normal area of mucosa (b, c, d). In (d), a 
red ring resulting from impression of the ferule on the mucosa is shown (laser switched off). Note that the 
acquisition time was the same of a normal measurement (~20 s) as shown by the time elapsed on the 
endoscopy monitor (left). Source of acquisition: Drs Coda & Thillainayagam, Endoscopy Unit, Charing Cross 
Hospital, Imperial College Healthcare NHS Trust. 
Excisional biopsy allowed confirmation of the clinical diagnosis and also ensured that any 
potentially photodamaged tissue was removed from the patient. It should be noted, however, 
that the average optical power at the sample was limited to 35 μW of UV and 200 μW of blue 
light (see section 7.2.2) in order to minimise the risk of tissue damage. The irradiance at these 
power levels (for both lasers) is lower than the MPE for skin, even for exposures of up to 1000 s 
in duration, and previous work in the literature indicates that these exposure levels caused no 
(a) (c)
(b) (d)
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increase in triphosphate-biotin nick end-labelling (TUNEL) positive cells above baseline 
compared to controls in porcine oesophagus and colon respectively [547]. 
For the in vivo measurements, the total acquisition time was reduced to approximately 20 s (5 s 
for each laser but only two repeat measurements were performed), compared to the 30 s 
acquisition used for ex vivo measurements (see section 7.2.2). This was because it is desirable to 
keep the total acquisition time as short as possible, so to prolong the clinical procedure only 
marginally, and avoid excessive motion of the measured tissue and probe slipping. 
After completion of the experiments, each measured region was assigned a unique number for 
identification purposes. 
The fibre probe was disinfected using the same procedure and disinfection cycle as per 
standard practice for the standard clinical endoscopes (high grade disinfection). This standard 
procedure involved a 30 minute cycle in an automated endoscope disinfection machine using 
Sterilox (PuriCore, UK), within the endoscope re-processing unit (ERU). Once disinfected, the 
fibre probe was stored within a disposable sterile plastic bag inside an instrument case until the 
beginning of the procedure and used within 3.5 hours of disinfection. Specific advice on this 
aspect was provided by the Decontamination Lead at Imperial College Healthcare NHS Trust. 
Prior to the procedure, the fibre probe was placed on a sterile tray on an endoscopy trolley and 
the proximal end was connected to the detection unit. The fibre probe was then passed to the 
endoscopist by a nurse/assistant when required. 
The endoscopist held the distal part of the probe gently (~10 cm from the metallic tip) with one 
hand, and used the other hand for holding the chassis of the endoscope (as per conventional 
practice when operating any other accessory device). The endoscopist then inserted and passed 
the probe through the instrument operating channel until the end of the probe came out from 
the endoscope working channel and appeared on the screen. 
The tip of the probe was then gently advanced until it came into contact with the mucosal 
surface to be studied. A circular area of ~2 mm was covered by the probe during the 
measurements and conventional endoscopic images were taken before and after the 
measurement as record. A minimum of 2 measurements were acquired for each lesion, one 
performed near the centre of an obvious or suspect lesion, the other on a normal area near to 
the lesion. During the data acquisition with the fibre probe, the endoscope light source was 
temporarily switched off to avoid damage to the fibre probe detector.  
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Table 8-1 shows the clinical and histological diagnoses of all the areas of tissue investigated. 
Tissue type Histological diagnosis No. of measurements 
Colon polyps 6 adenoma with LGD 
3 hyperplastic 
2 inflammatory 
1 quiescent colitis 
12 
Colon cancer 1 adenocarcinoma 1 
IBD 2 UC 2 
Oesophageal disease 2 BO (1 with LGD) 
1 high grade dysplasia 
2 oesophagitis 
5 
Gastric disease 1 gastritis 1 
Duodenal disease 1 duodenitis 1 
Normal colon 13 normal colon 
1 chronic inflammation 
14 
Normal oesophagus 4 normal oesophagus 4 
Normal stomach 1 normal stomach 1 
Normal duodenum 1 normal duodenum 1 
Total number of normal tissue measurements  20 
Total number of diseased tissue measurements  22 
Total number of measurements  42 
Table 8-1: Table showing the clinical and histological diagnoses of all the in vivo measurement sites 
investigated with the endoscopic spectrometer. 
8.3 Data analysis 
Exponential fitting and fluorescence data analysis were performed as described in section 7.3.  
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8.4 Results 
The laser caused no tissue damage that could be detected at the microscopic level using 
conventional H&E stain. As for the ex vivo experiments, all analysis was performed based on the 
histological diagnosis for each sample. Samples were excluded if histological analysis revealed 
normal tissue in abnormal samples or histological abnormalities in normal specimens. 
The results of this section refer to the analysis performed on colonic polyps, as for other clinical 
conditions only a small number of measurements were performed. 
Normal tissue characterization 
As for the ex vivo experiments, different regions of endoscopically and histologically normal 
colon (rectum, left and right colon) were compared with respect to their spectrally averaged 
normalised emission spectrum and mean fluorescence lifetime. 
Figure 8-5(a, b) shows that there is a blue shift in the fluorescence emission spectrum for the 
measurements obtained from the rectum and the left colon for 375 nm excitation, but the shift 
in mean emission wavelength was not found to be significant by 1-way ANOVA (grouping data 
by region) for either excitation wavelength (p = 0.0569 and p = 0.2867 for 375 nm and 435 nm 
excitation wavelengths, respectively).  
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Figure 8-5: Summary of results from normal tissues grouped according to the location that the 
measurement was performed. The number of specimens in each group was: rectum (n = 5), left (n = 5), right 
(n = 3). Figures (a) and (b) show the mean fluorescence emission spectra obtained with 375 and 435 nm 
excitation respectively. Figure (c) shows the spectrally averaged mean fluorescence lifetimes for both groups 
and for both excitation wavelengths. The error bars represent ± 1 standard deviation in all panels. 
The mean fluorescence lifetime obtained with both excitation wavelengths from the right colon 
is longer than that obtained from the other two regions, particularly between left and right 
colon with 375 nm - see figure 8-5(c). 
As mentioned above, we performed 1-way ANOVA on the spectrally averaged mean 
fluorescence lifetimes from histologically normal colon grouped according to region of colon 
and statistically significant differences were obtained for 375 nm excitation (p = 0.0017), with 
the greatest difference observed between right and left colon (p = 0.001), while the data 
obtained with 435 nm excitation showed no significant difference (p = 0.54). 
There is no similarity between the mean fluorescence emission spectra of normal colon 
measured ex vivo and in vivo, with a generally weaker fluorescence intensity observed in the in 
vivo measurements (see section 7.4). Nevertheless, the slight blue shift in the emission spectrum 
for the rectal specimens seen ex vivo at 375 nm excitation is confirmed in vivo, although not 
significant. In contrast, between ex vivo and in vivo measurements, there is a general agreement 
of values, within the quoted error bars, in the spectrally averaged mean lifetime between the 
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measured regions of normal colon (rectum, left colon, and right colon). It is also interesting to 
note that the rectal specimens, at both excitation wavelengths, maintained a mean fluorescence 
lifetime longer than that obtained from the left colon both ex vivo and in vivo. 
Diseased vs. normal tissue 
Colonic polyp was the disease type for which the greatest number of in vivo measurements was 
made. Of the 12 clinically identified polyps (see table 8-1), one was excluded as it was found to 
be normal by histopathology, and the polyp specimens included in our analysis are summarised 
in table 8-2. One measurement of normal colon was obtained from all patients. 
 Paired analysis 
No. of patients 9 
No. of polyps 11 
Neoplastic 6 
Non-neoplastic 5 
No. of normal measurements 9 
Total No. of measurements 20 
Table 8-2: Summary of colonic polyps included in the in vivo study. 
Figure 8-6(a, b) shows the normalised mean fluorescence spectra observed in normal colon 
tissue and in neoplastic (tubular and villous adenomas with LGD) and non-neoplastic 
(hyperplastic and inflammatory) colonic polyps for both excitation wavelengths, and the spectra 
overlap within the error bars. No statistically significant difference was obtained when 
comparing the mean fluorescence emission wavelength for either excitation wavelength. 
Figure 8-6(c, d) shows the mean fluorescence lifetimes averaged over all polyp patients and 
recorded in each spectral channel for healthy colon and for neoplastic and non-neoplastic 
polyps under UV (c) and blue (d) excitation. 
While no obvious trend was seen under 375 nm excitation, the mean fluorescence lifetimes for 
polyps were shorter than those observed in normal tissue for 435 nm excitation. The spectrally 
averaged mean fluorescence lifetime (weighted according to the intensity recorded in each 
spectral channel) is shown in figure 8-6(e). 
As can be seen from the size of the error bars on fluorescence lifetime measurements in figure 
8-6(e), there is significant inter-patient variability in the measured mean fluorescence lifetime 
from both normal and polyp specimens. 
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Figure 8-6: Comparison of normal colon versus neoplastic and non-neoplastic polyp measurements: 
Figures (a) and (b) show the mean fluorescence emission spectra obtained with 375 and 435 nm excitation 
respectively. Figures (c) and (d) show the spectrally resolved fluorescence lifetimes with 375 and 435 nm 
excitation respectively. Figure (e) shows the spectrally averaged mean fluorescence lifetimes for the three 
groups and for both excitation wavelengths. The error bars represent ± 1 standard deviation in all panels. 
Figure 8-7 shows the paired analysis calculating the difference in spectrally averaged mean 
fluorescence lifetime between normal and polyp measurements obtained from the same patient. 
This paired analysis was performed using a total of 20 specimens (see table 8-2). 
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Figure 8-7: Shift in the spectrally averaged mean fluorescence lifetime for (a) 375 nm and (b) 435 nm 
excitation of neoplastic (red bars) and non-neoplastic (green bars) polyp specimens. Lifetime shifts are 
calculated using a measurement of normal tissue obtained from the same or nearest region of colon (paired 
analysis). 
For each normal-lesion pair, both the shift in mean fluorescence emission wavelength and the 
shift in spectrally averaged mean fluorescence lifetime were calculated for both excitation 
wavelengths. The measured shift in mean fluorescence emission wavelength was not found to 
be statistically significant for either excitation wavelength. Figure 8-7 shows the shift in the 
spectrally averaged fluorescence lifetime (t) for each normal-lesion pair and the mean values 
calculated over all pairs were 119  1002 ps and -259  1035 ps for 375 nm and 435 nm 
excitation respectively. A Wilcoxon signed rank test was applied to all sets of paired difference 
values. The data obtained with both excitation wavelengths showed no significant difference in 
the fluorescence lifetime of polyps with respect to healthy tissue (p = 0.9658 and p = 0.6377 
with 375 nm and 435 nm excitation, respectively). 
The shift in spectrally averaged mean lifetime for patients with neoplastic polyps (tubular and 
villous adenomas with LGD) was also compared to those with non-neoplastic polyps 
(hyperplastic and inflammatory) and the means and standard deviations are presented in table 
8-3. No statistically significant differences were found (Wilcoxon rank sum test, p = 0.9307 and 
p = 0.7922 with 375 nm and 435 nm excitation, respectively). 
 Mean shift in spectrally averaged 
fluorescence lifetime of polyp 
compared to normal colon (ps) 
 UV Blue 
Neoplastic (n=6) -29  842 -399  1435 
Non-neoplastic (n=5) 298  1244 -91  199 
Table 8-3: Spectrally averaged fluorescence lifetime shift for neoplastic and non-neoplastic polyps. 
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Comparison of in vivo versus ex vivo data 
The data obtained in vivo is now compared to the ex vivo data reported in chapter 7. 
Figure 8-8 shows summary plots of all measured absolute mean emission wavelengths and 
mean fluorescence lifetimes of normal colon, neoplastic and non-neoplastic polyps ex vivo and in 
vivo for both wavelengths. For 375 nm excitation (figure 8-8(a)), there seems to be a shift 
towards longer mean emission wavelengths and shorter spectrally averaged mean fluorescence 
lifetimes for the in vivo data, whereas for 435 nm excitation (figure 8-8(b)), a clustering of data 
points can be seen, which suggests a reasonable agreement between ex vivo and in vivo data. 
 
Figure 8-8: Summary of all measured absolute mean fluorescence emission wavelengths and spectrally 
averaged mean fluorescence lifetimes for (a) 375 nm and (b) 435 nm excitation wavelengths between ex vivo 
(squares) and in vivo (circles) normal colon (blue),  and neoplastic (red) and non-neoplastic (green) polyps.  
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8.5 Discussion 
This work demonstrated that time-resolved autofluorescence measurements could be readily 
acquired in vivo during routine endoscopy. All technological constraints precluding the transfer 
from the laboratory to the hospital were successfully overcome. 
In this study, however, no significant differences between diseased and normal tissue were 
found, and this was due to the relatively large standard deviations on the lifetime shifts, the 
large interpatient variability, and the small number of measurements made for each disease 
type. Notably, in contrast with the ex vivo experiments, statistically significant differences were 
found for 375 nm excitation in the spectrally averaged mean fluorescence lifetimes from the 
three regions of normal colon investigated (p = 0.0017), with the greatest difference observed 
between right and left colon. However, significant variation would have been expected for both 
excitation wavelengths but no significant difference was observed for 435 nm excitation. To the 
best of our knowledge, this is the first time that autofluorescence variations in normal colonic 
tissue with region have been investigated. However, the number of specimens in each group 
was relatively small and a study on a larger number of patients would be needed to investigate 
this further. 
In comparison with the ex vivo experiments, we noticed a generally weaker autofluorescence 
emission in vivo, and this may have depended on the relatively shorter total acquisition time for 
each measurement, the peristaltic motion of the organs during the measurements, as well as on 
the altered absorption properties of the living tissue caused by greater haemoglobin content 
and higher oxygenation. 
Another limitation is the possible slippage of the probe during the acquisition. The integration 
of the fibre probe within the flexible shaft of a biopsy forceps would allow the pinching of the 
tissue in between the cups of the forceps, therefore ensuring a constant contact with the tissue 
under investigation. 
One promising result is the observation that, with 435 nm excitation, the spectrally averaged 
fluorescence lifetimes measured in both ex vivo and in vivo diseased and normal tissues agree to 
within the quoted standard deviation (see ratios ± total relative errors in table 8-4).  
The spectrally averaged mean lifetimes for five groups of ex vivo measurements (all normal 
colon specimens, normal colon for polyp specimens, normal colon for IBD specimens, polyps 
and IBD specimens) were tested for differences with those of the in vivo measurements using 
the Wilcoxon rank sum test (5% significance level) and the p values are presented in table 8-4. 
No statistically significant differences were found in all groups for 435 nm excitation, indicating 
that data in the ex vivo and in vivo measurement groups came from continuous distributions 
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with equal medians. In contrast, for 375 nm excitation, in three groups (all normal colon 
specimens, normal colon for polyp specimens, and polyps) the ex vivo and in vivo data were 
significantly different suggesting that the distributions did not have equal medians.  
The fact that the mean lifetime varied under 375-nm-excitation but not with excitation at 
435 nm is intriguing and may be partly explained by both the different penetration depths of the 
two lasers and the different anatomical (structural) and biochemical compositions of the wall of 
the GI tract through the various regions of colon. The blue light will penetrate further into tissue 
than the UV radiation, hence, the lifetimes observed with the blue laser are more likely to be 
sensitive to variations in the thickness of the colonic mucosa. Furthermore, the differences in 
the fluorescence lifetime detected between ex vivo and in vivo measurements may also be 
explained, as discussed above, by changes in haemoglobin content and tissue oxygenation, 
changes in the metabolic state of cells, tissue pH, and movement artifacts.  
While this observation is based on only a small number of in vivo measurements, it suggests that 
the trends documented ex vivo in the previous chapter may also be observed in vivo.  
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 Mean lifetime ± 
SD (ps) ex vivo 
Mean lifetime ± 
SD (ps) in vivo 
Ratio ± TRE 
ex vivo/in vivo 
p values 
Tissue type λex 
375 nm 
λex 
435 nm 
λex 
375 nm 
λex 
435 nm 
λex 
375 nm 
λex 
435 nm 
λex 
375 nm 
λex 
435 nm 
Normal colon 
(all) 
3356 ± 
718 
2552 ± 
679 
2224 ± 
1198 
2216 ± 
741 
1.51 ± 
0.58 
1.15 ± 
0.43 
0.01 0.25 
Normal colon 
(polyp) 
3378 ± 
694 
2683 ± 
723 
1913 ± 
1278 
2258 ± 
886 
1.77 ± 
0.70 
1.19 ± 
0.48 
0.011 0.23 
Normal colon 
(IBD) 
3232 ± 
979 
2018 ± 
269 
3212 ± 
980 
2069 ± 
436 
1.01 ± 
0.43 
0.98 ± 
0.25 
1 0.8 
Normal stomach 
3020 ± 
290 
2650 ± 
920 
3189 2650 0.95 1 - - 
Normal 
oesophagus 
4220 2730 3780 ± 
670 
3820 ± 
730 
1.12 0.71 - - 
Polyps 
3068 ± 
908 
2243 ± 
872 
1941 ± 
1274 
1964 ± 
659 
1.58 ± 
0.72 
1.14 ± 
0.51 
0.032 0.53 
IBD 
4748 ± 
1138 
2071 ± 
360 
2743 ± 
3047 
2203 ± 
1763 
1.73 ± 
1.14 
0.94 ± 
0.82 
0.381 1 
Colon cancer 
- - 2603 2800 - - - - 
Gastric disease 
3190 ± 
250 
2310 ± 
910 
2864 3238 1.11 0.71 - - 
Oesophageal 
disease 
4380 3090 3740 ± 
600 
3990 ± 
390 
1.17 0.77 - - 
Table 8-4: Mean spectrally averaged fluorescence lifetimes observed in all the tissues investigated in 
this study. Data are presented for both the UV and blue laser and for both ex vivo and in vivo measurements. 
Uncertainties denote one standard deviation from the mean. Where no standard deviation is shown, only one 
measurement was made. SD = standard deviation; TRE = total relative error. 
Previous in vivo FL studies of colonic polyps have shown 85% sensitivity and 91% specificity in 
distinguishing colonic adenomatous polyps from non-neoplastic polyps [265]. As in the ex vivo 
measurements, in this study we did not find any statistically significant differences in the 
spectrally averaged lifetime between neoplastic and non-neoplastic polyps for either excitation 
wavelength. This discrepancy between our work and that of Mycek et al. may again be explained 
by the different excitation wavelengths used. 
However, it is interesting to note that, at 435 nm excitation, polyps exhibited shorter mean FL 
values than normal tissue, and this, although not statistically significant, was consistent with 
both our ex vivo measurements with the FLS system (chapter 7) and with images acquired with 
the FLIM confocal microscope (chapter 4). 
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8.6 Conclusions 
In summary, time-resolved fluorescence lifetime spectroscopy using two excitation wavelengths 
has been applied to the study of tissue abnormalities in vivo during routine endoscopy.  The 
mean shift in spectrally averaged fluorescence lifetime of polyps compared to normal colon for 
435 nm excitation was found to be negative (-399  1435 ps), in agreement with the ex vivo data 
reported in chapter 7 (-690  640 ps, p = 0.0049), however, this was not found to be statistically 
significant. Spectrally averaged mean fluorescence lifetimes measured in vivo were not found to 
be statistically different from those measured ex vivo for 435 nm excitation. However, 
statistically significant differences were observed between in vivo and ex vivo measurements for 
375 nm excitation. Further improvements will be required to optimise this technique and a 
larger trial will be needed to rigorously assess its clinical utility. 
Current prospective diagnostic accuracy studies with the FLS system are underway to 
determine if contrast is present in other disease types. If established, it is desirable to progress 
to the exciting prospect of wide-field FLIM endoscopy imaging, which would be able to screen 
rapidly a field of view up to many centimetres across. Such a system has the potential to be used 
as a red-flag screening technique, alerting the clinician to areas requiring more detailed 
investigation, i.e. by conventional biopsy or a more detailed optical biopsy technique such as the 
FLS probe. 
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Chapter 9: Conclusions and outlook 
Optically-assisted diagnosis is a thriving field of research that is particularly applicable to the 
various medical conditions for which biopsies are still required to confirm and characterise the 
essential nature of diseases. One such example is detection of dysplasia, where an in situ “optical 
biopsy” would be of significant benefit, allowing real-time diagnosis during endoscopy and 
avoiding multiple and random unnecessary biopsies. Indeed, discrimination between dysplasia 
and inflammation is still one of the most important dilemmas in GI endoscopy and pathology. 
The aim of the work presented in this thesis was to investigate a spectrum of tissue types and 
states of disease, including premalignant and malignant conditions, by studying tissue 
autofluorescence and measuring fluorescence lifetime using fluorescence lifetime imaging and 
spectroscopy. In this thesis, attention was directed towards the differences in autofluorescence, 
and particularly fluorescence lifetime, found in skin cancer, colonic polyps and inflammatory 
bowel diseases. 
Chapter 2 introduced the clinical context of this research and discussed established and 
emerging endoscopic techniques, outlining their fundamental principles and pro et contra. The 
clinical and experimental experience was also reviewed and a summary of current unmet 
clinical needs is provided. In chapter 3, the scientific instrumentation context of this thesis was 
presented, along with a review of the pertinent published literature. A summary of the state-of 
the-art of fluorescence lifetime endoscopic instrumentation developments at Imperial College 
London was presented, along with a discussion of limitations in the currently available systems, 
and future prospects. 
Chapters 4 and 5 focussed on ex vivo FLIM microscopy-based studies of gastrointestinal disease 
and bladder cancer, respectively. Chapter 6 concerned the application of a time-resolved 
spectrometer to an in vivo study of skin cancer. This system was then redesigned to make it 
more compact and clinically compatible with flexible endoscopes, and applied to both ex vivo 
and in vivo investigations of GI disease and the results of these studies were presented in 
chapter 7 and chapter 8, respectively.  
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9.1 Summary of results 
9.2 Investigation of fluorescence lifetime imaging for label free contrast of 
gastrointestinal disease 
The experimental work discussed in chapter 4 was directed at the autofluorescence signatures 
of fresh endoscopically resected GI tissue in order to investigate the origins of the contrast 
generated by FLIM and the relative contributions to tissue autofluorescence from the different 
areas and structures within the tissue. This was achieved by imaging with a conventional FLIM 
microscope at 420 nm excitation a total of 71 endoscopic samples from different GI sites 
collected from 35 patients undergoing either upper or lower GI endoscopy as part of their 
clinical investigations. This excitation wavelength was used because the ultimate intention was 
to develop clinical FLIM endoscopes that were expected to utilise excitation in the blue. A total 
of 481 confocal images were acquired and the FLIM images generated were analysed using 
manual image processing. Samples were investigated for properties related to emission 
spectrum, fluorescence decay after pulsed excitation, morphological changes, and correlation 
with both endoscopic and histological diagnosis. 
FLIM was found to allow the visualization of tissue details in some of the most common GI 
diseases and provide contrast between normal and diseased tissue, particularly for colonic 
polyps and inflammatory bowel disease, where a statistically significant decrease in 
fluorescence lifetime relative to biopsy specimens of adjacent normal tissue was observed 
(p = 0.024 and p = 0.015 for polyps and IBD, respectively) although the mean fluorescence 
lifetime shift (i.e. τlesion - τnormal) for biopsies of colon cancer and Barrett’s oesophagus was not 
found to be statistically significant for the sample numbers studied. Interestingly, however, the 
mean fluorescence lifetime of colon cancer biopsies was longer than that of normal adjacent 
tissue with a mean delta tau shift of 220  187 ps, which is in agreement with a previous ex vivo 
study using wide field FLIM imaging on freshly resected (< 2 hours) surgical samples of colon 
cancer, although more samples are required to build a statistically significant sample size and 
this earlier result was obtained using a different excitation wavelength (355 nm) [273]. 
The autofluorescence signal may be primarily attributed to flavin and collagen fluorescence for 
the excitation wavelength used (420 nm). Fluorescence lifetime contrast may be due to changes 
in flavin fluorescence lifetime with disease state or changes in the relative amounts of flavins 
and collagen with disease, however, further work is needed to clarify this. The possible role of 
mucins in the fluorescence lifetime changes observed was also raised but further work would be 
necessary to support this supposition. 
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This study represents the most comprehensive analysis of confocal FLIM images in normal and 
diseased human GI mucosal tissues and the only study to use confocal FLIM at 420 nm 
excitation to image autofluorescence from freshly-resected specimens obtained from patients 
undergoing endoscopic procedures. Similarly, Professor Hillman’s group have presented 
hyperspectral two-photon microscopy (TPM) paired images and emission spectra from normal 
and transgenic mouse GI tissue [323]. However, their study involved freshly excised small 
intestine and colon from 15 (10 normal and 5 transgenic APC Min/+) mice, and was mainly 
carried out to determine the TPM excitation spectral properties of the four layers of the normal 
GI tract wall. The ability to generate lifetime contrast with blue excitation, as is likely to be used 
in FLIM endoscopes, supports the potential of FLIM for clinical applications including the in vivo 
detection and characterisation of dysplasia, and the discrimination of inflammatory diseases. 
Future work is more likely to involve the collection of a larger, more significant data set to allow 
confirmation of the observations made and build a bank of ex vivo data to permit detailed 
investigation of the optical signatures of other GI disease types meaning that the worth of 
confocal FLIM can be assessed over a wider range of GI conditions, including liver, biliary and 
pancreatic disorders. An increased database of information would also facilitate the 
development and implementation of FLIM in endoscopic instruments for clinical use, such as 
the FLIM confocal endomicroscope. 
9.3 Investigation of fluorescence lifetime confocal microscopy of bladder 
cancer as an adjunct to PpIX fluorescence induced PDD 
The concept behind a novel approach to PDD of bladder cancer was discussed in chapter 5 and 
results from a proof-of-principle study based on confocal FLIM microscopy were presented. The 
aim of this work was to assess whether the fluorescence signature of PpIX, which is known to 
accumulate preferentially in malignant tissue, could be detected by FLIM, and whether the 
fluorescence patterns seen could report on the disease state of the tissue. The study employed 
an imaging protocol that was similar to that described in chapter 4 and involved the comparison 
of the optical signatures of healthy and neoplastic regions of bladder excised from the same 
patient undergoing PDD cystoscopy. 
Although not significant (p = 0.06), an increase of the mean fluorescence lifetime for biopsies of 
bladder cancer was consistently observed at 405 nm excitation. The longer fluorescence lifetime 
in neoplastic tissue is consistent with a greater concentration of PpIX compared to normal 
tissue and with the longer fluorescence lifetime of PpIX compared to baseline tissue 
autofluorescence. Further work would be useful to characterize bladder biopsies obtained 
during PDD cystoscopy using FLIM and to correlate the morphological appearance seen in the 
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confocal FLIM images with the molecular basis of the fluorescence changes observed. A larger 
data set would also support the development of clinically viable diagnostic equipment such as a 
wide field FLIM flexible ureteroscope for in vivo use in combination with the blue light 
cystoscopy equipment, as PDD becomes increasingly applied to a great number of endoscopic 
urological procedures. 
9.4 Investigation of time-resolved autofluorescence spectroscopy of skin 
cancer 
Chapter 6 discussed the use of a prototype fluorescence lifetime spectrometer in the first in vivo 
clinical study of the autofluorescence lifetime signatures of skin cancer [403]. This system is a 
time-resolved fluorescence spectrometer, which records fluorescence decays in 16 spectral 
channels with two excitation wavelengths (355 nm and 445 nm). The system was transported 
with a van from London to Lund in Sweden by the Imperial investigators. It was assembled in 
the dermatology department of Lund University Hospital, and used to interrogate 27 clinically 
diagnosed skin lesions on a total of 25 patients. For each lesion, a parallel measurement of the 
neighbouring healthy tissue was also made for comparison. 
It was observed that with excitation at 445 nm, basal cell carcinomas (BCCs) – the disease type 
for which the greatest number of measurements was made – exhibited a statistically significant 
(p = 0.002) decrease in their spectrally averaged mean fluorescence lifetime, relative to the 
surrounding healthy skin. Importantly, in 9 out of 10 cases this decrease in lifetime was greater 
in magnitude than the mean intra-patient variation in the measured lifetimes. This indicates the 
future potential of time-resolved autofluorescence spectroscopy for use in clinical diagnosis. 
9.5 Investigation of time-resolved autofluorescence spectroscopy of 
colonic polyps and inflammatory bowel disease ex vivo 
Chapter 7 presented an ex vivo study of time-resolved autofluorescence spectra of colonic 
samples collected from patients undergoing endoscopy as part of their clinical investigation. 
Using a compact fibre-optic coupled fluorescence lifetime spectrometer, the autofluorescence 
signatures of freshly biopsied/removed colonic tissue were investigated. This instrument 
provides measurements of time-resolved fluorescence spectra (16 spectral detection channels) 
with two excitation wavelengths (375 nm and 435 nm) and was designed to be suitable for 
regular ex vivo/in vivo research use in the hospital setting, for which clinical input and 
contributions with regard to specifications and design were provided in order to meet the 
requirements of safety, capacity to be disinfected and easy portability. 
312 
 
First, the variation in the fluorescence lifetime of normal colon was assessed and it was 
observed that the lifetime varied based on the region of the colon from which the tissue was 
excised, with the greatest difference observed between rectum and the rest of the colon with 
435 nm excitation, although this shift was not found to be statistically significant for the sample 
size studied. Subsequently, the analysis of the disease types for which the greatest number of 
measurements was made (polyps and IBD) was undertaken.  
In a paired analysis between normal colon and neoplastic polyps obtained from the same 
patient, the decrease in 435 nm excited spectrally averaged mean fluorescence lifetime 
measured over all patients was found to be statistically significant (mean t = -570  740 ps, 
n = 12, p = 0.021). If a patient from whom it was not possible to obtain a normal sample from the 
same region of colon is excluded, then the level of statistical significance increases (mean 
t = -690  640 ps, n = 11, p = 0.0049) and the increase in mean emission wavelength also 
becomes statistically significant (mean λ = 2.6  3.1 nm, n = 11, p = 0.019). The shift in 
spectrally averaged mean fluorescence lifetime was found to be correlated with the shift in 
emission spectrum (R2 = 0.71) but the shift in the spectrally averaged mean fluorescence 
lifetime exhibited a less variation between patients than the shift in the mean emission 
wavelength. 
The number of IBD specimens studied was small (n = 4) and relatively large standard deviations 
on the spectral and lifetime shifts were obtained, so no statistically significant differences were 
observed. However, with 375 nm excitation, the fluorescence lifetimes of all four IBD samples 
were longer than those of the nearby normal colon tissue (mean t = 983  289 ps), and the 
increase in 375 nm excited fluorescence lifetime was correlated (R2 = 0.90) with an increase in 
fluorescence emission wavelength ( = 6.9  6.6 nm). 
To our knowledge this ex vivo study represents the first time that dual-excitation wavelength 
laser-induced time-resolved fluorescence spectra of normal and diseased GI tissue have been 
acquired from a significant number of patients and the first time that autofluorescence 
variations in normal colonic tissue with region or disease have been investigated. While further 
research is required, our results suggest that the combination of 375 nm and 435 nm excited 
fluorescence measurements could ultimately help endoscopists decide whether the nature of a 
lesion is proliferative or inflamed. 
9.6 In vivo measurements of endoscopic fluorescence lifetime 
spectroscopy of gastrointestinal disease 
Following on from the work presented in chapter 7, the eighth chapter of this thesis outlined the 
deployment of a clinically viable time-resolved spectrometer in vivo during endoscopy. To the 
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best of our knowledge this was the first in vivo study using a clinically compatible endoscopic 
spectrofluorometer to provide simultaneous measurements of time-resolved fluorescence 
spectra with two excitation wavelengths (375 nm and 435 nm). This investigation was 
performed at Charing Cross Hospital and involved the acquisition of 42 measurements from 17 
patients undergoing routine endoscopic procedures. 
Colonic polyp was the disease type for which the greatest number of measurements was made. 
Different regions of endoscopically and histologically normal colon (rectum, left and right colon) 
were first compared with respect to their spectrally averaged normalised emission spectrum 
and mean fluorescence lifetime. Statistically significant differences were obtained for 375 nm 
excitation (p = 0.0017), with the greatest difference observed between right and left colon 
(p = 0.001), although the data obtained with 435 nm excitation showed no significant difference 
(p = 0.54) for the number of samples studied. Interestingly, the mean fluorescence lifetime 
obtained with both excitation wavelengths from the right colon was longer than that obtained 
from the other two regions, particularly between left and right colon with 375 nm excitation. 
Subsequent analysis was undertaken to investigate the differences between normal colon and 
colonic polyps, as only a small number of measurements were performed for other clinical 
conditions. No statistically significant difference was obtained when comparing the mean 
fluorescence emission wavelength for either excitation wavelength. A negative shift in the 
spectrally averaged mean lifetime (i.e. τpolyp < τnormal) with 435 nm excitation was observed, in 
agreement with the result seen in the ex vivo study, although this was not statistically 
significant. In contrast, an opposite trend was seen with 375 nm excitation. The lack of 
statistical significance in the lifetime differences observed was probably due to the relatively 
large standard deviations on the lifetime shifts, the large inter-patient variability and the small 
number of measurements made for each disease type. 
In comparison with the ex vivo experiments, we noticed a generally weaker autofluorescence 
emission in vivo that may have been due to the relatively shorter total acquisition time for each 
measurement, the peristaltic motion of the organs during the measurements, or on the altered 
absorption properties of the living tissue caused by greater haemoglobin content and higher 
oxygenation. 
While this experimental work provided a useful step toward the translation of fluorescence 
lifetime technology to the clinic, a larger data set is required in order to confirm the trends 
observed and to permit investigation of further disease types. The spectroscopic data obtained 
could then be used to guide the development of future diagnostic equipment, for example in 
terms of the optimum excitation and detection wavelengths to be used. Looking ahead, the 
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integration of this technology in conventional instruments such as biopsy forceps or snares, or 
in FLIM endoscopes, could be clinically beneficial. 
9.7 Challenges and prospects: what went wrong and how could future 
studies be improved 
In this multidisciplinary PhD project, there a number of challenges that arose with respect to the 
photonics technology, the biomedical analysis and the practical clinical implementation of 
experimental studies. 
From the technological perspective, the clinical approved Cellvizio™ confocal endomicroscope 
that was developed for real-time FLIM using TCSPC proved unsuitable for imaging tissue 
autofluorescence at the desired (UV-blue) excitation wavelengths, due to the background 
fluorescence excited in the imaging fibre bundle. Accordingly, the planned observational work 
described in chapter 4 was performed using a time-resolved fluorescence lifetime imaging 
confocal microscope. The Cellvizio™ FLIM instrument was redirected towards tissue imaging 
with exogenous probes with longer excitation wavelengths.  
Throughout the project a range of different excitation wavelengths and optical 
excitation/detection geometries was employed due to the constraints of the specific 
components available for particular instruments.  This prevented direct comparisons between 
results from different instruments, leading to non-generalizable results and separate 
conclusions for each study.  The challenges and prospects specific to each of the studies are 
discussed below: 
Chapter 4 
The study presented in chapter 4 was primarily set as an exploration of signals and aimed to 
test the broad hypothesis that fluorescence lifetime measurements can contrast between 
different tissue types. 
The sample size was relatively small for each disease group investigated and more focus could 
have been placed on a specific condition to measure more samples to achieve a more 
statistically significant analysis. Reviewing the requests for endoscopy could help identify 
potential participants in advance and plan dedicated sessions for collecting research specimens 
without causing disruption to the clinical workflow.  
The study would have benefited from a precise histological registration to better establish the 
biomolecular composition and distribution of fluorophores in the tissues and therefore to 
identify the potential mechanisms responsible for the altered signals observed in the diseases 
investigated. 
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Orientating tissue under the microscope proved to be both difficult and time consuming and 
alternative approaches should be explored. For instance, the biopsy samples could be 
manipulated onto a microscope slide (instead of gauze) to keep the mucosal surface facing 
upward before sandwiching it with a glass coverslip.  
A ring of silicone paste could be used to create a sealed compartment for the sample and 
prevent unwanted movements of the coverslip during imaging. This method was recently 
described by Pavone et al. for imaging fresh endoscopic specimens of human colon using MPM 
[548]. 
Fluorescence was detected over a wide detection range (450-680 nm). Dividing the detection 
bandwidth into two narrower spectral channels (e.g. 430-490 and 500-560 to selectively collect 
NADH and FAD fluorescence, respectively) would help resolve fluorophores with overlapping 
fluorescence emission spectra but with different fluorescence decay times (e.g. flavins and 
lipofuscin).  
Each field of view was analysed using histograms of lifetimes across the whole field of view. It 
could be useful to identify and analyse specific regions of interest within FLIM fields of view, e.g. 
to calculate the redox ratio (balance between energy production and consumption) for cells in 
different tissue types, as described by Zhuo and associates [430]. This approach would remove 
extracellular fluorescence from the lifetime analysis, which could better define the cellular 
fluorescence.  
Manual processing of images was very time consuming. A novel global fitting software package 
called FLIMfit [549] has now been developed in-house that is able to automatically fit lifetime 
data in batches and therefore could avoid the manual selection and processing of many acquired 
images, one by one.  
It would be advantageous to move the microscope to the hospital as this would significantly 
reduce the excision to imaging time interval. 
Chapter 5 
The detection bandwidth used in this study was too wide to separate the relative contributions 
of baseline AF and PpIX fluorescence intensity.  In future work it is recommended that a 
narrower spectral band (e.g. 635-710 nm) be employed to select the fluorescence emission of 
PpIX.  
Chapter 6 
Of the results presented in this thesis, the in vivo experiments undertaken in Lund on skin and 
basal cell carcinoma indicate the highest diagnostic potential. In 9 out of 10 cases the decrease 
in lifetime for BCC was greater than the mean intra-patient variation in the measured lifetimes, 
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suggesting a potential sensitivity of 90%.  Future work on BCC could use the results from this 
study to perform power calculations to design future clinical trials. In future work it would be 
desirable to study lesions at an earlier stage and establish a better correlation between 
fluorescence lifetime and diffuse reflectance measurements.   
Chapter 7 
A limitation of this study is that emitted fluorescence spectra and lifetime were acquired ex vivo. 
All the specimens, although measured within a short time period (< 10 minutes) of excision, are 
therefore likely to have lower oxyhaemoglobin content compared to in vivo tissue. The resulting 
change in tissue oxygenation may have altered the absorption properties of the tissue and 
therefore affected the tissue volume sampled and the fluorescence lifetime detected. However, 
the measurement time for normal/diseased pairs in this study was reasonably well-matched.  
While only a very limited number of IBD specimens have been studied (n=4), a consistent 
increase in fluorescence lifetime with 375 nm excitation was seen in all specimens, which could 
be investigated further with a larger number of samples. 
In terms of data analysis, statistical testing and performance characterisation, recourse to 
megavariate analysis would be beneficial.  
Directions for future work will involve the generation of a diagnostic model based on both 
fluorescence emission spectrum and fluorescence lifetime data. However, this would require a 
greater number of samples than were obtained for this study. 
Chapter 8 
The main difficulty when using FLS system in vivo was to keep the fibre-probe sufficiently still to 
maintain a constant interface between tissue and tip of the probe. In the future, the integration 
of the fibre probe within the flexible shaft of biopsy forceps or the addition of a suction port at 
the tip of the probe would help to ensure a constant contact with the area of mucosa tissue 
under investigation.  
9.8 Final remarks 
The work presented in this thesis has used fluorescence lifetime spectroscopy and imaging to 
investigate tissue autofluorescence and lifetime variations in normal and diseased tissue from a 
variety of tissue types, including the GI tract, skin, and bladder. Central to the clinical translation 
of fluorescence lifetime technology for endoscopy is the development of compact instruments 
that can be deployed in a practical and safe manner by clinical investigators. During this PhD, 
the clinical application of a novel, compact, fluorescence lifetime spectroscopy (FLS) fibre-optic 
probe system developed for studying tissue autofluorescence in vivo was pioneered. The 
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usability of this instrument was demonstrated through its application to both ex vivo and in vivo 
measurements, making it a practical tool to investigate gastrointestinal disease. 
The FLS probe is immediately useable, being fully self-contained and trolley-based such that it 
can be readily clinically deployed. The fibre-optic probe is thin enough to pass down the 
working channel of a conventional endoscope to be brought into contact with the epithelium of 
the patient during endoscopy procedures performed as part of normal clinical care. The 
potential clinical impact of this new diagnostic approach was recognised by two awards at the 
major international GI conferences (2012, Cook Medical Marsha Dreyer Award, American 
Society for Gastrointestinal Endoscopy; 2011, €10,000 prize awarded by the European 
Federation of the International College of Surgeons). 
Further work is required to increase the sample size of the disease groups investigated. Its 
application could extend to a wide variety of GI diseases, including liver and pancreatic 
disorders, which was not possible within the time constrains of this project. In the future it is 
desirable to progress to studies using wide-field endoscopic FLIM, which could potentially 
enable rapid screening with fields of view extending over several centimetres. Moving to an 
imaging modality would provide the clinician with an immediate overview on the fluorescence 
lifetime of normal tissue, thus removing the need for paired measurements of normal and 
diseased tissue used in this work, and allow areas with differing fluorescence lifetimes to be 
rapidly located. Ultimately, the development of a rapid optical screening tool, either in the form 
of a probe or as an integrated endoscope, could permit the identification and treatment of a 
number of premalignant and malignant conditions at a curable stage, thus enabling to arrest 
disease progression while preserving organ function and avoiding recourse to aggressive 
surgery by means of minimally-invasive endoscopic procedures such as radiofrequency ablation 
(RFA), endoscopic mucosal resection (EMR), and submucosal dissection (ESD), and Natural 
orifice transluminal endoscopic surgery (NOTES).  
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8. IN NO EVENT SHALL WILEY OR ITS LICENSORS BE LIABLE TO YOU OR ANY OTHER PARTY OR ANY 
OTHER PERSON OR ENTITY FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, INDIRECT, 
EXEMPLARY OR PUNITIVE DAMAGES, HOWEVER CAUSED, ARISING OUT OF OR IN CONNECTION WITH 
THE DOWNLOADING, PROVISIONING, VIEWING OR USE OF THE MATERIALS REGARDLESS OF THE 
FORM OF ACTION, WHETHER FOR BREACH OF CONTRACT, BREACH OF WARRANTY, TORT, 
NEGLIGENCE, INFRINGEMENT OR OTHERWISE (INCLUDING, WITHOUT LIMITATION, DAMAGES 
BASED ON LOSS OF PROFITS, DATA, FILES, USE, BUSINESS OPPORTUNITY OR CLAIMS OF THIRD 
PARTIES), AND WHETHER OR NOT THE PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH 
DAMAGES. THIS LIMITATION SHALL APPLY NOTWITHSTANDING ANY FAILURE OF ESSENTIAL 
PURPOSE OF ANY LIMITED REMEDY PROVIDED HEREIN.  
9. Should any provision of this Agreement be held by a court of competent jurisdiction to be illegal, 
invalid, or unenforceable, that provision shall be deemed amended to achieve as nearly as possible the 
same economic effect as the original provision, and the legality, validity and enforceability of the 
remaining provisions of this Agreement shall not be affected or impaired thereby.  
10. The failure of either party to enforce any term or condition of this Agreement shall not constitute a 
waiver of either party's right to enforce each and every term and condition of this Agreement. No 
breach under this agreement shall be deemed waived or excused by either party unless such waiver or 
consent is in writing signed by the party granting such waiver or consent. The waiver by or consent of a 
party to a breach of any provision of this Agreement shall not operate or be construed as a waiver of or 
consent to any other or subsequent breach by such other party.  
11. This Agreement may not be assigned (including by operation of law or otherwise) by you without 
WILEY's prior written consent.  
12. Any fee required for this permission shall be non-refundable after thirty (30) days from receipt 
13. These terms and conditions together with CCCs Billing and Payment terms and conditions (which 
are incorporated herein) form the entire agreement between you and WILEY concerning this licensing 
transaction and (in the absence of fraud) supersedes all prior agreements and representations of the 
parties, oral or written. This Agreement may not be amended except in writing signed by both parties. 
This Agreement shall be binding upon and inure to the benefit of the parties' successors, legal 
representatives, and authorized assigns.  
14. In the event of any conflict between your obligations established by these terms and conditions and 
those established by CCCs Billing and Payment terms and conditions, these terms and conditions shall 
prevail.  
15. WILEY expressly reserves all rights not specifically granted in the combination of (i) the license 
details provided by you and accepted in the course of this licensing transaction, (ii) these terms and 
conditions and (iii) CCCs Billing and Payment terms and conditions.  
16. This Agreement will be void if the Type of Use, Format, Circulation, or Requestor Type was 
misrepresented during the licensing process.  
17. This Agreement shall be governed by and construed in accordance with the laws of the State of New 
York, USA, without regards to such states conflict of law rules. Any legal action, suit or proceeding 
arising out of or relating to these Terms and Conditions or the breach thereof shall be instituted in a 
court of competent jurisdiction in New York County in the State of New York in the United States of 
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America and each party hereby consents and submits to the personal jurisdiction of such court, waives 
any objection to venue in such court and consents to service of process by registered or certified mail, 
return receipt requested, at the last known address of such party.  
Wiley Open Access Terms and Conditions  
Wiley publishes Open Access articles in both its Wiley Open Access Journals program 
[http://www.wileyopenaccess.com/view/index.html] and as Online Open articles in its subscription 
journals. The majority of Wiley Open Access Journals have adopted the Creative Commons Attribution 
License (CC BY) which permits the unrestricted use, distribution, reproduction, adaptation and 
commercial exploitation of the article in any medium. No permission is required to use the article in this 
way provided that the article is properly cited and other license terms are observed. A small number of 
Wiley Open Access journals have retained the Creative Commons Attribution Non Commercial License 
(CC BY-NC), which permits use, distribution and reproduction in any medium, provided the original 
work is properly cited and is not used for commercial purposes. 
Online Open articles  Authors selecting Online Open are, unless particular exceptions apply, offered a 
choice of Creative Commons licenses. They may therefore select from the CC BY, the CC BY-NC and the 
Attribution-NoDerivatives (CC BY-NC-ND). The CC BY-NC-ND is more restrictive than the CC BY-NC as it 
does not permit adaptations or modifications without rights holder consent. 
Wiley Open Access articles are protected by copyright and are posted to repositories and websites in 
accordance with the terms of the applicable Creative Commons license referenced on the article. At the 
time of deposit, Wiley Open Access articles include all changes made during peer review, copyediting, 
and publishing. Repositories and websites that host the article are responsible for incorporating any 
publisher-supplied amendments or retractions issued subsequently. 
Wiley Open Access articles are also available without charge on Wiley's publishing platform, Wiley 
Online Library or any successor sites. 
Conditions applicable to all Wiley Open Access articles:  
 The authors' moral rights must not be compromised. These rights include the right of 
"paternity" (also known as "attribution" - the right for the author to be identified as such) and 
"integrity" (the right for the author not to have the work altered in such a way that the author's 
reputation or integrity may be damaged).  
 Where content in the article is identified as belonging to a third party, it is the obligation of the 
user to ensure that any reuse complies with the copyright policies of the owner of that content.  
 If article content is copied, downloaded or otherwise reused for research and other purposes as 
permitted, a link to the appropriate bibliographic citation (authors, journal, article title, volume, 
issue, page numbers, DOI and the link to the definitive published version on Wiley Online 
Library) should be maintained. Copyright notices and disclaimers must not be deleted. 
Creative Commons licenses are copyright licenses and do not confer any other rights, including 
but not limited to trademark or patent rights.  
 Any translations, for which a prior translation agreement with Wiley has not been agreed, must 
prominently display the statement: "This is an unofficial translation of an article that appeared 
in a Wiley publication. The publisher has not endorsed this translation."  
Conditions applicable to non-commercial licenses (CC BY-NC and CC BY-NC-ND) 
For non-commercial and non-promotional purposes individual non-commercial users may 
access, download, copy, display and redistribute to colleagues Wiley Open Access articles. In 
addition, articles adopting the CC BY-NC may be adapted, translated, and text- and data-mined 
subject to the conditions above. 
Use by commercial "for-profit" organizations  
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Use of non-commercial Wiley Open Access articles for commercial, promotional, or marketing 
purposes requires further explicit permission from Wiley and will be subject to a fee. 
Commercial purposes include:  
o Copying or downloading of articles, or linking to such articles for further 
redistribution, sale or licensing;  
o Copying, downloading or posting by a site or service that incorporates advertising with 
such content;  
o The inclusion or incorporation of article content in other works or services (other than 
normal quotations with an appropriate citation) that is then available for sale or 
licensing, for a fee (for example, a compilation produced for marketing purposes, 
inclusion in a sales pack)  
o Use of article content (other than normal quotations with appropriate citation) by for-
profit organizations for promotional purposes  
o Linking to article content in e-mails redistributed for promotional, marketing or 
educational purposes;  
o Use for the purposes of monetary reward by means of sale, resale, license, loan, 
transfer or other form of commercial exploitation such as marketing products  
o Print reprints of Wiley Open Access articles can be purchased from: 
corporatesales@wiley.com  
The modification or adaptation for any purpose of an article referencing the CC BY-NC-
ND License requires consent which can be requested from RightsLink@wiley.com .  
Other Terms and Conditions:  
BY CLICKING ON THE "I AGREE..." BOX, YOU ACKNOWLEDGE THAT YOU HAVE READ 
AND FULLY UNDERSTAND EACH OF THE SECTIONS OF AND PROVISIONS SET FORTH 
IN THIS AGREEMENT AND THAT YOU ARE IN AGREEMENT WITH AND ARE WILLING 
TO ACCEPT ALL OF YOUR OBLIGATIONS AS SET FORTH IN THIS AGREEMENT.  
v1.8  
If you would like to pay for this license now, please remit this license along with your payment 
made payable to "COPYRIGHT CLEARANCE CENTER" otherwise you will be invoiced within 48 
hours of the license date. Payment should be in the form of a check or money order referencing 
your account number and this invoice number RLNK501022678. 
Once you receive your invoice for this order, you may pay your invoice by credit card. Please 
follow instructions provided at that time. 
 
Make Payment To: 
Copyright Clearance Center 
Dept 001 
P.O. Box 843006 
Boston, MA 02284-3006 
 
For suggestions or comments regarding this order, contact RightsLink Customer Support: 
customercare@copyright.com or +1-877-622-5543 (toll free in the US) or +1-978-646-2777. 
 
Gratis licenses (referencing $0 in the Total field) are free. Please retain this printable license for 
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your reference. No payment is required. 
Figure 3-4 
JOHN WILEY AND SONS LICENSE 
TERMS AND CONDITIONS 
May 16, 2013 
 
 
This is a License Agreement between Sergio Coda ("You") and John Wiley and Sons ("John Wiley and 
Sons") provided by Copyright Clearance Center ("CCC"). The license consists of your order details, the 
terms and conditions provided by John Wiley and Sons, and the payment terms and conditions.  
All payments must be made in full to CCC. For payment instructions, please see information 
listed at the bottom of this form. 
License Number 3150841356538 
License date May 16, 2013 
Licensed content publisher John Wiley and Sons 
Licensed content publication Photochemistry and Photobiology 
Licensed content title In Vivo Fluorescence Spectroscopy and Imaging for Oncological 
Applications 
Licensed copyright line Copyright © 2008, John Wiley and Sons 
Licensed content author Georges A. Wagnieres,Willem M. Star,Brian C. Wilson 
Licensed content date Jan 2, 2008 
Start page 603 
End page 632 
Type of use Dissertation/Thesis 
 
Requestor type University/Academic 
Format Print and electronic 
Portion Figure/table 
Number of figures/tables 1 
Original Wiley figure/table 
number(s) 
Figure 1 
Will you be translating? No 
Total 0.00 USD 
 
Terms and Conditions 
 
TERMS AND CONDITIONS  
This copyrighted material is owned by or exclusively licensed to John Wiley & Sons, Inc. or one of its 
group companies (each a "Wiley Company") or a society for whom a Wiley Company has exclusive 
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publishing rights in relation to a particular journal (collectively WILEY). By clicking "accept" in 
connection with completing this licensing transaction, you agree that the following terms and 
conditions apply to this transaction (along with the billing and payment terms and conditions 
established by the Copyright Clearance Center Inc., ("CCCs Billing and Payment terms and conditions"), 
at the time that you opened your RightsLink account (these are available at any time at 
http://myaccount.copyright.com). 
Terms and Conditions 
1. The materials you have requested permission to reproduce (the "Materials") are protected by 
copyright.  
2.You are hereby granted a personal, non-exclusive, non-sublicensable, non-transferable, worldwide, 
limited license to reproduce the Materials for the purpose specified in the licensing process. This license 
is for a one-time use only with a maximum distribution equal to the number that you identified in the 
licensing process. Any form of republication granted by this license must be completed within two years 
of the date of the grant of this license (although copies prepared before may be distributed thereafter). 
The Materials shall not be used in any other manner or for any other purpose. Permission is granted 
subject to an appropriate acknowledgement given to the author, title of the material/book/journal and 
the publisher. You shall also duplicate the copyright notice that appears in the Wiley publication in your 
use of the Material. Permission is also granted on the understanding that nowhere in the text is a 
previously published source acknowledged for all or part of this Material. Any third party material is 
expressly excluded from this permission.  
3. With respect to the Materials, all rights are reserved. Except as expressly granted by the terms of the 
license, no part of the Materials may be copied, modified, adapted (except for minor reformatting 
required by the new Publication), translated, reproduced, transferred or distributed, in any form or by 
any means, and no derivative works may be made based on the Materials without the prior permission 
of the respective copyright owner. You may not alter, remove or suppress in any manner any copyright, 
trademark or other notices displayed by the Materials. You may not license, rent, sell, loan, lease, 
pledge, offer as security, transfer or assign the Materials, or any of the rights granted to you hereunder 
to any other person.  
4. The Materials and all of the intellectual property rights therein shall at all times remain the exclusive 
property of John Wiley & Sons Inc or one of its related companies (WILEY) or their respective licensors, 
and your interest therein is only that of having possession of and the right to reproduce the Materials 
pursuant to Section 2 herein during the continuance of this Agreement. You agree that you own no right, 
title or interest in or to the Materials or any of the intellectual property rights therein. You shall have no 
rights hereunder other than the license as provided for above in Section 2. No right, license or interest 
to any trademark, trade name, service mark or other branding ("Marks") of WILEY or its licensors is 
granted hereunder, and you agree that you shall not assert any such right, license or interest with 
respect thereto.  
5. NEITHER WILEY NOR ITS LICENSORS MAKES ANY WARRANTY OR REPRESENTATION OF ANY KIND 
TO YOU OR ANY THIRD PARTY, EXPRESS, IMPLIED OR STATUTORY, WITH RESPECT TO THE 
MATERIALS OR THE ACCURACY OF ANY INFORMATION CONTAINED IN THE MATERIALS, INCLUDING, 
WITHOUT LIMITATION, ANY IMPLIED WARRANTY OF MERCHANTABILITY, ACCURACY, 
SATISFACTORY QUALITY, FITNESS FOR A PARTICULAR PURPOSE, USABILITY, INTEGRATION OR NON-
INFRINGEMENT AND ALL SUCH WARRANTIES ARE HEREBY EXCLUDED BY WILEY AND ITS 
LICENSORS AND WAIVED BY YOU.  
6. WILEY shall have the right to terminate this Agreement immediately upon breach of this Agreement 
by you. 
7. You shall indemnify, defend and hold harmless WILEY, its Licensors and their respective directors, 
officers, agents and employees, from and against any actual or threatened claims, demands, causes of 
action or proceedings arising from any breach of this Agreement by you.  
8. IN NO EVENT SHALL WILEY OR ITS LICENSORS BE LIABLE TO YOU OR ANY OTHER PARTY OR ANY 
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OTHER PERSON OR ENTITY FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, INDIRECT, 
EXEMPLARY OR PUNITIVE DAMAGES, HOWEVER CAUSED, ARISING OUT OF OR IN CONNECTION WITH 
THE DOWNLOADING, PROVISIONING, VIEWING OR USE OF THE MATERIALS REGARDLESS OF THE 
FORM OF ACTION, WHETHER FOR BREACH OF CONTRACT, BREACH OF WARRANTY, TORT, 
NEGLIGENCE, INFRINGEMENT OR OTHERWISE (INCLUDING, WITHOUT LIMITATION, DAMAGES 
BASED ON LOSS OF PROFITS, DATA, FILES, USE, BUSINESS OPPORTUNITY OR CLAIMS OF THIRD 
PARTIES), AND WHETHER OR NOT THE PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH 
DAMAGES. THIS LIMITATION SHALL APPLY NOTWITHSTANDING ANY FAILURE OF ESSENTIAL 
PURPOSE OF ANY LIMITED REMEDY PROVIDED HEREIN.  
9. Should any provision of this Agreement be held by a court of competent jurisdiction to be illegal, 
invalid, or unenforceable, that provision shall be deemed amended to achieve as nearly as possible the 
same economic effect as the original provision, and the legality, validity and enforceability of the 
remaining provisions of this Agreement shall not be affected or impaired thereby.  
10. The failure of either party to enforce any term or condition of this Agreement shall not constitute a 
waiver of either party's right to enforce each and every term and condition of this Agreement. No 
breach under this agreement shall be deemed waived or excused by either party unless such waiver or 
consent is in writing signed by the party granting such waiver or consent. The waiver by or consent of a 
party to a breach of any provision of this Agreement shall not operate or be construed as a waiver of or 
consent to any other or subsequent breach by such other party.  
11. This Agreement may not be assigned (including by operation of law or otherwise) by you without 
WILEY's prior written consent.  
12. Any fee required for this permission shall be non-refundable after thirty (30) days from receipt 
13. These terms and conditions together with CCCs Billing and Payment terms and conditions (which 
are incorporated herein) form the entire agreement between you and WILEY concerning this licensing 
transaction and (in the absence of fraud) supersedes all prior agreements and representations of the 
parties, oral or written. This Agreement may not be amended except in writing signed by both parties. 
This Agreement shall be binding upon and inure to the benefit of the parties' successors, legal 
representatives, and authorized assigns.  
14. In the event of any conflict between your obligations established by these terms and conditions and 
those established by CCCs Billing and Payment terms and conditions, these terms and conditions shall 
prevail.  
15. WILEY expressly reserves all rights not specifically granted in the combination of (i) the license 
details provided by you and accepted in the course of this licensing transaction, (ii) these terms and 
conditions and (iii) CCCs Billing and Payment terms and conditions.  
16. This Agreement will be void if the Type of Use, Format, Circulation, or Requestor Type was 
misrepresented during the licensing process.  
17. This Agreement shall be governed by and construed in accordance with the laws of the State of New 
York, USA, without regards to such states conflict of law rules. Any legal action, suit or proceeding 
arising out of or relating to these Terms and Conditions or the breach thereof shall be instituted in a 
court of competent jurisdiction in New York County in the State of New York in the United States of 
America and each party hereby consents and submits to the personal jurisdiction of such court, waives 
any objection to venue in such court and consents to service of process by registered or certified mail, 
return receipt requested, at the last known address of such party.  
Wiley Open Access Terms and Conditions  
Wiley publishes Open Access articles in both its Wiley Open Access Journals program 
[http://www.wileyopenaccess.com/view/index.html] and as Online Open articles in its subscription 
journals. The majority of Wiley Open Access Journals have adopted the Creative Commons Attribution 
License (CC BY) which permits the unrestricted use, distribution, reproduction, adaptation and 
commercial exploitation of the article in any medium. No permission is required to use the article in this 
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way provided that the article is properly cited and other license terms are observed. A small number of 
Wiley Open Access journals have retained the Creative Commons Attribution Non Commercial License 
(CC BY-NC), which permits use, distribution and reproduction in any medium, provided the original 
work is properly cited and is not used for commercial purposes. 
Online Open articles  Authors selecting Online Open are, unless particular exceptions apply, offered a 
choice of Creative Commons licenses. They may therefore select from the CC BY, the CC BY-NC and the 
Attribution-NoDerivatives (CC BY-NC-ND). The CC BY-NC-ND is more restrictive than the CC BY-NC as it 
does not permit adaptations or modifications without rights holder consent. 
Wiley Open Access articles are protected by copyright and are posted to repositories and websites in 
accordance with the terms of the applicable Creative Commons license referenced on the article. At the 
time of deposit, Wiley Open Access articles include all changes made during peer review, copyediting, 
and publishing. Repositories and websites that host the article are responsible for incorporating any 
publisher-supplied amendments or retractions issued subsequently. 
Wiley Open Access articles are also available without charge on Wiley's publishing platform, Wiley 
Online Library or any successor sites. 
Conditions applicable to all Wiley Open Access articles:  
 The authors' moral rights must not be compromised. These rights include the right of 
"paternity" (also known as "attribution" - the right for the author to be identified as such) and 
"integrity" (the right for the author not to have the work altered in such a way that the author's 
reputation or integrity may be damaged).  
 Where content in the article is identified as belonging to a third party, it is the obligation of the 
user to ensure that any reuse complies with the copyright policies of the owner of that content.  
 If article content is copied, downloaded or otherwise reused for research and other purposes as 
permitted, a link to the appropriate bibliographic citation (authors, journal, article title, volume, 
issue, page numbers, DOI and the link to the definitive published version on Wiley Online 
Library) should be maintained. Copyright notices and disclaimers must not be deleted. 
Creative Commons licenses are copyright licenses and do not confer any other rights, including 
but not limited to trademark or patent rights.  
 Any translations, for which a prior translation agreement with Wiley has not been agreed, must 
prominently display the statement: "This is an unofficial translation of an article that appeared 
in a Wiley publication. The publisher has not endorsed this translation."  
Conditions applicable to non-commercial licenses (CC BY-NC and CC BY-NC-ND) 
For non-commercial and non-promotional purposes individual non-commercial users may 
access, download, copy, display and redistribute to colleagues Wiley Open Access articles. In 
addition, articles adopting the CC BY-NC may be adapted, translated, and text- and data-mined 
subject to the conditions above. 
Use by commercial "for-profit" organizations  
Use of non-commercial Wiley Open Access articles for commercial, promotional, or marketing 
purposes requires further explicit permission from Wiley and will be subject to a fee. 
Commercial purposes include:  
o Copying or downloading of articles, or linking to such articles for further 
redistribution, sale or licensing;  
o Copying, downloading or posting by a site or service that incorporates advertising with 
such content;  
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o The inclusion or incorporation of article content in other works or services (other than 
normal quotations with an appropriate citation) that is then available for sale or 
licensing, for a fee (for example, a compilation produced for marketing purposes, 
inclusion in a sales pack)  
o Use of article content (other than normal quotations with appropriate citation) by for-
profit organizations for promotional purposes  
o Linking to article content in e-mails redistributed for promotional, marketing or 
educational purposes;  
o Use for the purposes of monetary reward by means of sale, resale, license, loan, 
transfer or other form of commercial exploitation such as marketing products  
o Print reprints of Wiley Open Access articles can be purchased from: 
corporatesales@wiley.com  
The modification or adaptation for any purpose of an article referencing the CC BY-NC-
ND License requires consent which can be requested from RightsLink@wiley.com .  
Other Terms and Conditions:  
BY CLICKING ON THE "I AGREE..." BOX, YOU ACKNOWLEDGE THAT YOU HAVE READ 
AND FULLY UNDERSTAND EACH OF THE SECTIONS OF AND PROVISIONS SET FORTH 
IN THIS AGREEMENT AND THAT YOU ARE IN AGREEMENT WITH AND ARE WILLING 
TO ACCEPT ALL OF YOUR OBLIGATIONS AS SET FORTH IN THIS AGREEMENT.  
v1.8  
If you would like to pay for this license now, please remit this license along with your payment 
made payable to "COPYRIGHT CLEARANCE CENTER" otherwise you will be invoiced within 48 
hours of the license date. Payment should be in the form of a check or money order referencing 
your account number and this invoice number RLNK501022684. 
Once you receive your invoice for this order, you may pay your invoice by credit card. Please 
follow instructions provided at that time. 
 
Make Payment To: 
Copyright Clearance Center 
Dept 001 
P.O. Box 843006 
Boston, MA 02284-3006 
 
For suggestions or comments regarding this order, contact RightsLink Customer Support: 
customercare@copyright.com or +1-877-622-5543 (toll free in the US) or +1-978-646-2777. 
 
Gratis licenses (referencing $0 in the Total field) are free. Please retain this printable license for 
your reference. No payment is required.  
Figure 3-9 
From: prvs=84665f276=copyright@osa.org on behalf of pubscopyright  
<copyright@osa.org> 
Sent: 21 May 2013 20:53 
To: Coda, Sergio 
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Subject: RE: permission to reproduce figure in PhD thesis 
Dear Dr. Coda, 
Thank you for contacting The Optical Society. 
OSA considers your requested use of its copyrighted material to be Fair Use under United States  
Copyright Law.  It is requested that a complete citation of the original material be included in any 
publication.   
Let me know if you have any questions. 
Kind Regards, 
Susannah Lehman 
Susannah Lehman 
May 21, 2013 
Authorized Agent, The Optical Society 
 
From: Coda, Sergio [mailto:s.coda@imperial.ac.uk]   
Sent: Thursday, May 16, 2013 11:59 AM  
To: pubscopyright  
Subject: permission to reproduce figure in PhD thesis 
Dear Sir or Madam, 
I would like to request permission to reproduce the following figure in my PhD thesis: 
Re: McGinty, J., N. P. Galletly, C. Dunsby et al. 2010. Wide-field fluorescence lifetime imaging of cancer. 
Biomed. Opt. Express 1:627-640. 
Figure 2. page 633. 
The PhD thesis would be available in both print form and electronically. 
Title of thesis: An Investigation of the Diagnostic Potential of Autofluorescence Lifetime Spectroscopy and 
Imaging for Label-Free Contrast of Disease. 
I would also take this opportunity to express my sincere appreciation for your assistance. 
Kind regards, 
Dr Sergio Coda 
*********************************************************** 
Sergio Coda, MD 
Clinical Research Fellow 
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Department of Medicine 
Division of Experimental Medicine 
Imperial College London 
 
Room 612, Level 6, Blackett Laboratory 
South Kensington Campus 
Prince Consort Road 
London SW7 2AZ 
Telephone: 0044 (0) 20 7594 7738 
Fax: 0044 (0) 20 7594 7714 
E-Mail: s.coda@imperial.ac.uk 
URL: http://www1.imperial.ac.uk/medicine/people/s.coda/ 
*********************************************************** 
Figure 3-10 
AW: permission to reproduce figure in PhD thesis 
Rights DE [RIGHTS-and-LICENCES@wiley-vch.de] 
Sent: 17 May 2013 18:45 
To: Coda, Sergio 
Dear Sergio Coda 
  
We hereby grant permission for the requested use expected that due credit is given to the original 
source. 
  
If material appears within our work with credit to another source, authorisation from that source must be 
obtained. 
  
Credit must include the following components: 
  
- Books: Author(s)/ Editor(s) Name(s): Title of the Book. Page(s). Publication  year. Copyright Wiley-VCH 
Verlag GmbH & Co. KGaA. Reproduced with permission. 
- Journals: Author(s) Name(s): Title of the Article. Name of the Journal. Publication  year. Volume. Page(s). 
Copyright Wiley-VCH Verlag GmbH & Co. KGaA. Reproduced with permission. 
- Online Portal: Author(s): Title of the Online portal. Link or DOI. Publication  year. Copyright Wiley-VCH 
Verlag GmbH & Co. KGaA. Reproduced with permission. 
  
With kind regards 
  
Bettina Loycke 
Senior Rights Manager 
Rights & Licenses 
 
Wiley-VCH Verlag GmbH & Co. KGaA 
Boschstraße 12 
69469 Weinheim 
Germany 
www.wiley-vch.de 
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T          +(49) 6201 606-280 
F          +(49) 6201 606-332 
rightsDE@wiley.com 
 
 
Von: Goldweber, Paulette - Hoboken Im Auftrag von Permissions - US 
Gesendet: Freitag, 17. Mai 2013 15:44 
An: Rights DE 
Betreff: FW: permission to reproduce figure in PhD thesis 
  
From: Coda, Sergio [mailto:s.coda@imperial.ac.uk]  
Sent: Friday, May 17, 2013 4:59 AM 
To: Permissions - US 
Subject: permission to reproduce figure in PhD thesis 
  
Dear Sir or Madam, 
  
I would like to request permission to reproduce the following figure in my PhD thesis: 
  
Re: Kennedy, G. T., H. B. Manning, D. S. Elson et al. 2010. A fluorescence lifetime imaging scanning confocal 
endomicroscope. Journal of Biophotonics 3:103-107. 
Figure 1. page 104 
Permission to reproduce this content could not be granted via the RightsLink® service. 
The PhD thesis would be available in both print form and electronically. 
Title of thesis: An Investigation of the Diagnostic Potential of Autofluorescence Lifetime Spectroscopy and 
Imaging for Label-Free Contrast of Disease. 
I would also take this opportunity to express my sincere appreciation for your assistance. 
Kind regards, 
Dr Sergio Coda  
*********************************************************** 
Sergio Coda, MD 
Clinical Research Fellow 
Department of Medicine 
Division of Experimental Medicine 
Imperial College London 
  
Room 612, Level 6, Blackett Laboratory 
South Kensington Campus 
Prince Consort Road 
London SW7 2AZ 
Telephone: 0044 (0) 20 7594 7738 
Fax: 0044 (0) 20 7594 7714 
E-Mail: s.coda@imperial.ac.uk 
URL: http://www1.imperial.ac.uk/medicine/people/s.coda/ 
*********************************************************** 
 
 
Deutsch: 
WILEY-VCH Verlag GmbH & Co. KGaA – A company of John Wiley & Sons, Inc. - Sitz der Gesellschaft: 
Weinheim – Amtsgericht Mannheim, HRB 432833 – Vorsitzender des Aufsichtsrates:  
Stephen Michael Smith. Persönlich haftender Gesellschafter: John Wiley & Sons GmbH – Sitz der 
Gesellschaft: Weinheim – Amtsgericht Mannheim, HRB 432296 – Geschäftsführer:  
Bijan Ghawami, Dr. Jon Walmsley 
English: 
Wiley-VCH Verlag GmbH & Co. KGaA – A company of John Wiley & Sons, Inc. - Location of the Company: 
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Weinheim - Trade Register: Mannheim, HRB 432833.   
Chairman of the Supervisory Board: Stephen Michael Smith. General Partner: John Wiley & Sons GmbH, 
Location: Weinheim – Trade Register Mannheim, HRB 432296 –   
Managing Directors: Bijan Ghawami, Dr. Jon Walmsley 
Figure 3-11 
From: prvs=84665f276=copyright@osa.org on behalf of pubscopyright  
<copyright@osa.org> 
Sent: 21 May 2013 20:53 
To: Coda, Sergio 
Subject: RE: permission to reproduce figure in PhD thesis 
Dear Dr. Coda, 
Thank you for contacting The Optical Society. 
OSA considers your requested use of its copyrighted material to be Fair Use under United States  
Copyright Law.  It is requested that a complete citation of the original material be included in any 
publication.   
Let me know if you have any questions. 
Kind Regards, 
Susannah Lehman 
Susannah Lehman 
May 21, 2013 
Authorized Agent, The Optical Society 
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